Novel sulfonamide carboxamide compounds

ABSTRACT

The present invention relates to sulfonylureas and sulfonylthioureas comprising as-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, and wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

FIELD OF THE INVENTION

The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with at least one group containing an oxygen atom, wherein said oxygen atom is attached to the heteroaryl ring via at least two other atoms, and to associated salts, solvates, prodrugs and pharmaceutical compositions. The present invention further relates to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP3 inhibition.

BACKGROUND

The NOD-like receptor (NLR) family, pyrin domain-containing protein 3 (NLRP3) inflammasome is a component of the inflammatory process, and its aberrant activity is pathogenic in inherited disorders such as cryopyrin-associated periodic syndromes (CAPS) and complex diseases such as multiple sclerosis, type 2 diabetes, Alzheimer's disease and atherosclerosis.

NLRP3 is an intracellular signalling molecule that senses many pathogen-derived, environmental and host-derived factors. Upon activation, NLRP3 binds to apoptosis-associated speck-like protein containing a caspase activation and recruitment domain (ASC). ASC then polymerises to form a large aggregate known as an ASC speck. Polymerised ASC in turn interacts with the cysteine protease caspase-1 to form a complex termed the inflammasome. This results in the activation of caspase-1, which cleaves the precursor forms of the proinflammatory cytokines IL-1β and IL-18 (termed pro-IL-1β and pro-IL-18 respectively) to thereby activate these cytokines. Caspase-1 also mediates a type of inflammatory cell death known as pyroptosis. The ASC speck can also recruit and activate caspase-8, which can process pro-IL-1β and pro-IL-18 and trigger apoptotic cell death.

Caspase-1 cleaves pro-IL-1β and pro-IL-18 to their active forms, which are secreted from the cell. Active caspase-1 also cleaves gasdermin-D to trigger pyroptosis. Through its control of the pyroptotic cell death pathway, caspase-1 also mediates the release of alarmin molecules such as IL-33 and high mobility group box 1 protein (HMGBi). Caspase-1 also cleaves intracellular IL-1R2 resulting in its degradation and allowing the release of IL-1α. In human cells caspase-1 may also control the processing and secretion of IL-37. A number of other caspase-1 substrates such as components of the cytoskeleton and glycolysis pathway may contribute to caspase-1-dependent inflammation.

NLRP3-dependent ASC specks are released into the extracellular environment where they can activate caspase-1, induce processing of caspase-1 substrates and propagate inflammation.

Active cytokines derived from NLRP3 inflammasome activation are important drivers of inflammation and interact with other cytokine pathways to shape the immune response to infection and injury. For example, IL-1β signalling induces the secretion of the pro-inflammatory cytokines IL-6 and TNF. IL-1β and IL-18 synergise with IL-23 to induce IL-17 production by memory CD4 Th17 cells and by γδ T cells in the absence of T cell receptor engagement. IL-18 and IL-12 also synergise to induce IFN-γ production from memory T cells and NK cells driving a Th1 response.

The inherited CAPS diseases Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS) and neonatal-onset multisystem inflammatory disease (NOMID) are caused by gain-of-function mutations in NLRP3, thus defining NLRP3 as a critical component of the inflammatory process. NLRP3 has also been implicated in the pathogenesis of a number of complex diseases, notably including metabolic disorders such as type 2 diabetes, atherosclerosis, obesity and gout.

A role for NLRP3 in diseases of the central nervous system is emerging, and lung diseases have also been shown to be influenced by NLRP3. Furthermore, NLRP3 has a role in the development of liver disease, kidney disease and aging. Many of these associations were defined using Nlrp3−/− mice, but there have also been insights into the specific activation of NLRP3 in these diseases. In type 2 diabetes mellitus (T2D), the deposition of islet amyloid polypeptide in the pancreas activates NLRP3 and IL-1β signaling, resulting in cell death and inflammation.

Several small molecules have been shown to inhibit the NLRP3 inflammasome. Glyburide inhibits IL-1β production at micromolar concentrations in response to the activation of NLRP3 but not NLRC4 or NLRP1. Other previously characterised weak NLRP3 inhibitors include parthenolide, 3,4-methylenedioxy-β-nitrostyrene and dimethyl sulfoxide (DMSO), although these agents have limited potency and are nonspecific.

Current treatments for NLRP3-related diseases include biologic agents that target IL-1. These are the recombinant IL-1β receptor antagonist anakinra, the neutralizing IL-1β antibody canakinumab and the soluble decoy IL-1 receptor rilonacept. These approaches have proven successful in the treatment of CAPS, and these biologic agents have been used in clinical trials for other IL-1β-associated diseases.

Some diarylsulfonylurea-containing compounds have been identified as cytokine release inhibitory drugs (CRIDs) (Perregaux et al.; J. Pharmacol. Exp. Ther. 299, 187-197, 2001). CRIDs are a class of diarylsulfonylurea-containing compounds that inhibit the post-translational processing of IL-1β. Post-translational processing of IL-1β is accompanied by activation of caspase-1 and cell death. CRIDs arrest activated monocytes so that caspase-1 remains inactive and plasma membrane latency is preserved.

Certain sulfonylurea-containing compounds are also disclosed as inhibitors of NLRP3 (see for example, Baldwin et al., J. Med. Chem., 59(5), 1691-1710, 2016; and WO 2016/131098 A1, WO 2017/129897 A1, WO 2017/140778 A1, WO 2017/184604 A1, WO 2017/184623 A1, WO 2017/184624 A1, WO 2018/136890 A1 and WO 2018/015445 A1).

There is a need to provide compounds with improved pharmacological and/or physiological and/or physicochemical properties and/or those that provide a useful alternative to known compounds.

SUMMARY OF THE INVENTION

A first aspect of the invention provides a compound of formula (I):

wherein:

-   -   Q is selected from O or S;     -   W, X, Y and Z are each independently N, O, S, NH or CH, wherein         at least one of W, X, Y and Z is N or NH;     -   L is a saturated or unsaturated hydrocarbylene group, wherein         the hydrocarbylene group may be straight-chained or branched, or         be or include cyclic groups, wherein the hydrocarbylene group         may optionally be substituted, and wherein the hydrocarbylene         group may optionally include one or more heteroatoms N, O or S         in its carbon skeleton;     -   R¹ is hydrogen or a saturated or unsaturated hydrocarbyl group,         wherein the hydrocarbyl group may be straight-chained or         branched, or be or include cyclic groups, wherein the         hydrocarbyl group may optionally be substituted, and wherein the         hydrocarbyl group may optionally include one or more heteroatoms         N, O or S in its carbon skeleton;     -   optionally L and R¹ together with the oxygen atom to which they         are attached may form a 3- to 12-membered saturated or         unsaturated cyclic group, wherein the cyclic group may         optionally be substituted;     -   optionally R¹—O-L-, and any two adjacent W, X, Y or Z, may         together form a 3- to 12-membered saturated or unsaturated         cyclic group fused to ring A, wherein the cyclic group fused to         ring A may optionally be substituted;     -   R² is a cyclic group substituted at the α-position, wherein R²         may optionally be further substituted;     -   each R³ is independently a halo, —OH, —NO₂, —NH₂, —N₃, —SH, or a         saturated or unsaturated hydrocarbyl group, wherein the         hydrocarbyl group may be straight-chained or branched, or be or         include cyclic groups, wherein the hydrocarbyl group may         optionally be substituted, and wherein the hydrocarbyl group may         optionally include one or more heteroatoms N, O or S in its         carbon skeleton;     -   m is 0, 1, 2 or 3; and     -   optionally any R³, and any two adjacent W, X, Y or Z, may         together form a 3- to 12-membered saturated or unsaturated         cyclic group fused to ring A, wherein the cyclic group fused to         ring A may optionally be substituted;     -   provided that any atom of L or R¹ that is directly attached to         W, X, Y or Z is not the same atom of L or R¹ that is directly         attached to the oxygen atom of R¹—O-L-; and     -   provided that the compound is not:

In the context of the present specification, a “hydrocarbyl” substituent group or a hydrocarbyl moiety in a substituent group only includes carbon and hydrogen atoms but, unless stated otherwise, does not include any heteroatoms, such as N, O or S, in its carbon skeleton. A hydrocarbyl group/moiety may be saturated or unsaturated (including aromatic), and may be straight-chained or branched, or be or include cyclic groups wherein, unless stated otherwise, the cyclic group does not include any heteroatoms, such as N, O or S, in its carbon skeleton. Examples of hydrocarbyl groups include alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl and aryl groups/moieties and combinations of all of these groups/moieties. Typically a hydrocarbyl group is a C₁-C₂₀ hydrocarbyl group. More typically a hydrocarbyl group is a C₁-C₁₅ hydrocarbyl group. More typically a hydrocarbyl group is a C₁-C₁₀ hydrocarbyl group. A “hydrocarbylene” group is similarly defined as a divalent hydrocarbyl group.

An “alkyl” substituent group or an alkyl moiety in a substituent group may be linear (i.e. straight-chained) or branched. Examples of alkyl groups/moieties include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl and n-pentyl groups/moieties. Unless stated otherwise, the term “alkyl” does not include “cycloalkyl”. Typically an alkyl group is a C₁-C₁₂ alkyl group. More typically an alkyl group is a C₁-C₆ alkyl group. An “alkylene” group is similarly defined as a divalent alkyl group.

An “alkenyl” substituent group or an alkenyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon double bonds.

Examples of alkenyl groups/moieties include ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 1-hexenyl, 1,3-butadienyl, 1,3-pentadienyl, 1,4-pentadienyl and 1,4-hexadienyl groups/moieties. Unless stated otherwise, the term “alkenyl” does not include “cycloalkenyl”. Typically an alkenyl group is a C₂-C₁₂ alkenyl group. More typically an alkenyl group is a C₂-C₆ alkenyl group. An “alkenylene” group is similarly defined as a divalent alkenyl group.

An “alkynyl” substituent group or an alkynyl moiety in a substituent group refers to an unsaturated alkyl group or moiety having one or more carbon-carbon triple bonds. Examples of alkynyl groups/moieties include ethynyl, propargyl, but-1-ynyl and but-2-ynyl groups/moieties. Typically an alkynyl group is a C₂-C₁₂ alkynyl group. More typically an alkynyl group is a C₂-C₆ alkynyl group. An “alkynylene” group is similarly defined as a divalent alkynyl group.

A “cyclic” substituent group or a cyclic moiety in a substituent group refers to any hydrocarbyl ring, wherein the hydrocarbyl ring may be saturated or unsaturated (including aromatic) and may include one or more heteroatoms, e.g. N, O or S, in its carbon skeleton. Examples of cyclic groups include cycloalkyl, cycloalkenyl, heterocyclic, aryl and heteroaryl groups as discussed below. A cyclic group may be monocyclic, bicyclic (e.g. bridged, fused or spiro), or polycyclic. Typically, a cyclic group is a 3- to 12-membered cyclic group, which means it contains from 3 to 12 ring atoms. More typically, a cyclic group is a 3- to 7-membered monocyclic group, which means it contains from 3 to 7 ring atoms.

A “heterocyclic” substituent group or a heterocyclic moiety in a substituent group refers to a cyclic group or moiety including one or more carbon atoms and one or more (such as one, two, three or four) heteroatoms, e.g. N, O or S, in the ring structure. Examples of heterocyclic groups include heteroaryl groups as discussed below and non-aromatic heterocyclic groups such as azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, dioxolanyl, oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, dioxanyl, morpholinyl and thiomorpholinyl groups.

A “cycloalkyl” substituent group or a cycloalkyl moiety in a substituent group refers to a saturated hydrocarbyl ring containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. Unless stated otherwise, a cycloalkyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

A “cycloalkenyl” substituent group or a cycloalkenyl moiety in a substituent group refers to a non-aromatic unsaturated hydrocarbyl ring having one or more carbon-carbon double bonds and containing, for example, from 3 to 7 carbon atoms, examples of which include cyclopent-1-en-1-yl, cyclohex-1-en-1-yl and cyclohex-1,3-dien-1-yl. Unless stated otherwise, a cycloalkenyl substituent group or moiety may include monocyclic, bicyclic or polycyclic hydrocarbyl rings.

An “aryl” substituent group or an aryl moiety in a substituent group refers to an aromatic hydrocarbyl ring. The term “aryl” includes monocyclic aromatic hydrocarbons and polycyclic fused ring aromatic hydrocarbons wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of aryl groups/moieties include phenyl, naphthyl, anthracenyl and phenanthrenyl. Unless stated otherwise, the term “aryl” does not include “heteroaryl”.

A “heteroaryl” substituent group or a heteroaryl moiety in a substituent group refers to an aromatic heterocyclic group or moiety. The term “heteroaryl” includes monocyclic aromatic heterocycles and polycyclic fused ring aromatic heterocycles wherein all of the fused ring systems (excluding any ring systems which are part of or formed by optional substituents) are aromatic. Examples of heteroaryl groups/moieties include the following:

wherein G=O, S or NH.

For the purposes of the present specification, where a combination of moieties is referred to as one group, for example, arylalkyl, arylalkenyl, arylalkynyl, alkylaryl, alkenylaryl or alkynylaryl, the last mentioned moiety contains the atom by which the group is attached to the rest of the molecule. An example of an arylalkyl group is benzyl. For the purposes of the present specification, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a group independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —Si(R^(β))₃; —O—Si(R^(β))₃; —R^(α)—Si(R^(β))₃; —R^(α)—O—Si(R^(β))₃; —NH₂; —NHR^(β); —N(R^(β))₂; —N(O)(R^(β))₂; —N⁺(R^(β))₃; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —R^(α)—N(O)(R^(β))₂; —R^(α)—N⁺(R^(β))₃; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); —R^(α)—OCOR^(β); —C(═NH)R^(β); —C(═NH)NH₂; —C(═NH)NHR^(β); —C(═NH)N(R^(β))₂; —C(═NR^(β))R^(β); —C(═NR^(β))NHR^(β); —C(═NR^(β))N(R^(β))₂; —C(═NOH)R^(β); —C(N₂)R^(β); —R^(α)—C(═NH)R^(β); —R^(α)—C(═NH)NH₂; —R^(α)—C(═NH)NHR^(β); —R^(α)—C(═NH)N(R^(β))₂; —R^(α)—C(═NR^(β))R^(β); —R^(α)—C(═NR^(β))NHR^(β); —R^(α)—C(═NR^(β))N(R^(β))₂; —R^(α)—C(═NOH)R^(β); —R^(α)—C(N₂)R^(β); —NH—CHO; —NR^(β)—CHO; —NH—COR^(β); —NR^(β)—COR^(β); —CONH₂; —CONHR^(β); —CON(R^(β))₂; —R^(α)—NH—CHO; —R^(α)—NR^(β)—CHO; —R^(α)—NH—COR^(β); —R^(α)—NR^(β)—COR^(β); —R^(α)—CONH₂; —R^(α)—CONHR^(β); —R^(α)—CON(R^(β))₂; —O—R^(α)—OH; —O—R^(α)—OR^(β); —O—R^(α)—NH₂; —O—R^(α)—NHR^(β); —O—R^(α)—N(R^(β))₂; —O—R^(α)—N(O)(R^(β))₂; —O—R^(α)—N⁺(R^(β))₃; —NH—R^(α)—OH; —NH—R^(α)—OR^(β); —NH—R^(α)—NH₂; —NH—R^(α)—NHR^(β); —NH—R^(α)—N(R^(β))₂; —NH—R^(α)—N(O)(R^(β))₂; —NH—R^(α)—N⁺(R^(β))₃; —NR^(β)—R^(α)—OH; —NR^(β)—R^(α)—OR^(β); —NR^(β)—R^(α)—NH₂; —NR^(β)—R^(α)—NHR^(β); —NR^(β)—R^(α)—N(R^(β))₂; —NR^(β)—R^(α)—N(O)(R^(β))₂; —NR^(β)—R^(α)—N⁺(R^(β))₃; —N(O)R^(β)—R^(α)—OH; —N(O)R^(β)—R^(α)—OR^(β); —N(O)R^(β)—R^(α)—NH₂; —N(O)R^(β)—R^(α)—NHR^(β); —N(O)R^(β)—R^(α)—N(R^(β))₂; —N(O)R^(β)—R^(α)—N(O)(R^(β))₂; —N(O)R^(β)—R^(α)—N⁺(R^(β))₃; —N⁺(R^(β))₂—R^(α)—OH; —N⁺(R^(β))₂—R^(α)—OR^(β); —N⁺(R^(β))₂—R^(α)—NH₂; —N⁺(R^(β))₂—R^(α)—NHR^(β); —N⁺(R^(β))₂—R^(α)—N(R^(β))₂; or —N⁺(R^(β))₂—R^(α)—N(O)(R^(β))₂; and/or

(ii) any two hydrogen atoms attached to the same atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or

(iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N═N—, —N(R^(β))—, —N(O)(R^(β))—, —N⁺(R^(β))₂— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, wherein one or         more —CH₂— groups in the backbone of the alkylene, alkenylene or         alkynylene group may optionally be replaced by one or more         —N(O)(R^(β))— or —N⁺(R^(β))₂— groups, and wherein the alkylene,         alkenylene or alkynylene group may optionally be substituted         with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or         wherein any two or three —R^(β) attached to the same nitrogen         atom may, together with the nitrogen atom to which they are         attached, form a C₂-C₇ cyclic group, and wherein any —R^(β) may         optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ halocycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), —O(C₃-C₇         halocycloalkyl), —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl),         —COO(C₁-C₄ alkyl), —COO(C₁-C₄ haloalkyl), halo, —OH, —NH₂, —CN,         —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic group.

Typically, the compounds of the present invention comprise at most one quaternary ammonium group such as —N⁺(R^(β))₃ or —N⁺(R^(β))₂—.

Where reference is made to a —R^(α)—C(N₂)R^(β) group, what is intended is:

Typically, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a group independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); —R^(α)—OCOR^(β); —NH—CHO; —NR^(β)—CHO; —NH—COR^(β); —NR^(β)—COR^(β); —CONH₂; —CONHR^(β); —CON(R^(β))₂; —R^(α)—NH—CHO; —R^(α)—NR—CHO; —R^(α)—NH—COR^(β); —R^(α)—NR^(β)—COR^(β); —R^(α)—CONH₂; —R^(α)—CONHR^(β); —R^(α)—CON(R^(β))₂; —O—R^(α)—OH; —O—R^(α)—OR^(β); —O—R^(α)—NH₂; —O—R^(α)—NHR^(β); —O—R^(α)—N(R^(β))₂; —NH—R^(α)—OH; —NH—R^(α)—OR^(β); —NH—R^(α)—NH₂; —NH—R^(α)—NHR^(β); —NH—R^(α)—N(R^(β))₂; —NR^(β)—R^(α)—OH; —NR^(β)—R^(α)—OR^(β); —NR^(β)—R^(α)—NH₂; —NR^(β)—R^(α)—NHR^(β); or —NR^(β)—R^(α)—N(R^(β))₂; and/or

(ii) any two hydrogen atoms attached to the same carbon atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or

(iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N(R^(β))— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH,         —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic         group.

Alternately in the optionally substituted groups or moieties defined immediately above, each —R^(β) may be independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or any two —R^(β) attached to the same nitrogen atom may, together with the nitrogen atom to which they are attached, form a C₂-C₇ cyclic group, wherein any —R^(β) may optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ halocycloalkyl, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), —O(C₃-C₇ halocycloalkyl), halo, —OH, —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic group.

More typically, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a group independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β); and/or

(ii) any two hydrogen atoms attached to the same carbon atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or

(iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N(R^(β))— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH,         —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic         group.

Alternately in the optionally substituted groups or moieties defined immediately above, each —R^(β) may be independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or any two —R^(β) attached to the same nitrogen atom may, together with the nitrogen atom to which they are attached, form a C₂-C₇ cyclic group, wherein any —R^(β) may optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ halocycloalkyl, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), —O(C₃-C₇ halocycloalkyl), halo, —OH, —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic group.

More typically, in an optionally substituted group or moiety:

(i) each hydrogen atom may optionally be replaced by a group independently selected from halo; —CN; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β); and/or

(ii) any two hydrogen atoms attached to the same carbon atom may optionally be replaced by a π-bonded substituent independently selected from oxo (═O), ═S, ═NH or ═NR^(β); and/or

(iii) any two hydrogen atoms attached to the same or different atoms, within the same optionally substituted group or moiety, may optionally be replaced by a bridging substituent independently selected from —O—, —S—, —NH—, —N(R^(β))— or —R^(α)—;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, halo, —OH, or 4- to 6-membered heterocyclic         group.

Alternately in the optionally substituted groups or moieties defined immediately above, each —R^(β) may be independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or any two —R^(β) attached to the same nitrogen atom may, together with the nitrogen atom to which they are attached, form a C₂-C₇ cyclic group, wherein any —R^(β) may optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄ haloalkyl, halo, —OH, or 4- to 6-membered heterocyclic group.

Typically a substituted group comprises at most 1, 2, 3 or 4 non-halo substituents, more typically 1, 2 or 3 non-halo substituents, more typically 1 or 2 non-halo substituents, and more typically 1 non-halo substituent.

Typically a substituted group comprises 1, 2, 3 or 4 substituents, more typically 1, 2 or 3 substituents, more typically 1 or 2 substituents, and more typically 1 substituent.

Unless stated otherwise, any divalent bridging substituent (e.g. —O—, —S—, —NH—, —N(R^(β))—, —N(O)(R^(β))—, —N⁺(R^(β))₂— or —R^(α)—) of an optionally substituted group or moiety (e.g. R¹) must only be attached to the specified group or moiety and may not be attached to a second group or moiety (e.g. R²), even if the second group or moiety can itself be optionally substituted.

The term “halo” includes fluoro, chloro, bromo and iodo.

Unless stated otherwise, where a group is prefixed by the term “halo”, such as a haloalkyl or halomethyl group, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the corresponding group without the halo prefix. For example, a halomethyl group may contain one, two or three halo substituents. A haloethyl or halophenyl group may contain one, two, three, four or five halo substituents. Similarly, unless stated otherwise, where a group is prefixed by a specific halo group, it is to be understood that the group in question is substituted with one or more of the specific halo groups. For example, the term “fluoromethyl” refers to a methyl group substituted with one, two or three fluoro groups.

Unless stated otherwise, where a group is said to be “halo-substituted”, it is to be understood that the group in question is substituted with one or more halo groups independently selected from fluoro, chloro, bromo and iodo. Typically, the maximum number of halo substituents is limited only by the number of hydrogen atoms available for substitution on the group said to be halo-substituted. For example, a halo-substituted methyl group may contain one, two or three halo substituents. A halo-substituted ethyl or halo-substituted phenyl group may contain one, two, three, four or five halo substituents.

Unless stated otherwise, any reference to an element is to be considered a reference to all isotopes of that element. Thus, for example, unless stated otherwise any reference to hydrogen is considered to encompass all isotopes of hydrogen including deuterium and tritium.

Where reference is made to a hydrocarbyl or other group including one or more heteroatoms N, O or S in its carbon skeleton, or where reference is made to a carbon atom of a hydrocarbyl or other group being replaced by an N, O or S atom, what is intended is that:

is replaced by

-   -   —CH₂— is replaced by —NH—, —O— or —S—;     -   —CH₃ is replaced by —NH₂, —OH or —SH;     -   —CH═ is replaced by —N═;     -   CH₂═ is replaced by NH═, O═ or S═; or     -   CH≡ is replaced by N≡;

provided that the resultant group comprises at least one carbon atom. For example, methoxy, dimethylamino and aminoethyl groups are considered to be hydrocarbyl groups including one or more heteroatoms N, O or S in their carbon skeleton.

Where reference is made to a —CH₂— group in the backbone of a hydrocarbyl or other group being replaced by a —N(O)(R^(β))— or —N⁺(R^(β))₂— group, what is intended is that:

-   -   —CH₂— is replaced by

or

-   -   —CH₂— is replaced by

In the context of the present specification, unless otherwise stated, a C_(x)-C_(y) group is defined as a group containing from x to y carbon atoms. For example, a C₁-C₄ alkyl group is defined as an alkyl group containing from 1 to 4 carbon atoms. Optional substituents and moieties are not taken into account when calculating the total number of carbon atoms in the parent group substituted with the optional substituents and/or containing the optional moieties. For the avoidance of doubt, replacement heteroatoms, e.g. N, O or S, are not to be counted as carbon atoms when calculating the number of carbon atoms in a C_(x)-C_(y) group. For example, a morpholinyl group is to be considered a C₄ heterocyclic group, not a C₆ heterocyclic group.

As will be understood, ring A is a 5-membered heteroaryl group containing at least one nitrogen atom in the 5-membered ring structure. In one embodiment, ring A is monocyclic. In such an embodiment, the groups R¹—O-L- and, if present, R³ are monovalent, but may be or include cyclic groups. Examples of monocyclic 5-membered heteroaryl groups containing at least one nitrogen atom in the 5-membered ring structure include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl and thiadiazolyl groups.

As stated, W, X, Y and Z are each independently N, O, S, NH or CH, wherein at least one of W, X, Y and Z is N or NH. Typically, at least two of W, X, Y and Z are N or NH. Typically, at least one of W, X, Y and Z is CH. For the purposes of the present specification, where it is stated that W, X, Y or Z may be NH or CH, it is to be understood that this refers to W, X, Y and Z before possible substitution with R¹—O-L- or R³ is considered. Thus, where it is stated that W, X, Y or Z may be NH, it is to be understood that W, X, Y or Z may be NH, N—R or N-L-O—R¹ after substitution is considered. Similarly, where it is stated that W, X, Y or Z may be CH, it is to be understood that W, X, Y or Z may be CH, C—R³ or C-L-R¹ after substitution is considered.

In one embodiment, W, X, Y and Z are each independently N, NH or CH. Typically in such an embodiment, at least two of W, X, Y and Z are N or NH and at least one of W, X, Y and Z is CH. Examples of such groups include imidazolyl, pyrazolyl and triazolyl groups. More typically, at least one of W and Z is CH. Most typically, two of W, X, Y and Z are N or NH and two of W, X, Y and Z are CH. Thus, in this most typical embodiment ring A is an imidazolyl or a pyrazolyl group.

As will be understood, R¹—O-L- may be directly attached to any ring atom represented by W, X, Y or Z. Typically, R¹—O-L- is directly attached to X or Y.

For the purposes of the present specification, where it is stated that a first atom or group is “directly attached” to a second atom or group it is to be understood that the first atom or group is covalently bonded to the second atom or group with no intervening atom(s) or group(s) being present. So, for example, for the group —(C═O)N(CH₃)₂, the carbon atom of each methyl group is directly attached to the nitrogen atom and the carbon atom of the carbonyl group is directly attached to the nitrogen atom, but the carbon atom of the carbonyl group is not directly attached to the carbon atom of either methyl group.

In one embodiment, R¹—O-L- is directly attached to a ring nitrogen atom of ring A. Typically, R¹—O-L- is directly attached to X where X is NH, or R¹—O-L- is directly attached to Y where Y is NH. Thus, where R¹—O-L- is monovalent, the compound may have the formula (Ia) or (Ib):

In one embodiment, the group R¹—O-L-, including any optional substituents, contains only atoms selected from the group consisting of carbon, hydrogen, nitrogen, oxygen and halogen atoms. In a further embodiment, the group R¹—O-L-, including any optional substituents, contains only atoms selected from the group consisting of carbon, hydrogen, oxygen and halogen atoms.

In one embodiment, any atom of R¹—O-L- that is directly attached to W, X, Y or Z is a carbon atom. Typically, any atom of R¹—O-L- that is directly attached to W, X, Y or Z is a sp³ hybridised carbon atom.

In one embodiment, the oxygen atom of R¹—O-L- is not directly attached to a sp² hybridised carbon atom. Typically, the oxygen atom of R¹—O-L- is not directly attached to a sp² hybridised atom.

In another embodiment, no oxygen atom within the group R¹—O-L- is directly attached to a sp² hybridised atom.

In yet another embodiment, no oxygen or nitrogen atom within the group R¹—O-L- is directly attached to a sp² or sp¹ hybridised atom.

In a further embodiment, the group R¹—O-L-, including any optional substituents, is saturated. Typically in such an embodiment, R¹—O-L- is monovalent.

In one embodiment, the group:

including any optional substituents, does not contain an amide group. In a further embodiment, the group does not contain a carbonyl group.

For the purposes of the present specification, an “amide group” is considered to be any group comprising the structure:

Accordingly, the term “amide group” includes urea groups.

As stated above, L is a saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbylene group may optionally be substituted, and wherein the hydrocarbylene group may optionally include one or more heteroatoms N, O or S in its carbon skeleton. Since any atom of L that is directly attached to W, X, Y or Z is not the same atom of L that is directly attached to the oxygen atom of R¹—O-L-, L must comprise at least two atoms.

Typically, L contains from 2 to 10 atoms other than hydrogen or halogen. More typically, L contains from 2 to 8 atoms other than hydrogen or halogen. More typically still, L contains from 2 to 6 atoms other than hydrogen or halogen. Most typically, L contains from 2 to 4 atoms other than hydrogen or halogen.

In one embodiment, L is an alkylene or an alkenylene group, wherein the alkylene or alkenylene group may be straight-chained or branched, wherein the alkylene or alkenylene group may be optionally substituted, and wherein the alkylene or alkenylene group may optionally include one or more (e.g. one or two) heteroatoms N or O in its carbon skeleton. The alkylene or alkenylene group may be substituted with any optional substituent as outlined herein, including with one or more divalent bridging substituents such that L is or includes a cyclic group. Typically however L, including any optional substituents, contains the number of atoms other than hydrogen or halogen specified above.

In one embodiment, where L is substituted, it is substituted with:

(i) one or more substituents independently selected from halo, —CN, —OH, —NH₂, oxo (═O) and ═NH; and/or

(ii) one or more divalent bridging substituents independently selected from —O—, —NH—, C₁-C₄ alkylene and C₁-C₄ alkenylene groups, wherein the C₁-C₄ alkylene or C₁-C₄ alkenylene groups may straight-chained or branched, wherein the C₁-C₄ alkylene or C₁-C₄ alkenylene groups may optionally be substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂, oxo (═O) and ═NH, and wherein the C₁-C₄ alkylene or C₁-C₄ alkenylene groups optionally include one or more heteroatoms N or O in their carbon skeleton.

More typically, where L is substituted, it is substituted with:

(i) one or more substituents independently selected from halo, —OH, —NH₂ and oxo (═O); and/or

(ii) one or more divalent bridging substituents independently selected from —O—, —NH—, C₁-C₃ alkylene and C₁-C₃ alkenylene groups, wherein the C₁-C₃ alkylene or C₁-C₃ alkenylene groups may straight-chained or branched, wherein the C₁-C₃ alkylene or C₁-C₃ alkenylene groups may optionally be substituted with one or more substituents independently selected from halo, —OH, —NH₂ and oxo (═O), and wherein the C₁-C₃ alkylene or C₁-C₃ alkenylene groups optionally include one or more heteroatoms N or O in their carbon skeleton.

In another embodiment, where L is substituted, it is substituted with:

(i) one or more substituents independently selected from halo and —OH; and/or

(ii) a divalent bridging substituent selected from —O— and C₁-C₃ alkylene, wherein the C₁-C₃ alkylene group may straight-chained or branched, wherein the C₁-C₃ alkylene group may optionally be substituted with one or more substituents independently selected from halo and —OH, and wherein the C₁-C₃ alkylene group may optionally include one heteroatom N or O in its carbon skeleton.

Most typically, where L is substituted, it is substituted with:

(i) one or more substituents independently selected from fluoro, chloro, and —OH; and/or

(ii) a —CH₂— or —CH₂CH₂— group, wherein the —CH₂— or —CH₂CH₂— group may optionally be substituted with one or more substituents independently selected from fluoro, chloro, and —OH.

As stated above, R¹ is hydrogen or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton.

In one embodiment, R¹ is hydrogen or an alkyl, cycloalkyl or cycloalkyl-alkylene- group, wherein the alkyl, cycloalkyl or cycloalkyl-alkylene- group optionally includes one or more heteroatoms N or O in its carbon skeleton and wherein the alkyl, cycloalkyl or cycloalkyl-alkylene- group is optionally substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂, oxo (═O) and ═NH. More typically, R¹ is hydrogen or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group, wherein the C₁-C₆ alkyl or C₃-C₆ cycloalkyl group is optionally substituted with one or more substituents independently selected from halo, —OH, —NH₂ and oxo (═O). More typically still, R¹ is hydrogen or a C₁-C₄ alkyl group, wherein the C₁-C₄ alkyl group is optionally substituted with one or more fluoro and/or chloro groups. Most typically, R¹ is hydrogen or methyl.

Typically, where R¹ is not hydrogen, R¹ contains from 1 to 8 atoms other than hydrogen or halogen. More typically, where R¹ is not hydrogen, R¹ contains from 1 to 6 atoms other than hydrogen or halogen. Most typically, where R¹ is not hydrogen, R¹ contains from 1 to 4 atoms other than hydrogen or halogen.

In another embodiment, L and R¹ together with the oxygen atom to which they are attached may form a 3- to 12-membered saturated or unsaturated cyclic group, wherein the cyclic group may optionally be substituted. As will be appreciated, the resultant cyclic group is a heterocyclic group, typically a non-aromatic heterocyclic group. In such an embodiment, not all of L and/or R¹ need form the resultant cyclic group. Accordingly, the resultant group R¹—O-L- may for example be an alkyl-substituted heterocyclyl group, or a heterocyclyl-alkylene group.

Typically, L and R¹ together with the oxygen atom to which they are attached form a 3- to 7-membered saturated or unsaturated monocyclic group, wherein the monocyclic group may optionally be substituted. Typically, said monocyclic group is a monocyclic non-aromatic heterocyclic group. More typically, said monocyclic group is a 4 to 6-membered saturated heterocyclic group which includes the atoms O and C and optionally N in the ring structure. More typically still, said monocyclic group is a 4 or 5-membered saturated heterocyclic group which includes the atoms O and C and in the ring structure.

In one embodiment, R¹—O-L- has the formula R¹⁰-L²-, wherein:

-   -   R¹⁰ is a 3- to 12-membered saturated or unsaturated heterocyclic         group, wherein R¹ includes at least one oxygen atom in the ring         structure, wherein R¹⁰ optionally includes one or more         additional heteroatoms N, O or S in the ring structure, wherein         R¹⁰ is optionally substituted; and     -   L² is a bond or a saturated or unsaturated hydrocarbylene group,         wherein the hydrocarbylene group may be straight-chained or         branched, or be or include cyclic groups, wherein the         hydrocarbylene group may optionally be substituted, and wherein         the hydrocarbylene group may optionally include one or more         heteroatoms N, O or S in its carbon skeleton;     -   provided that at least one oxygen atom in the ring structure of         R¹⁰ is not directly attached to the same atom of R¹⁰-L²- that is         directly attached to W, X, Y or Z.

Typically, the group R¹⁰-L²- contains from 4 to 12 atoms other than hydrogen or halogen. More typically, the group R¹⁰-L²- contains from 4 to 10 atoms other than hydrogen or halogen. Most typically, the group R¹⁰-L²- contains from 5 to 8 atoms other than hydrogen or halogen.

Typically, R¹⁰ is a 3- to 7-membered saturated or unsaturated monocyclic group, wherein R¹ includes at least one oxygen atom in the ring structure, wherein R¹⁰ optionally includes one or more additional heteroatoms N or O in the ring structure, wherein R¹⁰ is optionally substituted. Typically, R¹⁰ is non-aromatic. More typically, R¹⁰ is a 4- to 6-membered saturated monocyclic group, wherein R¹⁰ includes at least one oxygen atom in the ring structure, wherein R¹⁰ optionally includes one or two additional heteroatoms N or O in the ring structure, and wherein R¹⁰ is optionally substituted. For example, R¹⁰ may be an optionally substituted oxetanyl, tetrahydrofuranyl, 1,3-dioxolany, tetrahydropyranyl, 1,4-dioxanyl or morpholinyl group. More typically still, R¹⁰ is a 4- or 5-membered saturated monocyclic group, wherein R¹⁰ includes three or four carbon atoms and one or two oxygen atoms in the ring structure, and wherein R¹⁰ is optionally substituted. Most typically, R¹⁰ is an optionally substituted oxetanyl or tetrahydrofuranyl group.

Typically, L² is a bond or an alkylene or an alkenylene group, wherein the alkylene or alkenylene group may be straight-chained or branched, wherein the alkylene or alkenylene group may be optionally substituted, and wherein the alkylene or alkenylene group may optionally include one or more heteroatoms N or O in its carbon skeleton. More typically, L² is a bond or an alkylene group, wherein the alkylene group may be straight-chained or branched, wherein the alkylene group may be optionally substituted, wherein the alkylene group may optionally include one or two heteroatoms N or O in its carbon skeleton, and wherein L², including any optional substituents, contains from 0 to 6 atoms other than hydrogen or halogen. More typically still, L² is a bond or a —CH₂—, —CO— or —N(Me)-CO— group.

Alternately, L² may be a bond or a —(C(R¹⁵)₂)_(x)— group, wherein x is 1 or 2, and each R¹⁵ is independently selected from hydrogen or a halo, methyl or halomethyl group, or any two R¹⁵ directly attached to the same carbon atom may together form a C₂ alkylene or C₂ haloalkylene group. Typically, each R¹⁵ is independently selected from hydrogen or a fluoro, chloro or methyl group, or any two R¹⁵ directly attached to the same carbon atom may together form a C₂ alkylene group, wherein any methyl or C₂ alkylene group may optionally be substituted with one or more fluoro and/or chloro groups.

Most typically, L² is a bond, i.e. R¹—O-L- has the formula R¹⁰— wherein R¹⁰ is as defined above.

Where R¹⁰ is substituted, typically it is substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂, oxo (═O), ═NH, —R², —OR²⁰, —NHR², —N(R²⁰)₂ or ═NHR², wherein each R²⁰ is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group, or any two R²⁰ directly attached to the same nitrogen atom may together form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group. More typically, where R¹⁰ is substituted, it is substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂, —R²⁰, —OR²⁰, —NHR²⁰ and —N(R²⁰)₂, wherein each R²⁰ is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group, or any two R²⁰ directly attached to the same nitrogen atom may together form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group. Typically, each R²⁰ is independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group. More typically still, where R¹⁰ is substituted, it is substituted with one or more substituents independently selected from fluoro, chloro, —OH, —NH₂, -Me, -Et, —OMe, —OEt, —NHMe, —NHEt, —N(Me)₂, —N(Me)Et and —N(Et)₂ groups, wherein any methyl (Me) or ethyl (Et) group may optionally be substituted with one or more fluoro and/or chloro groups. Most typically, where R¹⁰ is substituted, it is substituted with one or more substituents independently selected from fluoro, —OH, -Me, -Et, —OMe, —OEt, —N(Me)₂, —N(Me)Et and —N(Et)₂ groups, wherein any methyl (Me) or ethyl (Et) group may optionally be substituted with one or more fluoro groups.

Where L² is substituted, typically it is substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂, oxo (═O) and ═NH. More typically, where L² is substituted, it is substituted with one or more substituents independently selected from halo, —CN, —OH, —NH₂ and oxo (═O). Most typically, where L² is substituted, it is substituted with one or more substituents independently selected from fluoro, chloro, —OH and oxo (═O).

In one embodiment, R¹—O-L- is monovalent.

In a further embodiment, no oxygen or nitrogen atom within the group R¹—O-L- is directly attached to a sp² or sp¹ hybridised atom, and the group:

contains from 8 to 20 atoms other than hydrogen or halogen. Typically in such an embodiment, R¹—O-L- is monovalent. Typically in such an embodiment, R¹—O-L- is directly attached to X or Y. Typically in such an embodiment, the group R¹—O-L-, including any optional substituents, is saturated. Typically in such an embodiment, the group R¹—O-L-, including any optional substituents, contains only atoms selected from the group consisting of carbon, hydrogen, nitrogen, oxygen and halogen atoms. Typically in such an embodiment, m is 0 or 1 and R³ where present is selected from a C₁-C₄ alkyl or C₃-C₄ cycloalkyl group, wherein any C₁-C₄ alkyl or C₃-C₄ cycloalkyl group may optionally be substituted with one or more fluoro and/or chloro groups.

In a further embodiment, where R¹—O-L- is monovalent, R¹—O-L- has a saturated structure, wherein the saturated structure is branched or includes a saturated cyclic group, and wherein R¹—O-L- typically contains from 4 to 6 atoms other than hydrogen or halogen. Typically in such an embodiment, the compound has the formula (Ia) or (Ib), m is 0 or 1 and R³ where present is selected from a halo, methyl or halomethyl group.

Without wishing to be bound by theory, it is currently believed that the compounds of the two further embodiments immediately above are particularly suitable for administration via oral or intravenous routes due to their pharmacokinetic properties.

This is thought to apply particularly where:

-   -   (i) R² is a fused aryl or a fused heteroaryl group, wherein a         first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl         or heteroaryl ring is fused to the aryl or heteroaryl group         across the α,β positions and a second cycloalkyl, cycloalkenyl,         non-aromatic heterocyclic, aryl or heteroaryl ring is fused to         the aryl or heteroaryl group across the α′,β′ positions, and         wherein R² may optionally be further substituted; or     -   (ii) R² is a fused aryl or a fused heteroaryl group, wherein a         cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or         heteroaryl ring is fused to the aryl or heteroaryl group across         the α,β positions, wherein the aryl or heteroaryl group is         further substituted at the α′ position with an alkyl or         cycloalkyl group, and wherein R² may optionally be further         substituted; or     -   (iii) R² is an aryl or a heteroaryl group, wherein the aryl or         the heteroaryl group is substituted at the α and α′ positions,         wherein the substituents at the α and α′ positions are         independently selected from alkyl and cycloalkyl groups, and         wherein R² may optionally be further substituted; or     -   (iv) R² is an aryl or a heteroaryl group, wherein the aryl or         the heteroaryl group is substituted at the α-position with a         monovalent heterocyclic group or a monovalent aromatic group,         wherein a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic,         aryl or heteroaryl ring is fused to the aryl or heteroaryl group         across the α′,β′ positions, and wherein R² may optionally be         further substituted.

In another embodiment, where R¹—O-L- is monovalent, R¹—O-L- contains 7 or more atoms other than hydrogen or halogen and/or contains at least one amide group. Without wishing to be bound by theory, it is currently believed that the compounds of this embodiment are particularly suitable for administration via topical routes due to their pharmacokinetic properties.

In an alternate embodiment, R¹—O-L- and any two adjacent W, X, Y or Z may together form a 3- to 12-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted. Thus, it will be understood that in such an embodiment the group R¹—O-L- forms a divalent bridging substituent between two adjacent W, X, Y and Z. In such an embodiment, R¹ may be divalent, such that part or all of R¹ and part or all of L may together form the fused cyclic group, or L may be trivalent, such that part or all of L forms the fused cyclic group and R¹—O— does not form part of the fused cyclic group. Typically in such an embodiment, R¹—O-L- and any two adjacent W, X, Y or Z together form a 4- to 7-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted, such that the ring A and the fused cyclic group together form a fused bicyclic group.

As stated above, any atom of L or R¹ that is directly attached to W, X, Y or Z is not the same atom of L or R that is directly attached to the oxygen atom of R¹—O-L-. Typically, the oxygen atom of R¹—O-L- is directly attached to L at a position β, γ, δ, or ε relative to any ring atom W, X, Y or Z to which the group R¹—O-L- is directly attached. For example, where L is —(CH₂)₅— attached to the ring atom X, R¹O— may be directly attached at any of the β, γ, δ, or ε positions as shown, but may not be directly attached at the α position:

For the avoidance of doubt, heteroatoms O, N or S in the carbon skeleton of L are to be taken into consideration when allocating the nomenclature α, β, γ, etc. For example, where R¹O— is MeO— and L is —(CH₂)₂—N(Me)-CO— attached to the ring atom X, R¹O— is considered to be directly attached to L at the 5 position as shown:

Where R¹—O-L- is or includes a cyclic group, it will be understood that the oxygen atom of R¹—O-L- may be considered to be directly attached to L at more than one β, γ, δ, or ε position. For example, in the following structure the oxygen atom may be considered to be attached at the β or the γ position:

More typically, the oxygen atom of R¹—O-L- is directly attached to L at a position β or γ relative to any ring atom W, X, Y or Z to which the group R¹—O-L- is directly attached.

Most typically, the oxygen atom of R¹—O-L- is directly attached to L at a position β relative to any ring atom W, X, Y or Z to which the group R¹—O-L- is directly attached.

In one aspect of any of the above embodiments, R¹—O-L- is substituted with a group R¹¹—, wherein R¹¹— is directly attached to an atom of R¹—O-L- that is directly attached to W, X, Y or Z, and wherein R¹— is selected from the group consisting of halo, —OH, —NH₂, —R²¹, —OR²¹, —NHR²¹ and —N(R²¹)₂, wherein each R²¹ is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group, or any two R²¹ directly attached to the same nitrogen atom may together form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group. For example, R¹—O-L- may be substituted with a group R¹¹— wherein R¹¹— is attached to L at an a position relative to any ring atom W, X, Y or Z to which the group R¹—O-L- is directly attached. More typically, R¹¹— is selected from the group consisting of fluoro, chloro, —OH, —NH₂, —OMe, —OEt, —NHMe, —NHEt, —N(Me)₂, —N(Me)Et and —N(Et)₂, wherein any methyl (Me) or ethyl (Et) group may optionally be substituted with one or more fluoro and/or chloro groups. More typically still, R¹¹— is selected from the group consisting of —OH, —OMe and —OEt, wherein any methyl (Me) or ethyl (Et) group may optionally be substituted with one or more fluoro groups. Most typically, R¹¹— is —OMe.

In one embodiment, where R¹—O-L- has the formula R¹⁰—, R¹¹ is attached to the ring atom of R¹⁰ that is directly attached to W, X, Y or Z. In such an embodiment, R¹—O-L- may have the formula:

wherein:

-   -   R¹¹ is as previously defined;     -   p is 1, 2 or 3 and q is 1, 2 or 3, provided that p+q s 4     -   r is 0, 1, 2, 3 or 4;     -   each R¹² is independently selected from —CN, —OH, —NH₂, —R²²,         —OR²², —NHR²² and —N(R²²)₂;     -   each R¹³ is independently selected from hydrogen or halo group;         and     -   each R²² is independently selected from a C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group, or         any two R²² directly attached to the same nitrogen atom may         together form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group.

As will be understood, in the above formula, each R¹² where present substitutes an R¹³ group.

More typically, p is 1 or 2 and q is 1 or 2, r is 0, 1 or 2, each R¹² is independently selected from —OH, —NH₂, -Me, -Et, —OMe, —OEt, —NHMe, —NHEt, —N(Me)₂, —N(Me)Et and —N(Et)₂, wherein any methyl (Me) or ethyl (Et) group may optionally be substituted with one or more fluoro and/or chloro groups, and each R¹³ is independently selected from hydrogen, fluoro or chloro groups.

Most typically, p is 1, q is 1 or 2, r is 0, and each R¹³ is hydrogen.

In one embodiment, R¹—O-L- is selected from the group consisting of:

In one embodiment, the group:

contains from 8 to 20 atoms other than hydrogen or halogen. More typically, the group contains from 8 to 16 atoms other than hydrogen or halogen.

As stated above, m is 0, 1, 2 or 3. More typically, m is 0, 1 or 2. Most typically, m is 0 or 1.

As will be understood, each R³— where present may be directly attached to any ring atom represented by W, X, Y or Z. Typically, each R³— where present is directly attached to X or Y. More typically, where m is 1, R¹—O-L- is directly attached to one of X or Y and R³— is directly attached to the other of X or Y.

In any of the above embodiments, each R³ may be independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —Si(R^(β))₃; —O—Si(R^(β))₃; —R^(α)—Si(R^(β))₃; —R^(α)—O—Si(R^(β))₃; —NH₂; —NHR^(β); —N(R^(β))₂; —N(O)(R^(β))₂; —N⁺(R^(β))₃; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —R^(α)—N(O)(R^(β))₂; —R^(α)—N⁺(R^(β))₃; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); —R^(α)—OCOR^(β); —C(═NH)R^(β); —C(═NH)NH₂; —C(═NH)NHR^(β); —C(═NH)N(R^(β))₂; —C(═NR^(β))R^(β); —C(═NR^(β))NHR^(β); —C(═NR^(β))N(R^(β))₂; —C(═NOH)R^(β); —C(N₂)R^(β); —R^(α)—C(═NH)R^(β); —R^(α)—C(═NH)NH₂; —R^(α)—C(═NH)NHR^(β); —R^(α)—C(═NH)N(R^(β))₂; —R^(α)—C(═NR^(β))R^(β); —R^(α)—C(═NR^(β))NHR^(β); —R^(α)—C(═NR^(β))N(R^(β))₂; —R^(α)—C(═NOH)R^(β); —R^(α)—C(N₂)R^(β); —NH—CHO; —NR^(β)—CHO; —NH—COR^(β); —NR^(β)—COR^(β); —CONH₂; —CONHR^(β); —CON(R^(β))₂; —R^(α)—NH—CHO; —R^(α)—NR^(β)—CHO; —R^(α)—NH—COR^(β); —R^(α)—NR^(β)—COR^(β); —R^(α)—CONH₂; —R^(α)—CONHR^(β); —R^(α)—CON(R^(β))₂; —O—R^(α)—OH; —O—R^(α)—OR^(β); —O—R^(α)—NH₂; —O—R^(α)—NHR^(β); —O—R^(α)—N(R^(β))₂; —O—R^(α)—N(O)(R^(β))₂; —O—R^(α)—N⁺(R^(β))₃; —NH—R^(α)—OH; —NH—R^(α)—OR^(β); —NH—R^(α)—NH₂; —NH—R^(α)—NHR^(β); —NH—R^(α)—N(R^(β))₂; —NH—R^(α)—N(O)(R^(β))₂; —NH—R^(α)—N⁺(R^(β))₃; —NR^(β)—R^(α)—OH; —NR^(β)—R^(α)—OR^(β); —NR^(β)—R^(α)—NH₂; —NR^(β)—R^(α)—NHR^(β); —NR^(β)—R^(α)—N(R^(β))₂; —NR^(β)—R^(α)—N(O)(R^(β))₂; —NR^(β)—R^(α)—N⁺(R^(β))₃; —N(O)R^(β)—R^(α)—OH; —N(O)R^(β)—R^(α)—OR^(β); —N(O)R^(β)—R^(α)—NH₂; —N(O)R^(β)—R^(α)—NHR^(β); —N(O)R^(β)—R^(α)—N(R^(β))₂; —N(O)R^(β)—R^(α)—N(O)(R^(β))₂; —N(O)R^(β)—R^(α)—N⁺(R^(β))₃; —N⁺(R^(β))₂−R^(α)—OH; —N⁺(R^(β))₂—R^(α)—OR^(β); —N⁺(R^(β))₂—R^(α)—NH₂; —N⁺(R^(β))₂R^(α)—NHR^(β); —N⁺(R^(β))₂—R^(α)—N(R^(β))₂; or —N⁺(R^(β))₂—R^(α)—N(O)(R^(β))₂;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, wherein one or         more —CH₂— groups in the backbone of the alkylene, alkenylene or         alkynylene group may optionally be replaced by one or more         —N(O)(R^(β))— or —N⁺(R^(β))₂— groups, and wherein the alkylene,         alkenylene or alkynylene group may optionally be substituted         with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, or         wherein any two or three —R^(β) attached to the same nitrogen         atom may, together with the nitrogen atom to which they are         attached, form a C₂-C₇ cyclic group, and wherein any —R^(β) may         optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄         haloalkyl, C₃-C₇ cycloalkyl, C₃-C₇ halocycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), —O(C₃-C₇         halocycloalkyl), —CO(C₁-C₄ alkyl), —CO(C₁-C₄ haloalkyl),         —COO(C₁-C₄ alkyl), —COO(C₁-C₄ haloalkyl), halo, —OH, —NH₂, —CN,         —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic group.

In one embodiment, each R³ is independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); —R^(α)—OCOR^(β); —NH—CHO; —NR^(β)—CHO; —NH—COR^(β); —NR^(β)—COR^(β); —CONH₂; —CONHR^(β); —CON(R^(β))₂; —R^(α)—NH—CHO; —R^(α)—NR^(β)—CHO; —R^(α)—NH—COR^(β); —R^(α)—NR^(β)—COR^(β); —R^(α)—CONH₂; —R^(α)—CONHR^(β); —R^(α)—CON(R^(β))₂; —O—R^(α)—OH; —O—R^(α)—OR^(β); —O—R^(α)—NH₂; —O—R^(α)—NHR^(β); —O—R^(α)—N(R^(β))₂; —NH—R^(α)—OH; —NH—R^(α)—OR^(β); —NH—R^(α)—NH₂; —NH—R^(α)—NHR^(β); —NH—R^(α)—N(R^(β))₂; —NR^(β)—R^(α)—OH; —NR^(β)—R^(α)—OR^(β); —NR^(β)—R^(α)—NH₂; —NR^(β)—R^(α)—NHR^(β); or —NR^(β)—R^(α)—N(R^(β))₂;

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and     -   wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH,         —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic         group.

In another embodiment, each R³ is independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β);

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and         wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄         alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH,         —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic         group.

Alternatively, each R³ may be independently selected from halo; —CN; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β);

-   -   wherein each —R^(α)— is independently selected from an alkylene,         alkenylene or alkynylene group, wherein the alkylene, alkenylene         or alkynylene group contains from 1 to 6 atoms in its backbone,         wherein one or more carbon atoms in the backbone of the         alkylene, alkenylene or alkynylene group may optionally be         replaced by one or more heteroatoms N, O or S, and wherein the         alkylene, alkenylene or alkynylene group may optionally be         substituted with one or more halo and/or —R^(β) groups; and         wherein each —R^(β) is independently selected from a C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and         wherein any —R^(β) may optionally be substituted with one or         more C₁-C₄ alkyl, halo, —OH, or 4- to 6-membered heterocyclic         group.

In one embodiment, each R³ is monovalent. Alternatively or in addition, any R³, and any two adjacent W, X, Y or Z, may together form a 3- to 12-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted. Thus, it will be understood that in such an embodiment the group —R³— forms a divalent bridging substituent between two adjacent W, X, Y and Z. In such an embodiment, part or all of R³ may form the fused cyclic group. Typically in such an embodiment, —R³— and any two adjacent W, X, Y or Z together form a 4- to 7-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted, such that the ring A and the fused cyclic group together form a fused bicyclic group.

In one embodiment, each R³ is independently a halo, —OH, —NO₂, —NH₂, —N₃, —SH, —SO₂H, —SO₂NH₂, or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton.

More typically, each R³ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, wherein any C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group may optionally be substituted with one or more halo groups. More typically still, each R³ is independently selected from a C₁-C₄ alkyl or C₃-C₄ cycloalkyl group, wherein any C₁-C₄ alkyl or C₃-C₄ cycloalkyl group may optionally be substituted with one or more fluoro and/or chloro groups. Most typically each R³ is independently selected from a methyl, ethyl, isopropyl, cyclopropyl or t-butyl group.

In one aspect of any of the above embodiments, each R³ contains from 1 to 12 atoms other than hydrogen or halogen. More typically, each R³ contains from 1 to 6 atoms other than hydrogen or halogen. More typically still, each R³ contains from 1 to 4 atoms other than hydrogen or halogen. Most typically, each R³ contains from 1 to 3 atoms other than hydrogen or halogen.

R² is a cyclic group substituted at the α-position, wherein R² may optionally be further substituted. For the avoidance of doubt, it is noted that it is a ring atom of the cyclic group of R² that is directly attached to the nitrogen atom of the urea or thiourea group, not any substituent.

In one embodiment of the first aspect of the invention, R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α-position, and wherein R² may optionally be further substituted. Typically, R² is a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the heteroaryl group is substituted at the α-position, and wherein R² may optionally be further substituted. Typically, R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α and α′ positions, and wherein R² may optionally be further substituted. Typically, R² is a phenyl or a 5- or 6-membered heteroaryl group, wherein the phenyl or the heteroaryl group is substituted at the α and α′ positions, and wherein R² may optionally be further substituted. For example, R² may be a phenyl group substituted at the 2- and 6-positions or a phenyl group substituted at the 2-, 4- and 6-positions.

In one embodiment, the parent phenyl or 5- or 6-membered heteroaryl group of R² may be selected from phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl or oxadiazolyl. Typically, the parent phenyl or 5- or 6-membered heteroaryl group of R² may be selected from phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl or triazolyl. Typically, the parent phenyl or 5- or 6-membered heteroaryl group of R² may be selected from phenyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazolyl.

As used herein, the nomenclature α, β, α′, β′ in relation to R² refers to the position of the atoms of the cyclic group, relative to the point of attachment of the cyclic group to the remainder of the molecule. For example, where —R² is a 1,2,3,5,6,7-hexahydro-s-indacen-4-yl moiety, the α, β, α′ and β′ positions are as follows:

For the avoidance of doubt, where it is stated that a cyclic group, such as an aryl or a heteroaryl group, is substituted at the α and/or α′ positions, it is to be understood that one or more hydrogen atoms at the α and/or α′ positions respectively are replaced by one or more substituents, such as any optional substituent as defined above. Unless stated otherwise, the term “substituted” does not include the replacement of one or more ring carbon atoms by one or more ring heteroatoms.

In another embodiment, R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted. For example, R² may be a cycloalkyl, cycloalkenyl or non-aromatic heterocyclic group substituted at the α and α′ positions.

In any of the above embodiments, typical substituents at the α and/or α′ positions of the parent cyclic group of R² comprise a carbon atom. For example, typical substituents at the α and/or α′ positions may be independently selected from —R⁴, —OR⁴ and —COR⁴ groups, wherein each R⁴ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein each R⁴ is optionally further substituted with one or more halo groups. More typically, the substituents at the α and/or α′ positions are independently selected from alkyl and cycloalkyl groups, such as C₃-C₆ branched alkyl and C₃-C₆ cycloalkyl groups, e.g. isopropyl, cyclopropyl, cyclohexyl or t-butyl groups, wherein the alkyl and cycloalkyl groups are optionally further substituted with one or more fluoro and/or chloro groups.

In one aspect of any of the above embodiments, each substituent at the α and α′ positions comprises a carbon atom.

Other typical substituents at the α and/or α′ positions of the parent cyclic group of R² may include cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings which are fused to the parent cyclic group across the α,β and/or α′,β′ positions respectively. Such fused cyclic groups are described in greater detail below.

In one embodiment, R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl group is fused to one or more cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings, wherein R² may optionally be further substituted. Typically, a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α,β positions. Typically, the aryl or heteroaryl group is also substituted at the α′ position, for example with a substituent selected from —R⁴, —OR⁴ and —COR⁴, wherein each R⁴ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein each R⁴ is optionally further substituted with one or more halo groups. Typically in such an embodiment, R² is bicyclic or tricyclic.

More typically, R² is a fused phenyl or a fused 5- or 6-membered heteroaryl group, wherein the phenyl or the 5- or 6-membered heteroaryl group is fused to one or more cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings, wherein R² may optionally be further substituted. Typically, a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the phenyl or the 5- or 6-membered heteroaryl group across the α,β positions so as to form a 4- to 6-membered fused ring structure. Typically, the phenyl or the 5- or 6-membered heteroaryl group is also substituted at the α′ position, for example with a substituent selected from —R⁴, —OR⁴ and —COR⁴, wherein each R⁴ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein each R⁴ is optionally further substituted with one or more halo groups. Typically in such an embodiment, R² is bicyclic or tricyclic.

In another embodiment, R² is a fused aryl or a fused heteroaryl group, wherein the aryl or heteroaryl group is fused to two or more independently selected cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings, wherein R² may optionally be further substituted. Typically, the two or more cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings are each ortho-fused to the aryl or heteroaryl group, i.e. each fused cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring has only two atoms and one bond in common with the aryl or heteroaryl group. Typically, R² is tricyclic.

In yet another embodiment, R² is a fused aryl or a fused heteroaryl group, wherein a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α,β positions and a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α′,β′ positions, wherein R² may optionally be further substituted. Typically in such an embodiment, R² is tricyclic.

More typically, R² is a fused phenyl or a fused 5- or 6-membered heteroaryl group, wherein a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the phenyl or the 5- or 6-membered heteroaryl group across the α,β positions so as to form a first 4- to 6-membered fused ring structure, and a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the phenyl or the 5- or 6-membered heteroaryl group across the α′,β′ positions so as to form a second 4- to 6-membered fused ring structure, wherein R² may optionally be further substituted. Typically in such an embodiment, R² is tricyclic.

In one embodiment, —R² has a formula selected from:

wherein:

-   -   A¹ and A² are each independently selected from an optionally         substituted alkylene or alkenylene group, wherein one or more         carbon atoms in the backbone of the alkylene or alkenylene group         may optionally be replaced by one or more heteroatoms N, O or S;     -   each R^(a) is independently selected from —R^(aa), —OR^(aa) or         —COR^(aa);     -   each R^(b) is independently selected from hydrogen, halo, —NO₂,         —CN, —R^(aa), —OR^(aa) or —COR^(aa);     -   provided that any R^(a) or R^(b) that is directly attached to a         ring nitrogen atom is not halo, —NO₂, —CN, or —OR^(aa);     -   each R^(c) is independently selected from hydrogen, halo, —OH,         —NO₂, —CN, —R^(cc), —OR^(cc), —COR^(cc), —COOR^(cc), —CONH₂,         —CONHR^(cc) or —CON(R^(cc))₂;     -   each R^(aa) is independently selected from a C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl or a 3- to 7-membered cyclic group,         wherein each R^(aa) is optionally substituted; and     -   each R^(cc) is independently selected from a C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl or a 3- to 7-membered cyclic group, or         any two R^(c) attached to the same nitrogen atom may, together         with the nitrogen atom to which they are attached, form a 3- to         7-membered heterocyclic group, wherein each R is optionally         substituted.

Typically, any ring containing A¹ or A² is a 5- or 6-membered ring. Typically, A¹ and A² are each independently selected from an optionally substituted straight-chained alkylene group or an optionally substituted straight-chained alkenylene group, wherein one or two carbon atoms in the backbone of the alkylene or alkenylene group may optionally be replaced by one or two heteroatoms independently selected from nitrogen and oxygen. More typically, A¹ and A² are each independently selected from an optionally substituted straight-chained alkylene group, wherein one carbon atom in the backbone of the alkylene group may optionally be replaced by an oxygen atom. Typically, no heteroatom in A¹ or A² is directly attached to another ring heteroatom. Typically, A¹ and A² are unsubstituted or substituted with one or more substituents independently selected from halo, —OH, —CN, —NO₂, C₁-C₄ alkyl, C₁-C₄ haloalkyl, —O(C₁-C₄ alkyl) or —O(C₁-C₄ haloalkyl). More typically, A¹ and A² are unsubstituted or substituted with one or more fluoro and/or chloro groups. Where R² contains both A and A² groups, A¹ and A² may be the same or different. Typically, A¹ and A² are the same.

Where R^(aa) is a substituted C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group, typically the C₁-C₆ alkyl, C₂-C₆ alkenyl or C₂-C₆ alkynyl group is substituted with one or more (e.g. one or two) substituents independently selected from halo, —OH, —CN, —NO₂, —O(C₁-C₄ alkyl) or —O(C₁-C₄ haloalkyl).

Where R^(aa) is a substituted 3- to 7-membered cyclic group, typically the 3- to 7-membered cyclic group is substituted with one or more (e.g. one or two) substituents independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B¹, —OB¹, —NHB¹, —N(B)₂, —CONH₂, —CONHB¹, —CON(B¹)₂, —NHCOB¹, —NB¹COB¹, or —B¹¹—;

-   -   wherein each B¹ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B¹ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B¹ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB¹², —NHB¹² or         —N(B¹²)₂;     -   wherein each B¹¹ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB¹², —NHB¹² or         —N(B¹²)₂; and     -   wherein each B¹² is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group. Typically, any divalent group —B¹¹— forms         a 4- to 6-membered fused ring.

Typically, each R^(a) is —R^(aa). More typically, each R^(a) is independently selected from a C₁-C₆ alkyl (in particular C₃-C₆ branched alkyl) or C₃-C₆ cycloalkyl group, wherein each R^(a) is optionally further substituted with one or more halo groups. More typically, each R^(a) is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group. Where a group R^(a) is present at both the α- and α′-positions, each R^(a) may be the same or different. Typically, each R^(a) is the same.

Typically, each R^(b) is independently selected from hydrogen or halo. More typically, each R^(b) is hydrogen.

Typically, each R^(c) is independently selected from hydrogen, halo, —OH, —NO₂, —CN, —R^(cc) or —OR^(cc). More typically, each R^(c) is independently selected from hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl. Most typically, each R is independently selected from hydrogen or halo.

Typically, each R^(cc) is independently selected from a C₁-C₄ alkyl or C₃-C₆ cycloalkyl group, or any two R^(cc) attached to the same nitrogen atom may, together with the nitrogen atom to which they are attached, form a 3- to 6-membered saturated heterocyclic group, wherein each R^(cc) is optionally substituted. Where R^(cc) is substituted, typically R^(cc) is substituted with one or more halo, —OH, —CN, —NO₂, —O(C₁-C₄ alkyl) or —O(C₁-C₄ haloalkyl) groups. More typically, each R^(cc) is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group.

In one embodiment, —R² has a formula selected from:

wherein R⁵ and R⁶ are independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl, and R^(d) is hydrogen, halo, —OH, —NO₂, —CN, —R^(dd), —OR^(dd), —COR^(dd), —COOR^(dd), —CONH₂, —CONHR^(dd) or —CON(R^(dd))₂, wherein each —R^(dd) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. Typically, R⁵ and R⁶ are independently selected from C₁-C₄ alkyl, and R^(d) is hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl. More typically, R⁵ and R⁶ are independently selected from C₁-C₄ alkyl, and R^(d) is hydrogen or halo. In one aspect of such an embodiment, R⁵ and R⁶ are independently selected from C₁-C₄ alkyl, and R^(d) is halo.

Typically, —R² has a formula selected from:

In one embodiment, —R² has a formula selected from:

wherein A¹ and A² are each independently selected from an optionally substituted alkylene or alkenylene group, wherein one or more carbon atoms in the backbone of the alkylene or alkenylene group may optionally be replaced by one or more heteroatoms N, O or S, and wherein R^(e) is hydrogen or any optional substituent. R^(e) and any optional substituent attached to A¹ or A² may together with the atoms to which they are attached form a further fused cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which may itself be optionally substituted. Similarly, any optional substituent attached to A¹ and any optional substituent attached to A² may also together with the atoms to which they are attached form a further fused cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which may itself be optionally substituted.

In one embodiment, R^(e) is hydrogen, halo, —OH, —NO₂, —CN, —R^(ee), —OR^(ee), —COR^(ee), —COOR^(ee), —CONH₂, —CONHR^(ee) or —CON(R^(ee))₂, wherein each —R^(ee) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. Typically, R^(e) is hydrogen or a halo, hydroxyl, —CN, —NO₂, —R^(ee) or —OR^(ee) group, wherein R^(ee) is a C₁-C₄ alkyl group which may optionally be halo-substituted. More typically, R^(e) is hydrogen or a halo, hydroxyl, —CN, —R^(ee) or —OR^(ee) group, wherein R^(ee) is a C₁-C₄ alkyl group which may optionally be halo-substituted. More typically, R^(e) is hydrogen or halo.

Typically, any ring containing A¹ or A² is a 5- or 6-membered ring.

Typically, A¹ and A² are each independently selected from an optionally substituted straight-chained alkylene group or an optionally substituted straight-chained alkenylene group, wherein one or two carbon atoms in the backbone of the alkylene or alkenylene group may optionally be replaced by one or two heteroatoms independently selected from nitrogen and oxygen. More typically, A¹ and A² are each independently selected from an optionally substituted straight-chained alkylene group, wherein one carbon atom in the backbone of the alkylene group may optionally be replaced by an oxygen atom. Typically, no heteroatom in A¹ or A² is directly attached to another ring heteroatom. Typically, A¹ and A² are unsubstituted or substituted with one or more halo, hydroxyl, —CN, —NO₂, —B³ or —OB³ groups, wherein B³ is a C₁-C₄ alkyl group which may optionally be halo-substituted. More typically, A¹ and A² are unsubstituted or substituted with one or more halo, hydroxyl, —CN, —B³ or —OB³ groups, wherein B³ is a C₁-C₄ alkyl group which may optionally be halo-substituted. More typically, A¹ and A² are unsubstituted or substituted with one or more fluoro and/or chloro groups. Where R² contains both A¹ and A² groups, A¹ and A² may be the same or different. Typically, A¹ and A² are the same.

More typically, —R² has a formula:

wherein A¹ and A² are each independently selected from an optionally substituted straight-chained alkylene group, wherein one carbon atom in the backbone of the alkylene group may optionally be replaced by an oxygen atom, wherein any ring containing A¹ or A² is a 5- or 6-membered ring, wherein A¹ and A² are unsubstituted or substituted with one or more fluoro and/or chloro groups, and R^(e) is hydrogen or halo.

In a further embodiment, —R² has a formula selected from:

wherein R⁶ is C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl, and R^(f) is hydrogen, halo, —OH, —NO₂, —CN, —R^(ff), —OR^(ff), —COR^(ff), —COOR^(ff), —CONH₂, —CONHR^(ff) or —CON(R^(ff))₂, wherein each —R^(ff) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. Typically, R⁶ is C₁-C₄ alkyl, and R^(f) is hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl.

Typically, R⁶ is C₁-C₄ alkyl, and R^(f) is hydrogen or halo.

Typically, —R² has the formula:

More typically, —R² has the formula:

Yet other typical substituents at the α-position of the parent cyclic group of R² may include monovalent heterocyclic groups and monovalent aromatic groups, wherein a ring atom of the heterocyclic or aromatic group is directly attached via a single bond to the α-ring atom of the parent cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the parent cyclic group may optionally be further substituted. Such R² groups are described in greater detail below.

In one embodiment, the α-substituted parent cyclic group of R² is a 5- or 6-membered cyclic group, wherein the cyclic group may optionally be further substituted. In one embodiment, the α-substituted parent cyclic group of R² is an aryl or a heteroaryl group, all of which may optionally be further substituted. In one embodiment, the α-substituted parent cyclic group of R² is a phenyl or a 5- or 6-membered heteroaryl group, all of which may optionally be further substituted. In one embodiment, the α-substituted parent cyclic group of R² is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl or oxadiazolyl group, all of which may optionally be further substituted. In one embodiment, the α-substituted parent cyclic group of R² is a phenyl or pyrazolyl group, both of which may optionally be further substituted. In a further embodiment, the α-substituted parent cyclic group of R² is a phenyl group, which may optionally be further substituted.

In one embodiment, the α-substituted parent cyclic group of R² is substituted at the α and α′ positions, and may optionally be further substituted. For example, the α-substituted parent cyclic group of R² may be a phenyl group substituted at the 2- and 6-positions or a phenyl group substituted at the 2-, 4- and 6-positions.

In one embodiment, R² is a parent cyclic group substituted at the α-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the parent cyclic group may optionally be further substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl or a 5- or 6-membered heterocyclic group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, 1,3-dioxolanyl, 1,2-oxathiolanyl, 1,3-oxathiolanyl, piperidinyl, tetrahydropyranyl, piperazinyl, 1,4-dioxanyl, thianyl, morpholinyl, thiomorpholinyl or 1-methyl-2-oxo-1,2-dihydropyridinyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, azetinyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, pyrazolidinyl, imidazolidinyl, 1,3-dioxolanyl, 1,2-oxathiolanyl, 1,3-oxathiolanyl, piperidinyl, tetrahydropyranyl, thianyl, piperazinyl, 1,4-dioxanyl, morpholinyl or thiomorpholinyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, pyrrolyl, furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, piperidinyl or tetrahydropyranyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, tetrahydropyranyl or 1-methyl-2-oxo-1,2-dihydropyridinyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, isoxazolyl, thiazolyl or tetrahydropyranyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyrimidinyl or pyrazolyl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is an unsubstituted phenyl, pyridinyl, pyrimidinyl or pyrazolyl group. In one embodiment, the monovalent heterocyclic group at the α-position is a pyridin-2-yl, pyridin-3-yl or pyridin-4-yl group, all of which may optionally be substituted. In one embodiment, the monovalent heterocyclic group at the α-position is an unsubstituted pyridin-3-yl group or an optionally substituted pyridin-4-yl group.

For any of these monovalent heterocyclic or aromatic groups at the α-position mentioned in the immediately preceding paragraph, the monovalent heterocyclic or aromatic group may optionally be substituted with one or two substituents independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁴, —OB⁴, —NHB⁴, —N(B⁴)₂, —CONH₂, —CONHB⁴, —CON(B⁴)₂, —NHCOB⁴, —NB⁴COB⁴, or —B⁴⁴—;

-   -   wherein each B⁴ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁴ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁴ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁴⁵, —NHB⁴⁵ or         —N(B⁴⁵)₂;     -   wherein each B⁴⁴ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁴⁵, —NHB⁴⁵ or         —N(B⁴⁵)₂; and     -   wherein each B⁴⁵ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁴⁴— forms a 4- to 6-membered fused ring.

In one embodiment, the monovalent heterocyclic or aromatic group at the α-position is a phenyl, pyridinyl, pyrimidinyl or pyrazolyl group, all of which may optionally be substituted with one or two substituents independently selected from halo, —OH, —NH₂, —CN, —B⁴, —OB⁴, —NHB⁴ or —N(B⁴)₂, wherein each B⁴ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted. In one embodiment, the monovalent heterocyclic group at the α-position is a pyridin-2-yl, pyridin-3-yl or pyridin-4-yl group, all of which may optionally be substituted with one or two substituents independently selected from halo, —OH, —NH₂, —CN, —B⁴, —OB⁴, —NHB⁴ or —N(B⁴)₂, wherein each B⁴ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted. In one embodiment, the monovalent heterocyclic group at the α-position is an unsubstituted pyridin-3-yl group or a pyridin-4-yl group optionally substituted with one or two substituents independently selected from halo, —OH, —NH₂, —CN, —B⁴, —OB⁴, —NHB⁴ or —N(B⁴)₂, wherein each B⁴ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

In one embodiment, R² is a parent cyclic group substituted at the α-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the parent cyclic group may optionally be further substituted. In one embodiment, such further substituents are in the α′ position of the α-substituted parent cyclic group of R². Such further substituents may be independently selected from halo, —R⁶, —OR⁶ or —COR⁶ groups, wherein each R⁶ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein each R⁶ is optionally further substituted with one or more halo groups. Typically, such further substituents on the α-substituted parent cyclic group of R² are independently selected from halo, C₁-C₆ alkyl (in particular C₃-C₆ branched alkyl) or C₃-C₆ cycloalkyl groups, e.g. fluoro, chloro, isopropyl, cyclopropyl, cyclohexyl or t-butyl groups, wherein the alkyl and cycloalkyl groups are optionally further substituted with one or more fluoro and/or chloro groups.

In one embodiment, —R² has a formula selected from:

wherein R⁷ is C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₆ cycloalkyl or C₃-C₆ halocycloalkyl, R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group, and R^(g) is hydrogen, halo, —OH, —NO₂, —CN, —R^(gg), —OR^(gg), —COR^(gg), —COOR^(gg), —CONH₂, —CONHR^(gg) or —CON(R^(gg))₂, wherein each —R^(gg) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁵, —OB⁵, —NHB⁵, —N(B⁵)₂, —CONH₂, —CONHB⁵, —CON(B⁵)₂, —NHCOB⁵, —NB⁵COB⁵, or —B⁵⁵—;

-   -   wherein each B⁵⁵ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁵ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁵ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁵⁶, —NHB⁵⁶ or —N(B⁵⁶)     -   wherein each B⁵⁵ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁵⁶, —NHB⁵⁶ or         —N(B⁵⁶)₂; and     -   wherein each B⁵⁶ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁵⁵— forms a 4- to 6-membered fused ring. Typically, R⁷ is C₁-C₄ alkyl, R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group, and R^(g) is hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl. More typically, R⁷ is C₁-C₄ alkyl, R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group, and R^(g) is hydrogen or halo. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —B⁵, —OB⁵, —NHB⁵ or —N(B⁵)₂, wherein each B⁵ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

Typically, —R² has a formula selected from:

wherein R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁶, —OB⁶, —NHB⁶, —N(B⁶)₂, —CONH₂, —CONHB⁶, —CON(B⁶)₂, —NHCOB⁶, —NB⁶COB⁶, or —B⁶⁶—;

-   -   wherein each B⁶ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁶ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁶ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁶⁷, —NHB⁶⁷ or         —N(B⁶⁷)₂;     -   wherein each B⁶⁶ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁶⁷, —NHB⁶⁷ or         —N(B⁶⁷)₂; and     -   wherein each B⁶⁷ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁶⁶— forms a 4- to 6-membered fused ring. Typically, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —B⁶, —OB⁶, —NHB⁶ or —N(B⁶)₂, wherein each B⁶ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

In one embodiment, R² is a parent cyclic group substituted at the α-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the parent cyclic group may optionally be further substituted. The further substituents on the α-substituted parent cyclic group of R² also include cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings which are fused to the α-substituted parent cyclic group of R². Typically, the cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings are ortho-fused to the α-substituted parent cyclic group of R², i.e. each fused cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring has only two atoms and one bond in common with the α-substituted parent cyclic group of R². Typically, the cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl rings are ortho-fused to the α-substituted parent cyclic group of R² across the α′,β′ positions.

In one embodiment, —R² has a formula selected from:

wherein R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group, and R^(h) is hydrogen, halo, —OH, —NO₂, —CN, —R^(hh), —OR^(hh), —COR^(hh), —COOR^(hh), —CONH₂, —CONHR^(hh) or —CON(R^(hh))₂, wherein each —R^(hh) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁷, —OB⁷, —NHB⁷, —N(B⁷)₂, —CONH₂, —CONHB⁷, —CON(B⁷)₂, —NHCOB⁷, —NB⁷COB⁷, or —B⁷⁷—;

-   -   wherein each B⁷ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁷ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁷ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁷⁸, —NHB⁷⁸ or —N(B⁷⁸)     -   wherein each B⁷⁷ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁷⁸, —NHB⁷⁸ or         —N(B⁷⁸)₂; and     -   wherein each B⁷⁸ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁷⁷— forms a 4- to 6-membered fused ring. Typically, R^(h) is hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl. More typically, R^(h) is hydrogen or halo. Typically, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —B⁷, —OB⁷, —NHB⁷ or —N(B⁷)₂, wherein each B⁷ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

In one embodiment, —R² has a formula selected from:

wherein R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁸, —OB⁸, —NHB⁸, —N(B⁸)₂, —CONH₂, —CONHB⁸, —CON(B⁸)₂, —NHCOB⁸, —NB⁸COB⁸, or —B⁸⁸—;

-   -   wherein each B⁸ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁸ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁸ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁸⁹, —NHB⁸⁹ or         —N(B⁸⁹)₂;     -   wherein each B⁸⁸ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁸⁹, —NHB⁸⁹ or         —N(B⁸⁹)₂; and     -   wherein each B⁸⁹ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁸⁸— forms a 4- to 6-membered fused ring. Typically, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —B⁸, —OB⁸, —NHB⁸ or —N(B⁸)₂, wherein each B⁸ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

Typically, —R² has a formula selected from:

wherein R⁸ is a 5- or 6-membered, optionally substituted heterocyclic or aromatic group, and R^(i) is hydrogen, halo, —OH, —NO₂, —CN, —R^(ii), —OR^(ii), —COR^(ii), —COOR^(ii), —CONH₂, —CONHR^(ii) or —CON(R^(ii))₂, wherein each —R^(ii) is independently selected from C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl and C₃-C₄ halocycloalkyl. In one embodiment, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —NO₂, —B⁹, —OB⁹, —NHB⁹, —N(B⁹)₂, —CONH₂, —CONHB⁹, —CON(B⁹)₂, —NHCOB⁹, —NB⁹COB⁹, or —B⁹⁹—;

-   -   wherein each B⁹ is independently selected from a C₁-C₄ alkyl,         C₂-C₄ alkenyl, C₂-C₄ alkynyl, C₃-C₆ cycloalkyl or phenyl group,         or a 4- to 6-membered heterocyclic group containing one or two         ring heteroatoms N and/or O, or two B⁹ together with the         nitrogen atom to which they are attached may form a 4- to         6-membered heterocyclic group containing one or two ring         heteroatoms N and/or O, wherein any B⁹ may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁹⁸, —NHB⁹⁸ or —N(B⁹⁸)     -   wherein each B⁹⁹ is independently selected from a C₁-C₈ alkylene         or C₂-C₈ alkenylene group, wherein one or two carbon atoms in         the backbone of the alkylene or alkenylene group may optionally         be replaced by one or two heteroatoms N and/or O, and wherein         the alkylene or alkenylene group may optionally be         halo-substituted and/or substituted with one or two substituents         independently selected from —OH, —NH₂, —OB⁹⁸, —NHB⁹⁸ or         —N(B⁹⁸)₂; and     -   wherein each B⁹⁸ is independently selected from a C₁-C₃ alkyl or         C₁-C₃ haloalkyl group.

Typically, any divalent group —B⁹⁹— forms a 4- to 6-membered fused ring. Typically, R^(i) is hydrogen, halo, —CN, C₁-C₃ alkyl, C₁-C₃ haloalkyl, cyclopropyl or halocyclopropyl. More typically, R^(i) is hydrogen or halo. Typically, the optional substituents on the heterocyclic or aromatic group are independently selected from halo, —OH, —NH₂, —CN, —B⁹, —OB⁹, —NHB⁹ or —N(B⁹)₂, wherein each B⁹ is independently selected from a C₁-C₄ alkyl, C₂-C₄ alkenyl or C₂-C₄ alkynyl group all of which may optionally be halo-substituted.

In one embodiment, R² is a phenyl or a 5- or 6-membered heteroaryl group (such as phenyl, pyridinyl, pyridazinyl, pyrimidinyl or pyrazinyl); wherein

-   -   (i) the phenyl or 5- or 6-membered heteroaryl group is         substituted at the α position with a substituent selected from         —R⁴, —OR⁴ and —COR⁴, wherein R⁴ is selected from a C₁-C₆ alkyl,         C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein         R⁴ is optionally substituted with one or more halo groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted at the α′ position with a substituent         selected from —R⁴⁴, —OR⁴⁴ and —COR⁴⁴, wherein R⁴⁴ is selected         from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic         group and wherein R⁴⁴ is optionally substituted with one or more         halo groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted (typically with one, two or three         substituents independently selected from halo, —NO₂, —CN,         —COOR⁴⁵, —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is         independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl         group); or     -   (ii) the phenyl or 5- or 6-membered heteroaryl group is         substituted with a cycloalkyl, cycloalkenyl, non-aromatic         heterocyclic, aryl or heteroaryl ring which is fused to the         parent phenyl or 5- or 6-membered heteroaryl group across the         α,β positions and which is optionally substituted with one or         more halo groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted at the α′ position with a substituent         selected from —R⁴, —OR⁴ and —COR⁴, wherein R⁴ is selected from a         C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group         and wherein R⁴ is optionally substituted with one or more halo         groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted (typically with one or two substituents         independently selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂,         —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently         selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group); or     -   (iii) the phenyl or 5- or 6-membered heteroaryl group is         substituted with a first cycloalkyl, cycloalkenyl, non-aromatic         heterocyclic, aryl or heteroaryl ring which is fused to the         parent phenyl or 5- or 6-membered heteroaryl group across the         α,β positions and which is optionally substituted with one or         more halo groups; and     -   the phenyl or 5- or 6-membered heteroaryl group is substituted         with a second cycloalkyl, cycloalkenyl, non-aromatic         heterocyclic, aryl or heteroaryl ring which is fused to the         parent phenyl or 5- or 6-membered heteroaryl group across the         α′,β′ positions and which is optionally substituted with one or         more halo groups; and     -   optionally the phenyl group is further substituted (typically         with a substituent selected from halo, —NO₂, —CN, —COOR⁴⁵,         —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is         independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl         group); or     -   (iv) the phenyl or 5- or 6-membered heteroaryl group is         substituted at the α-position with a monovalent heterocyclic         group or a monovalent aromatic group selected from phenyl,         pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, triazolyl or         tetrahydropyranyl, wherein the monovalent heterocyclic or         aromatic group may optionally be substituted with one or two         substituents independently selected from halo, C₁-C₃ alkyl,         C₁-C₃ haloalkyl, —R⁴²—OR⁴³, —R⁴²—N(R⁴³)₂, —R⁴²—CN or         —R⁴²—C≡CR⁴³, and wherein a ring atom of the monovalent         heterocyclic or aromatic group is directly attached to the         α-ring atom of the parent phenyl or 5- or 6-membered heteroaryl         group; wherein R⁴² is independently selected from a bond or a         C₁-C₃ alkylene group; and R⁴³ is independently selected from         hydrogen or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted at the α′ position with a substituent         selected from —R⁴, —OR⁴ and —COR⁴, wherein R⁴ is selected from a         C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group         and wherein R⁴ is optionally substituted with one or more halo         groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted (typically with one, two or three         substituents independently selected from halo, —NO₂, —CN,         —COOR⁴⁵, —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is         independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl         group); or     -   (v) the phenyl or 5- or 6-membered heteroaryl group is         substituted at the α-position with a monovalent heterocyclic         group or a monovalent aromatic group selected from phenyl,         pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, triazolyl or         tetrahydropyranyl, wherein the monovalent heterocyclic or         aromatic group may optionally be substituted with one or two         substituents independently selected from halo, C₁-C₃ alkyl,         C₁-C₃ haloalkyl, —R⁴²—OR⁴³, —R⁴²—N(R⁴³)₂, —R⁴²—CN or         —R⁴²—C≡CR⁴³, and wherein a ring atom of the monovalent         heterocyclic or aromatic group is directly attached to the         α-ring atom of the parent phenyl or 5- or 6-membered heteroaryl         group; wherein R⁴² is independently selected from a bond or a         C₁-C₃ alkylene group; and R⁴³ is independently selected from         hydrogen or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted with a cycloalkyl, cycloalkenyl,         non-aromatic heterocyclic, aryl or heteroaryl ring which is         fused to the parent phenyl or 5- or 6-membered heteroaryl group         across the α′,β′ positions and which is optionally substituted         with one or more halo groups; and     -   optionally the phenyl or 5- or 6-membered heteroaryl group is         further substituted (typically with one or two substituents         independently selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂,         —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently         selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group).

In the embodiment directly above, where a group or moiety is optionally substituted with one or more halo groups, it may be substituted for example with one, two, three, four, five or six halo groups.

In one aspect of any of the above embodiments, R² contains from 10 to 50 atoms other than hydrogen. More typically, R² contains from 10 to 40 atoms other than hydrogen. More typically, R² contains from 10 to 35 atoms other than hydrogen. Most typically, R² contains from 12 to 30 atoms other than hydrogen.

In one aspect of any of the above embodiments, R² contains from 5 to 30 atoms other than hydrogen or halogen. More typically, R² contains from 8 to 25 atoms other than hydrogen or halogen. More typically, R² contains from 10 to 20 atoms other than hydrogen or halogen. Most typically, R² contains from 12 to 18 atoms other than hydrogen or halogen.

Q is selected from O or S. In one embodiment of the first aspect of the invention, Q is O.

In one aspect of any of the above embodiments, the compound of formula (I) has a molecular weight of from 250 to 2000 Da. Typically, the compound of formula (I) has a molecular weight of from 300 to 900 Da. More typically, the compound of formula (I) has a molecular weight of from 325 to 650 Da. More typically still, the compound of formula (I) has a molecular weight of from 350 to 600 Da.

In one aspect of any of the above embodiments, the compound is not:

or a tautomer thereof.

In a further aspect of any of the above embodiments, the compound is not:

or a tautomer thereof.

A second aspect of the invention provides a compound selected from the group consisting of:

A third aspect of the invention provides a pharmaceutically acceptable salt, solvate or prodrug of any compound of the first or second aspect of the invention.

The compounds of the present invention can be used both in their free base form and their acid addition salt form. For the purposes of this invention, a “salt” of a compound of the present invention includes an acid addition salt. Acid addition salts are preferably pharmaceutically acceptable, non-toxic addition salts with suitable acids, including but not limited to inorganic acids such as hydrohalogenic acids (for example, hydrofluoric, hydrochloric, hydrobromic or hydroiodic acid) or other inorganic acids (for example, nitric, perchloric, sulfuric or phosphoric acid); or organic acids such as organic carboxylic acids (for example, propionic, butyric, glycolic, lactic, mandelic, citric, acetic, benzoic, salicylic, succinic, malic or hydroxysuccinic, tartaric, fumaric, maleic, hydroxymaleic, mucic or galactaric, gluconic, pantothenic or pamoic acid), organic sulfonic acids (for example, methanesulfonic, trifluoromethanesulfonic, ethanesulfonic, 2-hydroxyethanesulfonic, benzenesulfonic, toluene-p-sulfonic, naphthalene-2-sulfonic or camphorsulfonic acid) or amino acids (for example, ornithinic, glutamic or aspartic acid). The acid addition salt may be a mono-, di-, tri- or multi-acid addition salt. A preferred salt is a hydrohalogenic, sulfuric, phosphoric or organic acid addition salt. A preferred salt is a hydrochloric acid addition salt.

Where a compound of the invention includes a quaternary ammonium group, typically the compound is used in its salt form. The counter ion to the quaternary ammonium group may be any pharmaceutically acceptable, non-toxic counter ion. Examples of suitable counter ions include the conjugate bases of the protic acids discussed above in relation to acid-addition salts.

The compounds of the present invention can also be used both, in their free acid form and their salt form. For the purposes of this invention, a “salt” of a compound of the present invention includes one formed between a protic acid functionality (such as a carboxylic acid group) of a compound of the present invention and a suitable cation. Suitable cations include, but are not limited to lithium, sodium, potassium, magnesium, calcium and ammonium. The salt may be a mono-, di-, tri- or multi-salt. Preferably the salt is a mono- or di-lithium, sodium, potassium, magnesium, calcium or ammonium salt. More preferably the salt is a mono- or di-sodium salt or a mono- or di-potassium salt.

Preferably any salt is a pharmaceutically acceptable non-toxic salt. However, in addition to pharmaceutically acceptable salts, other salts are included in the present invention, since they have potential to serve as intermediates in the purification or preparation of other, for example, pharmaceutically acceptable salts, or are useful for identification, characterisation or purification of the free acid or base.

The compounds and/or salts of the present invention may be anhydrous or in the form of a hydrate (e.g. a hemihydrate, monohydrate, dihydrate or trihydrate) or other solvate. Such other solvates may be formed with common organic solvents, including but not limited to, alcoholic solvents e.g. methanol, ethanol or isopropanol.

In some embodiments of the present invention, therapeutically inactive prodrugs are provided. Prodrugs are compounds which, when administered to a subject such as a human, are converted in whole or in part to a compound of the invention. In most embodiments, the prodrugs are pharmacologically inert chemical derivatives that can be converted in vivo to the active drug molecules to exert a therapeutic effect. Any of the compounds described herein can be administered as a prodrug to increase the activity, bioavailability, or stability of the compound or to otherwise alter the properties of the compound. Typical examples of prodrugs include compounds that have biologically labile protecting groups on a functional moiety of the active compound. Prodrugs include, but are not limited to, compounds that can be oxidized, reduced, aminated, deaminated, hydroxylated, dehydroxylated, hydrolyzed, dehydrolyzed, alkylated, dealkylated, acylated, deacylated, phosphorylated, and/or dephosphorylated to produce the active compound. The present invention also encompasses salts and solvates of such prodrugs as described above.

The compounds, salts, solvates and prodrugs of the present invention may contain at least one chiral centre. The compounds, salts, solvates and prodrugs may therefore exist in at least two isomeric forms. The present invention encompasses racemic mixtures of the compounds, salts, solvates and prodrugs of the present invention as well as enantiomerically enriched and substantially enantiomerically pure isomers. For the purposes of this invention, a “substantially enantiomerically pure” isomer of a compound comprises less than 5% of other isomers of the same compound, more typically less than 2%, and most typically less than 0.5% by weight.

The compounds, salts, solvates and prodrugs of the present invention may contain any stable isotope including, but not limited to ¹²C, ¹³C, ¹H, ²H (D), ¹⁴N, ¹⁵N, ¹⁶O, ¹⁷O, ¹⁸O, ¹⁹F and ¹²⁷I, and any radioisotope including, but not limited to ¹C, ¹⁴C, ³H (T), ¹³N, ¹⁵O, ¹⁸F, ¹²³I, ¹²⁴I, ¹²⁵I and ¹³¹I.

The compounds, salts, solvates and prodrugs of the present invention may be in any polymorphic or amorphous form.

A fourth aspect of the invention provides a pharmaceutical composition comprising a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, and a pharmaceutically acceptable excipient.

Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, “Aulton's Pharmaceutics—The Design and Manufacture of Medicines”, M. E. Aulton and K. M. G. Taylor, Churchill Livingstone Elsevier, 4^(th) Ed., 2013.

Pharmaceutically acceptable excipients including adjuvants, diluents or carriers that may be used in the pharmaceutical compositions of the invention are those conventionally employed in the field of pharmaceutical formulation, and include, but are not limited to, sugars, sugar alcohols, starches, ion exchangers, alumina, aluminium stearate, lecithin, serum proteins such as human serum albumin, buffer substances such as phosphates, glycerine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

In one embodiment, the pharmaceutical composition of the fourth aspect of the invention additionally comprises one or more further active agents.

In a further embodiment, the pharmaceutical composition of the fourth aspect of the invention may be provided as a part of a kit of parts, wherein the kit of parts comprises the pharmaceutical composition of the fourth aspect of the invention and one or more further pharmaceutical compositions, wherein the one or more further pharmaceutical compositions each comprise a pharmaceutically acceptable excipient and one or more further active agents.

A fifth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in medicine, and/or for use in the treatment or prevention of a disease, disorder or condition. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject. In one embodiment, the use comprises the co-administration of one or more further active agents.

The term “treatment” as used herein refers equally to curative therapy, and ameliorating or palliative therapy. The term includes obtaining beneficial or desired physiological results, which may or may not be established clinically. Beneficial or desired clinical results include, but are not limited to, the alleviation of symptoms, the prevention of symptoms, the diminishment of extent of disease, the stabilisation (i.e., not worsening) of a condition, the delay or slowing of progression/worsening of a condition/symptoms, the amelioration or palliation of the condition/symptoms, and remission (whether partial or total), whether detectable or undetectable. The term “palliation”, and variations thereof, as used herein, means that the extent and/or undesirable manifestations of a physiological condition or symptom are lessened and/or time course of the progression is slowed or lengthened, as compared to not administering a compound, salt, solvate, prodrug or pharmaceutical composition of the present invention. The term “prevention” as used herein in relation to a disease, disorder or condition, relates to prophylactic or preventative therapy, as well as therapy to reduce the risk of developing the disease, disorder or condition. The term “prevention” includes both the avoidance of occurrence of the disease, disorder or condition, and the delay in onset of the disease, disorder or condition. Any statistically significant (p≤0.05) avoidance of occurrence, delay in onset or reduction in risk as measured by a controlled clinical trial may be deemed a prevention of the disease, disorder or condition. Subjects amenable to prevention include those at heightened risk of a disease, disorder or condition as identified by genetic or biochemical markers. Typically, the genetic or biochemical markers are appropriate to the disease, disorder or condition under consideration and may include for example, inflammatory biomarkers such as C-reactive protein (CRP) and monocyte chemoattractant protein 1 (MCP-1) in the case of inflammation; total cholesterol, triglycerides, insulin resistance and C-peptide in the case of NAFLD and NASH; and more generally IL1β and IL18 in the case of a disease, disorder or condition responsive to NLRP3 inhibition.

A sixth aspect of the invention provides the use of a compound of the first or second aspect, or a pharmaceutically effective salt, solvate or prodrug of the third aspect, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject. In one embodiment, the treatment or prevention comprises the co-administration of one or more further active agents.

A seventh aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the step of administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to thereby treat or prevent the disease, disorder or condition. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

An eighth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic non-silent mutation in NLRP3. The mutation may be, for example, a gain-of-function or other mutation resulting in increased NLRP3 activity. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to the individual. In one embodiment, the use comprises the co-administration of one or more further active agents. The use may also comprise the diagnosis of an individual having a germline or somatic non-silent mutation in NLRP3, wherein the compound, salt, solvate, prodrug or pharmaceutical composition is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in NLRP3 in the individual may be by any suitable genetic or biochemical means.

A ninth aspect of the invention provides the use of a compound of the first or second aspect, or a pharmaceutically effective salt, solvate or prodrug of the third aspect, in the manufacture of a medicament for the treatment or prevention of a disease, disorder or condition in an individual, wherein the individual has a germline or somatic non-silent mutation in NLRP3. The mutation may be, for example, a gain-of-function or other mutation resulting in increased NLRP3 activity. Typically, the treatment or prevention comprises the administration of the compound, salt, solvate, prodrug or medicament to the individual. In one embodiment, the treatment or prevention comprises the co-administration of one or more further active agents. The treatment or prevention may also comprise the diagnosis of an individual having a germline or somatic non-silent mutation in NLRP3, wherein the compound, salt, solvate, prodrug or medicament is administered to an individual on the basis of a positive diagnosis for the mutation. Typically, identification of the mutation in NLRP3 in the individual may be by any suitable genetic or biochemical means.

A tenth aspect of the invention provides a method of treatment or prevention of a disease, disorder or condition, the method comprising the steps of diagnosing of an individual having a germline or somatic non-silent mutation in NLRP3, and administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to the positively diagnosed individual, to thereby treat or prevent the disease, disorder or condition. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

In general embodiments, the disease, disorder or condition may be a disease, disorder or condition of the immune system, the cardiovascular system, the endocrine system, the gastrointestinal tract, the renal system, the hepatic system, the metabolic system, the respiratory system, the central nervous system, may be a cancer or other malignancy, and/or may be caused by or associated with a pathogen.

It will be appreciated that these general embodiments defined according to broad categories of diseases, disorders and conditions are not mutually exclusive. In this regard any particular disease, disorder or condition may be categorized according to more than one of the above general embodiments. A non-limiting example is type I diabetes which is an autoimmune disease and a disease of the endocrine system.

In one embodiment of the fifth, sixth, seventh, eighth, ninth or tenth aspect of the invention, the disease, disorder or condition is responsive to NLRP3 inhibition. As used herein, the term “NLRP3 inhibition” refers to the complete or partial reduction in the level of activity of NLRP3 and includes, for example, the inhibition of active NLRP3 and/or the inhibition of activation of NLRP3.

There is evidence for a role of NLRP3-induced IL-1 and IL-18 in the inflammatory responses occurring in connection with, or as a result of, a multitude of different disorders (Menu et al., Clinical and Experimental Immunology, 166: 1-15, 2011; Strowig et al., Nature, 481:278-286, 2012).

NLRP3 has been implicated in a number of autoinflammatory diseases, including Familial Mediterranean fever (FMF), TNF receptor associated periodic syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), pyogenic arthritis, pyoderma gangrenosum and acne (PAPA), Sweet's syndrome, chronic nonbacterial osteomyelitis (CNO), and acne vulgaris (Cook et al., Eur. J. Immunol., 40: 595-653, 2010). In particular, NLRP3 mutations have been found to be responsible for a set of rare autoinflammatory diseases known as CAPS (Ozaki et al., J. Inflammation Research, 8:15-27, 2015; Schroder et al., Cell, 140: 821-832, 2010; and Menu et al., Clinical and Experimental Immunology, 166: 1-15, 2011). CAPS are heritable diseases characterized by recurrent fever and inflammation and are comprised of three autoinflammatory disorders that form a clinical continuum. These diseases, in order of increasing severity, are familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile cutaneous neurological articular syndrome (CINCA; also called neonatal-onset multisystem inflammatory disease, NOMID), and all have been shown to result from gain-of-function mutations in the NLRP3 gene, which leads to increased secretion of IL-1β.

A number of autoimmune diseases have been shown to involve NLRP3 including, in particular, multiple sclerosis, type-1 diabetes (T1D), psoriasis, rheumatoid arthritis (RA), Behcet's disease, Schnitzler syndrome, macrophage activation syndrome (Masters Clin. Immunol. 2013; Braddock et al. Nat. Rev. Drug Disc. 2004 3: 1-10; Inoue et al., Immunology 139: 11-18, Coll et al. Nat. Med. 2015 21(3):248-55; and Scott et al. Clin. Exp. Rheumatol 2016 34(1): 88-93), systemic lupus erythematosus (Lu et al. J Immunol. 2017198(3): 1119-29), and systemic sclerosis (Artlett et al. Arthritis Rheum. 2011; 63(11): 3563-74). NLRP3 has also been shown to play a role in a number of lung diseases including chronic obstructive pulmonary disorder (COPD), asthma (including steroid-resistant asthma), asbestosis, and silicosis (De Nardo et al., Am. J. Pathol., 184: 42-54, 2014 and Kim et al. Am J Respir Crit Care Med. 2017196(3): 283-97). NLRP3 has also been suggested to have a role in a number of central nervous system conditions, including Parkinson's disease (PD), Alzheimer's disease (AD), dementia, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis (Walsh et al., Nature Reviews, 15: 84-97, 2014, and Dempsey et al. Brain. Behav. Immun. 2017 61: 306-316), intracranial aneurysms (Zhang et al. J. Stroke & Cerebrovascular Dis. 2015 24; 5: 972-979), and traumatic brain injury (Ismael et al. J Neurotrauma. 2018 Jan. 2). NRLP3 activity has also been shown to be involved in various metabolic diseases including type 2 diabetes (T2D), atherosclerosis, obesity, gout, pseudo-gout, metabolic syndrome (Wen et al., Nature Immunology, 13: 352-357, 2012; Duewell et al., Nature, 464: 1357-1361, 2010; Strowig et al., Nature, 481: 278-286, 2012), and non-alcoholic steatohepatitis (Mridha et al. J Hepatol. 2017 66(5): 1037-46). A role for NLRP3 via IL-1β has also been suggested in atherosclerosis, myocardial infarction (van Hout et al. Eur. Heart J. 2017 38(11): 828-36), heart failure (Sano et al. J AM. Coll. Cardiol. 2018 71(8): 875-66), aortic aneurysm and dissection (Wu et al. Arterioscler. Thromb. Vasc. Biol. 2017 37(4): 694-706), and other cardiovascular events (Ridker et al., N Engl J Med., doi: 10.1056/NEJMoa1707914, 2017). Other diseases in which NLRP3 has been shown to be involved include: ocular diseases such as both wet and dry age-related macular degeneration (Doyle et al., Nature Medicine, 18: 791-798, 2012 and Tarallo et al. Cell 2012149(4): 847-59), diabetic retinopathy (Loukovaara et al. Acta Ophthalmol. 2017; 95(8): 803-808) and optic nerve damage (Puyang et al. Sci Rep. 2016 Feb. 19; 6:20998); liver diseases including non-alcoholic steatohepatitis (NASH) (Henao-Meija et al., Nature, 482: 179-185, 2012); inflammatory reactions in the lung and skin (Primiano et al. J Immunol. 2016 197(6): 2421-33) including contact hypersensitivity (such as bullous pemphigoid (Fang et al. J Dermatol Sci. 2016; 83(2): 116-23)), atopic dermatitis (Niebuhr et al. Allergy 2014 69(8): 1058-67), Hidradenitis suppurativa (Alikhan et al. 2009 J Am Acad Dermatol 60(4): 539-61), acne vulgaris (Qin et al. J Invest. Dermatol. 2014 134(2): 381-88), and sarcoidosis (Jager et al. Am J Respir Crit Care Med 2015 191: A5816); inflammatory reactions in the joints (Braddock et al., Nat. Rev. Drug Disc., 3: 1-10, 2004); amyotrophic lateral sclerosis (Gugliandolo et al. Inflammation 2018 41(1): 93-103); cystic fibrosis (Iannitti et al. Nat. Commun. 2016 7: 10791); stroke (Walsh et al., Nature Reviews, 15: 84-97, 2014); chronic kidney disease (Granata et al. PLoS One 2015 10(3): eo122272); and inflammatory bowel diseases including ulcerative colitis and Crohn's disease (Braddock et al., Nat. Rev. Drug Disc., 3: 1-10, 2004, Neudecker et al. J Exp. Med. 2017 214(6): 1737-52, and Lazaridis et al. Dig. Dis. Sci. 2017 62(9): 2348-56). The NLRP3 inflammasome has been found to be activated in response to oxidative stress, and UVB irradiation (Schroder et al., Science, 327: 296-300, 2010).

NLRP3 has also been shown to be involved in inflammatory hyperalgesia (Dolunay et al., Inflammation, 40: 366-386, 2017).

The inflammasome, and NLRP3 specifically, has also been proposed as a target for modulation by various pathogens including viruses such as DNA viruses (Amsler et al., Future Virol. (2013) 8(4), 357-370).

NLRP3 has also been implicated in the pathogenesis of many cancers (Menu et al., Clinical and Experimental Immunology 166: 1-15, 2011; and Masters Clin. Immunol. 2013). For example, several previous studies have suggested a role for IL-1β in cancer invasiveness, growth and metastasis, and inhibition of IL-1β with canakinumab has been shown to reduce the incidence of lung cancer and total cancer mortality in a randomised, double-blind, placebo-controlled trial (Ridker et al. Lancet, So140-6736(17)32247-X, 2017). Inhibition of the NLRP3 inflammasome or IL-1β has also been shown to inhibit the proliferation and migration of lung cancer cells in vitro (Wang et al. Oncol Rep. 2016; 35(4): 2053-64). A role for the NLRP3 inflammasome has been suggested in myelodysplastic syndromes (Basiorka et al. Blood. 2016 Dec. 22; 128(25):2960-2975) and also in the carcinogenesis of various other cancers including glioma (Li et al. Am J Cancer Res. 2015; 5(1): 442-449), inflammation-induced tumours (Allen et al. J Exp Med. 2010: 207(5): 1045-56 and Hu et al. PNAS. 2010; 107(50): 21635-40), multiple myeloma (Li et al. Hematology 2016 21(3): 144-51), and squamous cell carcinoma of the head and neck (Huang et al. J Exp Clin Cancer Res. 2017 2; 36(1): 116). Activation of the NLRP3 inflammasome has also been shown to mediate chemoresistance of tumour cells to 5-Fluorouracil (Feng et al. J Exp Clin Cancer Res. 2017 21; 36(1): 81), and activation of NLRP3 inflammasome in peripheral nerve contributes to chemotherapy-induced neuropathic pain (Jia et al. Mol Pain. 2017; 13:1-11).

NLRP3 has also been shown to be required for the efficient control of viral, bacterial, fungal, and helminth pathogen infections (Strowig et al., Nature, 481:278-286, 2012).

Accordingly, examples of diseases, disorders or conditions which may be responsive to NLRP3 inhibition and which may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention include:

(i) inflammation, including inflammation occurring as a result of an inflammatory disorder, e.g. an autoinflammatory disease, inflammation occurring as a symptom of a non-inflammatory disorder, inflammation occurring as a result of infection, or inflammation secondary to trauma, injury or autoimmunity;

(ii) auto-immune diseases such as acute disseminated encephalitis, Addison's disease, ankylosing spondylitis, antiphospholipid antibody syndrome (APS), anti-synthetase syndrome, aplastic anemia, autoimmune adrenalitis, autoimmune hepatitis, autoimmune oophoritis, autoimmune polyglandular failure, autoimmune thyroiditis, Coeliac disease, Crohn's disease, type 1 diabetes (T1D), Goodpasture's syndrome, Graves' disease, Guillain-Barré syndrome (GBS), Hashimoto's disease, idiopathic thrombocytopenic purpura, Kawasaki's disease, lupus erythematosus including systemic lupus erythematosus (SLE), multiple sclerosis (MS) including primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS) and relapsing remitting multiple sclerosis (RRMS), myasthenia gravis, opsoclonus myoclonus syndrome (OMS), optic neuritis, Ord's thyroiditis, pemphigus, pernicious anaemia, polyarthritis, primary biliary cirrhosis, rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis or Still's disease, refractory gouty arthritis, Reiter's syndrome, Sjögren's syndrome, systemic sclerosis a systemic connective tissue disorder, Takayasu's arteritis, temporal arteritis, warm autoimmune hemolytic anemia, Wegener's granulomatosis, alopecia universalis, Behçet's disease, Chagas' disease, dysautonomia, endometriosis, hidradenitis suppurativa (HS), interstitial cystitis, neuromyotonia, psoriasis, sarcoidosis, scleroderma, ulcerative colitis, Schnitzler syndrome, macrophage activation syndrome, Blau syndrome, vitiligo or vulvodynia;

(iii) cancer including lung cancer, pancreatic cancer, gastric cancer, myelodysplastic syndrome, leukaemia including acute lymphocytic leukaemia (ALL) and acute myeloid leukaemia (AML), adrenal cancer, anal cancer, basal and squamous cell skin cancer, bile duct cancer, bladder cancer, bone cancer, brain and spinal cord tumours, breast cancer, cervical cancer, chronic lymphocytic leukaemia (CLL), chronic myeloid leukaemia (CML), chronic myelomonocytic leukaemia (CMML), colorectal cancer, endometrial cancer, oesophagus cancer, Ewing family of tumours, eye cancer, gallbladder cancer, gastrointestinal carcinoid tumours, gastrointestinal stromal tumour (GIST), gestational trophoblastic disease, glioma, Hodgkin lymphoma, Kaposi sarcoma, kidney cancer, laryngeal and hypopharyngeal cancer, liver cancer, lung carcinoid tumour, lymphoma including cutaneous T cell lymphoma, malignant mesothelioma, melanoma skin cancer, Merkel cell skin cancer, multiple myeloma, nasal cavity and paranasal sinuses cancer, nasopharyngeal cancer, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung cancer, oral cavity and oropharyngeal cancer, osteosarcoma, ovarian cancer, penile cancer, pituitary tumours, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, skin cancer, small cell lung cancer, small intestine cancer, soft tissue sarcoma, stomach cancer, testicular cancer, thymus cancer, thyroid cancer including anaplastic thyroid cancer, uterine sarcoma, vaginal cancer, vulvar cancer, Waldenstrom macroglobulinemia, and Wilms tumour;

(iv) infections including viral infections (e.g. from influenza virus, human immunodeficiency virus (HIV), alphavirus (such as Chikungunya and Ross River virus), flaviviruses (such as Dengue virus and Zika virus), herpes viruses (such as Epstein Barr Virus, cytomegalovirus, Varicella-zoster virus, and KSHV), poxviruses (such as vaccinia virus (Modified vaccinia virus Ankara) and Myxoma virus), adenoviruses (such as Adenovirus 5), or papillomavirus), bacterial infections (e.g. from Staphylococcus aureus, Helicobacter pylori, Bacillus anthracis, Bordatella pertussis, Burkholderia pseudomallei, Corynebacterium diptheriae, Clostridium tetani, Clostridium botulinum, Streptococcus pneumoniae, Streptococcus pyogenes, Listeria monocytogenes, Hemophilus influenzae, Pasteurella multicida, Shigella dysenteriae, Mycobacterium tuberculosis, Mycobacterium leprae, Mycoplasma pneumoniae, Mycoplasma hominis, Neisseria meningitidis, Neisseria gonorrhoeae, Rickettsia rickettsii, Legionella pneumophila, Klebsiella pneumoniae, Pseudomonas aeruginosa, Propionibacterium acnes, Treponema pallidum, Chlamydia trachomatis, Vibrio cholerae, Salmonella typhimurium, Salmonella typhi, Borrelia burgdorferi or Yersinia pestis), fungal infections (e.g. from Candida or Aspergillus species), protozoan infections (e.g. from Plasmodium, Babesia, Giardia, Entamoeba, Leishmania or Trypanosomes), helminth infections (e.g. from schistosoma, roundworms, tapeworms or flukes) and prion infections;

(v) central nervous system diseases such as Parkinson's disease, Alzheimer's disease, dementia, motor neuron disease, Huntington's disease, cerebral malaria, brain injury from pneumococcal meningitis, intracranial aneurysms, traumatic brain injury, and amyotrophic lateral sclerosis;

(vi) metabolic diseases such as type 2 diabetes (T2D), atherosclerosis, obesity, gout, and pseudo-gout;

(vii) cardiovascular diseases such as hypertension, ischaemia, reperfusion injury including post-MI ischemic reperfusion injury, stroke including ischemic stroke, transient ischemic attack, myocardial infarction including recurrent myocardial infarction, heart failure including congestive heart failure and heart failure with preserved ejection fraction, embolism, aneurysms including abdominal aortic aneurysm, and pericarditis including Dressler's syndrome;

(viii) respiratory diseases including chronic obstructive pulmonary disorder (COPD), asthma such as allergic asthma and steroid-resistant asthma, asbestosis, silicosis, nanoparticle induced inflammation, cystic fibrosis and idiopathic pulmonary fibrosis;

(ix) liver diseases including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) including advanced fibrosis stages F3 and F4, alcoholic fatty liver disease (AFLD), and alcoholic steatohepatitis (ASH);

(x) renal diseases including chronic kidney disease, oxalate nephropathy, nephrocalcinosis, glomerulonephritis, and diabetic nephropathy;

(xi) ocular diseases including those of the ocular epithelium, age-related macular degeneration (AMD) (dry and wet), uveitis, corneal infection, diabetic retinopathy, optic nerve damage, dry eye, and glaucoma;

(xii) skin diseases including dermatitis such as contact dermatitis and atopic dermatitis, contact hypersensitivity, sunburn, skin lesions, hidradenitis suppurativa (HS), other cyst-causing skin diseases, and acne conglobata;

(xiii) lymphatic conditions such as lymphangitis and Castleman's disease;

(xiv) psychological disorders such as depression and psychological stress;

(xv) graft versus host disease;

(xvi) allodynia including mechanical allodynia; and

(xvii) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.

In one embodiment, the disease, disorder or condition is selected from:

-   -   (i) inflammation;     -   (ii) an auto-immune disease;     -   (iii) cancer;     -   (iv) an infection;     -   (v) a central nervous system disease;     -   (vi) a metabolic disease;     -   (vii) a cardiovascular disease;     -   (viii) a respiratory disease;     -   (ix) a liver disease;     -   (x) a renal disease;     -   (xi) an ocular disease;     -   (xii) a skin disease;     -   (xiii) a lymphatic condition;     -   (xiv) a psychological disorder;     -   (xv) graft versus host disease; and     -   (xvi) any disease where an individual has been determined to         carry a germline or somatic non-silent mutation in NLRP3.

In another embodiment, the disease, disorder or condition is selected from:

-   -   (i) inflammation;     -   (ii) an infection;     -   (iii) a cardiovascular disease;     -   (iv) a respiratory disease;     -   (v) a liver disease;     -   (vi) a renal disease;     -   (vii) an ocular disease;     -   (viii) a skin disease;     -   (ix) a psychological disorder;     -   (x) a lymphatic condition; and/or     -   (xi) any disease, disorder or condition in which an individual         has been determined to carry a germline or somatic non-silent         mutation in NLRP3.

In a further embodiment, the disease, disorder or condition is selected from:

-   -   (i) cancer;     -   (ii) an infection;     -   (iii) a central nervous system disease;     -   (iv) a cardiovascular disease;     -   (v) a liver disease;     -   (vi) an ocular disease; or     -   (vii) a skin disease.

More typically, the disease, disorder or condition is selected from:

-   -   (i) cancer;     -   (ii) an infection;     -   (iii) a central nervous system disease; or     -   (iv) a cardiovascular disease.

In one embodiment, the disease, disorder or condition is selected from:

(i) acne conglobata; (ii) atopic dermatitis; (iii) Alzheimer's disease; (iv) amyotrophic lateral sclerosis; (v) age-related macular degeneration (AMD); (vi) anaplastic thyroid cancer; (vii) cryopyrin-associated periodic syndromes (CAPS); (viii) contact dermatitis; (ix) cystic fibrosis; (x) congestive heart failure; (xi) chronic kidney disease; (xii) Crohn's disease; (xiii) familial cold autoinflammatory syndrome (FCAS); (xiv) Huntington's disease; (xv) heart failure; (xvi) heart failure with preserved ejection fraction; (xvii) ischemic reperfusion injury; (xviii) juvenile idiopathic arthritis; (xix) myocardial infarction; (xx) macrophage activation syndrome; (xxi) myelodysplastic syndrome; (xxii) multiple myeloma; (xxiii) motor neuron disease; (xxiv) multiple sclerosis; (xxv) Muckle-Wells syndrome; (xxvi) non-alcoholic steatohepatitis (NASH); (xxvii) neonatal-onset multisystem inflammatory disease (NOMID); (xxviii) Parkinson's disease; (xxix) systemic juvenile idiopathic arthritis; (xxx) systemic lupus erythematosus; (xxxi) traumatic brain injury; (xxxii) transient ischemic attack; and (xxxiii) ulcerative colitis.

In a further typical embodiment of the invention, the disease, disorder or condition is inflammation. Examples of inflammation that may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention include inflammatory responses occurring in connection with, or as a result of:

(i) a skin condition such as contact hypersensitivity, bullous pemphigoid, sunburn, psoriasis, atopical dermatitis, contact dermatitis, allergic contact dermatitis, seborrhoetic dermatitis, lichen planus, scleroderma, pemphigus, epidermolysis bullosa, urticaria, erythemas, or alopecia; (ii) a joint condition such as osteoarthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, relapsing polychondritis, rheumatoid arthritis, juvenile chronic arthritis, gout, or a seronegative spondyloarthropathy (e.g. ankylosing spondylitis, psoriatic arthritis or Reiter's disease); (iii) a muscular condition such as polymyositis or myasthenia gravis; (iv) a gastrointestinal tract condition such as inflammatory bowel disease (including Crohn's disease and ulcerative colitis), gastric ulcer, coeliac disease, proctitis, pancreatitis, eosinopilic gastro-enteritis, mastocytosis, antiphospholipid syndrome, or a food-related allergy which may have effects remote from the gut (e.g., migraine, rhinitis or eczema); (v) a respiratory system condition such as chronic obstructive pulmonary disease (COPD), asthma (including bronchial, allergic, intrinsic, extrinsic or dust asthma, and particularly chronic or inveterate asthma, such as late asthma and airways hyper-responsiveness), bronchitis, rhinitis (including acute rhinitis, allergic rhinitis, atrophic rhinitis, chronic rhinitis, rhinitis caseosa, hypertrophic rhinitis, rhinitis pumlenta, rhinitis sicca, rhinitis medicamentosa, membranous rhinitis, seasonal rhinitis e.g. hay fever, and vasomotor rhinitis), sinusitis, idiopathic pulmonary fibrosis (IPF), sarcoidosis, farmer's lung, silicosis, asbestosis, adult respiratory distress syndrome, hypersensitivity pneumonitis, or idiopathic interstitial pneumonia; (vi) a vascular condition such as atherosclerosis, Behcet's disease, vasculitides, or wegener's granulomatosis; (vii) an autoimmune condition such as systemic lupus erythematosus, Sjogren's syndrome, systemic sclerosis, Hashimoto's thyroiditis, type I diabetes, idiopathic thrombocytopenia purpura, or Graves disease; (viii) an ocular condition such as uveitis, allergic conjunctivitis, or vernal conjunctivitis; (ix) a nervous condition such as multiple sclerosis or encephalomyelitis; (x) an infection or infection-related condition, such as Acquired Immunodeficiency Syndrome (AIDS), acute or chronic bacterial infection, acute or chronic parasitic infection, acute or chronic viral infection, acute or chronic fungal infection, meningitis, hepatitis (A, B or C, or other viral hepatitis), peritonitis, pneumonia, epiglottitis, malaria, dengue hemorrhagic fever, leishmaniasis, streptococcal myositis, Mycobacterium tuberculosis, Mycobacterium avium intracellulare, Pneumocystis carinii pneumonia, orchitis/epidydimitis, legionella, Lyme disease, influenza A, epstein-barr virus, viral encephalitis/aseptic meningitis, or pelvic inflammatory disease; (xi) a renal condition such as mesangial proliferative glomerulonephritis, nephrotic syndrome, nephritis, glomerular nephritis, acute renal failure, uremia, or nephritic syndrome; (xii) a lymphatic condition such as Castleman's disease; (xiii) a condition of, or involving, the immune system, such as hyper IgE syndrome, lepromatous leprosy, familial hemophagocytic lymphohistiocytosis, or graft versus host disease; (xiv) a hepatic condition such as chronic active hepatitis, non-alcoholic steatohepatitis (NASH), alcohol-induced hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH) or primary biliary cirrhosis; (xv) a cancer, including those cancers listed above; (xvi) a burn, wound, trauma, haemorrhage or stroke; (xvii) radiation exposure; and/or (xviii) obesity; and/or (xix) pain such as inflammatory hyperalgesia.

In one embodiment of the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention, the disease, disorder or condition is an autoinflammatory disease such as cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), familial Mediterranean fever (FMF), neonatal onset multisystem inflammatory disease (NOMID), Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), deficiency of interleukin 1 receptor antagonist (DIRA), Majeed syndrome, pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), adult-onset Still's disease (AOSD), haploinsufficiency of A20 (HA20), pediatric granulomatous arthritis (PGA), PLCG2-associated antibody deficiency and immune dysregulation (PLAID), PLCG2-associated autoinflammatory, antibody deficiency and immune dysregulation (APLAID), or sideroblastic anaemia with B-cell immunodeficiency, periodic fevers and developmental delay (SIFD).

Examples of diseases, disorders or conditions which may be responsive to NLRP3 inhibition and which may be treated or prevented in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention are listed above. Some of these diseases, disorders or conditions are substantially or entirely mediated by NLRP3 inflammasome activity, and NLRP3-induced IL-1β and/or IL-18. As a result, such diseases, disorders or conditions may be particularly responsive to NLRP3 inhibition and may be particularly suitable for treatment or prevention in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention. Examples of such diseases, disorders or conditions include cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), neonatal onset multisystem inflammatory disease (NOMID), familial Mediterranean fever (FMF), pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA), hyperimmunoglobulinemia D and periodic fever syndrome (HIDS), Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS), systemic juvenile idiopathic arthritis, adult-onset Still's disease (AOSD), relapsing polychondritis, Schnitzler's syndrome, Sweet's syndrome, Behcet's disease, anti-synthetase syndrome, deficiency of interleukin 1 receptor antagonist (DIRA), and haploinsufficiency of A20 (HA20).

Moreover, some of the diseases, disorders or conditions mentioned above arise due to mutations in NLRP3, in particular, resulting in increased NLRP3 activity. As a result, such diseases, disorders or conditions may be particularly responsive to NLRP3 inhibition and may be particularly suitable for treatment or prevention in accordance with the fifth, sixth, seventh, eighth, ninth or tenth aspect of the present invention. Examples of such diseases, disorders or conditions include cryopyrin-associated periodic syndromes (CAPS), Muckle-Wells syndrome (MWS), familial cold autoinflammatory syndrome (FCAS), and neonatal onset multisystem inflammatory disease (NOMID).

An eleventh aspect of the invention provides a method of inhibiting NLRP3, the method comprising the use of a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, to inhibit NLRP3.

In one embodiment of the eleventh aspect of the present invention, the method comprises the use of a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, in combination with one or more further active agents.

In one embodiment of the eleventh aspect of the present invention, the method is performed ex vivo or in vitro, for example in order to analyse the effect on cells of NLRP3 inhibition.

In another embodiment of the eleventh aspect of the present invention, the method is performed in vivo. For example, the method may comprise the step of administering an effective amount of a compound of the first or second aspect, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect, or a pharmaceutical composition of the fourth aspect, to thereby inhibit NLRP3. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents. Typically, the administration is to a subject in need thereof.

Alternately, the method of the eleventh aspect of the invention may be a method of inhibiting NLRP3 in a non-human animal subject, the method comprising the steps of administering the compound, salt, solvate, prodrug or pharmaceutical composition to the non-human animal subject and optionally subsequently mutilating or sacrificing the non-human animal subject. Typically, such a method further comprises the step of analysing one or more tissue or fluid samples from the optionally mutilated or sacrificed non-human animal subject. In one embodiment, the method further comprises the step of co-administering an effective amount of one or more further active agents.

A twelfth aspect of the invention provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, for use in the inhibition of NLRP3. Typically, the use comprises the administration of the compound, salt, solvate, prodrug or pharmaceutical composition to a subject. In one embodiment, the compound, salt, solvate, prodrug or pharmaceutical composition is co-administered with one or more further active agents.

A thirteenth aspect of the invention provides the use of a compound of the first or second aspect of the invention, or a pharmaceutically effective salt, solvate or prodrug of the third aspect of the invention, in the manufacture of a medicament for the inhibition of NLRP3. Typically, the inhibition comprises the administration of the compound, salt, solvate, prodrug or medicament to a subject. In one embodiment, the compound, salt, solvate, prodrug or medicament is co-administered with one or more further active agents.

In any embodiment of any of the fifth to thirteenth aspects of the present invention that comprises the use or co-administration of one or more further active agents, the one or more further active agents may comprise for example one, two or three different further active agents.

The one or more further active agents may be used or administered prior to, simultaneously with, sequentially with or subsequent to each other and/or to the compound of the first or second aspect of the invention, the pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or the pharmaceutical composition of the fourth aspect of the invention. Where the one or more further active agents are administered simultaneously with the compound of the first or second aspect of the invention, or the pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, a pharmaceutical composition of the fourth aspect of the invention may be administered wherein the pharmaceutical composition additionally comprises the one or more further active agents.

In one embodiment of any of the fifth to thirteenth aspects of the present invention that comprises the use or co-administration of one or more further active agents, the one or more further active agents are selected from:

(i) chemotherapeutic agents; (ii) antibodies; (iii) alkylating agents; (iv) anti-metabolites; (v) anti-angiogenic agents; (vi) plant alkaloids and/or terpenoids; (vii) topoisomerase inhibitors; (viii) mTOR inhibitors; (ix) stilbenoids; (x) STING agonists; (xi) cancer vaccines; (xii) immunomodulatory agents; (xiii) antibiotics; (xiv) anti-fungal agents; (xv) anti-helminthic agents; and/or (xvi) other active agents.

It will be appreciated that these general embodiments defined according to broad categories of active agents are not mutually exclusive. In this regard any particular active agent may be categorized according to more than one of the above general embodiments. A non-limiting example is urelumab which is an antibody that is an immunomodulatory agent for the treatment of cancer.

In some embodiments, the one or more chemotherapeutic agents are selected from abiraterone acetate, altretamine, amsacrine, anhydrovinblastine, auristatin, azathioprine, adriamycin, bexarotene, bicalutamide, BMS 184476, bleomycin, N,N-dimethyl-L-valyl-L-valyl-N-methyl-L-valyl-L-prolyl-L-proline-t-butylamide, cisplatin, carboplatin, carboplatin cyclophosphamide, chlorambucil, cachectin, cemadotin, cyclophosphamide, carmustine, cryptophycin, cytarabine, docetaxel, doxetaxel, doxorubicin, dacarbazine (DTIC), dactinomycin, daunorubicin, decitabine, dolastatin, etoposide, etoposide phosphate, enzalutamide (MDV3100), 5-fluorouracil, fludarabine, flutamide, gemcitabine, hydroxyurea and hydroxyureataxanes, idarubicin, ifosfamide, irinotecan, leucovorin, lonidamine, lomustine (CCNU), larotaxel (RPR109881), mechlorethamine, mercaptopurine, methotrexate, mitomycin C, mitoxantrone, melphalan, mivobulin, 3′,4′-didehydro-4′-deoxy-8′-norvin-caleukoblastine, nilutamide, oxaliplatin, onapristone, prednimustine, procarbazine, paclitaxel, platinum-containing anti-cancer agents, 2,3,4,5,6-pentafluoro-N-(3-fluoro-4-methoxyphenyl)benzene sulphonamide, prednimustine, procarbazine, rhizoxin, sertenef, streptozocin, stramustine phosphate, tretinoin, tasonermin, taxol, topotecan, tamoxifen, teniposide, taxane, tegafur/uracil, vincristine, vinblastine, vinorelbine, vindesine, vindesine sulfate, and/or vinflunine.

Alternatively or in addition, the one or more chemotherapeutic agents may be selected from CD59 complement fragment, fibronectin fragment, gro-beta (CXCL2), heparinases, heparin hexasaccharide fragment, human chorionic gonadotropin (hCG), interferon alpha, interferon beta, interferon gamma, interferon inducible protein (IP-10), interleukin-12, kringle 5 (plasminogen fragment), metalloproteinase inhibitors (TIMPs), 2-methoxyestradiol, placental ribonuclease inhibitor, plasminogen activator inhibitor, platelet factor-4 (PF4), prolactin 16 kD fragment, proliferin-related protein (PRP), various retinoids, tetrahydrocortisol-S, thrombospondin-1(TSP-1), transforming growth factor-beta (TGF-β), vasculostatin, vasostatin (calreticulin fragment), and/or cytokines (including interleukins, such as interleukin-2 (IL-2), or IL-10).

In some embodiments, the one or more antibodies may comprise one or more monoclonal antibodies. In some embodiments, the one or more antibodies are selected from abciximab, adalimumab, alemtuzumab, atlizumab, basiliximab, belimumab, bevacizumab, bretuximab vedotin, canakinumab, cetuximab, ceertolizumab pegol, daclizumab, denosumab, eculizumab, efalizumab, gemtuzumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, ofatumumab, omalizumab, palivizumab, panitumuab, ranibizumab, rituximab, tocilizumab, tositumomab, and/or trastuzumab.

In some embodiments, the one or more alkylating agents may comprise an agent capable of alkylating nucleophilic functional groups under conditions present in cells, including, for example, cancer cells. In some embodiments, the one or more alkylating agents are selected from cisplatin, carboplatin, mechlorethamine, cyclophosphamide, chlorambucil, ifosfamide and/or oxaliplatin. In some embodiments, the alkylating agent may function by impairing cell function by forming covalent bonds with amino, carboxyl, sulfhydryl, and/or phosphate groups in biologically important molecules. In some embodiments, the alkylating agent may function by modifying a cell's DNA.

In some embodiments, the one or more anti-metabolites may comprise an agent capable of affecting or preventing RNA or DNA synthesis. In some embodiments, the one or more anti-metabolites are selected from azathioprine and/or mercaptopurine.

In some embodiments, the one or more anti-angiogenic agents are selected from endostatin, angiogenin inhibitors, angiostatin, angioarrestin, angiostatin (plasminogen fragment), basement-membrane collagen-derived anti-angiogenic factors (tumstatin, canstatin, or arrestin), anti-angiogenic antithrombin III, and/or cartilage-derived inhibitor (CDI).

In some embodiments, the one or more plant alkaloids and/or terpenoids may prevent microtubule function. In some embodiments, the one or more plant alkaloids and/or terpenoids are selected from a vinca alkaloid, a podophyllotoxin and/or a taxane. In some embodiments, the one or more vinca alkaloids may be derived from the Madagascar periwinkle, Catharanthus roseus (formerly known as Vinca rosea), and may be selected from vincristine, vinblastine, vinorelbine and/or vindesine. In some embodiments, the one or more taxanes are selected from taxol, paclitaxel, docetaxel and/or ortataxel. In some embodiments, the one or more podophyllotoxins are selected from an etoposide and/or teniposide.

In some embodiments, the one or more topoisomerase inhibitors are selected from a type I topoisomerase inhibitor and/or a type II topoisomerase inhibitor, and may interfere with transcription and/or replication of DNA by interfering with DNA supercoiling. In some embodiments, the one or more type I topoisomerase inhibitors may comprise a camptothecin, which may be selected from exatecan, irinotecan, lurtotecan, topotecan, BNP 1350, CKD 602, DB 67 (AR67) and/or ST 1481. In some embodiments, the one or more type II topoisomerase inhibitors may comprise an epipodophyllotoxin, which may be selected from an amsacrine, etoposid, etoposide phosphate and/or teniposide.

In some embodiments, the one or more mTOR (mammalian target of rapamycin, also known as the mechanistic target of rapamycin) inhibitors are selected from rapamycin, everolimus, temsirolimus and/or deforolimus.

In some embodiments, the one or more stilbenoids are selected from resveratrol, piceatannol, pinosylvin, pterostilbene, alpha-viniferin, ampelopsin A, ampelopsin E, diptoindonesin C, diptoindonesin F, epsilon-vinferin, flexuosol A, gnetin H, hemsleyanol D, hopeaphenol, trans-diptoindonesin B, astringin, piceid and/or diptoindonesin A.

In some embodiments, the one or more STING (Stimulator of interferon genes, also known as transmembrane protein (TMEM) 173) agonists may comprise cyclic di-nucleotides, such as cAMP, cGMP, and cGAMP, and/or modified cyclic di-nucleotides that may include one or more of the following modification features: 2′-0/3′-0 linkage, phosphorothioate linkage, adenine and/or guanine analogue, and/or 2′-OH modification (e.g. protection of the 2′-OH with a methyl group or replacement of the 2′-OH by —F or —N₃).

In some embodiments, the one or more cancer vaccines are selected from an HPV vaccine, a hepatitis B vaccine, Oncophage, and/or Provenge.

In some embodiments, the one or more immunomodulatory agents may comprise an immune checkpoint inhibitor. The immune checkpoint inhibitor may target an immune checkpoint receptor, or combination of receptors comprising, for example, CTLA-4, PD-1, PD-L1, PD-L2, T cell immunoglobulin and mucin 3 (TIM3 or HAVCR2), galectin 9, phosphatidylserine, lymphocyte activation gene 3 protein (LAG3), MHC class I, MHC class II, 4-1BB, 4-1BBL, OX40, OX40L, GITR, GITRL, CD27, CD70, TNFRSF25, TL1A, CD40, CD40L, HVEM, LIGHT, BTLA, CD160, CD80, CD244, CD48, ICOS, ICOSL, B7-H3, B7-H4, VISTA, TMIGD2, HHLA2, TMIGD2, a butyrophilin (including BTNL2), a Siglec family member, TIGIT, PVR, a killer-cell immunoglobulin-like receptor, an ILT, a leukocyte immunoglobulin-like receptor, NKG2D, NKG2A, MICA, MICB, CD28, CD86, SIRPA, CD47, VEGF, neuropilin, CD30, CD39, CD73, CXCR4, and/or CXCL12.

In some embodiments, the immune checkpoint inhibitor is selected from urelumab, PF-05082566, MEDI6469, TRX518, varlilumab, CP-870893, pembrolizumab (PD1), nivolumab (PD1), atezolizumab (formerly MPDL3280A) (PD-L1), MEDI4736 (PD-L1), avelumab (PD-L1), PDR001 (PD1), BMS-986016, MGA271, lirilumab, IPH2201, emactuzumab, INCB024360, galunisertib, ulocuplumab, BKT140, bavituximab, CC-90002, bevacizumab, and/or MNRP1685A.

In some embodiments, the one or more antibiotics are selected from amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, paromomycin, streptomycin, spectinomycin, geldanamycin, herbimycin, rifaximin, loracarbef, ertapenem, doripenem, imipenem, cilastatin, meropenem, cefadroxil, cefazolin, cefalotin, cefalothin, cefalexin, cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, cefpodoxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, cefepime, ceftaroline fosamil, ceftobiprole, teicoplanin, vancomycin, telavancin, dalbavancin, oritavancin, clindamycin, lincomycin, daptomycin, azithromycin, clarithromycin, dirithromycin, erythromycin, roxithromycin, troleandomycin, telithromycin, spiramycin, aztreonam, furazolidone, nitrofurantoin, linezolid, posizolid, radezolid, torezolid, amoxicillin, ampicillin, azlocillin, carbenicillin, cloxacillin, dicloxacillin, flucloxacillin, mezlocillin, methicillin, nafcillin, oxacillin, penicillin G, penicillin V, piperacillin, temocillin, ticarcillin, calvulanate, ampicillin, subbactam, tazobactam, ticarcillin, clavulanate, bacitracin, colistin, polymyxin B, ciprofloxacin, enoxacin, gatifloxacin, gemifloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, trovafloxacin, grepafloxacin, sparfloxacin, temafloxacin, mafenide, sulfacetamide, sulfadiazine, silver sulfadiazine, sulfadimethoxine, sulfamethoxazole, sulfanamide, sulfasalazine, sulfisoxazole, trimethoprim-sulfamethoxazole, sulfonamideochrysoidine, demeclocycline, minocycline, oytetracycline, tetracycline, clofazimine, dapsone, dapreomycin, cycloserine, ethambutol, ethionamide, isoniazid, pyrazinamide, rifampicin, rifabutin, rifapentine, streptomycin, arsphenamine, chloramphenicol, fosfomycin, fusidic acid, metronidazole, mupirocin, platensimycin, quinupristin, dalopristin, thiamphenicol, tigecycyline, tinidazole, trimethoprim, and/or teixobactin.

In some embodiments, the one or more antibiotics may comprise one or more cytotoxic antibiotics. In some embodiments, the one or more cytotoxic antibiotics are selected from an actinomycin, an anthracenedione, an anthracycline, thalidomide, dichloroacetic acid, nicotinic acid, 2-deoxyglucose, and/or chlofazimine. In some embodiments, the one or more actinomycins are selected from actinomycin D, bacitracin, colistin (polymyxin E) and/or polymyxin B. In some embodiments, the one or more antracenediones are selected from mitoxantrone and/or pixantrone. In some embodiments, the one or more anthracyclines are selected from bleomycin, doxorubicin (Adriamycin), daunorubicin (daunomycin), epirubicin, idarubicin, mitomycin, plicamycin and/or valrubicin.

In some embodiments, the one or more anti-fungal agents are selected from bifonazole, butoconazole, clotrimazole, econazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, efinaconazole, epoziconazole, fluconazole, isavuconazole, itraconazole, posaconazole, propiconazole, ravusconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, 5-fluorocytosine, griseofulvin, haloprogin, tolnaflate, undecylenic acid, and/or balsam of Peru.

In some embodiments, the one or more anti-helminthic agents are selected from benzimidazoles (including albendazole, mebendazole, thiabendazole, fenbendazole, triclabendazole, and flubendazole), abamectin, diethylcarbamazine, ivermectin, suramin, pyrantel pamoate, levamisole, salicylanilides (including niclosamide and oxyclozanide), and/or nitazoxanide.

In some embodiments, other active agents are selected from growth inhibitory agents, anti-inflammatory agents (including nonsteroidal anti-inflammatory agents), anti-psoriatic agents (including anthralin and its derivatives), vitamins and vitamin-derivatives (including retinoinds, and VDR receptor ligands), corticosteroids, ion channel blockers (including potassium channel blockers), immune system regulators (including cyclosporin, FK 506, and glucocorticoids), lutenizing hormone releasing hormone agonists (such as leuprolidine, goserelin, triptorelin, histrelin, bicalutamide, flutamide and/or nilutamide), and/or hormones (including estrogen).

Unless stated otherwise, in any of the fifth to thirteenth aspects of the invention, the subject may be any human or other animal. Typically, the subject is a mammal, more typically a human or a domesticated mammal such as a cow, pig, lamb, sheep, goat, horse, cat, dog, rabbit, mouse etc. Most typically, the subject is a human.

Any of the medicaments employed in the present invention can be administered by oral, parenteral (including intravenous, subcutaneous, intramuscular, intradermal, intratracheal, intraperitoneal, intraarticular, intracranial and epidural), airway (aerosol), rectal, vaginal, ocular or topical (including transdermal, buccal, mucosal, sublingual and topical ocular) administration.

Typically, the mode of administration selected is that most appropriate to the disorder, disease or condition to be treated or prevented. Where one or more further active agents are administered, the mode of administration may be the same as or different to the mode of administration of the compound, salt, solvate, prodrug or pharmaceutical composition of the invention.

For oral administration, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in the form of tablets, capsules, hard or soft gelatine capsules, caplets, troches or lozenges, as a powder or granules, or as an aqueous solution, suspension or dispersion.

Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose. Corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch and gelatine. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material, such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract. Tablets may also be effervescent and/or dissolving tablets.

Capsules for oral use include hard gelatine capsules in which the active ingredient is mixed with a solid diluent, and soft gelatine capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

Powders or granules for oral use may be provided in sachets or tubs. Aqueous solutions, suspensions or dispersions may be prepared by the addition of water to powders, granules or tablets.

Any form suitable for oral administration may optionally include sweetening agents such as sugar, flavouring agents, colouring agents and/or preservatives.

Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

For parenteral use, the compounds, salts, solvates or prodrugs of the present invention will generally be provided in a sterile aqueous solution or suspension, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride or glucose. Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate. The compounds of the invention may also be presented as liposome formulations.

For ocular administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in a form suitable for topical administration, e.g. as eye drops. Suitable forms may include ophthalmic solutions, gel-forming solutions, sterile powders for reconstitution, ophthalmic suspensions, ophthalmic ointments, ophthalmic emulsions, ophthalmic gels and ocular inserts. Alternatively, the compounds, salts, solvates or prodrugs of the invention may be provided in a form suitable for other types of ocular administration, for example as intraocular preparations (including as irrigating solutions, as intraocular, intravitreal or juxtascleral injection formulations, or as intravitreal implants), as packs or corneal shields, as intracameral, subconjunctival or retrobulbar injection formulations, or as iontophoresis formulations.

For transdermal and other topical administration, the compounds, salts, solvates or prodrugs of the invention will generally be provided in the form of ointments, cataplasms (poultices), pastes, powders, dressings, creams, plasters or patches.

Suitable suspensions and solutions can be used in inhalers for airway (aerosol) administration.

The dose of the compounds, salts, solvates or prodrugs of the present invention will, of course, vary with the disorder, disease or condition to be treated or prevented. In general, a suitable dose will be in the range of 0.01 to 500 mg per kilogram body weight of the recipient per day. The desired dose may be presented at an appropriate interval such as once every other day, once a day, twice a day, three times a day or four times a day. The desired dose may be administered in unit dosage form, for example, containing 1 mg to 50 g of active ingredient per unit dosage form.

For the avoidance of doubt, insofar as is practicable any embodiment of a given aspect of the present invention may occur in combination with any other embodiment of the same aspect of the present invention. In addition, insofar as is practicable it is to be understood that any preferred, typical or optional embodiment of any aspect of the present invention should also be considered as a preferred, typical or optional embodiment of any other aspect of the present invention.

By way of example, combinations of aspects and embodiments that are typical of the present invention include the following.

In a first combination, a compound of the first aspect of the invention is provided wherein the oxygen atom of R¹—O-L- is not directly attached to a sp² hybridised atom and wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted.

Typically, in such a first combination:

-   -   no oxygen or nitrogen atom within the group R¹—O-L- is directly         attached to a sp² or sp¹ hybridised atom;     -   R¹—O-L- is monovalent and contains only atoms selected from the         group consisting of carbon, hydrogen, nitrogen, oxygen and         halogen atoms;     -   the group:

-   -   contains from 8 to 20 atoms other than hydrogen or halogen;     -   Q is O;     -   R² contains from 8 to 25 atoms other than hydrogen or halogen;         and     -   (i) R² is a fused aryl or a fused heteroaryl group, wherein a         first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl         or heteroaryl ring is fused to the aryl or heteroaryl group         across the α,β positions and a second cycloalkyl, cycloalkenyl,         non-aromatic heterocyclic, aryl or heteroaryl ring is fused to         the aryl or heteroaryl group across the α′,β′ positions, and         wherein R² may optionally be further substituted; or     -   (ii) R² is a fused aryl or a fused heteroaryl group, wherein a         cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or         heteroaryl ring is fused to the aryl or heteroaryl group across         the α,β positions, wherein the aryl or heteroaryl group is         further substituted at the α′ position with an alkyl or         cycloalkyl group, and wherein R² may optionally be further         substituted; or     -   (iii) R² is an aryl or a heteroaryl group, wherein the aryl or         the heteroaryl group is substituted at the α-position with a         monovalent heterocyclic group or a monovalent aromatic group,         wherein a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic,         aryl or heteroaryl ring is fused to the aryl or heteroaryl group         across the α′,β′ positions, and wherein R² may optionally be         further substituted.

More typically in such a first combination:

-   -   Q is O;     -   W, X, Y and Z are each independently N, NH or CH, wherein at         least one of W, X, Y and Z is N or NH;     -   the group R¹—O-L-, including any optional substituents, is         monovalent, saturated, contains only atoms selected from the         group consisting of carbon, hydrogen, nitrogen, oxygen and         halogen atoms, and is directly attached to X or Y;     -   m is 0, 1 or 2;     -   each R³ is independently selected from a C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, wherein any C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group may         optionally be substituted with one or more halo groups;     -   the group:

-   -   contains from 8 to 20 atoms other than hydrogen or halogen;     -   R² is a fused aryl or a fused heteroaryl group, wherein a first         cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or         heteroaryl ring is fused to the aryl or heteroaryl group across         the α,β positions and a second cycloalkyl, cycloalkenyl,         non-aromatic heterocyclic, aryl or heteroaryl ring is fused to         the aryl or heteroaryl group across the α′,β′ positions, and         wherein R² may optionally be further substituted; and     -   R² contains from 10 to 20 atoms other than hydrogen or halogen.

In a second combination, a compound of the first aspect of the invention is provided wherein:

-   -   Q is O;     -   W, X, Y and Z are each independently N, NH or CH, wherein at         least one of W, X, Y and Z is N or NH;     -   R¹—O-L- is directly attached to X or Y;     -   m is 0, 1 or 2;     -   each R³ is independently selected from a C₁-C₆ alkyl, C₂-C₆         alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, wherein any C₁-C₆         alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group may         optionally be substituted with one or more halo groups;     -   R² is a phenyl or a 5- or 6-membered heteroaryl group, wherein:     -   (i) the phenyl or 5- or 6-membered heteroaryl group is         substituted with a cycloalkyl, cycloalkenyl, non-aromatic         heterocyclic, aryl or heteroaryl ring which is fused to the         parent phenyl or 5- or 6-membered heteroaryl group across the         α,β positions and which is optionally substituted with one or         more halo groups; and         -   the phenyl or 5- or 6-membered heteroaryl group is further             substituted at the α′ position with a substituent selected             from —R⁴, —OR⁴ and —COR⁴, wherein R⁴ is selected from a             C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic             group and wherein R⁴ is optionally substituted with one or             more halo groups; and         -   optionally the phenyl or 5- or 6-membered heteroaryl group             is further substituted with one or two substituents             independently selected from halo, —NO₂, —CN, —COOR⁴⁵,             —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is             independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl             group; or     -   (ii) the phenyl or 5- or 6-membered heteroaryl group is         substituted with a first cycloalkyl, cycloalkenyl, non-aromatic         heterocyclic, aryl or heteroaryl ring which is fused to the         parent phenyl or 5- or 6-membered heteroaryl group across the         α,β positions and which is optionally substituted with one or         more halo groups; and         -   the phenyl or 5- or 6-membered heteroaryl group is             substituted with a second cycloalkyl, cycloalkenyl,             non-aromatic heterocyclic, aryl or heteroaryl ring which is             fused to the parent phenyl or 5- or 6-membered heteroaryl             group across the α′,β′ positions and which is optionally             substituted with one or more halo groups; and         -   optionally the phenyl group is further substituted with a             substituent selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂,             —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently             selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group; or     -   (iii) the phenyl or 5- or 6-membered heteroaryl group is         substituted at the α-position with a monovalent heterocyclic         group or a monovalent aromatic group selected from phenyl,         pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, triazolyl or         tetrahydropyranyl, wherein the monovalent heterocyclic or         aromatic group may optionally be substituted with one or two         substituents independently selected from halo, C₁-C₃ alkyl,         C₁-C₃ haloalkyl, —R⁴²—OR⁴³, —R⁴²—N(R⁴³)₂, —R⁴²—CN or         —R⁴²—C≡CR⁴³, and wherein a ring atom of the monovalent         heterocyclic or aromatic group is directly attached to the         α-ring atom of the parent phenyl or 5- or 6-membered heteroaryl         group; wherein each R⁴² is independently selected from a bond or         a C₁-C₃ alkylene group; and each R⁴³ is independently selected         from hydrogen or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group; and         -   the phenyl or 5- or 6-membered heteroaryl group is further             substituted with a cycloalkyl, cycloalkenyl, non-aromatic             heterocyclic, aryl or heteroaryl ring which is fused to the             parent phenyl or 5- or 6-membered heteroaryl group across             the α′,β′ positions and which is optionally substituted with             one or more halo groups; and         -   optionally the phenyl or 5- or 6-membered heteroaryl group             is further substituted with one or two substituents             independently selected from halo, —NO₂, —CN, —COOR⁴⁵,             —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is             independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl             group; and     -   L is an alkylene group, wherein the alkylene group may be         straight-chained or branched, wherein the alkylene group may         optionally include one or two heteroatoms N or O in its carbon         skeleton, and wherein the alkylene group may be optionally         substituted with (i) one or more substituents independently         selected from halo and —OH, and/or (ii) a divalent bridging         substituent selected from —O— and C₁-C₃ alkylene, wherein the         C₁-C₃ alkylene group may be straight-chained or branched,         wherein the C₁-C₃ alkylene group may optionally be substituted         with one or more substituents independently selected from halo         and —OH, and wherein the C₁-C₃ alkylene group may optionally         include one heteroatom N or O in its carbon skeleton; and     -   R¹ is hydrogen or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group,         wherein the C₁-C₆ alkyl or C₃-C₆ cycloalkyl group is optionally         substituted with one or more substituents independently selected         from halo, —OH and —NH₂;     -   provided that L contains from 2 to 8 atoms other than hydrogen         or halogen, and that the atom of L that is directly attached to         X or Y is a carbon atom and is not the same atom of L that is         directly attached to the oxygen atom of R¹—O-L-; or     -   R¹—O-L- has the formula R¹⁰-L²-, wherein:         -   R¹⁰ is a 4- to 6-membered saturated monocyclic group,             wherein R¹⁰ includes at least one oxygen atom in the ring             structure, wherein R¹⁰ optionally includes one or two             additional heteroatoms N or O in the ring structure, wherein             R¹⁰ is optionally substituted with one or more substituents             independently selected from halo, —OH, —NH₂, —R²⁰, —OR²⁰,             —NHR²⁰ and —N(R²⁰)₂, wherein each R²⁰ is independently             selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄             cycloalkyl or C₃-C₄ halocycloalkyl group, or any two R²⁰             directly attached to the same nitrogen atom may together             form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group; and         -   L² is a bond or a —(C(R¹⁵)₂)_(x)— group, wherein x is 1 or             2, and each R¹⁵ is independently selected from hydrogen or a             halo, methyl or halomethyl group, or any two R¹⁵ directly             attached to the same carbon atom may together form a C₂             alkylene or C₂ haloalkylene group;         -   provided that the atom of R¹⁰-L²- that is directly attached             to X or Y is a carbon atom and at least one oxygen atom in             the ring structure of R¹⁰ is not directly attached to the             same atom of R¹⁰-L²- that is directly attached to X or Y.

More typically in such a second combination:

-   -   Q is O;     -   W, X, Y and Z are each independently N, NH or CH, wherein at         least two of W, X, Y and Z are N or NH and at least one of W, X,         Y and Z is CH;     -   R¹—O-L- is directly attached to X or Y;     -   m is 0 or 1;     -   R³ is selected from a C₁-C₄ alkyl or C₃-C₄ cycloalkyl group,         wherein any C₁-C₄ alkyl or C₃-C₄ cycloalkyl group may optionally         be substituted with one or more fluoro and/or chloro groups;     -   R² has a formula:

-   -   wherein A1 and A² are each independently selected from a         straight-chained alkylene group, wherein one carbon atom in the         backbone of the alkylene group may optionally be replaced by an         oxygen atom, wherein any ring containing A1 or A² is a 5- or         6-membered ring, wherein A¹ and A² are unsubstituted or         substituted with one or more fluoro and/or chloro groups, and         R^(e) is hydrogen or halo; and     -   L is an alkylene group, wherein the alkylene group may be         straight-chained or branched, wherein the alkylene group may         optionally include one heteroatom N or O in its carbon skeleton,         and wherein the alkylene group may be optionally substituted         with (i) one or more substituents independently selected from         fluoro, chloro, and —OH, and/or (ii) a —CH₂— or —CH₂CH₂— group,         wherein the —CH₂— or —CH₂CH₂— group may optionally be         substituted with one or more substituents independently selected         from fluoro, chloro, and —OH; and     -   R¹ is hydrogen or a C₁-C₄ alkyl group, wherein the C₁-C₄ alkyl         group is optionally substituted with one or more fluoro and/or         chloro groups;     -   provided that L contains from 2 to 6 atoms other than hydrogen         or halogen, and that the atom of L that is directly attached to         X or Y is a carbon atom and is not the same atom of L that is         directly attached to the oxygen atom of R¹—O-L-; or     -   R¹—O-L- has the formula R¹⁰-L²-, wherein:         -   R¹⁰ is an oxetanyl or tetrahydrofuranyl group, wherein the             oxetanyl or tetrahydrofuranyl group is optionally             substituted with one or more substituents independently             selected from fluoro, chloro, —OH, —NH₂, -Me, -Et, —OMe,             —OEt, —NHMe, —NHEt, —N(Me)₂, —N(Me)Et and —N(Et)₂ groups,             wherein any methyl (Me) or ethyl (Et) group may optionally             be substituted with one or more fluoro and/or chloro groups;             and         -   L² is a bond or a —(C(R¹⁵)₂)_(x) group, wherein x is 1 or 2,             and each R¹⁵ is independently selected from hydrogen or a             fluoro, chloro or methyl group, or any two R¹⁵ directly             attached to the same carbon atom may together form a C₂             alkylene group, wherein any methyl or C₂ alkylene group may             optionally be substituted with one or more fluoro and/or             chloro groups;         -   provided that the oxygen atom in the ring structure of R¹⁰             is not directly attached to the same atom of R¹⁰-L²- that is             directly attached to X or Y.

Without wishing to be bound by theory, it is currently believed that the compounds of the first and second combinations described immediately above are particularly suitable for administration via oral or intravenous routes due to their pharmacokinetic properties.

In a third combination, a compound of the first aspect of the invention is provided wherein ring A is monocyclic, wherein R² is a cyclic group substituted at the α and α′ positions, wherein each substituent at the α and α′ positions comprises a carbon atom and wherein R² may optionally be further substituted.

In a fourth combination, a compound of the first aspect of the invention is provided wherein ring A is monocyclic, wherein the group R¹—O-L-, including any optional substituents, contains only atoms selected from the group consisting of carbon, hydrogen, oxygen and halogen atoms, and wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted.

In a fifth combination, a compound of the first aspect of the invention is provided wherein W, X, Y and Z are each independently N, NH or CH, and wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted.

In a sixth combination, a compound of the first aspect of the invention is provided wherein at least two of W, X, Y and Z are N or NH, and wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted.

In a seventh combination, a compound of the first aspect of the invention is provided wherein R¹—O-L- is directly attached to a ring nitrogen atom of ring A and wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted.

In an eighth combination, a compound of the first aspect of the invention is provided wherein R¹—O-L- is directly attached to a ring nitrogen atom of ring A and wherein R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α-position, and wherein R² may optionally be further substituted.

A ninth combination provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, wherein the oxygen atom of R¹—O-L- is not directly attached to a sp² hybridised atom and wherein R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α-position, and wherein R² may optionally be further substituted, for use in medicine.

A tenth combination provides a compound of the first or second aspect of the invention, or a pharmaceutically acceptable salt, solvate or prodrug of the third aspect of the invention, or a pharmaceutical composition of the fourth aspect of the invention, wherein ring A is monocyclic, for use in the treatment or prevention of a disease, disorder or condition selected from:

-   -   (i) inflammation;     -   (ii) an infection;     -   (iii) a cardiovascular disease;     -   (iv) a respiratory disease;     -   (v) a liver disease;     -   (vi) a renal disease;     -   (vii) an ocular disease;     -   (viii) a skin disease;     -   (ix) a psychological disorder;     -   (x) a lymphatic condition; and/or     -   (xi) any disease, disorder or condition in which an individual         has been determined to carry a germline or somatic non-silent         mutation in NLRP3.

Typically, in any of the above exemplary combinations, Q is O.

Typically, in any of the above exemplary combinations, R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α and α′ positions, and wherein R² may optionally be further substituted.

Typically, in any of the above exemplary combinations, R² contains from 8 to 25 atoms other than hydrogen or halogen.

Typically, in any of the above exemplary combinations, the group:

contains from 8 to 20 atoms other than hydrogen or halogen.

As will be appreciated the above combinations are exemplary only and other combinations of aspects and embodiments, including combinations of the above combinations, may readily be envisaged.

EXAMPLES—COMPOUND SYNTHESIS

All solvents, reagents and compounds were purchased and used without further purification unless stated otherwise.

Abbreviations

-   2-MeTHF 2-methyltetrahydrofuran -   Ac₂O acetic anhydride -   AcOH acetic acid -   aq aqueous -   Boc tert-butyloxycarbonyl -   br broad -   Cbz carboxybenzyl -   CDI 1,1-carbonyl-diimidazole -   conc concentrated -   d doublet -   DABCO 1,4-diazabicyclo[2.2.2]octane -   DCE 1,2-dichloroethane, also called ethylene dichloride -   DCM dichloromethane -   DIPEA N,N-diisopropylethylamine, also called Hünig's base -   DMA dimethylacetamide -   DMAP 4-dimethylaminopyridine, also called     N,N-dimethylpyridin-4-amine -   DME dimethoxyethane -   DMF N,N-dimethylformamide -   DMSO dimethyl sulfoxide -   eq or equiv equivalent -   (ES+) electrospray ionization, positive mode -   Et ethyl -   EtOAc ethyl acetate -   EtOH ethanol -   h hour(s) -   HATU     1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium     3-oxid hexafluorophosphate -   HPLC high performance liquid chromatography -   LC liquid chromatography -   m multiplet -   m-CPBA 3-chloroperoxybenzoic acid -   Me methyl -   MeCN acetonitrile -   MeOH methanol -   (M+H)+ protonated molecular ion -   MHz megahertz -   min minute(s) -   MS mass spectrometry -   Ms mesyl, also called methanesulfonyl -   MsCl mesyl chloride, also called methanesulfonyl chloride -   MTBE methyl tert-butyl ether, also called tert-butyl methyl ether -   m/z mass-to-charge ratio -   NaO^(t)Bu sodium tert-butoxide -   NBS 1-bromopyrrolidine-2,5-dione, also called N-bromosuccinimide -   NCS 1-chloropyrrolidine-2,5-dione, also called N-chlorosuccinimide -   NMP N-methylpyrrolidine -   NMR nuclear magnetic resonance (spectroscopy) -   Pd(dba)₃ tris(dibenzylideneacetone) dipalladium(o) -   Pd(dppf)Cl₂     [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) -   PE petroleum ether -   Ph phenyl -   PMB p-methoxybenzyl, also called 4-methoxybenzyl -   prep-HPLC preparative high performance liquid chromatography -   prep-TLC preparative thin layer chromatography -   PTSA p-toluenesulfonic acid -   q quartet -   RP reversed phase -   RT room temperature -   s singlet -   Sept septuplet -   sat saturated -   SCX solid supported cation exchange (resin) -   t triplet -   T3P propylphosphonicanhydride -   TBME tert-butyl methyl ether, also called methyl tert-butyl ether -   TEA triethylamine -   TFA 2,2,2-trifluoroaceticacid -   THF tetrahydrofuran -   TLC thin layer chromatography -   wt % weight percent or percent by weight

Experimental Methods Nuclear Magnetic Resonance

NMR spectra were recorded at 300, 400 or 500 MHz. Spectra were measured at 298 K, unless indicated otherwise, and were referenced relative to the solvent resonance. The chemical shifts are reported in parts per million. Spectra were recorded using one of the following machines:

-   -   a Bruker Avance III spectrometer at 400 MHz fitted with a BBO 5         mm liquid probe,     -   a Bruker 400 MHz spectrometer using ICON-NMR, under TopSpin         program control,     -   a Bruker Avance III HD spectrometer at 500 MHz, equipped with a         Bruker 5 mm SmartProbe™,     -   an Agilent VNMRS 300 instrument fitted with a 7.05 Tesla magnet         from Oxford instruments, indirect detection probe and direct         drive console including PFG module, or     -   an Agilent MercuryPlus 300 instrument fitted with a 7.05 Tesla         magnet from Oxford instruments, 4 nuclei auto-switchable probe         and Mercury plus console.

LC-MS

LC-MS Methods: Using SHIMADZU LCMS-2020, Agilent 1200 LC/G1956A MSD and Agilent 1200†G6110A, Agilent 1200 LC & Agilent 6110 MSD. Mobile Phase: A: 0.025% NH₃—H₂ in water (v/v); B: acetonitrile. Column: Kinetex EVO C18 2.1×30 mm, 5 μm.

Reversed Phase HPLC Conditions for the LCMS Analytical Methods

Methods 1a and 1b:

Waters Xselect CSH C18 XP column (4.6×30 mm, 2.5 μm) at 40° C.; flow rate 2.5-4.5 mL min-1 eluted with a H₂O-MeCN gradient containing either 0.1% v/v formic acid (Method 1a) or 10 mM NH₄HCO₃ in water (Method 1b) over 4 min employing UV detection at 254 nm. Gradient information: 0-3.00 min, ramped from 95% water-5% acetonitrile to 5% water-95% acetonitrile; 3.00-3.01 min, held at 5% water-95% acetonitrile, flow rate increased to 4.5 mL min⁻¹; 3.01-3.50 min, held at 5% water-95% acetonitrile; 3.50-3.60 min, returned to 95% water-5% acetonitrile, flow rate reduced to 3.50 mL min⁻¹; 3.60-3.90 min, held at 95% water-5% acetonitrile; 3.90-4.00 min, held at 95% water-5% acetonitrile, flow rate reduced to 2.5 mL min⁻¹.

Method 1c:

Agilent 1290 series with UV detector and HP 6130 MSD mass detector using Waters XBridge BEH C18 XP column (2.1×50 mm, 2.5 μm) at 35° C.; flow rate 0.6 mL/min; mobile phase A: ammonium acetate (10 mM); water/MeOH/acetonitrile (900:60:40); mobile phase B: ammonium acetate (10 mM); water/MeOH/acetonitrile (100:540:360); over 4 min employing UV detection at 215 and 238 nm. Gradient information: 0-0.5 min, held at 80% A-20% B; 0.5-2.0 min, ramped from 80% A-20% B to 100% B.

Reversed Phase HPLC Conditions for the UPLC Analytical Methods

Methods 2a and 2b:

Waters BEH C18 (2.1×30 mm, 1.7 μm) at 40° C.; flow rate 0.77 mL min-1 eluted with a H₂O-MeCN gradient containing either 0.1% v/v formic acid (Method 2a) or 10 mM NH₄HCO₃ in water (Method 2b) over 3 min employing UV detection at 254 nm. Gradient information: 0-0.11 min, held at 95% water-5% acetonitrile, flow rate 0.77 mL min⁻¹; 0.11-2.15 min, ramped from 95% water-5% acetonitrile to 5% water-95% acetonitrile; 2.15-2.49 min, held at 5% water-95% acetonitrile, flow rate 0.77 mL min⁻¹; 2.49-2.56 min, returned to 95% water-5% acetonitrile; 2.56-3.00 min, held at 95% water-5% acetonitrile, flow rate reduced to 0.77 mL min⁻¹.

Preparative Reversed Phase HPLC General Methods

Method 1 (Acidic Preparation):

Waters X-Select CSH column C18, 5 μm (19×50 mm), flow rate 28 mL min-1 eluting with a H₂O-MeCN gradient containing 0.1% v/v formic acid over 6.5 min using UV detection at 254 nm. Gradient information: 0.0-0.2 min, 20% MeCN; 0.2-5.5 min, ramped from 20% MeCN to 40% MeCN; 5.5-5.6 min, ramped from 40% MeCN to 95% MeCN; 5.6-6.5 min, held at 95% MeCN.

Method 2 (Basic Preparation):

Waters X-Bridge Prep column C18.5 μm (19×50 mm), flow rate 28 mL min-1 eluting with a 10 mM NH₄HCO₃-MeCN gradient over 6.5 min using UV detection at 254 nm. Gradient information: 0.0-0.2 min, 10% MeCN; 0.2-5.5 min, ramped from 10% MeCN to 40% MeCN; 5.5-5.6 min, ramped from 40% MeCN to 95% MeCN; 5.6-6.5 min, held at 95% MeCN.

Method 3:

Phenomenex Gemini column, 10 μm (150×25 mm), flow rate=25 mL/min eluting with a water-acetonitrile gradient containing 0.04% NH₃ at pH 10 over 9 minutes using UV detection at 220 and 254 nm. Gradient information: 0-9 minutes, ramped from 8% to 35% acetonitrile; 9-9.2 minutes, ramped from 35% to 100% acetonitrile; 9.2-15.2 minutes, held at 100% acetonitrile.

Method 4:

Revelis C18 reversed-phase 12 g cartridge [carbon loading 18%; surface area 568 m²/g; pore diameter 65 Angstrom; pH (5% slurry) 5.1; average particle size 40 μm], flow rate=30 mL/min eluting with a water-methanol gradient over 35 minutes using UV detection at 215, 235, 254 and 280 nm. Gradient information: 0-5 minutes, held at 0% methanol; 5-30 minutes, ramped from 0% to 70% methanol; 30-30.1 minutes, ramped from 70% to 100% methanol; 30.1-35 minutes, held at 100% methanol.

Synthesis of Intermediates Intermediate P1: 1-(Tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide Step A: Lithium 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-sulfinate

A solution of BuLi (100 mL, 250 mmol, 2.5M in hexanes) was added slowly to a solution of 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole (36.2 g, 238 mmol) in THF (500 mL) keeping the temperature below −65° C. The mixture was stirred for 1.5 hours, then sulfur dioxide was bubbled through for 10 minutes. The mixture was allowed to warm to room temperature, the solvent evaporated and the residue triturated with TBME (300 mL) and filtered. The solid was washed with TBME and isohexane and dried to afford the crude title compound (54.89 g, 99%).

¹H NMR (DMSO-d6) δ 7.26 (d, J=1.6 Hz, 1H), 6.10 (d, J=1.7 Hz, 1H), 5.99 (dd, J=10.0, 2.5 Hz, 1H), 3.92-3.87 (m, 1H), 3.56-3.49 (m, 1H), 2.25-2.15 (m, 1H), 2.00-1.91 (m, 1H), 1.75-1.69 (m, 1H), 1.66-1.46 (m, 3H).

LCMS; m/z 215 (M−H)⁻ (ES⁻).

Step B: N,N-Bis(4-methoxybenzyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-sulfonamide

NCS (12.0 g, 90 mmol) was added to a suspension of lithium 1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-sulfinate (20 g, 90 mmol) in DCM (250 mL) cooled in an ice bath. The mixture was stirred for 4 hours, quenched with water (100 mL), and then partitioned between DCM (300 mL) and water (200 mL). The organic phase was washed with water (200 mL), dried (MgSO₄), filtered and evaporated to-50 mL. The solution was added to a mixture of bis(4-methoxybenzyl)amine (24 g, 93 mmol) and triethylamine (40 mL, 287 mmol) in DCM (300 mL) cooled in an ice bath. After stirring for 1 hour, the mixture was warmed to room temperature, and then partitioned between DCM (300 mL) and water (250 mL). The organic layer was washed with water (250 mL), aq 1M HCl (2×250 mL), water (250 mL), dried (MgSO₄), filtered, and evaporated to afford the crude title compound (41.02 g, 97%) as a brown oil.

LCMS; m/z 494.2 (M+Na)⁺ (ES⁺).

Step C: N,N-Bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

A mixture of N,N-bis(4-methoxybenzyl)-1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole-5-sulfonamide (41 g, 87 mmol) and aq 1M HCl (30 mL) in THF (300 mL) and MeOH (50 mL) was stirred at room temperature for 18 hours. The solvent was evaporated and the residue partitioned between EtOAc (400 mL) and aq 1M HCl (200 mL). The organic layer was washed with 10% brine (200 mL), dried (MgSO₄), filtered and evaporated. The residue was triturated with TBME, filtered and dried to afford the title compound (24.87 g, 69%) as an off white solid.

¹H NMR (CDCl₃) δ 7.88 (d, J=2.4 Hz, 1H), 7.06-7.02 (m, 4H), 6.79-6.75 (m, 4H), 6.63 (d, J=2.4 Hz, 1H), 4.31 (s, 4H), 3.78 (s, 6H). Exchangeable proton not visible.

LCMS; m/z 388 (M+H)⁺ (ES⁺); 386 (M−H)⁻ (ES⁻).

Step D: N,N-Bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide

Under nitrogen, a mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (0.5 g, 1.290 mmol) and K₂CO₃ (0.35 g, 2.53 mmol) was suspended in dry acetonitrile (5 mL). 3-Bromotetrahydrofuran (0.25 g, 1.656 mmol) was added in a single portion and the cloudy mixture was heated to 65° C. (bath temperature) for 16 hours. The mixture was diluted with water (5 mL) and extracted with DCM (3×25 mL). The organic phase was dried by passing through a hydrophobic frit and concentrated in vacuo. The crude product was purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (461 mg, 77%) as a colourless solid.

¹H NMR (CDCl₃) δ 7.51 (d, J=2.4 Hz, 1H), 7.10-7.04 (m, 4H), 6.80-6.75 (m, 4H), 6.67 (d, J=2.4 Hz, 1H), 5.05-4.98 (m, 1H), 4.32 (s, 4H), 4.13-4.06 (m, 1H), 4.04 (d, J=4.6 Hz, 2H), 3.94 (td, J=8.6, 5.4 Hz, 1H), 3.78 (s, 6H), 2.54-2.42 (m, 1H), 2.33-2.23 (m, 1H).

LCMS; m/z 458 (M+H)⁺ (ES⁺).

Step E: 1-(Tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide

N,N-Bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (0.455 g, 0.994 mmol) was dissolved in DCM (1 mL) and TFA (2 mL, 26.0 mmol) was added. The mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated in vacuo, suspended in toluene (5 mL) and concentrated again. The residue was dissolved in DCM and purified by chromatography on silica gel (12 g column, 0-10% MeOH/DCM) to afford the title compound (187 mg, 87%) as a thick colourless oil.

¹H NMR (DMSO-d6) δ 7.93 (d, J=2.4 Hz, 1H), 7.41 (s, 2H), 6.61 (d, J=2.4 Hz, 1H), 5.14-5.07 (m, 1H), 4.03-3.96 (m, 2H), 3.91 (dd, J=9.6, 3.5 Hz, 1H), 3.82 (td, J=8.3, 5.6 Hz, 1H), 2.48-2.38 (m, 1H), 2.32-2.23 (m, 1H). LCMS; m/z 218 (M+H)⁺ (ES⁺); 216 (M−H)⁻ (ES⁻)

Intermediate P2: 1-(2-Methoxyethyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-(2-methoxyethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 1-bromo-2-methoxyethane to afford the title compound (417 mg, 54%) as a pale yellow oil.

¹H NMR (CDCl₃) δ 7.55 (d, J=2.3 Hz, 1H), 7.11-7.04 (m, 4H), 6.82-6.76 (m, 4H), 6.65 (d, J=2.3 Hz, 1H), 4.40-4.32 (m, 2H), 4.33 (s, 4H), 3.81 (s, 6H), 3.80-3.72 (m, 2H), 3.37 (s, 3H).

LCMS; m/z 468.4 (M+Na)⁺ (ES⁺).

Step B: 1-(2-Methoxyethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-(2-methoxyethyl)-1H-pyrazole-3-sulfonamide to afford the title compound (95 mg, 62%) as a solid.

LCMS; m/z 206 (M+H)⁺ (ES⁺).

Intermediate P3: 1-((Tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 2-(bromomethyl)tetrahydrofuran to afford the title compound (486 mg, 74%) as a colourless oil.

¹H NMR (CDCl₃) δ 7.57 (d, J=2.3 Hz, 1H), 7.07-7.01 (m, 4H), 6.79-6.74 (m, 4H), 6.64 (d, J=2.3 Hz, 1H), 4.37-415 (m, 2H), 4.31 (s, 2H), 4.29 (s, 2H), 3.88-3.74 (m, 2H), 3.78 (s, 6H), 2.07-1.96 (m, 1H), 1.94-1.82 (m, 1H), 1.82-1.70 (m, 1H), 1.65-1.51 (m, 2H).

LCMS; m/z 472 (M+H)⁺ (ES⁺).

Step B: 1-((Tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide to afford the title compound (215 mg, 87%) as a thick colourless oil.

¹H NMR (DMSO-d6) δ 7.83 (d, J=2.3 Hz, 1H), 7.39 (s, 2H), 6.57 (d, J=2.3 Hz, 1H), 4.29-4.13 (m, 3H), 3.78-3.71 (m, 1H), 3.68-3.61 (m, 1H), 2.01-1.90 (m, 1H), 1.86-1.71 (m, 2H), 1.64-1.54 (m, 1H).

LCMS; m/z 232 (M+H)⁺ (ES⁺); 230 (M−H)⁻ (ES⁻).

Intermediate P4: 1-((Tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 3-(bromomethyl)tetrahydrofuran to afford the title compound (445 mg, 72%) as a colourless oil.

¹H NMR (DMSO-d6) δ 8.01 (d, J=2.3 Hz, 1H), 7.07-6.97 (m, 4H), 6.85-6.78 (m, 4H), 6.73 (d, J=2.3 Hz, 1H), 4.22, d, J=9.1 Hz, 2H), 4.21 (s, 4H), 3.77 (td, J=8.1, 5.5 Hz, 1H), 3.72 (s, 6H), 3.70-3.60 (m, 2H), 3.45 (dd, J=8.7, 5.6 Hz, 1H), 2.77-2.64 (m, 1H), 1.96-1.85 (m, 1H), 1.65-1.54 (m, 1H).

LCMS; m/z 494 (M+Na)⁺ (ES⁺); 470 (M−H)⁻ (ES⁻).

Step B: 1-((Tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide to afford the title compound (205 mg, 90%) as a pale brown oil.

¹H NMR (DMSO-d6) δ 7.92 (d, J=2.3 Hz, 1H), 7.39 (s, 2H), 6.59 (d, J=2.3 Hz, 1H), 4.17 (d, J=7.5 Hz, 2H), 3.77 (td, J=8.1, 5.6 Hz, 1H), 3.69-3.61 (m, 2H), 3.47 (dd, J=8.7, 5.4 Hz, 1H), 2.77-2.66 (m, 1H), 1.97-1.87 (m, 1H), 1.65-1.55 (m, 1H).

Intermediate P5: 1-(3-Hydroxypropyl)-1H-pyrazole-3-sulfonamide Step A: 1-(3-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 3-bromopropan-1-ol to afford the title compound (355 mg, 60%) as an oil.

LCMS; m/z 446 (M+Na)⁺ (ES⁺).

Step B: 1-(3-Hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(3-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (56 mg, 32%) as a white solid.

¹H NMR (DMSO-d6) δ 7.86 (d, J=2.3 Hz, 1H), 7.37 (s, 2H), 6.57 (d, J=2.3 Hz, 1H), 4.63 (t, J=5.1 Hz, 1H), 4.27-4.18 (m, 2H), 3.40 (td, J=6.1, 5.0 Hz, 2H), 1.95-1.92 (m, 2H).

Intermediate P6: 1-(2-Hydroxyethyl)-1H-pyrazole-3-sulfonamide Step A: 1-(2-Hydroxyethyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 2-bromoethanol to afford the title compound (3.50 g, 68%) as a yellow oil.

¹H NMR (DMSO-d6) δ 7.93 (d, J=2.3 Hz, 1H), 7.03-6.98 (m, 4H), 6.84-6.78 (m, 4H), 6.71 (d, J=2.4 Hz, 1H), 5.01 (t, J=5.2 Hz, 1H), 4.27 (t, J=5.5 Hz, 2H), 4.19 (s, 4H), 3.81-3.74 (m, 2H), 3.72 (s, 6H).

LCMS; m/z 454.5 (M+Na)⁺ (ES⁺).

Step B: 1-(2-Hydroxyethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(2-hydroxyethyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (273 mg, 54%) as a yellow oil.

¹H NMR (DMSO-d6) δ 7.84 (d, J=2.3 Hz, 1H), 7.39 (s, 2H), 6.57 (d, J=2.3 Hz, 1H), 4.99 (t, J=5.2 Hz, 1H), 4.21 (t, J=5.5 Hz, 2H), 3.78-3.71 (m, 2H).

LCMS; m/z 192.0 (M+H)⁺ (ES⁺).

Intermediate P7: 1-((3-Methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 3-(bromomethyl)-3-methyloxetane to afford the title compound (450 mg, 76%) as a colourless oil.

LCMS; m/z 472 (M+H)⁺ (ES⁺).

Step B: 1-((3-Methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide to afford the title compound (20 mg, 10%) as a white solid.

¹H NMR (DMSO-d6) δ 8.28 (d, J=2.8 Hz, 1H), 6.77 (d, J=2.7 Hz, 1H), 5.28 (br s, 2H), 4.51-4.44 (m, 2H), 4.25-4.23 (m, 2H), 3.44 (s, 2H), 1.26 (s, 3H).

Intermediate P8: 1-(2-Hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide Step A: 1-(2-Hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 2,2-dimethyloxirane to afford the title compound (6.09 g, 92%) as a thick colourless oil.

¹H NMR (DMSO-d6) δ 7.86 (d, J=2.4 Hz, 1H), 7.04-6.97 (m, 4H), 6.82-6.76 (m, 4H), 6.72 (d, J=2.4 Hz, 1H), 4.81 (s, 1H), 4.18 (s, 4H), 4.13 (s, 2H), 3.71 (s, 6H), 1.07 (s, 6H).

LCMS; m/z 482.5 (M+Na)⁺ (ES⁺).

Step B: 1-(2-Hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(2-hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (2.48 g, 80%) as a clear crystalline solid.

¹H NMR (DMSO-d6) δ 7.76 (d, J=2.3 Hz, 1H), 7.36 (s, 2H), 6.57 (d, J=2.3 Hz, 1H), 4.74 (s, 1H), 4.07 (s, 2H), 1.07 (s, 6H).

LCMS; m/z 242.3 (M+Na)⁺ (ES⁺).

Intermediate P9: (S)-1-(2-Hydroxypropyl)-1H-pyrazole-3-sulfonamide Step A: (S)-1-(2-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and (S)-2-methyloxirane to afford the title compound (180 mg, 40%) as a clear colourless oil.

¹H NMR (CDCl₃) δ 7.50 (d, J=2.3 Hz, 1H), 7.13-7.05 (m, 4H), 6.84-6.75 (m, 4H), 6.69 (d, J=2.3 Hz, 1H), 4.35 (s, 4H), 4.27-3.99 (m, 3H), 3.81 (s, 6H), 1.28 (d, J=6.3 Hz, 3H).

Step B: (S)-1-(2-Hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (S)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (58 mg, 69%) as a white solid.

¹H NMR (DMSO-d6) δ 7.80 (d, J=2.3 Hz, 1H), 7.37 (br s, 2H), 6.56 (d, J=2.3 Hz, 1H), 4.98 (d, J=4.9 Hz, 1H), 4.15-4.01 (m, 2H), 4.04-3.93 (m, 1H), 1.06 (d, J=6.1 Hz, 3H).

Intermediate P10: 1-(Oxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-(oxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C), 3-bromooxetane and KI (1 equiv.) to afford the title compound (289 mg, 49%) as a clear colourless oil.

¹H NMR (CDCl₃) δ 7.62 (d, J=2.4 Hz, 1H), 7.15-7.10 (m, 4H), 6.83-6.77 (m, 4H), 6.76 (d, J=2.4 Hz, 1H), 5.54-5.46 (m, 1H), 5.08-4.98 (m, 4H), 4.38 (s, 4H), 3.81 (s, 6H).

LCMS; m/z 466 (M+Na)⁺ (ES⁺); 442 (M−H)⁻ (ES⁻).

Step B: 1-(Oxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-(oxetan-3-yl)-1H-pyrazole-3-sulfonamide to afford the title compound (64 mg, 64%) as a white solid.

¹H NMR (DMSO-d6) δ 8.04 (d, J=2.4 Hz, 1H), 7.48 (s, 2H), 6.65 (d, J=2.4 Hz, 1H), 5.68-5.64 (m, 1H), 5.00-4.80 (m, 4H).

LCMS; m/z 204 (M+H)⁺ (ES⁺).

Intermediate P1: (R)-1-(1-Hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide Step A: (R)-1-(1-Hydroxypropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and (S)-2-bromopropan-1-ol to afford the title compound (410 mg, 70%) as a clear colourless oil.

Step B: (R)-1-(1-Hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (R)-1-(1-hydroxypropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (110 mg, 41%) as a white solid.

¹H NMR (DMSO-d6) δ 7.80 (d, J=2.3 Hz, 1H), 7.37 (s, 2H), 6.56 (d, J=2.3 Hz, 1H), 5.03-4.95 (m, 1H), 4.16-4.01 (m, 2H), 1.06 (d, J=6.1 Hz, 3H).

LCMS; m/z 206 (M+H)⁺ (ES⁺).

Intermediate P12: 1-(2-Methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide Step A: 1-(2-Methoxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 1-bromo-2-methoxy-2-methylpropane to afford the title compound (775 mg, 60%) as a clear colourless oil.

¹H NMR (CDCl₃) δ 7.57 (d, J=2.4 Hz, 1H), 7.11-7.05 (m, 4H), 6.82-6.75 (m, 4H), 6.67 (d, J=2.4 Hz, 1H), 4.32 (s, 4H), 4.19 (s, 2H), 3.80 (s, 6H), 3.27 (s, 3H), 1.14 (s, 6H).

LCMS; m/z 496 (M+Na)⁺ (ES⁺); 472 (M−H)⁻ (ES⁻).

Step B: 1-(2-Methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(2-methoxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (119 mg, 79%) as a light brown gum.

¹H NMR (DMSO-d6) δ 7.73 (d, J=2.3 Hz, 1H), 7.38 (br s, 2H), 6.58 (d, J=2.3 Hz, 1H), 4.19 (s, 2H), 3.17 (s, 3H), 1.09 (s, 6H).

LCMS; m/z 234 (M+H)⁺ (ES⁺); 232 (M−H)⁻ (ES⁻).

Intermediate P13: (S)-1-(1-Hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide Step A: (S)-1-(1-Hydroxypropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and (R)-2-bromopropan-1-ol to afford the title compound (225 mg, 37%) as a clear colourless oil.

¹H NMR (CDCl₃) δ 7.52 (d, J=2.3 Hz, 1H), 7.13-7.04 (m, 4H), 6.84-6.76 (m, 4H), 6.69 (d, J=2.3 Hz, 1H), 4.35 (s, 4H), 4.28-4.11 (m, 2H), 4.09-3.99 (m, 1H), 3.81 (s, 6H), 1.25 (d, J=6.3 Hz, 3H).

Step B: (S)-1-(1-Hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (S)-1-(1-hydroxypropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (150 mg, 30%) as a white solid.

¹H NMR (DMSO-d6) δ 7.80 (d, J=2.3 Hz, 1H), 7.37 (s, 2H), 6.56 (d, J=2.3 Hz, 1H), 5.02-4.97 (m, 1H), 4.13-3.91 (m, 3H), 1.06 (d, J=6.1 Hz, 3H).

LCMS; m/z 206 (M+H)⁺ (ES⁺).

Intermediate P14: (R)-1-(2-Hydroxypropyl)-1H-pyrazole-3-sulfonamide Step A: (R)-1-(2-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and (R)-2-methyloxirane to afford the title compound (210 mg, 46%) as a clear colourless oil.

¹H NMR (CDCl₃) δ 7.50 (d, J=2.3 Hz, 1H), 7.13-7.05 (m, 4H), 6.87-6.75 (m, 4H), 6.69 (d, J=2.3 Hz, 1H), 4.35 (s, 4H), 4.28-3.99 (m, 3H), 3.81 (s, 6H), 1.28 (d, J=6.3 Hz, 3H).

LCMS; m/z 446 (M+H)⁺ (ES⁺).

Step B: (R)-1-(2-Hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (R)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (56 mg, 49%) as a white solid.

¹H NMR (DMSO-d6) δ 7.80 (d, J=2.3 Hz, 1H), 7.37 (s, 2H), 6.56 (d, J=2.3 Hz, 1H), 4.98 (d, J=4.9 Hz, 1H), 4.09-3.95 (m, 3H), 1.06 (d, J=6.1 Hz, 3H).

Intermediate P15: 1-(1-Hydroxy-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide Step A: 2-(3-(N,N-Bis(4-methoxybenzyl)sulfamoyl)-1H-pyrazol-yl)-2-methylpropanoic acid

A solution of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) (2.00 g, 5.16 mmol) and 1,1,1-trichloro-2-methylpropan-2-ol hemihydrate (2.00 g, 10.37 mmol) in THF (50 mL) at 0° C. was treated portionwise with sodium hydroxide (1.04 g, 26.0 mmol). The reaction was then left to warm to room temperature and stirred for 3 days.

Additional 1,1,1-trichloro-2-methylpropan-2-ol hemihydrate (0.6 g) and sodium hydroxide (0.6 g) were added and the reaction was left to stir for a further 24 hours. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (2×50 mL). The aqueous layer was acidified to pH1 with 1M HCl, and extracted with EtOAc (2×50 mL). The combined organic layers were dried (MgSO₄), filtered and evaporated under reduced pressure to afford the title compound (490 mg, 17%) as a dark yellow oil.

LCMS; m/z 496.5 (M+Na)⁺ (ES⁺).

Step B: 1-(1-Hydroxy-2-methylpropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

2M Lithium aluminium hydride in THF (1.4 mL, 2.80 mmol) was added dropwise to a stirred solution of 2-(3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-1H-pyrazol-1-yl)-2-methylpropanoic acid (0.49 g, 0.880 mmol) in THF (15 mL) cooled to 0° C. The mixture was stirred at room temperature for 4 hours. Further 2M lithium aluminium hydride in THF (1.4 mL, 2.80 mmol) was added, and the reaction was stirred for a further 3 days at room temperature. The mixture was quenched carefully at 0° C. with saturated aqueous ammonium chloride. The reaction mixture was diluted with water (20 mL) and EtOAc (30 mL) and precipitated salts filtered. The organic layer was separated and the aqueous layer was washed with EtOAc (2×20 mL). The combined organic layers were dried (MgSO₄), filtered and evaporated to give a yellow oil. The crude product was purified by chromatography on silica gel (12 g column, 0-100% EtOAc/isohexane) to afford the title compound (130 mg, 30.2%) as a colourless oil. ¹H NMR (CD₃OD) δ 7.88 (d, J=2.5 Hz, 1H), 7.08-6.99 (m, 4H), 6.82-6.72 (m, 4H), 6.66 (d, J=2.5 Hz, 1H), 4.28 (s, 4H), 3.76 (s, 6H), 3.75 (s, 2H), 1.57 (s, 6H).

Exchangeable proton not visible.

LCMS; m/z 482.1 (M+Na)⁺ (ES⁺).

Step C: 1-(1-Hydroxy-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide

1-(1-Hydroxy-2-methylpropan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (130 mg, 0.283 mmol) was dissolved in TFA (5 mL) and water (0.5 mL). The reaction mixture was stirred at room temperature for 18 hours. Additional TFA (3 mL) was added and the reaction left to stir at room temperature for 4 hours. A further portion of TFA (3 mL) was added and the reaction left to stir at room temperature for a further 19 hours. The reaction mixture was evaporated to dryness and purified by chromatography on silica gel (12 g column, 0-10% MeOH/DCM) to afford the title compound (43 mg, 68%) as a colourless film.

¹H NMR (CD₃OD) δ 7.80 (d, J=2.5 Hz, 1H), 6.61 (d, J=2.5 Hz, 1H), 3.73 (s, 2H), 1.54 (s, 6H). Three exchangeable protons not visible.

LCMS; m/z 220.3 (M+H)⁺ (ES⁺).

Intermediate P16: (S)-1-(2-Hydroxybutyl)-1H-pyrazole-3-sulfonamide Step A: (S)-1-(2-Hydroxybutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

A mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) (1 g, 2.58 mmol), (S)-2-ethyloxirane (0.29 mL, 3.37 mmol), Cs₂CO₃ (2.52 g, 7.74 mmol) and acetonitrile (10 mL) was subjected to microwave irradiation at 100° C. for 6 hours. The mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (1.13 g, 85%) as a clear colourless oil. ¹H NMR (DMSO-d6) δ 7.89 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.7 Hz, 4H), 6.81 (d, J=8.7 Hz, 4H), 6.70 (d, J=2.3 Hz, 1H), 4.96 (d, J=5.6 Hz, 1H), 4.23-413 (m, 5H), 4.10 (dd, J=13.7, 7.3 Hz, 1H), 3.78-3.72 (m, 1H), 3.71 (s, 6H), 1.46-1.24 (m, 2H), 0.91 (t, J=7.3 Hz, 3H).

LCMS; m/z 482.3 (M+Na)⁺ (ES⁺).

Step B: (S)-1-(2-Hydroxybutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (S)-1-(2-hydroxybutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (128 mg, 48%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.79 (d, J=2.3 Hz, 1H), 7.36 (s, 2H), 6.55 (d, J=2.3 Hz, 1H), 4.93 (s, 1H), 4.14 (dd, J=13.7, 4.4 Hz, 1H), 4.03 (dd, J=13.7, 7.5 Hz, 1H), 3.76-3.67 (m, 1H), 1.46-1.25 (m, 2H), 0.89 (t, J=7.4 Hz, 3H).

LCMS; m/z 220.3 (M+H)⁺ (ES⁺).

Intermediate P17: 1-(2-Hydroxycyclopentyl)-1H-pyrazole-3-sulfonamide (racemic anti) Step A: 1-(2-Hydroxycyclopentyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic anti)

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 6-oxabicyclo[3.1.0]hexane to afford the title compound (1.06 g, 82%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 7.98 (d, J=2.4 Hz, 1H), 7.01 (d, J=8.7 Hz, 4H), 6.81 (d, J=8.7 Hz, 4H), 6.70 (d, J=2.4 Hz, 1H), 5.18 (d, J=5.1 Hz, 1H), 4.47 (td, J=7.9, 5.9 Hz, 1H), 4.22-4.20 (m, 1H), 4.19 (s, 4H), 3.71 (s, 6H), 2.24-2.13 (m, 1H), 2.00-1.88 (m, 2H), 1.77 (dq, J=8.3, 7.0 Hz, 2H), 1.64-1.51 (m, 1H).

LCMS; m/z 494.8 (M+Na)⁺ (ES⁺).

Step B: 1-(2-Hydroxycyclopentyl)-1H-pyrazole-3-sulfonamide (racemic anti)

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(2-hydroxycyclopentyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic anti) to afford the title compound (29.5 mg, 11%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.89 (d, J=2.3 Hz, 1H), 7.37 (s, 2H), 6.57 (d, J=2.3 Hz, 1H), 5.14 (s, 1H), 4.41 (td, J=8.3, 6.2 Hz, 1H), 4.20 (q, J=6.7 Hz, 1H), 2.23-2.10 (m, 1H), 2.02-1.88 (m, 2H), 1.82-1.70 (m, 2H), 1.63-1.50 (m, 1H).

LCMS; m/z 232.3 (M+H)⁺ (ES⁺).

Intermediate P18: 1-(3-Hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,R and S,S enantiomers) Step A: 1-(3-Hydroxybutan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic—R,R and S,S enantiomers)

A mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) (1 g, 2.58 mmol), (2S,3S)-2,3-dimethyloxirane (0.3 mL, 3.35 mmol) and Cs₂CO₃ (2.52 g, 7.74 mmol) in acetonitrile (15 mL) was heated to 80° C. and stirred for 4 days. The mixture was transferred into a microwave vial and irradiated at 130° C. for 6 hours, then diluted with H₂O (20 mL) and extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (452 mg, 3%) as a sticky yellow oil.

¹H NMR (DMSO-d6) δ 7.95 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.7 Hz, 4H), 6.81 (d, J=8.7 Hz, 4H), 6.70 (d, J=2.4 Hz, 1H), 5.06 (d, J=5.2 Hz, 1H), 4.30-4.20 (m, 1H), 4.19 (s, 2H), 4.18 (s, 2H), 3.89-3.79 (m, 1H), 3.71 (s, 6H), 1.46 (d, J=6.9 Hz, 3H), 0.88 (d, J=6.3 Hz, 3H).

LCMS; m/z 482.5 (M+Na)⁺ (ES⁺).

Step B: 1-(3-Hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,R and S,S enantiomers)

A solution of 1-(3-hydroxybutan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic—R,R and S,S enantiomers) (450 mg, 0.979 mmol) in TFA (3 mL, 47.1 mmol), H₂O (0.1 mL) and DCM (5 mL) was stirred at room temperature overnight. The solvent was removed and the residue loaded onto silica and purified by chromatography on silica gel (12 g column, 0-10% MeOH/DCM) to afford the title compound (72.9 mg, 33%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.85 (d, J=2.4 Hz, 1H), 7.36 (s, 2H), 6.56 (d, J=2.4 Hz, 1H), 5.01 (s, 1H), 4.26-4.14 (m, 1H), 3.88-376 (m, 1H), 1.44 (d, J=6.8 Hz, 3H), 0.89 (d, J=6.3 Hz, 3H).

LCMS; m/z 220.3 (M+H)⁺ (ES⁺).

Intermediate P1: 1-(1-(Hydroxymethyl)cyclobutyl)-1H-pyrazole-3-sulfonamide Step A: Ethyl 1-(3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-1H-pyrazol-1-yl)cyclobutanecarboxylate

A solution of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C (1 g, 2.58 mmol) in DMF (15 mL) was cooled to 0° C. before sodium hydride (60% in mineral oil) (134 mg, 3.35 mmol) was added. The mixture was warmed to room temperature and stirred for 30 minutes before ethyl 1-bromocyclobutanecarboxylate (0.46 mL, 2.84 mmol) was added slowly. The resulting mixture was stirred at room temperature for 5 days, then diluted with EtOAc (80 mL), H₂O (40 mL) was added and the layers were separated. The aqueous layer was extracted with EtOAc (2×80 mL) and the combined organic extracts were washed with brine (4×50 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (711 mg, 40%) as a 3:1 mixture of regioisomers as a clear colourless oil.

LCMS; m/z 536.1 (M+Na)⁺ (ES⁺).

Step B: 1-(1-(Hydroxymethyl)cyclobutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

To a solution of ethyl 1-(3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-1H-pyrazol-1-yl)cyclobutanecarboxylate (710 mg, 1.037 mmol) in THF (20 mL) at 0° C. was added slowly LiAlH₄ (2M in THF) (2.1 mL, 4.20 mmol) and the mixture was warmed to room temperature and stirred overnight. The reaction was sequentially quenched with H₂O (0.2 mL), 2M NaOH (0.5) and H₂O (1 mL). Na₂SO₄ was added, the mixture was stirred for 30 minutes and then filtered through a plug of Celite® with EtOAc. The filtrate was evaporated and the residue loaded onto silica and purified by chromatography on silica gel (40 g column, 15-100% EtOAc/isohexane) to afford the title compound (410 mg, 83%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.89 (d, J=2.4 Hz, 1H), 7.01 (d, J=8.7 Hz, 4H), 6.82 (d, J=8.7 Hz, 4H), 6.70 (d, J=2.4 Hz, 1H), 5.20 (t, J=5.6 Hz, 1H), 4.20 (s, 4H), 3.75 (d, J=5.6 Hz, 2H), 3.72 (s, 6H), 2.48-2.39 (m, 2H), 2.39-2.27 (m, 2H), 1.95-1.80 (m, 2H).

LCMS; m/z 494.0 (M+Na)⁺ (ES⁺).

Step C: 1-(1-(Hydroxymethyl)cyclobutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(1-(hydroxymethyl)cyclobutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (31-5 mg, 14%) as a clear colourless crystalline solid.

¹H NMR (DMSO-d6) δ 7.80 (d, J=2.4 Hz, 1H), 7.37 (s, 2H), 6.56 (d, J=2.4 Hz, 1H), 5.16 (s, 1H), 3.73 (s, 2H), 2.48-2.43 (m, 2H), 2.33-2.27 (m, 2H), 1.92-1.80 (m, 2H).

LCMS; m/z 232.2 (M+H)⁺ (ES⁺).

Intermediate P20: (R)-1-(2-Hydroxybutyl)-1H-pyrazole-3-sulfonamide Step A: (R)-1-(2-Hydroxybutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

A mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) (1 g, 2.58 mmol), (R)-2-ethyloxirane (0.29 mL, 3.37 mmol), Cs₂CO₃ (2.52 g, 7.74 mmol) and acetonitrile (10 mL) was subjected to microwave irradiation at 110° C. for 6 hours. The mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (1.01 g, 83%) as a clear colourless oil. ¹H NMR (DMSO-d6) δ 7.90 (d, J=2.3 Hz, 1H), 7.01 (d, J=8.6 Hz, 4H), 6.81 (d, J=8.6 Hz, 4H), 6.70 (d, J=2.3 Hz, 1H), 4.96 (d, J=5.6 Hz, 1H), 4.24-4.06 (m, 6H), 3.79-372 (m, 1H), 3.71 (s, 6H), 1.46-1.36 (m, 1H), 1.35-1.25 (m, 1H), 0.91 (t, J=7.4 Hz, 3H).

LCMS; m/z 482.6 (M+Na)⁺ (ES⁺).

Step B: (R)-1-(2-Hydroxybutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from (R)-1-(2-hydroxybutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (113 mg, 40%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.79 (d, J=2.3 Hz, 1H), 7.36 (s, 2H), 6.55 (d, J=2.3 Hz, 1H), 4.92 (s, 1H), 4.14 (dd, J=13.7, 4.3 Hz, 1H), 4.04 (dd, J=13.7, 7.5 Hz, 1H), 3.76-3.67 (m, 1H), 1.47-1.35 (m, 1H), 1.35-1.25 (m, 1H), 0.90 (t, J=7.5 Hz, 3H).

LCMS; m/z 220.3 (M+H)⁺ (ES⁺).

Intermediate P21: 1-(3-Hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers) Step A: 1-(3-Hydroxybutan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers)

A mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) (1 g, 2.58 mmol), (2S,3R)-2,3-dimethyloxirane (0.3 mL, 3.35 mmol) and Cs₂CO₃ (2.52 g, 7.74 mmol) in acetonitrile (10 mL) was subjected to microwave irradiation at 110° C. for 8 hours. The mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3×40 mL). The combined organic extracts were washed with brine (30 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (1.05 g, 85%) as a sticky yellow oil.

¹H NMR (DMSO-d6) δ 7.91 (d, J=2.4 Hz, 1H), 7.00 (d, J=8.6 Hz, 4H), 6.80 (d, J=8.6 Hz, 4H), 6.69 (d, J=2.4 Hz, 1H), 4.95 (d, J=5.1 Hz, 1H), 4.37-4.25 (m, 1H), 4.18 (s, 4H), 3.93-3.81 (m, 1H), 3.71 (s, 6H), 1.41 (d, J=6.9 Hz, 3H), 1.02 (d, J=6.3 Hz, 3H).

LCMS; m/z 482.6 (M+Na)⁺ (ES⁺).

Step B: 1-(3-Hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers)

A solution of 1-(3-hydroxybutan-2-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers) (515 mg, 1.121 mmol) in TFA (3 mL, 47.1 mmol), H₂O (0.1 mL) and DCM (5 mL) was stirred at room temperature overnight. The solvent was removed and the residue loaded onto silica and purified by chromatography on silica gel (24 g column, 0-10% MeOH/DCM) to afford the title compound (110 mg, 36%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.81 (d, J=2.3 Hz, 1H), 7.34 (s, 2H), 6.55 (d, J=2.3 Hz, 1H), 4.85 (s, 1H), 4.30-4.20 (m, 1H), 3.92-3.79 (m, 1H), 1.39 (d, J=7.0 Hz, 3H), 1.00 (d, J=6.3 Hz, 3H).

LCMS; m/z 220.6 (M+H)⁺ (ES⁺).

Intermediate P22: (R)-1-(2-Hydroxypropyl)-1H-imidazole-4-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide

A solution of 1H-imidazole-4-sulfonyl chloride (2.5 g, 15.01 mmol) in DCM (10 mL) was added slowly to a solution of bis(4-methoxybenzyl)amine (4 g, 15.54 mmol) and Et₃N (4.5 mL, 32.3 mmol) in DCM (50 mL) cooled in an ice bath. The mixture was stirred for 30 minutes, warmed to room temperature and stirred for 2 hours. The DCM was removed under pressure and replaced with dioxane (50 mL) and the mixture heated under reflux for 48 hours, cooled, and then partitioned between EtOAc (200 mL) and water (200 mL). The organic layer was dried (MgSO₄), filtered and evaporated to give an oil that was purified by chromatography on silica gel (120 g column, 0-100% EtOAc/isohexane). The product was triturated in TBME/EtOAc, filtered and dried to afford the title compound (2.864 g, 48%) as a solid.

¹H NMR (CDCl₃) δ 7.92 (d, J=1.3 Hz, 1H), 7.52 (d, J=1.3 Hz, 1H), 7.06-7.02 (m, 4H), 6.79-6.75 (m, 4H), 4.30 (s, 4H), 3.77 (s, 6H). Exchangeable proton not visible.

LCMS; m/z 388 (M+H)⁺ (ES⁺); 386 (M−H)⁻ (ES⁻).

Step B: (R)-1-(2-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide

A mixture of N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide (500 mg, 1.29 mmol), (R)-2-methyloxirane (0.18 ml, 2.57 mmol) and K₂CO₃ (535 mg, 3.87 mmol) in acetonitrile (10 mL) was stirred at 60° C. overnight. Upon cooling to room temperature, the reaction mixture was diluted with H₂O (20 mL) and extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (30 mL), passed through a phase separator, and concentrated in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (468 mg, 68%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.82 (d, J=1.3 Hz, 1H), 7.81 (d, J=1.3 Hz, 1H), 7.03 (d, J=8.6 Hz, 4H), 6.80 (d, J=8.6 Hz, 4H), 4.18 (s, 4H), 4.06-4.00 (m, 2H), 3.95-3.86 (m, 2H), 3.71 (s, 6H), 1.04 (d, J=5.9 Hz, 3H).

LCMS; m/z 446.4 (M+H)⁺ (ES⁺).

Step C: (R)-1-(2-Hydroxypropyl)-1H-imidazole-4-sulfonamide

A mixture of (R)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide (460 mg, 0.857 mmol) and TFA (5.5 mL) was stirred at room temperature for 2 days. The reaction mixture was concentrated in vacuo and the residue loaded onto silica and purified by chromatography on silica gel (12 g column, 0-10% MeOH/DCM) to afford a clear colourless oil, which was further purified by prep-HPLC to afford the title compound (123 mg, 68%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.71 (d, J=1.3 Hz, 1H), 7.59 (d, J=1.3 Hz, 1H), 7.12 (s, 2H), 5.00 (d, J=4.1 Hz, 1H), 4.07-3.96 (m, 1H), 3.93-3.79 (m, 2H), 1.03 (d, J=6.0 Hz, 3H).

LCMS; m/z 206.2 (M+H)⁺ (ES⁺).

Intermediate P23: (S)-1-(2-Hydroxypropyl)-1H-imidazole-4-sulfonamide Step A: (S)-1-(2-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide

Prepared according to the general procedure of (R)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide (Intermediate P22, Step B) from N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide (Intermediate P22, Step A) and (S)-2-methyloxirane to afford the title compound (160 mg, 37%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.81 (d, J=1.2 Hz, 1H), 7.80 (d, J=1.2 Hz, 1H), 7.02 (d, J=8.7 Hz, 4H), 6.80 (d, J=8.7 Hz, 4H), 5.04 (d, J=4.6 Hz, 1H), 4.18 (s, 4H), 4.06-3.99 (m, 1H), 3.97-3.84 (m, 2H), 3.71 (s, 6H), 1.04 (d, J=5.9 Hz, 3H).

LCMS; m/z 446.2 (M+H)⁺ (ES⁺).

Step B: (S)-1-(2-Hydroxypropyl)-1H-imidazole-4-sulfonamide

Prepared according to the general procedure of (R)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide (Intermediate P22, Step C) from (S)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-imidazole-4-sulfonamide to afford the title compound (56 mg, 70%1 as a clear colourless oil.

¹H NMR (DMSO-d6) δ 7.71 (d, J=1.3 Hz, 1H), 7.59 (d, J=1.3 Hz, 1H), 7.11 (s, 2H), 5.00 (d, J=4.6 Hz, 1H), 4.04-3.95 (m, 1H), 3.92-3.80 (m, 2H), 1.03 (d, J=6.0 Hz, 3H).

LCMS; m/z 206.2 (M+H)⁺ (ES⁺).

Intermediate P24: 1-(3,3,3-Trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 3-bromo-1,1,1-trifluoropropan-2-ol to afford the title compound (183 mg, 28%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 8.01 (d, J=2.4 Hz, 1H), 7.02 (d, J=8.7 Hz, 4H), 6.84-6.78 (m, 5H), 6.74 (d, J=2.4 Hz, 1H), 4.56-4.35 (m, 3H), 4.19 (s, 4H), 3.71 (s, 6H).

LCMS; m/z 522.4 (M+Na)⁺ (ES⁺).

Step B: 1-(3,3,3-Trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide to afford the title compound (74 mg, 89%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 7.92 (d, J=2.3 Hz, 1H), 7.43 (s, 2H), 6.79 (d, J=6.5 Hz, 1H), 6.60 (d, J=2.3 Hz, 1H), 4.51-4.28 (m 3H).

LCMS; m/z 260.1 (M+H)⁺ (ES⁺); 258.0 (M−H)⁻ (ES⁻).

Intermediate P25: 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide Step A: 3-Nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole

3-Nitro-1H-pyrazole (1.5 g, 13.27 mmol) was combined with K₂CO₃ (3.67 g, 26.5 mmol) and tetrabutylammonium iodide (0.588 g, 1.592 mmol) in DMF (30 mL) and treated with 4-bromotetrahydro-2H-pyran (1.791 mL, 15.92 mmol). The resultant mixture was heated at 60° C. for 24 hours, then additional K₂CO₃ (1.8 g) and 4-bromotetrahydro-2H-pyran (0.8 mL) were added and the reaction stirred another 18 hours. The reaction mixture was diluted with TBME (50 mL), water (100 mL) and brine (100 mL). The organic layer was washed with water (2×100 mL), dried (MgSO₄), filtered and concentrated to give a brown oil. The brown oil was purified by chromatography on silica gel (80 g column, 0-100% EtOAc/isohexane) to afford the title compound (1.02 g, 37.0%) as a thick yellow oil.

¹H NMR (CDCl₃) δ 7.51 (d, J=2.6 Hz, 1H), 6.92 (d, J=2.6 Hz, 1H), 4.52-4.28 (m, 1H), 4.25-3.99 (m, 2H), 3.67-3.37 (m, 2H), 2.34-1.90 (m, 4H).

LCMS; m/z 198.1 (M+H)⁺ (ES⁺).

Step B: 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-amine

In a 30-mL vial, 3-nitro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole (1 g, 4.82 mmol) and 10% Pd/C (wet) Type 87 L (0.021 g) were suspended in methanol (10 mL) and ethyl acetate (10 mL). The Baskerville vessel was purged with N₂ three times, and then filled with H₂ three times. The reaction mixture was stirred at room temperature under 5 bar of H₂ for 17 hours. The reaction mixture was filtered through a pad of Celite® and the filter cake was washed with EtOAc (2×10 mL). The combined filtrates were concentrated to dryness to give the title compound (0.662 g, 94%) as a white solid.

¹H NMR (CDCl₃) δ 7.18 (d, J=2.4 Hz, 1H), 5.60 (d, J=2.4 Hz, 1H), 4.18-3.99 (m, 3H), 3.50 (td, J=11.8, 2.5 Hz, 2H), 3.07 (s, 2H), 2.15-1.85 (m, 4H).

LCMS; m/z 168.0 (M+H)⁺ (ES⁺).

Step C: 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonyl chloride

In a 100-mL 3-necked round-bottomed flask, a mixture of HCl (1.42 mL, 46.8 mmol) in water (0.95 mL) and acetonitrile (4.75 mL) was cooled to −10° C. (acetone/dry ice bath) and treated dropwise with an aqueous solution of NaNO₂ (0.314 g, 4.55 mmol) in water (0.570 mL), maintaining internal temperature below 0° C. The solution was stirred for 10 minutes and then treated with a solution of 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-amine (0.66 g, 3.79 mmol) in acetonitrile (4.75 mL) (with 0.2 mL of concentrated HCl for solubility) (which was pre-cooled to 0° C.) at 0° C. over 15 minutes. The resulting reaction mixture was stirred at 0° C. for 45 minutes. Cold AcOH (1.9 mL, 33.2 mmol), Cu(II)Cl (0.255 g, 1.895 mmol) and Cu(I)Cl (0.019 g, 0.189 mmol) were sequentially added to the reaction mixture and the reaction mixture was purged with sulfur dioxide gas for 20 minutes at 0° C. (exotherm). The reaction was stirred for a further 50 minutes at 0° C., diluted with water (15 mL) and extracted with EtOAc (3×30 mL), then dried (MgSO₄), filtered and concentrated to dryness to give a black paste. The crude product was purified by chromatography on silica gel (40 g column, 0-100% DCM/isohexane, monitored at 215 nm) to afford the title compound (250 mg, 21%) as a clear yellow oil.

¹H NMR (CDCl₃) δ 7.58 (d, J=2.5 Hz, 1H), 6.91 (d, J=2.5 Hz, 1H), 4.58-4.45 (m, 1H), 4.18-4.06 (m, 2H), 3.62-3.50 (m, 2H), 2.26-2.04 (m, 4H).

Step D: 1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide

A solution of 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonyl chloride (0.250 g, 0.798 mmol) in THF (1.6 mL) was treated with 0.5 M ammonia in dioxane (4.79 mL, 2.393 mmol). The reaction mixture was then left to stir at room temperature for 17 hours. The reaction mixture was concentrated to dryness and the residue obtained was quenched with water (1 mL) and extracted with EtOAc (2×10 mL). The combined organic layers were dried over MgSO₄, filtered and concentrated to dryness. The white residue obtained was taken up in DCM (1 mL) and precipitated by addition of isohexane (3 mL). The remaining liquid was removed by pipette and the solid washed with isohexane (2×3 mL) and the decantation process repeated. The residual solid was then dried under vacuum to give the title compound (170 mg, 91%) as a white solid. ¹H NMR (DMSO-d6) δ 7.96 (d, J=2.4 Hz, 1H), 7.39 (s, 2H), 6.59 (d, J=2.4 Hz, 1H), 4.49 (dt, J=10.4, 5.2 Hz, 1H), 4.11-3.74 (m, 2H), 3.57-3.37 (m, 2H), 2.04-1.82 (m, 4H).

LCMS; m/z 231.9 (M+H)⁺ (ES⁺); 229.9 (M−H)⁻ (ES⁻).

Intermediate P26: (R)-2-(2-Hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide Step A: (R)-1-(4-(Benzylthio)-2H-1,2,3-triazol-2-yl)propan-2-ol

A mixture of 4-(benzylthio)-1H-1,2,3-triazole (6 g, 31.4 mmol), K₂CO₃ (13 g, 94 mmol) and (R)-2-methyloxirane (3 ml, 42.8 mmol) in MeCN (100 ml) was heated at 50° C. for 3 days. A further portion of (R)-2-methyloxirane (1 ml) was added and heated for a further 3 days. The mixture was cooled to room temperature and partitioned between EtOAc (400 ml) and water (300 ml). The organic layer was washed with brine (300 ml), dried (MgSO₄), filtered and evaporated. The residue was purified by chromatography on silica gel (120 g column, 0-50% EtOAc/isohexane) to afford the title compound (2.83 g, 17%), (R)-1-(5-(benzylthio)-1H-1,2,3-triazol-1-yl)propan-2-ol (1.47 g, 17%) and (R)-1-(4-(benzylthio)-1H-1,2,3-triazol-1-yl)propan-2-ol (2.37 g, 30%) all as colourless oils.

¹H NMR (CDCl₃) δ 7.38 (s, 1H), 7.33-7.24 (m, 5H), 4.49-4.26 (m, 3H), 4.12 (s, 2H), 1.24 (d, J=6.3 Hz, 3H). Exchangeable proton not visible.

LCMS; m/z 250.0 (M+H)⁺ (ES⁺); 248.7 (M−H)⁻ (ES⁻).

Step B: (R)-2-(2-(Benzyloxy)propyl)-4-(benzylthio)-2H-1,2,3-triazole

To a solution of (R)-1-(4-(benzylthio)-2H-1,2,3-triazol-2-yl)propan-2-ol (2.83 g, 11.35 mmol) in THF (50 ml) at 0° C. was added sodium hydride (60% in mineral oil) (0.6 g, 15.00 mmol) and the mixture was stirred for 15 minutes. (Bromomethyl)benzene (1.5 ml, 12.61 mmol) was added and the mixture was warmed to room temperature and stirred overnight. Additional sodium hydride (60% in mineral oil) (0.6 g, 11.35 mmol) was added and the mixture was stirred at room temperature for 4 days. The mixture was quenched with water (30 mL) and extracted with EtOAc (3×60 mL). The combined organic extracts were washed with brine (50 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (80 g column, 0-100% EtOAc/isohexane) to afford the title compound (2.92 g, 73%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 7.71 (s, 1H), 7.29-7.20 (m, 8H), 7.17-7.12 (m, 2H), 4.47-4.41 (m, 3H), 4.31 (d, J=12.0 Hz, 1H), 4.17 (s, 2H), 4.04-3.92 (m, 1H), 1.13 (d, J=6.3 Hz, 3H).

LCMS; m/z 340.3 (M+H)⁺ (ES⁺).

Step C: (R)-2-(2-(Benzyloxy)propyl)-2H-1,2,3-triazole-4-sulfonamide

To a mixture of (R)-2-(2-(benzyloxy)propyl)-4-(benzylthio)-2H-1,2,3-triazole (2.91 g, 8.32 mmol) in AcOH (60 mL) and H₂O (30 mL) was added NCS (4.5 g, 33.7 mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was partitioned between EtOAc (300 ml) and H₂O (300 ml) and the organic layer was sequentially washed with sat aq NaHCO₃ (2×200 ml) and brine (300 ml), passed through a phase separator and the solvent was removed in vacuo. TBME (60 mL) was added to the residue and the white solid removed by filtration. The filtrate was concentrated to give a pale yellow oil which as was dissolved in TBME (30 mL). Ammonia (0.5 M in dioxane) (so mL, 25.00 mmol) was added and the mixture was stirred at room temperature overnight. The volatiles were evaporated and the residue was partitioned between EtOAc (500 mL) and H₂ (150 mL). The organic layer was washed with brine (100 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (80 g cartridge, 0-100% EtOAc/isohexane) to afford the title compound (1.99 g, 77%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 8.11 (s, 1H), 7.81 (s, 2H), 7.34-7.21 (m, 3H), 7.17-7.12 (m, 2H), 4.64 (dd, J=13.9, 4.4 Hz, 1H), 4.55 (dd, J=13.9, 7.3 Hz, 1H), 4.48 (d, J=12.0 Hz, 1H), 4.36 (d, J=12.0 Hz, 1H), 4.12-3.99 (m, 1H), 1.20 (d, J=6.3 Hz, 3H).

LCMS; m/z 297.2 (M+H)⁺ (ES⁺).

Step D: (R)-2-(2-Hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide

A mixture of (R)-2-(2-(benzyloxy)propyl)-2H-1,2,3-triazole-4-sulfonamide (1.99 g, 6.38 mmol) and 5% Pd/C (Type 87L, 58-5% moisture) (1.73 g, 0-337 mmol) in EtOH (15 mL) was hydrogenated at 5 bar overnight. The mixture was filtered through Celite® and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g cartridge, 0-10% MeOH/DCM) to afford the title compound (1.235 g, 90%) as a clear colourless oil.

¹H NMR (DMSO-d6) δ 8.08 (s, 1H), 7.77 (s, 2H), 5.04 (d, J=5.3 Hz, 1H), 4.41 (dd, J=13.5, 5.0 Hz, 1H), 4.36 (dd, J=13.5, 7.3 Hz, 1H), 4.19-4.09 (m, 1H), 1.11 (d, J=6.3 Hz, 3H).

LCMS; m/z 207.0 (M+H)⁺ (ES⁺).

Intermediate P27: 1-(3-Hydroxycyclobutyl)-1H-pyrazole-3-sulfonamide Step A: 1-(3-(Benzyloxy)cyclobutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

To a solution of 3-(benzyloxy)cyclobutanol (0.52 ml, 3.14 mmol) in DCM (15 mL) at 0° C. was added N-ethyl-N-isopropylpropan-2-amine (0.72 ml, 4.12 mmol) and methanesulfonyl chloride (0.28 ml, 3.59 mmol). The mixture was warmed to room temperature and stirred for 3 hours. The reaction was quenched with aqueous NaHCO₃ (15 mL) and extracted with DCM (2×20 mL). The combined organic extracts were washed with brine (15 mL), passed through a phase separator and the solvent was concentrated in vacuo. The residue was dissolved in THF (7-5 mL) and added to a mixture of N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) (1 g, 2.58 mmol) and K₂CO₃ (1.4 g, 10.13 mmol) in THF (7-5 mL). The resulting mixture was stirred at 60° C. overnight for 4 days. The mixture was quenched with H₂O (30 mL) and extracted with EtOAc (3×60 mL). The combined organic extracts were washed with brine (50 mL), passed through a phase separator and the solvent was removed in vacuo. The residue was loaded onto silica and purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (725 mg, 49%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 8.03 (d, J=2.4 Hz, 1H), 7.36-7.27 (m, 5H), 7.03 (d, J=8.7 Hz, 4H), 6.81 (d, J=8.7 Hz, 4H), 6.72 (d, J=2.4 Hz, 1H), 5.14-5.03 (m, 1H), 4.43 (s, 2H), 4.37-4.31 (m, 1H), 4.21 (s, 4H), 3.71 (s, 6H), 2.66-2.52 (m, 4H).

LCMS; m/z 570.4 (M+Na)⁺ (ES⁺).

Step B: 1-(3-(Benzyloxy)cyclobutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-(3-(benzyloxy)cyclobutyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (379 mg, 87%) as a pale yellow oil.

¹H NMR (DMSO-d6) δ 7.96 (d, J=2.3 Hz, 1H), 7.41 (s, 2H), 7.38-7.34 (m, 4H), 7.33-7.27 (m, 1H), 6.59 (d, J=2.4 Hz, 1H), 5.14-5.02 (m, 1H), 4.44 (s, 2H), 4.39-4.31 (m, 1H), 2.71-2.61 (m, 2H), 2.61-2.52 (m, 2H).

LCMS; m/z 308.2 (M+H)⁺ (ES⁺).

Step C: 1-(3-Hydroxycyclobutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of (R)-2-(2-hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide (Intermediate P26, Step D) from 1-(3-(benzyloxy) cyclobutyl)-1H-pyrazole-3-sulfonamide to afford the title compound (156 mg, 91%) as a colourless solid.

¹H NMR (DMSO-d6) δ 7.94 (d, J=2.3 Hz, 1H), 7.39 (s, 2H), 6.58 (d, J=2.3 Hz, 1H), 5.26 (d, J=5.0 Hz, 1H), 5.05-4.97 (m, 1H), 4.49-4.40 (m, 1H), 2.66-2.58 (m, 2H), 2.41-2.33 (m, 2H).

LCMS; m/z 218.1 (M+H)⁺ (ES⁺).

Intermediate P28:5-(3-Hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: N,N-Bis-(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of 1-methyl-1H-pyrazole-3-sulfonyl chloride (13.0 g, 72.0 mmol) in DCM (30 mL) was added slowly to a solution of bis-(4-methoxybenzyl)amine (20 g, 78 mmol) and triethylamine (20 mL, 143 mmol) in DCM (250 mL) cooled in an ice bath. The mixture was stirred for 30 minutes, warmed to room temperature and stirred for 2 hours. The mixture was washed with water (200 mL), hydrochloric acid (aqueous, 1 M, 200 mL) and water (200 mL), then dried (MgSO₄), filtered and concentrated in vacuo. The residue was triturated with TBME (250 mL), filtered, and then purified by chromatography on silica gel (330 g column, 0-60% EtOAc/iso-hexane) to afford the title compound (27.66 g, 93%) as a white solid.

¹H NMR (CDCl₃) δ 7.42 (d, J=2.3, 1H), 7.11-7.07 (m, 4H), 6.81-6.77 (m, 4H), 6.65 (d, J=2.3, 1H), 4.33 (s, 4H), 3.99 (s, 3H) and 3.81 (s, 6H).

LCMS m/z 402 (M+H)⁺ (ES⁺).

Step B: 5-(3-Hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of n-BuLi (2.5 M in hexanes; 2.0 mL, 5.00 mmol) was added dropwise to a stirred solution of N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (2 g, 4.98 mmol) in THF (35 mL) cooled to −78° C. The reaction mixture was stirred for 1 hour and then a solution of oxetan-3-one (0.292 mL, 4.98 mmol) in THF (16 mL) was added. The reaction mixture was left at −78° C. for 5 minutes and then allowed to warm to room temperature and stirred for 1 hour. The reaction was quenched with saturated aq NH₄Cl solution (20 mL) and extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO₄), filtered and evaporated in vacuo to give an orange oil. The crude product was purified by chromatography on silica gel (80 g column, 0-75% EtOAc/isohexane) to afford the title compound (1.44 g, 61%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.10-7.00 (m, 4H), 6.90 (s, 1H), 6.85-6.78 (m, 4H), 6.75 (s, 1H), 4.89 (d, J=7.3 Hz, 2H), 4.76 (d, J=7.2 Hz, 2H), 4.23 (s, 4H), 3.81 (s, 3H), 3.71 (s, 6H).

LCMS; m/z 496.1 (M+Na)⁺ (ES⁺).

Step C: 5-(3-Hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of ceric ammonium nitrate (289 mg, 0.528 mmol) in water (0.5 mL) was added portionwise over 5 minutes to a stirred solution of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (50 mg, 0.106 mmol) in MeCN (2 mL). The orange mixture was stirred at room temperature for 17 hours and then diluted with water (2 mL) and extracted with EtOAc (3×5 mL). The combined organic phases were dried (MgSO₄), filtered and concentrated in vacuo to give an orange oil. The crude product was purified by chromatography on silica gel (4 g column, 0-8% MeOH/DCM) to afford the title compound (21 mg, 77%) as an orange residue.

1H NMR (DMSO-d6) δ 7.41 (s, 2H), 6.77 (s, 1H), 6.73 (s, 1H), 4.90-4.85 (m, 2H), 4.78-4.73 (m, 2H), 3.79 (s, 3H).

LCMS; m/z 234.0 (M+H)⁺ (ES⁺).

Intermediate P29: 5-(3-Methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Sodium hydride (60% in mineral oil) (71.5 mg, 1.787 mmol) was added portionwise to 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) (705 mg, 1.489 mmol) in dry DMF (9 mL) at 0° C. The reaction mixture was stirred for 30 minutes at 0° C., then iodomethane (2M in MTBE; 2.98 mL, 5.96 mmol) was added in a single portion and the mixture was stirred for a further 2 hours while warming to room temperature. The reaction mixture was quenched by slow addition of saturated aqueous ammonium chloride (10 mL) and then partitioned between EtOAc (30 mL) and brine (100 mL). The aqueous layer was separated and the organic layer was washed with brine (100 mL), dried (MgSO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel (24 g column, 0-70% EtOAc/isohexane) to afford the title compound (620 mg, 78%) as a colourless oil.

¹H NMR (CDCl₃) δ 7.22-7.06 (m, 4H), 6.83-6.75 (m, 4H), 6.57 (s, 1H), 4.90 (dd, J=6.8, 0.7 Hz, 2H), 4.78 (dd, J=6.8, 0.8 Hz, 2H), 4.35 (s, 4H), 3.81-3.74 (m, 9H), 3.04 (s, 3H).

LCMS m/z 488.2 (M+H)⁺ (ES⁺).

Step B: 5-(3-Methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step C) from N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (357 mg, 40%) as a colourless solid. 1H NMR (DMSO-d6) δ 7.46 (s, 2H), 6.92 (s, 1H), 4.94-4.82 (m, 2H), 4.83-4.70 (m, 2H), 3.73 (s, 3H), 2.99 (s, 3H).

LCMS m/z 248.3 (M+H)⁺ (ES⁺).

Intermediate P30: (R)-1-(2-Hydroxypropyl)-1H-1,2,4-triazole-3-sulfonamide Step A: (R)-1-(3-(Benzylthio)-1H-1,2,4-triazol-1-yl)propan-2-ol

Prepared according to the general procedure of (R)-1-(4-(benzylthio)-2H-1,2,3-triazol-2-yl)propan-2-ol (Intermediate P26, Step A) from 3-(benzylthio)-1H-1,2,4-triazole and (R)-2-methyloxirane to afford the title compound (1.01 g, 35.6%) and (R)-1-(3-(benzylthio)-4H-1,2,4-triazol-4-yl)propan-2-ol (783 mg, 30%), both as yellow oils. ¹H NMR (DMSO-d6) δ 8.43 (s, 1H), 7.38 (d, J=7.2 Hz, 2H), 7.34-7.20 (m, 3H), 4.98 (d, J=4.7 Hz, 1H), 4.32 (s, 2H), 4.10-3.90 (m, 3H), 1.05 (d, J=5.8 Hz, 3H).

LCMS; m/z 250.3 (M+H)⁺ (ES⁺).

Step B: (R)-1-(2-(Benzyloxy)propyl)-3-(benzylthio)-1H-1,2,4-triazole

Prepared according to the general procedure of (R)-2-(2-(benzyloxy)propyl)-4-(benzylthio)-2H-1,2,3-triazole (Intermediate P26, Step B) from (R)-1-(3-(benzylthio)-1H-1,2,4-triazol-1-yl)propan-2-ol to afford the title compound (923 mg, 65%) as a colourless oil.

¹H NMR (DMSO-d6) δ 8.47 (s, 1H), 7.39-7.33 (m, 2H), 7.32-7.18 (m, 6H), 7.16-7.11 (m, 2H), 4.47 (d, J=12.0 Hz, 1H), 4.32-4.28 (m, 3H), 4.23 (dd, J=14.1, 4.3 Hz, 1H), 4.17 (dd, J=14.1, 7.1 Hz, 1H), 3.89-3.80 (m, 1H), 1.13 (d, J=6.3 Hz, 3H).

LCMS; m/z 340.2 (M+H)⁺ (ES⁺).

Step C: (R)-1-(2-(Benzyloxy)propyl)-1H-1,2,4-triazole-3-sulfonamide

Prepared according to the general procedure of (R)-2-(2-(benzyloxy)propyl)-2H-1,2,3-triazole-4-sulfonamide (Intermediate P26, Step C) from (R)-1-(2-(benzyloxy)propyl)-3-(benzylthio)-1H-1,2,4-triazole to afford the title compound (314 mg, 37%) as a colourless solid.

¹H NMR (DMSO-d6) δ 8.66 (s, 1H), 7.76 (bs, 2H), 7.34-7.23 (m, 3H), 7.19-7.13 (m, 2H), 4.53 (d, J=12.1 Hz, 1H), 4.41-4.29 (m, 3H), 3.96-3.88 (m, 1H), 1.18 (d, J=6.3 Hz, 3H).

LCMS; m/z 297.2 (M+H)⁺ (ES⁺).

Step D: (R)-1-(2-Hydroxypropyl)-1H-1,2,4-triazole-3-sulfonamide

Prepared according to the general procedure of (R)-2-(2-hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide (Intermediate P26, Step D) from (R)-1-(2-(benzyloxy)propyl)-1H-1,2,4-triazole-3-sulfonamide to afford the title compound (178 mg, 69%) as a colourless oil.

1H NMR (DMSO-d6) δ 8.61 (s, 1H), 7.82-7.66 (m, 2H), 5.09 (d, J=5.0 Hz, 1H), 4.21 (dd, J=13.7, 4.0 Hz, 1H), 4.14-4.07 (m, 2H), 1.10 (d, J=6.2 Hz, 3H).

LCMS; m/z 207.4 (M+H)⁺ (ES⁺).

Intermediate P31: 1-Cyclopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: 1-Cyclopropyl-3-nitro-1H-pyrazole

To a solution of cyclopropylboronic acid (36.77 g, 428.04 mmol) in 1,2-dichloroethane (500 mL) was added 3-nitro-1H-pyrazole (44 g, 389.12 mmol), 2,2-bipyridine (60.77 g, 389.12 mmol) and Na₂CO₃ (64.59 g, 609.44 mmol) at 25° C. The mixture was stirred at 25° C. for 30 minutes. Then Cu(OAc)₂ (70.68 g, 389.12 mmol) was added and the reaction mixture was warmed to 70° C. and stirred at 70° C. for 15.5 hours. The reaction mixture was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography on silica gel (3-25% EtOAc/petroleum ether) to give crude product (26.7 g). The crude product was dissolved in pyrrolidine (10 mL) and the resulting mixture was stirred at 70° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to remove pyrrolidine. The residue was diluted with H₂O (33 mL) and the pH was adjusted to 5-6 with aqueous HCl solution (1 N). The mixture was extracted with EtOAc (3×50 mL). The combined organic layers were washed with brine (2×33 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound (17.7 g, 30%) as a yellow oil.

¹H NMR (CDCl₃) δ 7.54 (d, 1H), 6.84 (d, 1H), 3.73-3.67 (m, 1H), 1.24-1.22 (m, 2H), 1.13-1.07 (m, 2H).

Step B: 1-Cyclopropyl-1H-pyrazol-3-amine

To a solution of 1-cyclopropyl-3-nitro-1H-pyrazole (36 g, 235.08 mmol) in EtOH (400 mL) was added a solution of NH₄Cl (62.87 g, 1.18 mol, 41.09 mL) in H₂ (150 mL). Then the reaction mixture was warmed to 60° C. and iron powder (39.38 g, 705.24 mmol) was added in portions. The reaction mixture was stirred at 60° C. for 16 hours and then concentrated under reduced pressure. The residue was diluted with H₂O (500 mL) and extracted with EtOAc (3×500 mL). The combined organic layers were washed with brine (2×250 mL dried over NaSO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (3-50% EtOAc/petroleum ether) to give the title compound (20 g, 69%) as a yellow oil.

¹H NMR (CDCl₃) δ 7.14 (d, 1H), 5.11 (d, 1H), 3.57 (br s, 2H), 3.38-3.32 (m, 1H), 0.99-0.95 (m, 2H), 0.90-0.87 (m, 2H).

LCMS m/z 124.2 (M+H)⁺ (ES⁺).

Step C: 1-Cyclopropyl-1H-pyrazole-3-sulfonyl chloride

To a solution of 1-cyclopropyl-1H-pyrazol-3-amine (19 g, 154.28 mmol) in MeCN (500 mL) and H₂O (50 mL) at 0° C. was added concentrated HCl solution (50 mL). Then an aqueous solution of NaNO₂ (12.77 g, 185.13 mmol) in H₂O (50 mL) was added slowly. The resulting solution was stirred at 0° C. for 40 minutes. AcOH (50 mL), CuCl₂ (10.37 g, 77.14 mmol) and CuCl (763 mg, 7.71 mmol, 184.46 L) were added into the reaction mixture. Then SO₂ gas (15 psi) was bubbled into the reaction mixture for 20 minutes at 0° C. The reaction mixture was stirred at 0° C. for 1 hour and then concentrated under reduced pressure. The residue was diluted with H₂O (250 mL) and extracted with EtOAc (3×250 mL). The combined organic layers were washed with brine (2×150 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (0-50% EtOAc/petroleum ether) to give the title compound (14 g, 44%) as a yellow oil.

¹H NMR (CDCl₃) δ 7.62 (d, 1H), 6.83 (d, 1H), 3.78-3.72 (m, 1H), 1.28-1.24 (m, 2H), 1.16-1.12 (m, 2H).

Step D: 1-Cyclopropyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

To a solution of 1-cyclopropyl-1H-pyrazole-3-sulfonyl chloride (28 g, 135.49 mmol) in THF (300 mL) was added triethylamine (27.42 g, 270.99 mmol, 37.72 mL) and bis(4-methoxybenzyl)amine (34.87 g, 135-49 mmol). The mixture was stirred at 25° C. for 1 hour. Then the reaction mixture was diluted with H₂O (500 mL) and extracted with EtOAc (3×500 mL). The combined organic layers were washed with brine (2×500 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by reversed phase flash chromatography (MeCN/NH₃.H₂O (0.5% NH₃.H₂O)) and the collected eluting solution was concentrated under reduced pressure to remove most of the MeCN. Then the mixture was extracted with EtOAc (3×1000 mL). The combined organic layers were washed with brine (2×500 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure to give the title compound (30 g, 52%).

¹H NMR (CDCl₃) δ 7.49 (d, 1H), 7.08-7.06 (m, 4H), 6.79-6.77 (m, 4H), 6.62 (d, 1H), 4.32 (s, 4H), 3.80 (s, 6H), 3.68-3.64 (m, 1H), 1.15-1.13 (m, 2H), 1.09-1.06 (m, 2H).

LCMS m/z 428.2 (M+H)⁺ (ES⁺).

Step E: 1-Cyclopropyl-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from 1-cyclopropyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide and oxetan-3-one to afford the title compound (830 mg, 63%) as a colourless solid.

1H NMR (DMSO-d6) δ=7.08-7.03 (m, 4H), 6.89 (s, 1H), 6.84-6.79 (m, 4H), 6.77 (s, 1H), 4.95 (d, J=7.0 Hz, 2H), 4.78 (d, J=7.0 Hz, 2H), 4.21 (s, 4H), 3.77-3.69 (m, 1H), 3.72 (s, 6H), 1.09-0.93 (m, 4H).

LCMS; m/z 522.1 (M+Na)⁺ (ES⁺).

Step F: 1-Cyclopropyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29, Step A) from 1-cyclopropyl-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (450 mg, 97%) as a pale yellow oil.

LCMS; m/z 536.4 (M+Na)⁺ (ES⁺).

Step G: 1-Cyclopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-cyclopropyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide to afford the title compound (101 mg, 87%) as a colourless solid.

LCMS m/z 273.9 (M+H)⁺ (ES⁺).

Intermediate P32: 1-(tert-Butyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: 1-(tert-Butyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

To a solution of 1-(tert-butyl)-1H-pyrazole-3-sulfonyl chloride (40 g, 179.6 mmol) in THF (400 mL) was added TEA (54.53 g, 538.9 mmol, 75.00 mL) and bis(4-methoxybenzyl)amine (13.87 g, 53.9 mmol). The mixture was stirred at 25° C. for 16 hours. The reaction mixture was poured into H₂O (1 L) and extracted with EtOAc (3×1 L). The combined organic layers were dried (Na₂SO₄), filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel (30:1 to 2:1 petroleum ether/EtOAc) and then purified by reversed phase flash chromatography (0.1% NH₃.H₂O/CH₃CN) to give the title compound (15 g, 19%) as a yellow oil. 1H NMR (CDCl₃) δ 7.54 (d, 1H), 7.07 (d, 4H), 6.77 (d, 4H), 6.66 (d, 1H), 4.32 (s, 4H), 3.79 (s, 6H), and 1.60 (s, 9H).

LCMS: m/z 444.1 (M+H)⁺ (ES⁺).

Step B: 1-(tert-Butyl)-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from 1-(tert-butyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide and oxetan-3-one to afford the title compound (330 mg, 19%) as a colourless solid.

1H NMR (DMSO-d6) δ=7.09-7.03 (m, 4H), 6.90 (s, 1H), 6.86 (s, 1H), 6.85-6.79 (m, 4H), 4.95 (d, J=7.0, 2H), 4.68 (d, J=7.2, 2H), 4.24 (s, 4H), 3.72 (s, 6H), 1.53 (s, 9H).

LCMS; m/z 516.2 (M+H)⁺ (ES⁺).

Step C: 1-(tert-Butyl)-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29, Step A) from 1-(tert-butyl)-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (310 mg, 94%) as a yellow oil.

LCMS; m/z 530.2 (M+H)⁺ (ES⁺).

Step D: 1-(tert-Butyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step C) from 1-(tert-butyl)-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide to afford the title compound (80 mg, 7%) as a colourless solid.

1H NMR (DMSO-d6) δ=7.43 (s, 2H), 6.88 (s, 1H), 4.91 (d, J=7.5 Hz, 2H), 4.76 (d, J=7.5 Hz, 2H), 3.00 (s, 3H), 1.52 (s, 9H).

Intermediate P33: 5-(3-Ethoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(3-Ethoxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of n-BuLi (2.5 M in hexanes; 1.519 ml, 3.80 mmol) was added dropwise to a stirred solution of N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (1.51 g, 3.72 mmol) in THF (30 ml) at −78° C. The reaction was stirred for 1 hour at −78° C. Then a solution of oxetan-3-one (0.268 ml, 4.10 mmol) in THF (1.5 mL) was added and the mixture was stirred for 10 minutes at −78° C., before warming to room temperature and stirring for 18 hours. Then the reaction mixture was cooled to 0° C. and sodium hydride (60% in mineral oil) (0.179 g, 4.47 mmol) was added portionwise. After 15 minutes, ethyl iodide (0.391 ml, 4.84 mmol) was added and the reaction mixture was warmed to room temperature and stirred for 20 hours. A further portion of ethyl iodide (0.391 ml, 4.84 mmol) was added and the mixture was heated at 45° C. for 4 days. The reaction mixture was quenched with saturated aqueous NH₄Cl solution (10 mL) and diluted with EtOAc (50 mL) and the layers were separated. The aqueous phase was extracted with EtOAc (2×50 mL) and the combined organic phases were washed with brine (30 mL), dried over MgSO₄, filtered, and concentrated in vacuo to give a yellow oil. The crude material was purified by chromatography on silica gel (40 g column, 0-70% EtOAc/isohexane) to afford the title compound (1.394 g, 73%) as a white solid.

1H NMR (DMSO-d6) δ 7.10-7.03 (m, 4H), 7.00 (s, 1H), 6.85-6.78 (m, 4H), 4.87 (d, J=7.3 Hz, 2H), 4.78 (d, J=7.3 Hz, 2H), 4.24 (s, 4H), 3.74 (s, 3H), 3.72 (s, 6H), 3.07 (q, J=7.0 Hz, 2H), 1.10 (t, J=7.0 Hz, 3H).

LCMS m/z 524.4 (M+Na)⁺ (ES⁺).

Step B: 5-(3-Ethoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 5-(3-ethoxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (555 mg, 76%) as a colourless solid.

LCMS m/z 262.4 (M+H)⁺ (ES⁺).

Intermediate P34: 5-(3-Hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide Step A: N,N-Bis-(4-methoxybenzyl)-1-isopropyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis-(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step A) from 1-isopropyl-1H-pyrazole-3-sulfonyl chloride to afford the title compound as a white solid (16.6 g, 80%). 1H NMR (DMSO-d6) δ 8.00 (d, J=2.4 Hz, 1H), 7.07-6.96 (m, 4H), 6.85-6.76 (m, 4H), 6.70 (d, J=2.4 Hz, 1H), 4.61 (sept, J=6.7 Hz, 1H), 4.20 (s, 4H), 3.71 (s, 6H), 1.44 (d, J=6.7 Hz, 6H).

LCMS m/z 452.2 (M+Na)⁺ (ES⁺).

Step B: 5-(3-Hydroxyoxetan-3-yl)-1-isopropyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from N,N-bis-(4-methoxybenzyl)-1-isopropyl-1H-pyrazole-3-sulfonamide and oxetan-3-one to afford the title compound (1.8 g, 61%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.10-7.00 (m, 4H), 6.87 (s, 1H), 6.86-6.80 (m, 4H), 6.78 (s, 1H), 4.88 (d, J=7.1 Hz, 2H), 4.78 (d, J=6.9 Hz, 2H), 4.53-4.36 (m, 1H), 4.23 (s, 4H), 3.72 (s, 6H), 1.37 (d, J=6.5 Hz, 6H).

LCMS; m/z 524.4 (M+Na)⁺ (ES⁺).

Step C: 5-(3-Hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 5-(3-hydroxyoxetan-3-yl)-1-isopropyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (260 mg, 95%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.41 (s, 2H), 6.75 (s, 1H), 6.72 (s, 1H), 4.89-4.82 (m, 2H), 4.81-4.73 (m, 2H), 4.42 (sept, J=6.5 Hz, 1H), 1.39 (d, J=6.5 Hz, 6H).

LCMS m/z 260.1 (M−H)⁻ (ES⁻).

Intermediate P35: 1-Isopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: 1-Isopropyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29, Step A) from 5-(3-hydroxyoxetan-3-yl)-1-isopropyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P34, Step B) to afford the title compound (911 mg, 88%) as a colourless solid.

1H NMR (DMSO-d6) δ 6.36-6.25 (m, 4H), 6.06-5.97 (m, 4H), 5.95 (s, 1H), 4.13-4.07 (m, 4H), 3.58-3.50 (m, 5H), 2.97 (s, 6H), 2.27 (s, 3H), 0.62 (d, J=6.5 Hz, 6H).

LCMS m/z 538.2 (M+Na)⁺ (ES⁺).

Step B: 1-Isopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-isopropyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide to afford the title compound (241 mg, 86%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.46 (s, 2H), 6.87 (s, 1H), 4.91-4.78 (m, 4H), 4.26 (sept, J=6.6 Hz, 1H), 3.32 (s, 3H), 1.38 (d, J=6.5 Hz, 6H).

LCMS m/z 276.30 (M+H)⁺ (ES⁺).

Intermediate P36: 1-Ethyl-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: 1-Ethyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

To a solution of 1-ethyl-1H-pyrazole-3-sulfonyl chloride (41.0 g, 210 mmol) in THF (400 mL) was added TEA (63.9 g, 631 mmol) and bis(4-methoxybenzyl)amine (10.8 g, 42.1 mmol). The mixture was stirred at 25° C. for 1.5 hours. The reaction mixture was diluted with water (800 mL) and extracted with EtOAc (3×800 mL). The combined organic layers were dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by reversed phase flash chromatography (0.1% NH₃ in water/MeCN) to give the title compound (18.7 g, 21%) as a yellow oil.

¹H NMR (CDCl₃) δ 7.44 (d, 1H), 7.06 (d, 4H), 6.77 (d, 4H), 6.64 (d, 1H), 4.32 (s, 4H), 4.27-4.21 (m, 2H), 3.79 (s, 6H), 1.52 (t, 3H).

LCMS: m/z 416.1 (M+H)⁺ (ES⁺).

Step B: 1-Ethyl-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from 1-ethyl-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide and oxetan-3-one to afford the title compound (902 mg, 78%) as a pale yellow oil. 1H NMR (DMSO-d6) δ 7.09-7.02 (m, 4H), 6.88 (s, 1H), 6.85-6.77 (m, 5H), 4.87 (d, 2H), 4.76 (d, 2H), 4.23 (s, 4H), 4.07 (q, 2H), 3.72 (s, 6H), 1.34 (t, 3H). Exchangeable proton not visible.

LCMS; m/z 510.4 (M+Na)⁺ (ES⁺).

Step C: 1-Ethyl-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-ethyl-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide to afford the title compound (127 mg, 83%) as a colourless solid.

LCMS m/z 248.4 (M+H)⁺ (ES⁺).

Intermediate P37: 1-Ethyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide Step A: 1-Ethyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29, Step A) from 1-ethyl-5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P36, Step B) to afford the title compound (480 mg, 77%) as a pale yellow oil.

LCMS m/z 524.5 (M+Na)⁺ (ES⁺).

Step B: 1-Ethyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 1-ethyl-N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide to afford the title compound (189 mg, 76%) as a colourless solid.

LCMS m/z 262.4 (M+H)⁺ (ES⁺).

Intermediate P38: 5-(3-Methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(3-Hydroxytetrahydrofuran-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide and dihydrofuran-3(2H)-one to afford the title compound (114 mg, 16%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.06 (d, J=8.7 Hz, 4H), 6.81 (d, J=8.7 Hz, 4H), 6.57 (s, 1H), 4.21 (s, 4H), 3.98 (s, 3H), 3.99-3.80 (m, 3H), 3.71 (s, 6H), 3.33 (s, 2H), 2.27 (dd, J=7.8, 6.2 Hz, 2H).

LCMS; m/z 510.3 (M+Na)⁺ (ES⁺).

Step B: N,N-Bis(4-methoxybenzyl)-5-(3-methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29, Step A) from 5-(3-hydroxytetrahydrofuran-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (80 mg, 71%) as a yellow oil. 1H NMR (DMSO-d6) δ 7.07 (d, J=8.7 Hz, 4H), 6.82 (d, J=8.7 Hz, 4H), 6.69 (s, 1H), 4.23 (s, 4H), 4.13 (dd, J=9.7, 1.0 Hz, 1H), 3.91 (s, 3H), 3.90-3.79 (m, 3H), 3.71 (s, 6H), 2.93 (s, 3H), 2.48-2.41 (m, 1H), 2.25 (dt, J=13.2, 8.3 Hz, 1H).

LCMS m/z 502.1 (M+H)⁺ (ES⁺).

Step C: 5-(3-Methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-5-(3-methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (43 mg, 98%) as a brown oil.

1H NMR (DMSO-d6) δ 7.41 (s, 2H), 6.67 (s, 1H), 4.14 (dd, J=9.7, 1.0 Hz, 1H), 3.91 (s, 3H), 3.91-3.81 (m, 3H), 2.96 (s, 3H), 2.50-2.42 (m, 1H), 2.28 (dt, J=13.1, 8.3 Hz, 1H).

LCMS m/z 262.4 (M+H)⁺ (ES⁺).

Intermediate P39: 5-(3-Fluorooxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(3-Fluorooxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

5-(3-Hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) (0.5 g, 1.003 mmol) was dissolved in DCM (10 mL) and DBU (0.3 ml, 1.990 mmol) was added follow by XtalFluor-E® (0.35 g, 1.528 mmol) as a solid in a single portion. The reaction mixture was stirred at room temperature overnight. The reaction mixture was quenched with sat aq NaHCO₃ (5 mL) and stirred for 1 hour at room temperature. The organic phase was dried by passing through a hydrophobic frit and then concentrated in vacuo. The crude product was purified by chromatography on silica gel (40 g column, 0-100% EtOAc/isohexane) to afford the title compound (0.113 g, 22%) as a colourless solid on standing. 1H NMR (CDCl₃) δ 7.14-7.07 (m, 4H), 6.82-6.76 (m, 4H), 6.57 (d, J=2.4 Hz, 1H), 5.11 (ddd, J=20.1, 8.1, 1.3 Hz, 2H), 4.90 (ddd, J=21.3, 8.1, 1.3 Hz, 2H), 4.34 (s, 4H), 3.83 (d, J=1.5 Hz, 3H), 3.78 (s, 6H).

LCMS; m/z 498 (M+Na)⁺ (ES⁺).

Step B: 5-(3-Fluorooxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 5-(3-fluorooxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (48 mg, 96%) as a yellow solid.

1H NMR (DMSO-d6) δ 7.51 (s, 2H), 7.03 (d, J=2.6 Hz, 1H), 5.20-4.96 (m, 4H), 3.81 (d, J=1.3 Hz, 3H).

LCMS m/z 236.4 (M+H)⁺ (ES⁺); 234 (M−H)⁻ (ES⁻).

Intermediate P40: 5-(2-Hydroxy-2-methylpropyl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(2-Hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide and isobutylene oxide to afford the title compound (152 mg, 12%) as a colourless solid.

1H NMR (CDCl₃) δ 7.12-7.08 (m, 4H), 6.81-6.77 (m, 4H), 6.48 (s, 1H), 4.34 (s, 4H), 3.93 (s, 3H), 3.80 (s, 6H), 2.82 (s, 2H), 1.31 (s, 6H). Exchangeable proton not visible.

Step B: 5-(2-Hydroxy-2-methylpropyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from 5-(2-hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (51 mg, 55%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.30 (s, 2H), 6.41 (s, 1H), 4.57 (s, 1H), 3.83 (s, 3H), 2.75 (s, 2H), 1.15 (s, 6H).

LCMS m/z 234 (M+H)⁺ (ES⁺).

Intermediate P41: 5-(4-Hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(4-Hydroxytetrahydro-2H-pyran-4-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step B) from N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide and dihydro-2H-pyran-4(3H)-one to afford the title compound (483 mg, 48%) as a colourless solid. 1H NMR (DMSO-d6) δ 7.20-6.96 (m, 4H), 6.93-6.70 (m, 4H), 6.46 (s, 1H), 5.56 (br s, 1H), 4.21 (s, 4H), 4.03 (s, 3H), 3.81-3.60 (m, 10H), 1.97-1.75 (m, 4H).

LCMS m/z 502.2 (M+H)⁺ (ES⁺).

Step B: 5-(4-Hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(3-hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step C) from 5-(4-hydroxytetrahydro-2H-pyran-4-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (197 mg, 85%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.36 (s, 2H), 6.46 (s, 1H), 5.56 (s, 1H), 4.02 (s, 3H), 3.87-3.51 (m, 4H), 2.02-1.71 (m, 4H).

LCMS m/z 262.1 (M+H)⁺ (ES⁺); 260.1 (M−H)⁻ (ES⁻).

Intermediate P42: 1-(Oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-1-(oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N,N-bis(4-methoxybenzyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step D) from N,N-bis(4-methoxybenzyl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step C) and 2-(chloromethyl)oxazole to afford the title compound (523 mg, 83%) as a colourless crystalline solid.

1H NMR (CDCl₃) δ 7.68 (d, J=0.9 Hz, 1H), 7.58 (d, J=2.4 Hz, 1H), 7.17 (d, J=1.0 Hz, 1H), 7.06-6.99 (m, 4H), 6.79-6.72 (m, 4H), 6.69 (d, J=2.4 Hz, 1H), 5.50 (s, 2H), 4.30 (s, 4H), 3.78 (s, 6H).

LCMS; m/z 491 (M+Na)⁺ (ES⁺).

Step B: 1-(Oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P1, Step E) from N,N-bis(4-methoxybenzyl)-1-(oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide to afford the title compound (146 mg, 59%) as a colourless crystalline solid.

1H NMR (DMSO-d6) δ 8.14 (d, J=0.9 Hz, 1H), 8.03 (d, J=2.4 Hz, 1H), 7.45 (s, 2H), 7.25 (d, J=0.8 Hz, 1H), 6.65 (d, J=2.4 Hz, 1H), 5.64 (s, 2H).

Intermediate P43: 2-Methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide

2-Methyl-1H-imidazole-4-sulfonylchloride (1 g, 5.5 mmol) was suspended in DCM (30 mL) at room temperature. To this suspension was added bis(4-methoxybenzyl)amine (1.5 g, 6 mmol) and potassium tert-butoxide (0.25 g, 2 mmol) and the mixture was stirred for 18 hours at room temperature. The DCM layer was washed with water and brine, dried (sodium sulfate), filtered and evaporated. The residue was further purified by column chromatography on silica gel (0-5% MeOH/DCM) to afford the title compound (2.4 g, 100%) as a brown oil.

¹H NMR (CDCl₃): δ 7.37 (s, 1H), 7.07 (d, 4H), 6.76 (d, 4H), 4.30 (s, 4H), 3.80 (s, 6H), 2.43 (s, 3H).

Step B: 2-Methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide

N,N-Bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide (280 mg, 0.64 mmol) was dissolved in DMF (1 mL). Potassium carbonate (500 mg, 3.6 mmol) was added, followed by 3-bromomethylfuran (400 mg, 2.5 mmol). The reaction mixture was stirred for 48 hours at room temperature. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was dried (sodium sulphate), filtered and evaporated. The residue was purified by chromatography over silica gel to afford the title compound (242 mg, 78%) as a solid.

¹H NMR (CDCl₃) δ 7.45 (s, 1H), 7.10 (d, 4H), 6.76 (d, 4H), 4.32 (s, 4H), 3.97 (dd, 1H), 3.82 (m, 2H), 3.78 (s, 6H), 2.44 (s, 3H), 2.07 (m, 1H), 1.89 (m, 2H), 1.61 (m, 1H).

Step C: 2-Methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide

N,N-Bis(4-methoxybenzyl)-2-methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide (0.2 g, 0.42 mmol) was dissolved in DCM (10 mL). Trifluoroacetic acid (10 mL) was added and the mixture was stirred for 18 hours at room temperature. The solvents were evaporated and a 7N solution of ammonia in methanol was added to the residue. The solvents were evaporated and the residue was triturated with water, filtered and lyophilized. The residue was further purified by chromatography over silica gel (3.5 M ammonia in methanol/DCM) to afford the title compound (45 mg, 45%) as a white solid.

¹H NMR (CD₃OD) δ 7.56 (s, 1H), 4.11 (m, 2H), 3.96 (dd, 1H), 3.80 (m, 2H), 2.40 (s, 3H), 2.07 (m, 1H), 1.89 (m, 2H), 1.61 (m, 1H).

Intermediate P44: 1-(2-Hydroxyethyl)-2-methyl-1H-imidazole-4-sulfonamide Step A: 1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-N,N-bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide

N,N-Bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide (Intermediate P43, Step A) (280 mg, 0.64 mmol) was dissolved in DMF (10 mL). Potassium carbonate (500 mg, 3.6 mmol) was added, followed by (2-bromoethoxy)(tert-butyl)dimethylsilane (600 mg, 2.5 mmol). The reaction mixture was stirred for 48 hours at room temperature. The reaction mixture was diluted with DCM and washed with water and brine. The organic layer was dried (sodium sulphate), filtered and evaporated. The residue was purified over silica to afford the title compound (350 mg, 100%).

¹H NMR (CDCl₃) δ 7.40 (s, 1H), 7.10 (d, 4H), 6.76 (d, 4H), 4.29 (s, 4H), 3.97 (t, 2H), 3.86 (t, 2H), 3.78 (s, 6H), 2.45 (s, 3H), 0.84 (s, 9H), −0.03 (s, 6H).

Step B: 1-(2-Hydroxyethyl)-N,N-bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide

1-(2-((tert-Butyldimethylsilyl)oxy)ethyl)-N,N-bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide (350 mg, 0.63 mmol) was dissolved in DCM (10 mL). Tetrabutylammonium fluoride (0.60 g, 1.90 mmol) was added and the mixture was stirred overnight at room temperature. The DCM layer was washed with brine, dried, filtered and evaporated to afford the title compound, which was used as such for the next step.

Step C: 1-(2-Hydroxyethyl)-2-methyl-1H-imidazole-4-sulfonamide

1-(2-Hydroxyethyl)-N,N-bis(4-methoxybenzyl)-2-methyl-1H-imidazole-4-sulfonamide (0.28 g, 0.64 mmol) was dissolved in DCM (10 mL). Trifluoroacetic acid (10 mL) was added and the mixture was stirred for 18 hours at room temperature. The solvents were evaporated and a 7N solution of ammonia in methanol was added to the residue. The solvents were evaporated and the residue was triturated with water, filtered and lyophilized. The residue was further purified by chromatography over silica gel (3.5 M ammonia in methanol/DCM) to afford the title compound (340 mg, 100%) as a solid, still containing inorganic salts.

¹H NMR (CD₃OD) δ 7.59 (s, 1H), 4.07 (t, 2H), 3.81 (t, 2H), 2.42 (s, 3H).

Intermediate P45: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt Step A: Ethyl 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt

2 M Sodium tert-butoxide in THF (1.005 mL, 2.009 mmol) was added to a solution of ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate (0.5 g, 1-914 mmol) in THF (15 mL) and stirred at room temperature for 1 hour to give a white suspension. Then 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (0.419 g, 2.105 mmol) in THF (5 mL) was added and stirred at room temperature overnight. The resultant colourless precipitate was collected by filtration, washing with THF (4 mL), and dried in vacuo to afford the title compound (930 mg, 91%) as a colourless solid. ¹H NMR (DMSO-d₆) δ 7.51 (s, 1H), 6.96 (s, 1H), 6.77 (s, 1H), 4.28 (q, J=7.1 Hz, 2H), 4.05 (s, 3H), 2.74 (t, J=7.4 Hz, 4H), 2.66 (t, J=7.3 Hz, 4H), 1.90 (p, J=7.4 Hz, 4H), 1.30 (t, J=7.1 Hz, 3H).

LCMS; m/z 433.4 (M+H)⁺ (ES⁺).

Step B: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt

Ethyl 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt (3.15 g, 6.24 mmol) was dissolved in MeOH (20 mL), 2 M aqueous NaOH (3.12 mL, 6.24 mmol) was added and stirred for 6 hours. The reaction mixture was concentrated under reduced pressure to afford the title compound (2.80 g, 99%) as a colourless solid.

¹H NMR (DMSO-d₆) δ 7.57 (s, 1H), 6.76 (s, 1H), 6.44 (s, 1H), 4.02 (s, 3H), 2.74 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.4 Hz, 4H), 1.89 (p, J=7.4 Hz, 4H).

LCMS; m/z 405.4 (M+H)⁺ (ES⁺).

Intermediate P46: 3-(N-((2,6-Diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-1-carboxylic acid, disodium salt Step A: Ethyl 3-(N-((2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt

Prepared according to the general procedure of ethyl 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt (Intermediate P45, Step A) from ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate and 2-isocyanato-1,3-diisopropylbenzene (Intermediate A6) to afford the title compound as a colourless solid (2.16 g, 60%)

1H NMR (DMSO-d6) δ 7.35 (s, 1H), 7.15-7.05 (m, 1H), 7.05-6.95 (m, 2H), 6.93 (s, 1H), 4.28 (q, J=7.1 Hz, 2H), 4.05 (s, 3H), 3.20-3.02 (m, 2H), 1.28 (t, J=7.1 Hz, 3H), 1.03 (d, J=6.9 Hz, 12H).

LCMS; m/z 437.4 (M+H)⁺ (ES⁺).

Step B: 3-(N-((2,6-Diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-s-carboxylic acid, disodium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45, Step B) from ethyl 3-(N-((2,6-diisopropylphenyl) carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt to afford the title compound (2.0 g, 99%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.44 (s, 1H), 7.13-7.05 (m, 1H), 7.05-6.94 (m, 2H), 6.42 (s, 1H), 4.00 (s, 3H), 3.16-3.03 (m, 2H), 1.01 (d, J=6.8 Hz, 12H).

LCMS; m/z 409.4 (M+H)⁺ (ES⁺).

Intermediate P47: 5-(3-(Dimethylamino)oxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-(3-Aminooxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of n-BuLi (2.5 M in hexanes; 0.70 mL, 1.750 mmol) was added dropwise to a stirred solution of N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step A) (0.70 g, 1.74 mmol) in THF (15 mL) at −78° C. The reaction was stirred for 1 hour, then a solution of 2-methyl-N-(oxetan-3-ylidene) propane-2-sulfinamide (0.40 g, 2.28 mmol) in THF (5 mL) was added. The reaction mixture was left at −78° C. for 5 minutes and then allowed to warm to room temperature and stirred for 1 hour. The reaction was quenched with saturated aqueous ammonium chloride (15 mL) and extracted with DCM (3×20 mL). The organic extracts were dried (MgSO₄), filtered and concentrated in vacuo. The resultant orange gum was dissolved in MeOH (18 mL) and HCl (3.7 M in 1,4-dioxane, 1.7 mL, 6.29 mmol) was added. The solution was stirred for 16 hours and then concentrated in vacuo. The crude product was loaded onto a column (SCX; 5 g) in MeOH and the column was washed with MeOH and then the product was eluted with 0.7 M ammonia in MeOH. The resultant mixture was concentrated in vacuo to afford the title compound (0.25 g, 41%) as a thick brown gum.

¹H NMR (DMSO-d₆) δ 7.09-7.04 (m, 4H), 6.86-6.8 (m, 4H), 6.79 (s, 1H), 4.87 (d, J=6.4 Hz, 2H), 4.65 (d, J=6.4 Hz, 2H), 4.22 (s, 4H), 3.84 (s, 3H), 3.71 (s, 6H), 3.16 (s, 2H).

LCMS; m/z 473.5 (M+H)⁺ (ES⁺).

Step B: 5-(3-(Dimethylamino)oxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of 5-(3-aminooxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (0.25 g, 0.41 mmol), formaldehyde (37% in H₂O, 10% MeOH) (0.31 mL, 4.16 mmol) and formic acid (0.16 mL, 4.17 mmol) was stirred at 60° C. for 18 hours. The mixture was concentrated in vacuo and the crude product was loaded onto a column (SCX; 1 g) in MeOH and the column was washed with MeOH and then the product was eluted with 0.7 M ammonia in DCM:MeOH (9:1.50 mL). The resultant mixture was concentrated in vacuo to afford the title compound (0.17 g, 61%) as an orange oil.

¹H NMR (DMSO-d6) δ 7.11-7.03 (m, 4H), 6.86-6.78 (m, 4H), 6.77 (s, 1H), 4.93 (d, J=7.2 Hz, 2H), 4.74 (d, J=7.2 Hz, 2H), 4.23 (s, 4H), 3.75 (s, 3H), 3.72 (s, 6H), 2.19 (s, 6H).

LCMS m/z 501.4 (M+H)⁺ (ES⁺).

Step C: 5-(3-(Dimethylamino)oxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

5-(3-(Dimethylamino)oxetan-3-yl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (0.17 g, 0.25 mmol) was dissolved in TFA (3 mL) and stirred at room temperature for 23 hours. Additional TFA (3 mL) was added and the mixture was stirred for a further 3 hours at room temperature. The mixture was then evaporated to dryness and purified by chromatography on silica gel (12 g column, 0-10% MeOH/DCM) to afford an orange solid. The product was further purified by precipitation on addition of isohexane to a solution of the product in 19:1 DCM:MeOH. The product was collected by filtration to afford the title compound (65 mg, 84%) as an orange solid.

¹H NMR (DMSO-d₆) δ 7.46 (s, 2H), 6.79 (s, 1H), 5.00 (d, J=7.6 Hz, 2H), 4.85 (d, J=7.6 Hz, 2H), 3.76 (s, 3H), 2.38 (br s, 6H).

LCMS; m/z 261.1 (M+H)⁺ (ES⁺).

Intermediate P48: 5-(((2-Hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: 5-Formyl-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of n-BuLi (2.5M in hexanes; 4.0 ml, 10 mmol) was added dropwise to a stirred solution of N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28, Step A) (4.00 g, 9.96 mmol) in THF (40 mL) at −78° C. The reaction was stirred for 1 hour. Then DMF (0.85 ml, 11.0 mmol) in THF (15 mL) were added dropwise, whilst maintaining the temperature below −65° C. The reaction mixture was stirred for a further 1 hour at −78° C. The reaction was quenched with saturated aqueous ammonium chloride and extracted with EtOAc (3×50 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO₄), filtered and concentrated in vacuo. The crude product was purified by chromatography on silica gel (80 g column, 0-60% EtOAc/isohexane) to afford the title compound (4.0 g, 93%) as a white solid.

¹H NMR (DMSO-d6) δ 9.90 (s, 1H), 7.41 (s, 1H), 7.11-7.02 (m, 4H), 6.87-6.78 (m, 4H), 4.25 (s, 4H), 4.17 (s, 3H), 3.72 (s, 6H).

LCMS m/z 448.1 (M+H₃O)+(ES⁺).

Step B: 5-(((2-Hydroxyethyl)(methyl)amino)methyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

2-(Methylamino)ethanol (112 μL, 1.40 mmol) was added to a solution of 5-formyl-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (0.40 g, 0.93 mmol) in dry THF (20 mL) containing 4 Å molecular sieves and stirred for 1 hour. Sodium triacetoxyborohydride (0.30 g, 1.42 mmol) and acetic acid (6 μL, 0.1 mmol) were added and the reaction was stirred at room temperature for 3 days. An additional portion of acetic acid (54 μL, 0.94 mmol) was added and the reaction mixture stirred for 20 hours at 60° C. Then 2-(methylamino)ethanol (112 μL, 1.39 mmol) and more sodium triacetoxyborohydride (0.30 g, 1.42 mmol) were added and the reaction was heated at 60° C. for another 20 hours. The reaction was quenched with water (1 mL) and loaded onto a column (SCX). The column was washed with 20% MeOH in DCM and then the crude product was eluted with 0.7M ammonia in DCM:MeOH (9:1, 50 mL). The resultant mixture was concentrated in vacuo and the crude product was further purified by chromatography on silica gel (12 g column, 0-20% (0.7M ammonia in MeOH)/DCM) to afford the title compound (0.19 g, 41%) as a colourless gum.

¹H NMR (DMSO-d₆) δ 7.07-6.99 (m, 4H), 6.86-6.77 (m, 4H), 6.61 (s, 1H), 4.49 (t, J=5.3 Hz, 1H), 4.20 (s, 4H), 3.91 (s, 3H), 3.72 (s, 6H), 3.60 (s, 2H), 3.54 (td, J=5.2, 6.1 Hz, 2H), 2.47 (t, J=6.1 Hz, 2H), 2.17 (s, 3H).

LCMS; m/z 489.2 (M+H)⁺ (ES⁺).

Step C: 5-(((2-Hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide

5-(((2-Hydroxyethyl)(methyl)amino)methyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (0.19 g, 0.39 mmol) was dissolved in TFA (5.0 mL, 65 mmol) and stirred for 4 hours. The solution was diluted with toluene (20 mL) and concentrated in vacuo. The crude product was loaded onto a column (SCX) in THF and the column was washed with MeOH and then the product was eluted with 0.7M ammonia in 10% MeOH/DCM. The resultant mixture was concentrated in vacuo to afford the title compound (95 mg, 95%) as a colourless gum.

¹H NMR (DMSO-d6) δ 7.34 (s, 2H), 6.49 (s, 1H), 4.47 (t, J=5.3 Hz, 1H), 3.87 (s, 3H), 3.58 (s, 2H), 3.56-3.48 (m, 2H), 2.45 (t, J=6.1 Hz, 2H), 2.17 (s, 3H).

LCMS m/z 249.1 (M+H)⁺ (ES⁺).

Intermediate P49: 5-(((2-Methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide Step A: N,N-Bis(4-methoxybenzyl)-5-(((2-methoxyethyl)(methyl)amino) methyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(((2-hydroxyethyl)(methyl)amino) methyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48, Step B) from 5-formyl-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48, Step A) and 2-methoxy-N-methylethanamine to afford the title compound (0.41 g, 86%) as a pale colourless oil.

¹H NMR (DMSO-d6) δ 7.08-6.99 (m, 4H), 6.86-6.77 (m, 4H), 6.59 (s, 1H), 4.20 (s, 4H), 3.90 (s, 3H), 3.72 (s, 6H), 3.60 (s, 2H), 3.46 (t, J=5.7 Hz, 2H), 3.24 (s, 3H), 2.55 (t, J=5.7 Hz, 2H), 2.17 (s, 3H).

LCMS; m/z 503.4 (M+H)⁺ (ES⁺).

Step B: 5-(((2-Methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(((2-hydroxyethyl)(methyl)amino) methyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48, Step C) from N,N-bis(4-methoxybenzyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide to afford the title compound (0.20 g, 91%) as a white solid. 15 ¹H NMR (DMSO-d6) δ 7.34 (s, 2H), 6.49 (s, 1H), 3.86 (s, 3H), 3.58 (s, 2H), 3.45 (t, J=5.8 Hz, 2H), 3.24 (s, 3H), 2.54 (t, J=5.8 Hz, 2H), 2.18 (s, 3H).

LCMS m/z 263.1 (M+H)⁺ (ES⁺).

Intermediate P50: 1-Methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide Step A: 5-(Hydroxymethyl)-1-methyl-1H-pyrazole-3-sulfonamide

A solution of LiBH₄ (2 M in THF; 4.3 mL, 8.6 mmol) was added dropwise over 5 minutes to a stirred solution of ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate (1.00 g, 4.29 mmol) in THF (10 mL) at 0° C. The reaction was allowed to warm to room temperature, stirred for 3 hours and then heated at 40° C. for 20 hours. The reaction was cooled to 0° C. LiAlH₄ (2 M in THF; 0.55 mL, 1.10 mmol) was added and the reaction was stirred for a further 2 days at 40° C. The reaction was cooled to 0° C. and aqueous saturated ammonium chloride (10 mL) was cautiously added dropwise over 10 minutes. The mixture was allowed to warm to room temperature and EtOAc (30 mL) was added. The reaction mixture was stirred vigorously for 10 minutes and then filtered through a pad of Celite®. The layers were separated and the aqueous layer was saturated with NaCl and extracted further with EtOAc (5×20 mL). The combined organic extracts were dried (MgSO₄), filtered and evaporated in vacuo to afford the title compound (0.67 g, 78%) as a white solid.

¹H NMR (DMSO-d₆) δ 5.70 (s, 1H), 3.73 (s, 2H), 3.02 (s, 3H). Three exchangeable protons not observed.

LCMS; m/z 192.0 (M+H)⁺ (ES⁺).

Step B: 5-Formyl-1-methyl-1H-pyrazole-3-sulfonamide

Manganese(IV) oxide (1.00 g, 11.5 mmol) was added to a solution of 5-(hydroxymethyl)-1-methyl-1H-pyrazole-3-sulfonamide (0.55 g, 2.88 mmol) in 1,2-dimethoxyethane (30 mL). The reaction mixture was stirred for 20 hours at room temperature and then at 40° C. for a further 6 hours. Further manganese(IV) oxide (0.50 g, 5.75 mmol) was added and the reaction was heated at 40° C. for 2 days. The mixture was cooled to room temperature and filtered through a pad of Celite®, washing with 1,2-dimethoxyethane. The filtrate was concentrated in vacuo to afford the title compound (0.29 g, 52%), as a yellow gum.

¹H NMR (DMSO-d₆) δ 9.92 (s, 1H), 7.64 (s, 2H), 7.31 (s, 1H), 4.16 (s, 3H).

LCMS; m/z 189.9 (M+H)⁺ (ES⁺).

Step C: 1-Methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of 5-(((2-hydroxyethyl)(methyl)amino) methyl)-N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48, Step B) from 5-formyl-1-methyl-1H-pyrazole-3-sulfonamide and morpholine to afford the title (73 mg, 25%) as a colourless gum.

¹H NMR (DMSO-d6) δ 7.36 (s, 2H), 6.50 (s, 1H), 3.87 (s, 3H), 3.57 (m, 4H), 3.56 (s, 2H), 2.37 (m, 4H).

LCMS m/z 261.0 (M+H)⁺ (ES⁺).

Intermediate P51: 3-(N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt Step A: Ethyl 3-(N-((4-chloro-2,6-diisopropylphenyl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt

Prepared according to the general procedure of ethyl 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt (Intermediate P45, Step A) from ethyl 1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxylate and 5-chloro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A9) to afford the title compound (1.32 g, 92%) as a colourless solid.

1H NMR (DMSO-d6), rotamers; δ 7.41 (s, 1H), 7.01 (s, 2H), 6.92 (s, 1H), 4.29 (q, J=7.1 Hz, 2H), 4.05 (s, 3H), 3.13 (br s, 2H), 1.29 (t, J=7.1 Hz, 3H), 1.04 (d, J=6.8 Hz, 12H).

LCMS; m/z 471.4 (M+H)⁺ (ES⁺).

Step B: 3-(N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45, Step B) from ethyl 3-(N-((4-chloro-2,6-diisopropylphenyl) carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylate, sodium salt to afford the title compound (1.0 g, 77%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.49 (s, 1H), 7.00 (s, 2H), 6.42 (s, 1H), 4.01 (s, 3H), 3.09 (br s, 2H), 1.02 (d, J=6.8 Hz, 12H).

LCMS; m/z 443.4 (M+H)⁺ (ES⁺).

Intermediate P52: N,N-Bis(2-methoxyethyl)-1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxamide Step A: 1-Methyl-1H-pyrazole-3-sulfonyl chloride

A solution of 1-methyl-1H-pyrazol-3-amine (25 g, 257.42 mmol, 1 eq) in MeCN (600 mL) at 0° C. was treated with concentrated HCl (60 mL) and H₂O (60 mL). Then an aqueous solution of NaNO₂ (21.31 g, 308.90 mmol, 1.2 eq) in H₂O (60 mL) was added slowly. The resulting mixture was stirred at 0° C. for 40 minutes. AcOH (6 mL), CuCl₂ (17.31 g, 128.71 mmol, 0.5 eq) and CuCl (1.27 g, 12.87 mmol, 307.78 μL, 0.05 eq) were added, then SO₂ gas (15 psi) was bubbled into the mixture for 15 minutes at 0° C. The reaction mixture was concentrated in vacuo to remove most of the MeCN. Then the reaction mixture was treated with H₂O (2.5 L) and extracted with EtOAc (2×1.2 L). The combined organic layers were washed with brine (3×2 L), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=15:1 to 5:1) to give the title compound (19 g, 41%) as a yellow oil.

¹H NMR (CDCl₃): δ 7.52 (d, 1H), 6.89 (d, 1H) and 4.07 (s, 3H).

Step B: N,N-Bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide

To a solution of bis(4-methoxybenzyl)amine (99.83 g, 387.96 mmol, 0.91 eq) in THF (1 L) was added TEA (86.28 g, 852.65 mmol, 118.68 mL, 2 eq), followed by 1-methyl-1H-pyrazole-3-sulfonyl chloride (77 g, 426.33 mmol, 1 eq). Then the reaction mixture was stirred at 25° C. for 12 hours. The reaction mixture was concentrated in vacuo to remove most of the THF. The reaction mixture was quenched by addition of aqueous HCl (1 M, 500 mL) and then extracted with EtOAc (2×500 mL). The combined organic layers were washed with brine (2×600 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was triturated with a mixture of petroleum ether and ethyl acetate (70 mL, v:v=5:1) to give the title compound (138 g, 81%) as a white solid.

¹H NMR (CDCl₃): δ 7.40 (d, 1H), 7.08 (d, 4H), 6.78 (d, 4H), 6.65-6.63 (m, 1H), 4.32 (s, 4H), 3.98 (s, 3H) and 3.79 (s, 6H).

LCMS: m/z 402.2 (M+H)⁺ (ES⁺).

Step C: 3-(N,N-Bis(4-methoxybenzyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid

A solution of N,N-bis(4-methoxybenzyl)-1-methyl-1H-pyrazole-3-sulfonamide (100 g, 249.08 mmol, 1 eq) in THF (1.35 L) was cooled to −70° C. Then n-BuLi (2.5 M, 104.61 mL, 1.05 eq) was added dropwise. The reaction mixture was stirred at −70° C. for 1 hour, then CO₂ (15 psi) was bubbled into the mixture for 15 minutes. The reaction mixture was stirred at −70° C. for another 1 hour. The reaction mixture was quenched with H₂O (1.2 L) and adjusted with aqueous HCl (1 M) to pH=3. Then the mixture was extracted with EtOAc (2×1). The combined organic layers were washed with brine (2×1 L), dried over Na₂SO₄, filtered and concentrated in vacuo. The residue was triturated with a mixture of petroleum ether and ethyl acetate (300 mL, v:v=1:1) to give the title compound (94 g, 84% yield, 99% purity on LCMS) as a white solid.

¹H NMR (DMSO-d₆): δ 6.98-7.16 (m, 5H), 6.82 (d, 4H), 4.25 (s, 4H), 4.15 (s, 3H) and 3.72 (s, 6H).

LCMS: m/z 468.2 (M+Na)⁺ (ES⁺).

Step D: 3-(N,N-Bis(4-methoxybenzyl)sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide

To a solution of 3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid (8 g, 17.96 mmol, 1 eq) in DMF (100 mL) was added with HATU (10.24 g, 26.94 mmol, 1.5 eq), DIPEA (6.96 g, 53.87 mmol, 3 eq) and bis(2-methoxyethyl)amine (2.87 g, 21.55 mmol, 1.2 eq). The reaction mixture was stirred at 25° C. for 1 hour. Then the reaction mixture was diluted with EtOAc (50 mL), washed with saturated aqueous NH₄C solution (3×50 mL) and brine (3×50 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by reversed phase flash chromatography (0.05% NH₃.H₂O-MeCN) to give the title compound (8 g, 79%) as a red oil.

¹H NMR (CD₃OD): δ 7.05 (d, 4H), 6.81-6.77 (m, 5H), 4.29 (s, 4H), 3.90 (s, 3H), 3.79-3.72 (m, 8H), 3.68-3.57 (m, 4H), 3.48-3.46 (m, 2H), 3.38 (s, 3H) and 3.27 (s, 3H).

LCMS: m/z 561.3 (M+H)⁺ (ES⁺).

Step E: N,N-Bis(2-methoxyethyl)-1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxamide

To a solution of 3-(N,N-bis(4-methoxybenzyl)sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide (8 g, 14.27 mmol, 1 eq) in DCM (50 mL) was added TFA (56 g, 491.13 mmol, 34.42 eq). The reaction mixture was stirred at 25° C. for 12 hours and then concentrated in vacuo. The residue was triturated with a mixture of EtOAc and PE (50 mL, v:v=3:2) to give the title compound (4.0 g, 88%) as a white solid.

¹H NMR (DMSO-d₆): δ 7.50 (s, 2H), 6.74 (s, 1H), 3.84 (s, 3H), 3.63 (t, 4H), 3.43-340 (m, 4H), 3.28 (s, 3H) and 3.18 (s, 3H).

Intermediate P53: 1-(2-Hydroxy-2-methylpropyl)-1H-pyrazole-4-sulfonamide Step A: 1-(2-Hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide

To a solution of N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide (500 mg, 1.29 mmol, 1 eq) in MeCN (10 mL) was added K₂CO₃ (356 mg, 2.58 mmol, 2 eq) and 2,2-dimethyloxirane (279 mg, 3.87 mmol, 343.78 μL, 3 eq). The mixture was stirred at 80° C. for 12 hours under nitrogen. The reaction mixture was filtered through a Celite® pad and the filtrate was concentrated under reduced pressure. The residue was triturated with a mixture of MTBE and EtOAc (20 mL, v:v=10:1) to give the title compound (550 mg, 1.08 mmol, 83% yield, 90% purity) as a white solid.

¹H NMR (DMSO-d₆): δ 8.24 (s, 1H), 7.78 (s, 1H), 7.08-7.04 (m, 4H), 6.82-6.79 (m, 4H), 4.15 (d, 4H), 4.08 (s, 2H), 3.71 (s, 6H) and 1.07 (s, 6H).

LCMS: m/z 460.0 (M+H)⁺ (ES⁺).

Step B: 1-(2-Hydroxy-2-methylpropyl)-1H-pyrazole-4-sulfonamide

To a solution of 1-(2-hydroxy-2-methylpropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide (500 mg, 979.20 μmol, 1 eq) in DCM (4 mL) was added TFA (12.32 g, 108.05 mmol, 8 mL, 110.34 eq). The reaction mixture was stirred at 25° C. for 12 hours and then concentrated under reduced pressure. The residue was treated with resin (Amberlyst® A-21, ion exchange resin) to give the title compound (150 mg, 615.70 μmol, 63% yield, 90% purity) as a pale yellow oil, which was used into the next step without further purification.

¹H NMR (DMSO-d₆): δ 8.05 (s, 1H), 7.73 (s, 1H), 7.07-7.5 (br s, 2H), 4.06 (s, 2H) and 1.05 (d, 6H).

LCMS: m/z 219.9 (M+H)⁺ (ES⁺).

Intermediate P54: (R)-1-(2-Hydroxypropyl)-1H-pyrazole-4-sulfonamide Step A: (R)-1-(2-Hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide

To a solution of N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide (400 mg, 1.03 mmol, 1 eq) in CH₃CN (10 mL) was added K₂CO₃ (285 mg, 2.06 mmol, 2 eq) and (2R)-2-methyloxirane (120 mg, 2.06 mmol, 144.66 μL, 2 eq). The mixture was stirred at 70° C. for 12 hours. The reaction mixture was filtered through a Celite® pad and the filtrate was concentrated under reduced pressure to give the title compound (450 mg, crude) as a white solid, which was used directly in the next step.

LCMS: m/z 446.2 (M+H)⁺ (ES⁺).

Step B: (R)-1-(2-Hydroxypropyl)-1H-pyrazole-4-sulfonamide

To a solution of (R)-1-(2-hydroxypropyl)-N,N-bis(4-methoxybenzyl)-1H-pyrazole-4-sulfonamide (450 mg, 898.93 μmol, 1 eq) in DCM (3 mL) was added TFA (9.24 g, 81.04 mmol, 6 mL, 90.15 eq). The reaction mixture was stirred at 25° C. for 12 hours and then concentrated under reduced pressure. The residue was treated with resin (Amberlyst® A-21, ion exchange resin) to give the title compound (200 mg, crude) as a brown oil. ¹H NMR (DMSO-d₆): δ 8.10 (s, 1H), 7.71 (s, 1H), 7.25 (s, 1H), 4.97 (d, 1H), 4.12-4.10 (m, 2H), 3.96-4.00 (m, 1H) and 1.05 (d, 3H).

LCMS: m/z 206.2 (M+H)⁺ (ES⁺).

Intermediate A1: 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene

To a solution of phosgene (4.45 mL, 20% weight in toluene, 8.4 mmol) in EtOAc (90 mL) was added dropwise a solution of 1,2,3,5,6,7-hexahydro-s-indacen-4-amine (589 mg, 3.4 mmol) in EtOAc (45 mL) at ambient temperature. The resulting reaction mixture was then heated to reflux for 3 hours and upon cooling was filtered and concentrated in vacuo to afford the title compound as a brown oil (756 mg, 100%). The crude product was used directly in the next step without further purification.

¹H NMR (CDCl₃) δ 6.8 (s, 1H), 2.89 (m, 8H) and 2.09 (m, 4H).

Intermediate A2: 5-Fluoro-2-isocyanato-1,3-diisopropylbenzene

4-Fluoro-2,6-diisopropylaniline (1 g, 5.12 mmol) and triethylamine (0.785 mL, 5.63 mmol) were dissolved in THF (10 mL) and cooled to 0° C. Triphosgene (0.760 g, 2.56 mmol) was added to the mixture portionwise and the reaction mixture was stirred for 16 hours at room temperature. The mixture was concentrated in vacuo. Isohexane (50 mL) was added and the suspension filtered through silica (3 g). The filtrate was dried under reduced pressure to afford the title compound (900 mg, 75%) as a colourless oil.

¹H NMR (DMSO-d6) δ 6.80 (d, J=9.4 Hz, 2H), 3.27-3.12 (m, 2H), 1.23 (d, J=6.8 Hz, 12H).

Intermediate A3: 7-Fluoro-5-(pyridin-3-yl)-2,3-dihydro-1H-inden-4-amine Step A: N-(7-Fluoro-2,3-dihydro-1H-inden-4-yl)pivalamide

To an ice-cooled solution of N-(2,3-dihydro-1H-inden-4-yl)pivalamide (2.5 g, 11.50 mmol) in dry DCM (50 mL) was added pyridine hydrofluoride (9 mL, 69.9 mmol). The pale yellow mixture was stirred for 30 minuted at 0° C. A solution of bis(tert-butylcarbonyloxy)iodobenzene (7.5 g, 17.91 mmol) in DCM (10 mL) was then slowly added over 10 minutes. The reaction was slowly allowed to reach room temperature and stirred overnight. It was then quenched with triethylamine (0.5 mL, 3.58 mmol) and the mixture was absorbed onto silica gel and purified by chromatography on silica gel (120 g column, 0-30% EtOAc/isohexane) to afford the title compound (0.64 g, 22%) as a yellow crystalline solid.

¹H NMR (CDCl₃) δ 7.68 (dd, J=8.8, 4.5 Hz, 1H), 7.14 (s, 1H), 6.87 (t, J=8.6 Hz, 1H), 3.01 (t, J=7.5 Hz, 2H), 2.85 (t, J=7.5 Hz, 2H), 2.18 (p, J=7.5 Hz, 2H), 1.34 (s, 9H).

LCMS; m/z 236.3 (M+H)⁺ (ES⁺); 234.2 (M−H)⁻ (ES⁻).

Step B: 7-Fluoro-2,3-dihydro-1H-inden-4-amine

N-(7-Fluoro-2,3-dihydro-1H-inden-4-yl)pivalamide (0.632 g, 2.69 mmol) was dissolved in ethanol (5 mL) and stirred at room temperature. H₂SO₄ (95% aqueous) (5 mL, 89 mmol) was slowly added to water (5 mL) and this mixture was then added to the reaction mixture. The slurry was heated to 100° C. (bath temperature) over the weekend. The reaction mixture was cooled to room temperature, diluted with water (10 mL) and then basified with 2 M aqueous NaOH. The mixture was extracted with DCM (3×100 mL). The combined organic phases were washed, dried by passing through a hydrophobic frit and concentrated in vacuo. The crude product was purified by chromatography on silica gel (24 g column, 0-30% EtOAc/isohexane) to afford the title compound (350 mg, 82%) as a pale pink oil that solidified on standing.

¹H NMR (CDCl₃) δ 6.71 (dd, J=9.0, 8.2 Hz, 1H), 6.46 (dd, J=8.5, 3.9 Hz, 1H), 3.45 (s, 2H), 2.96 (t, J=7.6 Hz, 2H), 2.77 (t, J=7.5 Hz, 2H), 2.16 (p, J=7.6 Hz, 2H).

LCMS; m/z 152.3 (M+H)⁺ (ES⁺).

Step C: 5-Bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine

7-Fluoro-2,3-dihydro-1H-inden-4-amine (345 mg, 2.282 mmol) was dissolved in DCM (1 mL). NBS (450 mg, 2.53 mmol) was added at room temperature in a single portion. The mixture turned dark brown immediately and was stirred for 15 minutes at room temperature. The reaction mixture was partitioned between DCM (20 mL) and 1 M aqueous NaOH (20 mL) and stirred for 15 minutes. The organic phase was separated and washed with brine (1 mL), and then dried by passing through a hydrophobic frit. The solvent was removed in vacuo to give a dark brown oil. The crude product was purified by chromatography on silica gel (24 g column, 0-20% EtOAc/isohexane) to afford the title compound (323 mg, 55%) as a dark purple oil.

¹H NMR (CDCl₃) δ 7.08 (d, J=7.8 Hz, 1H), 3.06 (t, J=7.5 Hz, 2H), 2.95 (t, J=7.5 Hz, 2H), 2.20 (p, J=7.6 Hz, 2H). NH₂ not observed.

Step D: 7-Fluoro-5-(pyridin-3-yl)-2,3-dihydro-1H-inden-4-amine

5-Bromo-7-fluoro-2,3-dihydro-1H-inden-4-amine (0.45 g, 1-956 mmol) was dissolved in dioxane (5 mL). A solution of potassium carbonate (0.8 g, 5.79 mmol) in water (1 mL) was added along with pyridin-3-ylboronic acid (0.27 g, 2.197 mmol). The mixture was degassed with nitrogen for 15 minutes and then Pd(dppf)Cl₂.DCM (0.080 g, 0.098 mmol) was added. The reaction mixture was heated to 80° C. (bath temperature) for 18 hours. The mixture was cooled to room temperature and partitioned between DCM (30 mL) and water (1 mL). The organic phase was dried by passing through a hydrophobic frit and concentrated in vacuo to give a brown solid. The crude product was purified by chromatography on silica gel (12 g column, 0-100% EtOAc/isohexane) to afford the title compound (0.32 g, 68%) as a green crystalline solid.

¹H NMR (CDCl₃) δ 8.79 (s, 1H), 8.65 (s, 1H), 8.00 (d, J=7.1 Hz, 1H), 7.56 (s, 1H), 6.71 (d, J=8.9 Hz, 1H), 3.04 (t, J=7.6 Hz, 2H), 2.83 (t, J=7.4 Hz, 2H), 2.24 (p, J=7.5 Hz, 2H). NH₂ not observed.

LCMS; m/z 229.3 (M+H)⁺ (ES⁺).

Intermediate A4: 4-Fluoro-2-isopropyl-6-(pyridin-3-yl)aniline Step A: 2-Bromo-4-fluoro-6-isopropylaniline

N-Bromosuccinimide (5.64 g, 31.7 mmol) was added portionwise to 4-fluoro-2-isopropylaniline (4.62 g, 30.2 mmol) in DCM (72 mL) at 0° C. The resulting mixture was stirred at 0° C. for 1 hour and then left to warm to room temperature over 21 hours. The reaction mixture was washed with a solution of aqueous sodium hydroxide (2 M, 2×50 mL), dried (MgSO₄), filtered and concentrated in vacuo to give a brown residue. The crude product was then filtered through a plug of silica (50 g) and washed through with 50% DCM in iso-hexane (500 mL). The red filtrate was concentrated to dryness and the crude product was purified by chromatography on silica gel (120 g column, 0-10% DCM/iso-hexane) to afford the title compound (4.99 g, 70%) as a red oil.

¹H NMR (CDCl₃) δ 7.07 (dd, 1H), 6.86 (dd, 1H), 4.14 (s, 2H), 2.93 (sept, 1H) and 1.25 (d, 6H). NH₂ not observed.

LCMS; m/z 232.2/234.3 (M+H)⁺ (ES⁺).

Step B: 4-Fluoro-2-isopropyl-6-(pyridin-3-yl)aniline

To a stirred, nitrogen-degassed mixture of 2-bromo-4-fluoro-6-isopropylaniline (1.00 g, 4.27 mmol) was added pyridin-3-ylboronic acid (0.577 g, 4.69 mmol), Pd(dppf)Cl₂ (0.156 g, 0.213 mmol) and potassium carbonate (1.769 g, 12.80 mmol) in a 10:1 mixture of 1,4-dioxane:water (33 mL). The reaction mixture was then heated to 80° C. under a nitrogen atmosphere for 2 days, left to cool to room temperature, filtered through a pad of Celite® (10 g) and the filter cake washed with EtOAc (2×30 mL). The filtrate was poured onto water (50 mL) and the organic layer collected. The aqueous layer was extracted with EtOAc (2×20 mL). The combined organic layers were dried (magnesium sulfate), filtered and evaporated to dryness. The crude product was purified by chromatography on silica gel (80 g column, 0-60% EtOAc/iso-hexane) to afford the title compound (273 mg, 27%) as a brown gum.

¹H NMR (CDCl₃) δ 8.70 (dd, 1H), 8.63 (dd, 1H), 7.82 (ddd, 1H), 7.48-7.34 (m, 1H), 6.94 (dd, 1H), 6.70 (dd, 1H), 2.93 (sept, 1H), 3.98-2.44 (br s, 2H) and 1.29 (d, 6H).

LCMS; m/z 231.1 (M+H)⁺ (ES⁺).

The following intermediate was synthesised following the general procedure for Intermediate A4:

Intermediate Structure Analytical data A5

¹H NMR (CDCl₃) δ 8.25 (d, 1H), 7.00 (dd, 1H), 6.93 (dd, 1H), 6.85 (s, 1H), 6.71 (dd, 1H), 4.01 (s, 3H), 2.92 (sept, 1H) and 1.28 (d, 6H). Exchangeable NH₂ observed as broad signal from 4.5-0.5 ppm. LCMS m/z 261.1 (M + H)⁺ (ES⁺). (174 mg, 78%)

Intermediate A6: 2-Isocyanato-1,3-diisopropylbenzene

2,6-Diisopropylaniline (3.07 g, 17-14 mmol) was dissolved in dry THF (40 mL) and Et₃N (3 mL, 21.52 mmol) was added. A solution of triphosgene (4.26 g, 14.35 mmol) in dry THF (12 mL) was added over 5 minutes, resulting in the formation of a thick colourless precipitate. The reaction mixture was stirred at room temperature overnight. The THF was removed in vacuo and toluene (50 mL) was added. The mixture was filtered through a short silica plug eluting with toluene (150 mL). The filtrate was concentrated in vacuo to afford the title compound (2.76 g, 92%) as a colourless oil.

¹H NMR (CDCl₃) δ 7.20-7.10 (m, 3H), 3.22 (hept, J=6.9 Hz, 2H), 1.26 (d, J=6.8 Hz, 12H).

Intermediate A7: 4-(5-Fluoro-2-isocyanato-3-isopropylphenyl)-2-isopropoxypyridine Step A: 4-Fluoro-2-(prop-1-en-2-yl)aniline

To a mixture of 2-bromo-4-fluoroaniline (39 g, 205.25 mmol, 1 eq), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (36.21 g, 215.51 mmol, 1.05 eq) and K₂CO₃ (70.92 g, 513.12 mmol, 2.5 eq) in dioxane (200 mL) and H₂O (40 mL) was added Pd(dppf)Cl₂ (7.51 g, 10.26 mmol, 0.05 eq) under N₂ atmosphere. Then the reaction mixture was stirred at 80° C. for 5 hours. The reaction mixture was quenched by addition of H₂O (600 mL) and extracted with EtOAc (2×500 mL). The combined organic layers were washed with brine (2×600 mL), dried over anhydrous Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate=1:0 to 100:1) to give the title compound (27 g, 77% yield, 89% purity on LCMS) as a yellow oil.

¹H NMR (CDCl₃): δ 6.81-6.76 (m, 2H), 6.66-6.62 (m, 1H), 5.38 (s, 1H), 5.08 (s, 1H), 3.69 (br s, 2H) and 1.25 (s, 3H).

LCMS: m/z 152.2 (M+H)⁺ (ES⁺).

Step B: 4-Fluoro-2-isopropylaniline

To a solution of 4-fluoro-2-(prop-1-en-2-yl)aniline (21 g, 138.91 mmol, 1 eq) in MeOH (300 mL) was added Pd/C (2.1 g, 178.59 mmol, 10 wt % loading on activated carbon) under N₂ atmosphere. The reaction mixture was degassed in vacuo and purged with H₂ several times. The reaction mixture was stirred at 25° C. for 12 hours under H₂ (50 psi). The reaction mixture was filtered and the filtrate was concentrated in vacuo to give the title compound (20 g, crude) as a yellow oil.

¹H NMR (CDCl₃): δ 6.86 (dd, 1H), 6.75-6.72 (m, 1H), 6.63-6.61 (m, 1H), 3.50 (br s, 2H), 2.95-2.84 (m, 1H) and 1.25 (d, 6H).

LCMS: m/z 154.2 (M+H)⁺ (ES⁺).

Step C: 2-Bromo-4-fluoro-6-isopropylaniline

To a solution of 4-fluoro-2-isopropylaniline (20 g, 130.55 mmol, 1 eq) in toluene (250 mL) was added NBS (23.24 g, 130-55 mmol, 1 eq) at 25° C. The reaction mixture was stirred at 25° C. for 10 minutes. Then the reaction mixture was poured into H₂O (300 mL) and extracted with EtOAc (2×250 mL). The organic phases were washed with brine (2×400 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (eluting only by using petroleum ether) to give the title compound (30 g, 99%) as a black brown oil.

¹H NMR (CDCl₃): δ 6.99 (dd, 1H), 6.78 (dd, 1H), 3.91 (br s, 2H), 2.88-2.71 (m, 1H) and 1.17 (d, 6H).

LCMS: m/z 232.1 (M+H)⁺ (ES⁺).

Step D: 4-Bromo-2-isopropoxypyridine

To a solution of 4-bromo-2-chloropyridine (20 g, 103.93 mmol, 1 eq) in THF (400 mL) was added NaH (6.24 g, 155.89 mmol, 60% purity, 1.5 eq) at 0° C. Then the mixture was stirred for 0.5 hour. Propan-2-ol (6.87 g, 114.32 mmol, 8.75 mL, 1.1 eq) was added and the resulting mixture was warmed to 50° C. and stirred for 12 hours. The reaction mixture was quenched with H₂O (1 L) at 25° C. and extracted with EtOAc (2×200 mL). The combined organic layers were washed with brine (200 mL), dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography (SiO₂, petroleum ether:ethyl acetate=50:1 to 40:1) to give the title compound (22 g, 98%) as a light yellow oil.

¹H NMR (CDCl₃): δ 7.96 (d, 1H), 6.98 (dd, 1H), 6.89 (d, 1H), 5.44-5.24 (m, 1H) and 1.34 (d, 6H).

Step E: 2-Isopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine

To a solution of 4-bromo-2-isopropoxypyridine (19 g, 87.93 mmol, 1 eq) and 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (22.33 g, 87.93 mmol, 1 eq) in 1,4-dioxane (300 mL) was added KOAc (25.89 g, 263.80 mmol, 3 eq) followed by Pd(dppf)Cl₂ (1.93 g, 2.64 mmol, 0.03 eq) under nitrogen. Then the reaction mixture was heated to 80° C. and stirred for 12 hours. The mixture was concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate=50:1 to 20:1) to give the title compound (22 g, 95%) as a light yellow oil.

¹H NMR (CDCl₃): δ 8.16 (d, 1H), 7.13 (d, 1H), 7.08 (s, 1H), 5.32-5.24 (m, 1H), 1.34 (s, 12H) and 1.27 (s, 6H).

LCMS: m/z 264.2 (M+H)⁺ (ES⁺).

Step F: 4-Fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropylaniline

To a solution of 2-bromo-4-fluoro-6-isopropylaniline (10.94 g, 47.12 mmol, 1 eq) and 2-isopropoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine (12.4 g, 47.12 mmol, 1 eq) in 1,4-dioxane (200 mL) and H₂O (20 mL) was added Pd(dppf)Cl₂ (1.72 g, 2.36 mmol, 0.05 eq) followed by K₂CO₃ (19.54 g, 141-37 mmol, 3 eq) at 25° C. Then the reaction mixture was heated to 80° C. and stirred for 2 hours. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate=50:1 to 20:1) to give the title compound (10.3 g, 69% yield, 91% purity on LCMS) as a brown oil.

¹H NMR (CDCl₃): δ 8.21 (d, 1H), 6.94-6.91 (m, 2H), 6.76 (s, 1H), 6.72 (dd, 1H), 5.38-5.29 (m, 1H), 3.64 (br s, 2H), 2.98-2.89 (m, 1H), 1.38 (d, 6H) and 1.30-1.27 (m, 6H).

LCMS: m/z 289.2 (M+H)⁺ (ES⁺).

Step G: 4-(5-Fluoro-2-isocyanato-3-isopropylphenyl)-2-isopropoxypyridine

To a solution of 4-fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropylaniline (4 g, 13.87 mmol, 1 eq) in THF (80 mL) was added TEA (2.81 g, 27.74 mmol, 3.86 mL, 2 eq). The mixture was cooled to 0° C. and then triphosgene (1.65 g, 5.55 mmol, 0.4 eq) was added to the mixture. The resulting mixture was heated to 70° C. and stirred for 1 hour. The mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate=100:1 to 30:1) to give the title compound (1.9 g, 44% yield) as a yellow oil, which was used directly in the next step.

Intermediate A8: 4-(4-Isocyanato-2,3-dihydro-1H-inden-5-yl)-2-methoxypyridine Step A: 4-Nitro-2,3-dihydro-1H-indene

To a mixture of 2,3-dihydro-1H-indene (60 g, 507.72 mmol, 62.50 mL, 1 eq) in concentrated H₂SO₄ (30 mL) was added a mixture of HNO₃ (50 mL, 69 wt % in water) and concentrated H₂SO₄ (50 mL) dropwise at 0° C. over a period of 3.5 hours. The reaction mixture was stirred at 0° C. for 0.5 hour. Then the reaction mixture was poured into ice water (600 mL) and extracted with ethyl acetate (2×400 mL). The combined organic layers were washed with water (500 mL), saturated aqueous NaHCO₃ solution (500 mL) and brine (2×500 mL). The organic layer was dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate, 1:0 to 100:1) to give the title compound (55 g, 66%) as a colourless oil.

¹H NMR (CDCl₃): δ 7.98 (d, 1H), 7.51 (d, 1H), 7.30 (t, 1H), 3.41 (t, 2H), 302 (t, 2H) and 2.22-2.20 (m, 2H).

Step B: 2,3-Dihydro-1H-inden-4-amine

To a solution of 4-nitro-2,3-dihydro-1H-indene (55 g, contained another regio-isomer) in MeOH (500 mL) was added Pd/C (5 g, 10 wt % loading on activated carbon) under N₂ atmosphere. The suspension was degassed under vacuum and purged with H₂ several times. The reaction mixture was stirred under H₂ (50 psi) at 20° C. for 12 hours. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate, 1:0 to 100:4) to give the title compound (19.82 g, 43% yield, 96.39% purity on LCMS) as a brown oil.

¹H NMR (CDCl₃): δ 7.01 (t, 1H), 6.71 (d, 1H), 6.51 (d, 1H), 3.57 (br s, 2H), 2.93 (t, 2H), 2.75 (t, 2H) and 2.16-2.08 (m, 2H).

LCMS: m/z 134.2 (M+H)⁺ (ES⁺).

Step C: N-(2,3-Dihydro-1H-inden-4-yl)acetamide

To a solution of 2,3-dihydro-1H-inden-4-amine (19.8 g, 148.66 mmol, 1 eq) and TEA (19.56 g, 193.26 mmol, 1.3 eq) in DCM (300 mL) was added dropwise Ac₂O (17.45 g, 170.96 mmol, 1.15 eq) over 6 minutes at 0° C. Then the reaction mixture was warmed to 16° C. and stirred for 1.4 hours. The mixture was poured into water (500 mL) and extracted with DCM (2×300 mL). The combined organic phases were washed with brine (2×500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo to give the title compound (25.74 g, 96% yield, 96.69% purity on LCMS) as a white solid.

¹H NMR (CDCl₃): δ 7.70 (d, 1H), 7.15 (t, 1H), 7.02 (d, 1H), 2.95 (t, 2H), 2.81 (t, 2H), 2.18 (s, 3H) and 2.15-2.08 (m, 2H).

LCMS: m/z 176.2 (M+H)⁺ (ES⁺).

Step D: N-(5-Bromo-2,3-dihydro-1H-inden-4-yl)acetamide

N-(2,3-dihydro-1H-inden-4-yl)acetamide (34.6 g, 197.46 mmol, 1 eq), p-toluenesulfonic acid (18.70 g, 108.60 mmol, 0.55 eq) and Pd(OAc)₂ (2.22 g, 9.87 mmol, 0.05 eq) were suspended in toluene (400 mL) and stirred at 20° C. for 0.5 hour under air atmosphere. NBS (38.66 g, 217.20 mmol, 1.1 eq) was added. Then the reaction mixture was stirred at 20° C. for 2 hours. The reaction mixture was poured into water (500 mL) and extracted with ethyl acetate (2×500 mL). The combined organic phases were washed with brine (2×500 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate, 10: 1 to 2:1) to give the title compound (13.9 g, 27% yield, 98.1% purity on LCMS) as a white solid.

¹H NMR (CDCl₃): δ 7.33 (d, 1H), 7.16 (s, 1H), 6.98 (d, 1H), 2.92-2.83 (m, 4H), 2.21 (s, 3H) and 2.10-2.02 (m, 2H).

LCMS: m/z 254.1 (M+H)⁺ (ES⁺).

Step E: 5-Bromo-2,3-dihydro-1H-inden-4-amine

A mixture of N-(5-bromo-2,3-dihydro-1H-inden-4-yl)acetamide (45.68 g, 179.76 mmol, 1 eq) in EtOH (200 mL) and concentrated HCl (300 mL, 36 wt % in water) was stirred at 80° C. for 36 hours. The reaction mixture was cooled to 0° C. in an ice bath and some solid precipitated. The suspension was filtered. The filter cake was washed with ice water (50 mL) and dried in vacuo to give the title compound (34.1 g, 72% yield, 94.08% purity on LCMS, HCl salt) as a grey solid.

¹H NMR (DMSO-d₆): δ 7.67 (br S, 2H), 7.24 (d, 1H), 6.69 (d, 1H), 2.85 (t, 2H), 2.79 (t, 2H) and 2.04-1.96 (m, 2H).

LCMS: m/z 212.0 (M+H)⁺ (ES⁺).

Step F: 5-(2-Methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-amine

A solution of (2-methoxypyridin-4-yl)boronic acid (25.11 g, 164.15 mmol, 1.2 eq), 5-bromo-2,3-dihydro-1H-inden-4-amine (34 g, 136.80 mmol, 1 eq, HCl salt) and K₂CO₃ (60.50 g, 437-74 mmol, 3.2 eq) in dioxane (500 mL) and H₂O (100 mL) was degassed with nitrogen for 15 minutes before Pd(dppf)Cl₂.CH₂Cl₂ (6 g, 7.35 mmol, 0.053 eq) was added. The reaction mixture was heated to 80° C. for 12 hours. The mixture was poured into water (500 mL) and extracted with ethyl acetate (2×500 mL). The combined organic phases were washed with brine (2×700 mL), dried over anhydrous Na₂SO₄, filtered and concentrated in vacuo. The residue was purified by silica gel column chromatography (SiO₂, petroleum ether:ethyl acetate, 1:0 to 10:1) to give the title compound (27.4 g, 79% yield, 95% purity on LCMS) as a white solid.

¹H NMR (CDCl₃): δ 8.22 (d, 1H), 7.03-7.00 (m, 1H), 6.99 (d, 1H), 6.87 (s, 1H), 6.77 (d, 1H), 3.99 (s, 3H), 3.77 (br s, 2H), 2.97 (t, 2H), 2.77 (t, 2H) and 2.21-2.13 (m, 2H).

LCMS: m/z 241.2 (M+H)⁺ (ES⁺).

Step G: 4-(4-Isocyanato-2,3-dihydro-1H-inden-5-yl)-2-methoxypyridine

To a solution of 5-(2-methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-amine (11 g, 45.78 mmol, 1 eq) and TEA (5.10 g, 50-35 mmol, 1.1 eq) in THF (275 mL) was added bis(trichloromethyl) carbonate (4.93 g, 16.61 mmol, 0.36 eq) in portions at 0° C. Then the reaction mixture was stirred at 16° C. for 0.5 hour. The reaction mixture was filtered and the filter cake was washed with THF (2 L). The filtrate was concentrated in vacuo to give the title compound (9.04 g, 74%) as a light yellow solid.

¹H NMR (CDCl₃): δ 8.28 (d, 1H), 7.20-7.16 (m, 3H), 7.02 (s, 1H), 4.16 (s, 3H), 3.04-2.99 (m 4H) and 2.23-2.15 (m, 2H).

Intermediate A9: 5-Chloro-2-isocyanato-1,3-diisopropylbenzene

To a solution of 4-chloro-2,6-diisopropylaniline (0.105 g, 0.496 mmol) in toluene (1 mL) was added a phosgene solution (0.65 mL, 20 wt % in toluene, 1.22 mmol) and the reaction mixture was refluxed for 1 hour. Upon cooling, the mixture was concentrated in vacuo to afford the title compound as an orange oil (0.111 g, 94%).

¹H NMR (CDCl₃) δ 7.07 (d, 2H), 3.17 (h, 2H), 1.24 (d, 12H).

Preparation of Examples Example 1: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide

1-(Tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate PI) (47 mg, 0.216 mmol) was dissolved in dry THF (2 mL) and sodium tert-butoxide (2M in THF) (108 μl, 0.216 mmol) was added. After stirring for 30 minutes, a solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (43.1 mg, 0.216 mmol) in THF (1 mL) was added. The cloudy reaction mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo, dissolved in DMSO (2 mL) and purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (37.1 mg, 39%) as a colourless powder.

¹H NMR (DMSO-d6) δ 7.88 (d, J=2.4 Hz, 1H), 7.83 (s, 1H), 6.87 (s, 1H), 6.63 (d, J=2.4 Hz, 1H), 5.13-5.05 (m, 1H), 4.01-3.93 (m, 2H), 3.89 (dd, J=9.5, 3.6 Hz, 1H), 3.81 (td, J=8.3, 5.6 Hz, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 2.46-235 (m, 1H), 2.29-2.20 (m, 1H), 1.93 (p, J=7.4 Hz, 4H). One exchangeable proton not visible.

LCMS; m/z 417 (M+H)⁺ (ES⁺); 415 (M−H)⁻ (ES⁻).

Example 2: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-methoxyethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-methoxyethyl)-1H-pyrazole-3-sulfonamide (Intermediate P2) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (6 mg, 4%) as a white solid.

¹H NMR (DMSO-d6) δ 10.81 (br s, 1H), 7.95-7.75 (m, 2H), 6.89 (s, 1H), 6.63 (s, 1H), 4.32 (t, J=5.3 Hz, 2H), 3.69 (t, J=5.3 Hz, 2H), 3.22 (s, 3H), 2.78 (t, J=7.4 Hz, 4H), 2.64-2.60 (m, 4H), 1.98-1.90 (m, 4H).

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 3: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-((tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-((tetrahydrofuran-2-yl)methyl)-1H-pyrazole-3-sulfonamide (Intermediate P3) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (44.8 mg, 44%) as a white solid.

¹H NMR (DMSO-d6) δ 7.81 (s, 1H), 7.76 (s, 1H), 6.87 (s, 1H), 6.59 (s, 1H), 4.26-4.11 (m, 3H), 3.76-3.69 (m, 1H), 3.66-3.59 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.62 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H), 1.97-1.86 (m, 1H), 1.81-1.67 (m, 2H), 1.63-1.53 (m, 1H).

One exchangeable proton not visible.

LCMS; m/z 431 (M+H)⁺ (ES⁺); 429 (M−H)⁻ (ES⁻).

Enantiomers were separated using chiral preparative scale SFC purification (Amy-C column; isocratic elution using 35:65 MeOH:CO₂ (0.2% v/v NH₃), 4 minute run)

Example 4: Enantiomer 1 (Elutes at 1.9 Minutes)

¹H NMR (DMSO-d6) δ 7.89 (s, 1H), 7.80 (d, J=2.3 Hz, 1H), 6.89 (s, 1H), 6.63 (d, J=2.4 Hz, 1H), 4.30-4.07 (m, 3H), 3.79-3.65 (m, 1H), 3.67-3.56 (m, 1H), 2.77 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.3 Hz, 4H), 2.00-1.83 (m, 5H), 1.82-1.65 (m, 2H), 1.64-1.51 (m, 1H). One exchangeable proton not visible.

LCMS; m/z 431.4 (M+H)⁺ (ES⁺); 429.4 (M−H)⁻ (ES⁻).

Example 5: Enantiomer 2 (Elutes at 2.8 Minutes)

¹H NMR (DMSO-d6) δ 10.81 (s, 1H), 7.98 (s, 1H), 7.86 (d, J=2.4 Hz, 1H), 6.92 (s, 1H), 6.71 (d, J=2.4 Hz, 1H), 4.31-4.10 (m, 3H), 3.82-3.67 (m, 1H), 3.66-3.58 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 2.00-1.86 (m, 5H), 1.83-1.65 (m, 2H), 1.64-1.50 (m, 1H).

LCMS; m/z 431.4 (M+H)⁺ (ES⁺); 429.3 (M−H)⁻ (ES⁻).

Example 6: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-((tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-((tetrahydrofuran-3-yl)methyl)-1H-pyrazole-3-sulfonamide (Intermediate P4) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (7.2 mg, 7%) as a colourless powder.

¹H NMR (DMSO-d6) δ 10.81 (br s, 1H), 7.93 (s, 2H), 6.91 (s, 1H), 6.69 (s, 1H), 4.19 (d, J=7.6 Hz, 2H), 3.75 (td, J=8.1, 5.6 Hz, 1H), 3.66-3.58 (m, 2H), 3.45 (dd, J=8.7, 5.5 Hz, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.75-2.66 (m, 1H), 2.60 (t, J=7.3 Hz, 4H), 1.94 (pent, J=7.4 Hz, 4H), 1.93-1.84 (m, 1H), 1.66-1.53 (m, 1H).

LCMS; m/z 431 (M+H)⁺ (ES⁺); 429 (M−H)⁻ (ES⁻).

Example 7: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(3-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(3-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P5) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (31 mg, 30%) as a white solid.

¹H NMR (DMSO-d6) δ 10.81 (s, 1H), 8.02 (s, 1H), 7.94 (d, J=2.3 Hz, 1H), 6.94 (s, 1H), 6.74 (d, J=2.4 Hz, 1H), 4.64 (t, J=5.1 Hz, 1H), 4.26 (t, J=7.1 Hz, 2H), 3.39 (td, J=6.1, 5.0 Hz, 2H), 2.79 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.5 Hz, 4H), 1.97-1.90 (m, 6H).

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 8: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxyethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-hydroxyethyl)-1H-pyrazole-3-sulfonamide (Intermediate P6) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (11 mg, 9%) as a white solid.

¹H NMR (DMSO-d6) δ 7.81-7.64 (m, 2H), 6.84 (s, 1H), 6.52 (s, 1H), 4.95 (t, J=5.2 Hz, 1H), 4.16 (t, J=5.7 Hz, 2H), 3.75-3.71 (m, 2H), 2.77 (t, J=7.4 Hz, 4H), 2.64 (t, J=7.4 Hz, 4H), 1.95-1.89 (m 4H). One exchangeable proton not visible.

LCMS; m/z 391 (M+H)⁺ (ES⁺).

Example 9: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide, partial ammonium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-((3-methyloxetan-3-yl)methyl)-1H-pyrazole-3-sulfonamide (Intermediate P7) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (2.6 mg, 7%) as a white solid.

¹H NMR (DMSO-d6) δ 8.38 (d, J=2.9 Hz, 1H), 7.90 (br s, 1H), 6.93 (d, J=2.8 Hz, 1H), 6.81 (s, 1H), 5.12 (br s, 1H), 4.69 (d, J=12.5 Hz, 1H), 4.49 (d, J=11.8 Hz, 1H), 4.42 (d, J=12.5 Hz, 1H), 4.28 (d, J=11.8 Hz, 1H), 3.49-3.40 (m, 2H), 2.75 (t, J=7.3 Hz, 4H), 2.64 (t, J=7.4 Hz, 4H), 1.94-1.86 (m, 4H), 1.24 (s, 3H).

LCMS; m/z 431 (M+H)⁺ (ES⁺).

Example 10:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide (Intermediate P8) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (10.6 mg, 8%) as a colourless solid.

¹H NMR (DMSO-d6) δ 10.74, (br s, 1H), 7.89 (s, 1H), 7.76 (d, J=2.4 Hz, 1H), 6.90 (s, 1H), 6.66 (d, J=2.3 Hz, 1H), 4.77 (s, 1H), 4.08 (s, 2H), 2.78 (t, J=7.4 Hz, 4H), 2.60 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.5 Hz, 4H), 1.05 (s, 6H).

LCMS; m/z 419 (M+H)⁺ (ES⁺); 417 (M−H)⁻ (ES⁻).

Example 11: (S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (S)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P9) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (15.4 mg, 30%) as a white solid.

¹H NMR (DMSO-d6) δ 7.98 (s, 1H), 7.84 (d, J=2.4 Hz, 1H), 6.93 (s, 1H), 6.70 (d, J=2.4 Hz, 1H), 5.01 (d, J=5.0 Hz, 1H), 4.09 (dd, J=5.9, 2.0 Hz, 2H), 3.98-3.96 (m, 1H), 2.79 (t, J=7.4 Hz, 4H), 2.63-2.57 (m, 4H), 1.98-1.91 (m, 4H), 1.03 (d, J=6.2 Hz, 3H).

One exchangeable proton not visible.

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 12: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(oxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(oxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P10) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (26 mg, 19%) as a white solid.

¹H NMR (DMSO-d6) δ 7.84 (br s, J=2.3 Hz, 1H), 7.51 (s, 1H), 6.77 (s, 1H), 6.45 (d, J=2.3 Hz, 1H), 5.58-5.55 (m, 1H), 4.95-4.81 (m, 4H), 2.75 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.3 Hz, 4H), 1.92-1.89 (m, 4H). One exchangeable proton not visible.

LCMS; m/z 403 (M+H)⁺ (ES⁺).

Example 13: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-1-(1-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide (Intermediate P11) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (34 mg, 13%) as a white solid.

¹H NMR (DMSO-d6) δ 10.82 (br s, 1H), 7.96 (s, 1H), 7.83 (s, 1H), 6.92 (s, 1H), 6.69 (s, 1H), 5.00 (d, J=5.0 Hz, 1H), 4.09 (dd, J=5.0, 1.8 Hz, 2H), 4.05-395 (m, 1H), 2.79 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 1.98-1.91 (m, 4H), 1.03 (d, J=6.2 Hz, 3H).

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 14: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide (Intermediate P12) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (42.2 mg, 38%) as a colourless powder.

¹H NMR (DMSO-d6) δ 10.81 (s, 1H), 8.00 (s, 1H), 7.78 (d, J=2.4 Hz, 1H), 6.94 (s, 1H), 6.75 (d, J=2.4 Hz, 1H), 4.23 (s, 2H), 3.16 (s, 3H), 2.79 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 1.95 (p, J=7.4 Hz, 4H), 1.07 (s, 6H).

LCMS; m/z 433 (M+H)⁺ (ES⁺); 431 (M−H)⁻ (ES⁻).

Example 15: (S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (S)-1-(1-hydroxypropan-2-yl)-1H-pyrazole-3-sulfonamide (Intermediate P13) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (16 mg, 14%) as a white solid.

¹H NMR (DMSO-d6) δ 7.90-7.76 (m, 1H), 7.70 (s, 1H), 6.83 (s, 1H), 6.54-6.48 (m, 1H), 5.02-4.93 (m, 1H), 4.06-3.92 (m, 3H), 2.76 (t, J=7.2 Hz, 4H), 2.63 (t, J=7.1 Hz, 4H), 1.95-1.91 (m, 4H), 1.03 (d, J=6.1 Hz, 3H). One exchangeable proton not visible.

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 16: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P14) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (42 mg, 38%) as a white solid.

¹H NMR (DMSO-d6) δ 7.62 (d, J=2.3 Hz, 1H), 7.55 (s, 1H), 6.77 (s, 1H), 6.37 (d, J=2.3 Hz, 1H), 4.99 (br s, 1H), 4.05-3.90 (m, 3H), 2.75 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.4 Hz, 4H), 1.93-1.86 (m, 4H), 1.01 (d, J=5.9 Hz, 3H). One exchangeable proton not visible.

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 17: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-1-(2-methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-methoxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide (Intermediate P12) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (17.9 mg, 23%) as a colourless solid.

¹H NMR (DMSO-d6) δ 11.02 (s, 1H), 7.75 (s, 1H), 7.75 (s, 1H), 6.91 (d, J=9.9 Hz, 2H), 6.70 (s, 1H), 4.21 (s, 2H), 3.17 (s, 3H), 2.94 (sept, J=7.4 Hz, 2H), 1.08 (s, 6H), 1.05 (br S, 12H).

LCMS; m/z 455 (M+H)⁺ (ES⁺); 453 (M−H)⁻ (ES⁻).

Example 8: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide (Intermediate P8) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (87 mg, 62%) as a clear colourless crystalline solid.

¹H NMR (DMSO-d6) δ 7.69 (s, 1H), 7.60 (s, 1H), 6.86 (s, 1H), 6.83 (s, 1H), 6.55 (s, 1H), 4.75 (s, 1H), 4.03 (s, 2H), 3.08-2.96 (m, 2H), 1.05 (s, 6H), 1.03 (d, J=6.8 Hz, 12H).

One exchangeable proton not visible.

LCMS; m/z 441.2 (M+H)⁺ (ES⁺).

Example 19: N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-3-sulfonamide (Intermediate P8) and 5-chloro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A9) to afford the title compound (19.1 mg, 13%) as a light yellow crystalline solid.

¹H NMR (DMSO-d6) δ 7.71 (s, 2H), 7.08 (s, 2H), 6.58 (s, 1H), 4.76 (s, 1H), 4.04 (s, 2H), 3.05-2.93 (m, 2H), 1.05 (s, 6H), 1.04 (d, J=6.6 Hz, 12H). One exchangeable proton not visible.

LCMS; m/z 457.5 (M+H)⁺ (ES⁺).

Example 20: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(1-hydroxy-2-methylpropan-2-yl)-1H-pyrazole-3-sulfonamide (Intermediate P15) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (13 mg, 16%) as a white solid.

¹H NMR (DMSO-d6) δ 10.75 (br s, 1H), 7.93 (s, 2H), 6.91 (s, 1H), 6.67 (s, 1H), 5.11 (t, J=5.5 Hz, 1H), 3.57 (d, J=5.6 Hz, 2H), 2.78 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.3 Hz, 4H), 1.93 (p, J=7.5 Hz, 4H), 1.47 (s, 6H).

LCMS; m/z 419.2 (M+H)⁺ (ES⁺); 417.4 (M−H)⁻ (ES⁻).

Example 21: (S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxybutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (S)-1-(2-hydroxybutyl)-1H-pyrazole-3-sulfonamide (Intermediate P16) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (19.7 mg, 20%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 10.78 (s, 1H), 7.94 (s, 1H), 7.82 (d, J=2.3 Hz, 1H), 6.91 (s, 1H), 6.67 (d, J=2.3 Hz, 1H), 4.96 (d, J=5.6 Hz, 1H), 4.14 (dd, J=13.7, 4.7 Hz, 1H), 4.06 (dd, J=13.7, 7.2 Hz, 1H), 3.75-3.66 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 1.94 (p, J=7.4 Hz, 4H), 1.43-1.33 (m, 1H), 1.33-1.22 (m, 1H), 0.87 (t, J=7.4 Hz, 3H).

LCMS; m/z 419.8 (M+H)⁺ (ES⁺).

Example 22: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxycyclopentyl)-1H-pyrazole-1-sulfonamide (racemic anti)

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(2-hydroxycyclopentyl)-1H-pyrazole-3-sulfonamide (racemic anti) (Intermediate P17) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (9.7 mg, 16%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 10.82 (s, 1H), 7.98 (s, 1H), 7.94 (d, J=2.4 Hz, 1H), 6.92 (s, 1H), 6.71 (d, J=2.4 Hz, 1H), 5.17 (d, J=5.1 Hz, 1H), 4.49-4.41 (m, 1H), 4.32-3.96 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 2.23-2.11 (m, 1H), 2.01-1.88 (m, 6H), 1.81-1.70 (m, 2H), 1.62-1.51 (m, 1H).

LCMS; m/z 431.3 (M+H)⁺ (ES⁺).

Example 23: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(3-hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide, partial ammonium salt (racemic—R,R and S,S enantiomers)

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(3-hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,R and S,S enantiomers) (Intermediate P8) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (80.7 mg, 50%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 7.90 (s, 1H), 7.86 (d, J=2.4 Hz, 1H), 6.90 (s, 1H), 6.66 (d, J=2.4 Hz, 1H), 5.04 (d, J=5.3 Hz, 1H), 4.25-413 (m, 1H), 3.86-3.75 (m, 1H), 2.77 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 2.00-1.86 (m, 4H), 1.44 (d, J=6.8 Hz, 3H), 0.84 (d, J=6.3 Hz, 3H). One exchangeable proton not visible.

LCMS; m/z 419.4 (M+H)⁺ (ES⁺).

Example 24: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(1-(hydroxymethyl)cyclobutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(1-(hydroxymethyl)cyclobutyl)-1H-pyrazole-3-sulfonamide (Intermediate P19) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (16.4 mg, 28%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 7.78 (s, 1H), 7.74 (d, J=2.4 Hz, 1H), 6.85 (s, 1H), 6.55 (d, J=2.4 Hz, 1H), 5.15 (t, J=5.5 Hz, 1H), 3.72 (d, J=5.5 Hz, 2H), 2.77 (t, J=7.4 Hz, 4H), 2.62 (t, J=7.4 Hz, 4H), 2.48-2.41 (m, 2H), 2.34-2.24 (m, 2H), 1.97-1.78 (m, 6H). One exchangeable proton not visible.

LCMS; m/z 431.3 (M+H)⁺ (ES⁺).

Example 25: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxybutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-1-(2-hydroxybutyl)-1H-pyrazole-3-sulfonamide (Intermediate P20) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (112 mg, 50%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 8.01 (s, 1H), 7.84 (d, J=2.4 Hz, 1H), 6.92 (s, 1H), 6.70 (d, J=2.4 Hz, 1H), 4.99 (d, J=5.6 Hz, 1H), 4.15 (dd, J=13.7, 4.5 Hz, 1H), 4.07 (dd, J=13.7, 7.2 Hz, 1H), 3.76-3.66 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.60 (t, J=7.4 Hz, 4H), 1.98-1.89 (m, 4H), 1.44-132 (m, 1H), 1.32-1.21 (m, 1H), 0.87 (t, J=7.4 Hz, 3H). One exchangeable proton not visible.

LCMS; m/z 419.1 (M+H)⁺ (ES⁺).

Example 26: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(3-hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers)

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(3-hydroxybutan-2-yl)-1H-pyrazole-3-sulfonamide (racemic—R,S and S,R enantiomers) (Intermediate P21) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (35 mg, 16%) as a clear colourless solid.

¹H NMR (DMSO-d6) δ 10.77 (s, 1H), 8.00 (s, 1H), 7.86 (d, J=2.4 Hz, 1H), 6.92 (s, 1H), 6.71 (d, J=2.4 Hz, 1H), 4.96 (d, J=5.0 Hz, 1H), 4.35-4.24 (m, 1H), 3.90-379 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 2.00-1.88 (m, 4H), 1.39 (d, J=7.0 Hz, 3H), 0.96 (d, J=6.3 Hz, 3H).

LCMS; m/z 419.4 (M+H)⁺ (ES⁺).

Example 27: (R)—N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P14) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (62 mg, 49%) as a colourless solid.

¹H NMR (DMSO-d6) δ 11.00 (s, 1H), 7.88 (d, J=2.4 Hz, 1H), 7.83 (s, 1H), 6.93 (d, J=9.9 Hz, 2H), 6.73 (d, J=2.3 Hz, 1H), 5.03 (d, J=4.9 Hz, 1H), 4.11 (d, J=5.8 Hz, 2H), 4.06-3.91 (m, 1H), 3.05-2.83 (m, 2H), 1.26-0.88 (m, 15H).

LCMS; m/z 427.3 (M+H)⁺ (ES⁺).

Example 28: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide

To a solution of (R)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide (Intermediate P22) (120 mg, 0.573 mmol) in THF (2 mL) was added sodium tert-butoxide (2M in THF) (0.3 mL, 0.600 mmol) and the mixture was stirred at room temperature for 1 hour. 4-Isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (120 mg, 0.602 mmol) in THF (2 mL) was added and the mixture was stirred at room temperature overnight. The volatiles were evaporated, the residue dissolved in DMSO and purified by prep-HPLC to afford the title compound (29 mg, 12%) as a white solid.

¹H NMR (DMSO-d6) δ 8.02 (s, 1H), 7.79 (d, J=1.3 Hz, 1H), 7.76 (d, J=1.3 Hz, 1H), 6.90 (s, 1H), 5.01 (d, J=4.1 Hz, 1H), 4.05-3.96 (m, 1H), 3.92-3.82 (m, 2H), 2.77 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H), 1.01 (d, J=5.8 Hz, 3H).

One exchangeable proton not visible.

LCMS; m/z 405.3 (M+H)⁺ (ES⁺).

Example 29: (S)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide

Prepared according to the general procedure of (R)—N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide (Example 28) from (S)-1-(2-hydroxypropyl)-1H-imidazole-4-sulfonamide (Intermediate P23) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (13 mg, 13%) as a white solid.

¹H NMR (DMSO-d6) δ 8.75 (br s, 1H), 7.98 (s, 1H), 7.73 (s, 2H), 6.88 (s, 1H), 5.01 (d, J=4.1 Hz, 1H), 4.08-3.93 (m, 1H), 3.92-3.79 (m, 2H), 2.77 (t, J=7.4 Hz, 4H), 2.60 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H), 1.01 (d, J=5.8 Hz, 3H).

LCMS; m/z 405.3 (M+H)⁺ (ES⁺).

Example 30: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(3,3,3-trifluoro-2-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P24) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (66 mg, 50%) as a white solid.

¹H NMR (DMSO-d6) δ 7.92-7.79 (m, 2H), 6.87 (s, 1H), 6.80 (d, J=6.3 Hz, 1H), 6.67-6.59 (m, 1H), 4.48-4.25 (m, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.63 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H). One exchangeable proton not visible.

LCMS; m/z 459.3 (M+H)⁺ (ES⁺).

Example 31: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide, sodium salt

1-(Tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide (Intermediate P25) (30 mg, 0.130 mmol) was dissolved in THF (5 mL) and 60% sodium hydride (7.78 mg, 0.195 mmol) added. After 1 hour, 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (25.8 mg, 0.130 mmol) was added and the mixture stirred at room temperature for 15 hours. The suspension was filtered and washed with THF (1 mL). The collected solid was triturated with ethyl acetate (10 mL) for 10 hours and filtered. The collected solid was dried under reduced pressure to afford the title compound (47 mg, 74%) as a white solid.

¹H NMR (DMSO-d6) δ 7.74 (d, J=2.2 Hz, 1H), 7.53 (s, 1H), 6.77 (s, 1H), 6.40 (d, J=2.3 Hz, 1H), 4.40-4.38 (m, 1H), 3.96 (dt, J=11.5, 3.4 Hz, 2H), 3.50-3.37 (m, 2H), 2.75 (t, J=7.3 Hz, 4H), 2.65 (t, J=7.4 Hz, 4H), 2.02-1.83 (m, 8H). One exchangeable proton not visible.

LCMS; m/z 431 (M+H)⁺ (ES⁺).

Example 32: N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide, sodium salt

Sodium tert-butoxide (0.114 mL, 0.227 mmol) was added to a solution of 1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide (Intermediate P25) (50 mg, 0.216 mmol) in THF (1 mL) and stirred at room temperature for 1 hour to give a white suspension. Then 5-chloro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A9) (56.5 mg, 0.238 mmol) in THF (1 mL) was added and stirred at room temperature overnight. The resultant colourless precipitate was collected by filtration, washed with THF (10 mL) and EtOAc (10 mL), and dried in vacuo to afford a colourless solid. The residue was triturated with TBME (3×10 mL). The resultant solid was filtered, rinsed with TBME (10 mL), and dried in vacuo to afford the title compound (25 mg, 22%) as a colourless solid.

¹H NMR (DMSO-d6) δ 7.73 (d, J=2.3 Hz, 1H), 7.45 (br. s, 1H), 7.01 (s, 2H), 6.38 (br. s, 1H), 4.44-4.30 (m, 1H), 3.96 (dt, J=3.3, 11.1 Hz, 2H), 3.50-339 (m, 2H), 3.22-307 (m, 2H), 1.98-1.88 (m, 4H), 1.03 (d, J=6.8 Hz, 12H). One exchangeable proton not visible.

LCMS; m/z 469.4 (M+H)⁺ (ES⁺).

Example 33: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-2-(2-hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide, partial ammonium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-2-(2-hydroxypropyl)-2H-1,2,3-triazole-4-sulfonamide (Intermediate P26) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (39 mg, 25%) as a white solid.

1H NMR (DMSO-d6) δ 8.05 (s, 1H), 7.87 (s, 1H), 7.08 (br s, 1H), 6.87 (s, 1H), 5.04 (d, J=5.4 Hz, 1H), 4.39-4.30 (m, 2H), 4.11 (app sept, J=6.3 Hz, 1H), 2.77 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 1.92 (p, J=7.4 Hz, 4H), 1.07 (d, J=6.3 Hz, 3H).

LCMS; m/z 406.4 (M+H)⁺ (ES⁺).

Example 34: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(3-hydroxycyclobutyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(3-hydroxycyclobutyl)-1H-pyrazole-3-sulfonamide (Intermediate P27) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (27 mg, 20%) as a white solid.

1H NMR (DMSO-d6) δ 7.95 (d, J=2.3 Hz, 1H), 7.92 (s, 1H), 6.90 (s, 1H), 6.67 (d, J=2.3 Hz, 1H), 5.26 (d, J=5.0 Hz, 1H), 5.07-4.98 (m, 1H), 4.47-4.37 (m, 1H), 2.77 (t, J=7.4 Hz, 4H), 2.66-2.56 (m, 6H), 2.40-2.33 (m, 2H), 1.93 (p, J=7.4 Hz, 4H). NH not resolved.

LCMS; m/z 417.4 (M+H)⁺ (ES⁺).

Example 35: N-((7-Fluoro-5-(pyridin-3-yl)-2,3-dihydro-1H-inden-4-yl) carbamoyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

7-Fluoro-5-(pyridin-3-yl)-2,3-dihydro-1H-inden-4-amine (150 mg, 0.657 mmol) (Intermediate A3) was dissolved in dry THF (2 mL). Triethylamine (101 μl, 0.723 mmol) and a solution of bis(trichloromethyl) carbonate (195 mg, 0.657 mmol) in THF (1 mL) was added. The reaction mixture was stirred for 2 hours and then concentrated in vacuo. The residue was suspended in toluene (10 mL) and filtered through a phase separation cartridge washing with toluene (10 mL). The combined filtrates were concentrated in vacuo and then dissolved in dry THF (4 mL) to give a stock solution of 3-(7-fluoro-4-isocyanato-2,3-dihydro-1H-inden-5-yl)pyridine (0.165 M in THF). 5-(3-Methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29) (40 mg, 0.162 mmol) was dissolved in dry THF (2 mL). Sodium tert-butoxide (2 M in THF) (80 μl, 0.160 mmol) was added and the mixture was stirred at room temperature for 1 hour. Then a solution of 3-(7-fluoro-4-isocyanato-2,3-dihydro-1H-inden-5-yl)pyridine (1 mL, 0.165M in THF) was added and the mixture was stirred overnight. The THF was removed in vacuo and the residue was dissolved in DMSO (2 mL) and then purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (3 mg, 3.6%) as a colourless powder.

1H NMR (DMSO-d6) δ 10.94 (s, 1H), 8.56 (dd, J=4.8, 1.7 Hz, 1H), 8.48 (s, 1H), 7.84 (s, 1H), 7.75-7.70 (m, 1H), 7.43 (dd, J=7.9, 4.9 Hz, 1H), 7.02 (d, J=9.2 Hz, 1H), 6.96 (s, 1H), 4.89 (d, J=7.3 Hz, 2H), 4.80 (d, J=7.4 Hz, 2H), 3.76 (s, 3H), 2.98 (s, 3H), 2.95 (t, J=7.5 Hz, 2H), 2.71 (t, J=7.5 Hz, 2H), 2.04 (p, J=7.6 Hz, 2H).

LCMS; m/z 502.4 (M+H)⁺ (ES⁺); 500.3 (M−H)− (ES−).

Example 36: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-1,2,4-triazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from (R)-1-(2-hydroxypropyl)-1H-1,2,4-triazole-3-sulfonamide (Intermediate P30) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (18 mg, 14%) as a colourless solid.

1H NMR (DMSO-d6) δ 11.23 (bs, 1H), 8.56 (s, 1H), 7.92 (s, 1H), 6.87 (s, 1H), 5.08 (d, J=5.0 Hz, 1H), 4.25-4.03 (m, 2H), 4.03-3.92 (m, 1H), 2.77 (t, J=7.4 Hz, 4H), 2.64 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.5 Hz, 4H), 1.07 (d, J=6.2 Hz, 3H).

LCMS; m/z 406.4 (M+H)⁺ (ES⁺).

Example 37: (R)—N-((4-Fluoro-2-isopropyl-6-(pyridin-3-yl)phenyl) carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide

To a solution of 4-fluoro-2-isopropyl-6-(pyridin-3-yl)aniline (Intermediate A4) (4 g, 17.37 mmol) in THF (20 mL) was added TEA (3.52 g, 34.74 mmol) and triphosgene (2.06 g, 6.95 mmol) at 5′C. The mixture was stirred at 70° C. for 20 minutes. The reaction mixture was filtered and the filtrate was concentrated in vacuo. The residue was purified by silica gel chromatography (30:1 PE/EtOAc) to give 3-(5-fluoro-2-isocyanato-3-isopropylphenyl)pyridine (1.9 g, 43%) as a yellow oil.

To a solution of (R)-1-(2-hydroxypropyl)-1H-pyrazole-3-sulfonamide (Intermediate P14) (300 mg, 1.46 mmol) in THF (5 mL) was added CH₃ONa (87 mg, 1.61 mmol) and the mixture was stirred at 30° C. for 30 minutes. 3-(5-Fluoro-2-isocyanato-3-isopropylphenyl)pyridine (412 mg, 1.61 mmol) was added and the reaction was stirred at 30° C. for 15.5 hours. The mixture was concentrated under reduced pressure. The residue was purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (62 mg, 9%) as a white solid.

1H NMR (DMSO-d6) δ 8.52-8.48 (m, 2H), 7.75-7.70 (m, 3H), 7.34-7.32 (m, 1H), 7.18-7.15 (m, 1H), 7.03-7.02 (m, 1H), 6.43 (s, 1H), 5.05 (s, 1H), 4.11-3.96 (m, 3H), 3.07-3.05 (m, 1H), 1.09 (d, J=6.4 Hz, 6H), 1.04 (d, J=6.4 Hz, 3H).

LCMS; m/z 462.2 (M+H)⁺ (ES⁺).

EE analysis by SFC: retention time 1.134 min, 100% ee value.

Example 38: 1-Cyclopropyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-cyclopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P31) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (46 mg, 34%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.97 (s, 1H), 7.03 (s, 1H), 6.90 (s, 1H), 4.92 (d, J=7.4 Hz, 2H), 4.80 (d, J=7.3 Hz, 2H), 3.61-3.51 (m, 1H), 3.00 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.57 (t, J=7.3 Hz, 4H), 1.92 (p, J=7.4 Hz, 4H), 1.14-1.05 (m, 2H), 0.99-0.92 (m, 2H). NH missing.

LCMS; m/z 473.4 (M+H)⁺ (ES⁺).

Example 39: 1-(tert-Butyl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(tert-butyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P32) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (32 mg, 29%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.96 (s, 1H), 6.98 (s, 1H), 6.89 (s, 1H), 4.91 (d, J=7.4 Hz, 2H), 4.74 (d, J=7.4 Hz, 2H), 2.97 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 1.91 (p, J=7.4 Hz, 4H), 1.50 (s, 9H). NH missing.

LCMS; m/z 511.4 (M+H)⁺ (ES⁺).

Example 40: N-((4-Fluoro-2-isopropyl-6-(2-methoxypyridin-4-yl)phenyl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

4-Fluoro-2-isopropyl-6-(2-methoxypyridin-4-yl)aniline (Intermediate A5) (50 mg, 0.192 mmol) was dissolved in dry THF (1 mL). Triethylamine (35 μl, 0.251 mmol) was added, followed by a solution of bis(trichloromethyl) carbonate (55 mg, 0.185 mmol) in THF (1 mL). The cloudy reaction mixture was stirred for 1 hour at room temperature and then the mixture was diluted with toluene (5 mL), filtered through a hydrophobic frit and concentrated in vacuo to give the crude isocyanate.

5-(3-Methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29) (48 mg, 0.194 mmol) was dissolved in dry THF (2 mL). Sodium tert-butoxide (2 M in THF) (110 μl, 0.220 mmol) was added and the mixture was stirred for 1 hour at room temperature. A solution of the previously prepared isocyanate in dry THF (2 mL) was added via syringe and the mixture was stirred overnight. The THF was removed in vacuo and the residue was dissolved in DMSO (2 mL) and then purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (23 mg, 22%) as a colourless solid.

1H NMR (DMSO-d6) δ 11.08 (s, 1H), 8.12 (d, J=5.3 Hz, 1H), 7.89 (s, 1H), 7.23 (dd, J=10.1, 2.9 Hz, 1H), 7.05 (dd, J=8.8, 2.9 Hz, 1H), 6.99 (s, 1H), 6.92 (dd, J=5.4, 1.5 Hz, 1H), 6.79 (s, 1H), 4.86 (d, J=7.4 Hz, 2H), 4.79 (d, J=7.3 Hz, 2H), 3.75 (s, 3H), 3.34 (s, 3H), 3.04 (sept, J=7.0 Hz, 1H), 2.95 (s, 3H), 1.09 (br s, 6H).

LCMS; m/z 534.4 (M+H)⁺ (ES⁺); 532.2 (M−H)− (ES−).

Example 41: 5-(3-Ethoxyoxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-ethoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P33) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (47 mg, 33%) as a colourless solid.

1H NMR (DMSO-d6) δ=7.89 (s, 1H), 6.95 (s, 1H), 6.88 (s, 1H), 4.86 (d, J=7.2 Hz, 2H), 4.79 (d, J=7.2 Hz, 2H), 3.72 (s, 3H), 3.10 (q, J=7.0 Hz, 2H), 2.77 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 1.91 (p, J=7.4 Hz, 4H), 1.08 (t, J=7.0 Hz, 3H). NH missing.

LCMS; m/z 461.5 (M+H)⁺ (ES⁺).

Example 42:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-isopropyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P35) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (42 mg, 40%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.90 (s, 1H), 6.94 (s, 1H), 6.88 (s, 1H), 4.89-4.73 (m, 4H), 4.24 (sept, J=6.7 Hz, 1H), 2.99 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 1.97-1.84 (m, 4H), 1.36 (d, J=6.5 Hz, 6H). NH not observed.

LCMS; m/z 475.3 (M+H)⁺ (ES⁺).

Example 43: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-5-(3-hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide (Intermediate P34) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (58 mg, 52%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.73 (s, 1H), 6.90 (s, 1H), 6.87 (s, 1H), 6.75 (d, J=3.2 Hz, 2H), 4.82 (d, J=6.8 Hz, 2H), 4.76 (d, J=6.8 Hz, 2H), 4.52-4.28 (m, 1H), 3.13-2.95 (m, 2H), 1.37 (d, J=6.5 Hz, 6H), 1.06 (d, J=6.8 Hz, 12H). NH not observed.

LCMS; m/z 483.3 (M+H)⁺ (ES⁺).

Example 44: 1-Ethyl-N-((4-fluoro-2,6-diisopropylphenyl)carbamoyl)-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-ethyl-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P36) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (49 mg, 40%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.74 (s, 1H), 6.87 (d, J=10.0 Hz, 2H), 6.76 (s, 1H), 6.74 (s, 1H), 4.80 (d, J=6.8 Hz, 2H), 4.75 (d, J=6.8 Hz, 2H), 4.03 (q, J=7.2 Hz, 2H), 3.12-2.96 (m, 2H), 1.34 (t, J=7.2 Hz, 3H), 1.05 (d, J=6.8 Hz, 12H). OH missing.

LCMS; m/z 469.5 (M+H)⁺ (ES⁺).

Example 45: 1-Ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-ethyl-5-(3-methoxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P37) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (44 mg, 42%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.91 (s, 1H), 6.95 (s, 1H), 6.88 (s, 1H), 4.89-4.73 (m, 4H), 3.94 (q, J=7.2 Hz, 2H), 2.98 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 1.91 (p, J=7.4 Hz, 4H), 1.32 (t, J=7.2 Hz, 3H). NH missing.

LCMS; m/z 461.5 (M+H)⁺ (ES⁺).

Example 46: 1-Ethyl-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-ethyl-5-(3-hydroxyoxetan-3-yl)-1H-pyrazole-3-sulfonamide (Intermediate P36) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (29 mg, 27%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.76 (s, 1H), 6.84 (s, 1H), 6.71 (s, 1H), 6.70 (s, 1H), 4.82 (d, J=6.8 Hz, 2H), 4.74 (d, J=6.8 Hz, 2H), 4.01 (q, J=7.2 Hz, 2H), 2.76 (t, J=7.4 Hz, 4H), 2.64 (t, J=7.4 Hz, 4H), 1.91 (p, J=8.3, 6.4 Hz, 4H), 1.33 (t, J=7.2 Hz, 3H). NH missing.

LCMS; m/z 447.5 (M+H)⁺ (ES⁺).

Example 47:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-hydroxyoxetan-3-yl)-1-isopropyl-1H-pyrazole-3-sulfonamide (Intermediate P34) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (26 mg, 24%) as a colourless solid.

1H NMR (DMSO-d6) δ 10.90 (s, 1H), 7.95 (s, 1H), 6.91 (s, 1H), 6.85 (s, 1H), 6.77 (s, 1H), 4.85 (d, J=6.9 Hz, 2H), 4.77 (d, J=6.9 Hz, 2H), 4.53-4.31 (m, 1H), 2.78 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 2.00-1.85 (m, 4H), 1.38 (d, J=6.5 Hz, 6H).

LCMS; m/z 461.3 (M+H)⁺ (ES⁺).

Example 48: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-methoxytetrahydrofuran-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P38) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (36 mg, 50%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.93 (s, 1H), 6.88 (s, 1H), 6.76 (s, 1H), 4.14 (dd, J=9.7, 1.0 Hz, 1H), 3.90 (s, 3H), 3.88-3.80 (m, 3H), 2.95 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 2.48-2.43 (m, 1H), 2.31-2.22 (m, 1H), 1.91 (p, J=7.5 Hz, 4H). NH missing.

LCMS; m/z 461.3 (M+H)⁺ (ES⁺).

Example 49: 5-(3-Fluorooxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-fluorooxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P39) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (4 mg, 9%) as a colourless solid.

1H NMR (DMSO-d6) δ 10.95 (s, 1H), 7.91 (s, 1H), 7.11 (s, 1H), 6.87 (s, 1H), 5.16-4.94 (m, 4H), 3.78 (d, J=1.2 Hz, 3H), 2.75 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 1.91 (p, J=7.5 Hz, 4H).

LCMS; m/z 435 (M+H)⁺ (ES⁺); 433 (M−H)⁻ (ES⁻).

Example 50: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(2-hydroxy-2-methylpropyl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide, sodium salt (Example 31) from 5-(2-hydroxy-2-methylpropyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P40) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (77 mg, 74%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.53 (s, 1H), 6.76 (s, 1H), 6.23 (s, 1H), 4.50 (s, 1H), 3.75 (s, 3H), 2.75 (t, J=7.4 Hz, 4H), 2.71-2.61 (m, 6H), 1.93-1.86 (m, 4H), 1.13 (s, 6H).

LCMS; m/z 433 (M+H)⁺ (ES⁺).

Example 51: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-hydroxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P28) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (15 mg, 20%) as a colourless solid.

1H NMR (DMSO-d6) δ 10.84 (br s, 1H), 8.00 (s, 1H), 6.93 (s, 2H), 6.75 (s, 1H), 4.91-4.84 (m, 2H), 4.75 (d, J=7.1 Hz, 2H), 3.81 (s, 3H), 2.79 (t, J=7.4 Hz, 4H), 2.62 (t, J=7.4 Hz, 4H), 1.99-1.92 (m, 4H).

LCMS; m/z 433 (M+H)⁺ (ES⁺).

Example 52: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide, partial ammonium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (48 mg, 58%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.55 (s, 1H), 6.96-6.67 (m, 3H), 4.85-4.59 (m, 4H), 3.67 (s, 3H), 3.24-2.99 (m, 2H), 2.95 (s, 3H), 1.04 (d, J=6.8 Hz, 12H). N—H not observed.

LCMS; m/z 469.5 (M+H)⁺ (ES⁺); 467.3 (M−H)− (ES−).

Example 53: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(3-methoxyoxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P29) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (44 mg, 57%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.74 (s, 1H), 6.88-6.80 (m, 2H), 4.84 (d, J=7.5 Hz, 2H), 4.78 (d, J=7.3 Hz, 2H), 3.68 (s, 3H), 2.97 (s, 3H), 2.76 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 1.90 (p, J=7.4 Hz, 4H). NH not observed.

LCMS; m/z 447.5 (M+H)⁺ (ES⁺); 445.3 (M−H)− (ES−).

Example 54: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-5-(4-hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 5-(4-hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P41) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (43 mg, 46%) as a colourless solid.

1H NMR (DMSO-d6) δ 7.72 (s, 1H), 6.88 (d, J=9.9 Hz, 2H), 6.49 (s, 1H), 5.53 (s, 1H), 4.00 (s, 3H), 3.84-3.51 (m, 2H), 3.70-3.62 (m, 2H), 3.12-3.00 (m, 2H), 1.95-1.73 (m, 4H), 1.06 (d, J=6.8 Hz, 12H). One exchangeable proton not seen.

LCMS; m/z 483.5 (M+H)⁺ (ES⁺); 481.3 (M−H)− (ES−).

Example 55: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(4-hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-3-sulfonamide, sodium salt (Example 31) from 5-(4-hydroxytetrahydro-2H-pyran-4-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P41) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (43 mg, 53%) as a colourless solid. 1H NMR (DMSO-d6) δ 7.55 (s, 1H), 6.77 (s, 1H), 6.29 (s, 1H), 5.45 (s, 1H), 3.94 (s, 3H), 3.81-3.62 (m, 4H), 2.75 (t, J=7.3 Hz, 4H), 2.67 (t, J=7.3 Hz, 4H), 1.96-1.76 (m, 8H).

LCMS; m/z 461.4 (M+H)⁺ (ES⁺); 459.3 (M−H)− (ES−).

Example 56: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-(tetrahydrofuran-3-yl)-1H-pyrazole-3-sulfonamide (Example 1) from 1-(oxazol-2-ylmethyl)-1H-pyrazole-3-sulfonamide (Intermediate P42) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (27 mg, 25%) as a white solid.

1H NMR (DMSO-d6) δ 8.11 (d, J=0.9 Hz, 1H), 7.99 (s, 1H), 7.84 (s, 1H), 7.24 (d, J=0.9 Hz, 1H), 6.89 (s, 1H), 6.70 (s, 1H), 5.62 (s, 2H), 2.78 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H). NH not observed.

LCMS; m/z 428 (M+H)⁺ (ES⁺); 426 (M−H)⁻ (ES⁻).

Example 57: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide, potassium salt

To a solution of 2-methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide (Intermediate P43) (45 mg, 0.18 mmol) in THF (3 mL) was added potassium tert-butoxide (21 mg, 0.18 mmol). The mixture was stirred for 40 minutes. A solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (37 mg, 0.18 mmol) in THF (1 mL) was added and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated in vacuo and DMSO (1 mL) was added. The solution (suspensions were filtered first over cotton wool) was submitted for purification by reversed phase column chromatography (see “Experimental Methods”) to afford the title compound (43 mg, 53%) as a white solid.

1H NMR (Methanol-d4) δ 7.49 (s, 1H), 6.85 (s, 1H), 4.18-4.01 (m, 2H), 4.01-3.86 (m, 1H), 3.88-3.59 (m, 2H), 2.76 (m, 9H), 2.38 (s, 3H), 2.18-1.91 (m, 4H), 1.89-1.71 (m, 2H), 1.70-1.41 (m, 1H).

LCMS; m/z 445 (M+H)⁺ (ES⁺); 443 (M−H)⁻ (ES⁻).

Example 58:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxyethyl)-2-methyl-1H-imidazole-4-sulfonamide, potassium salt

Prepared as described for N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-2-methyl-1-((tetrahydrofuran-2-yl)methyl)-1H-imidazole-4-sulfonamide, potassium salt (Example 57) using 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) and 1-(2-hydroxyethyl)-2-methyl-1H-imidazole-4-sulfonamide (Intermediate P44) to afford the title compound (5 mg, 14%) as a white solid.

¹H NMR (Methanol-d4) δ 7.60 (s, 1H), 6.90 (s, 1H), 4.04 (d, 2H), 3.80 (t, 2H), 2.94-2.61 (m, 9H), 2.41 (s, 3H), 2.12-1.94 (m, 4H).

LCMS; m/z 405 (M+H)⁺ (ES⁺).

Example 50: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(2-hydroxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt

2-(Methylamino)ethanol (19.25 μL, 0.240 mmol) and HATU (72 mg, 0.189 mmol) were successively added to a suspension of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (70 mg, 0.156 mmol) in DMF (1 mL) and stirred for 20 hours. The solution was purified by chromatography on RP Flash C18 (12 g column, 5-50% MeCN/10 mM ammonium bicarbonate) to afford the title compound (39 mg, 54%) as a white solid.

1H NMR (DMSO-d6), rotamers; δ 7.69 (s, 1H), 7.10 (s, 1H), 7.10 & 6.74 (2×s, 1H), 6.82 (s, 1H), 4.96 & 4.84 (2×t, J=5.5 Hz, 1H), 3.84 & 3.80 (2×s, 3H), 3.59 (m, 1H), 3.55-3.41 (m, 3H), 3.06 & 2.97 (2×s, 3H), 2.76 (t, J=7.4 Hz, 4H), 2.64 (t, J=7.5 Hz, 4H), 1.92 (p, J=7.5 Hz, 4H).

LCMS; m/z 462.42 (M+H)⁺ (ES⁺); 460.30 (M−H)− (ES−).

Example 60: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N,1-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-5-carboxamide, sodium salt

HATU (49.3 mg, 0.130 mmol) was added to a solution of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (67.3 mg, 0.150 mmol) and N-methyltetrahydro-2H-pyran-4-amine (14.93 mg, 0.130 mmol) in DMF (1 mL) and the reaction mixture was stirred at room temperature for 20 hours. Water (1 mL) was slowly added and the reaction mixture was stirred for 1 hour. The suspension was filtered and the collected solid triturated in water (3 mL) for 0.5 hour. The suspension was filtered and the collected solid was washed with water (0.5 mL) and TBME (1 mL). The solid was dried under reduced pressure for 6 hours to afford 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N,1-dimethyl-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazole-5-carboxamide. The solid was dissolved in THF (2 mL) and 2 M sodium tert-butoxide in THF (54.0 μL, 0.108 mmol) was added. The suspension was stirred at room temperature for 2 hours and filtered. The collected solid was washed with EtOAc (2 mL) and dried under reduced pressure for 6 hours to afford the title compound (46 mg, 80%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 7.47 (s, 1H), 6.77 (s, 1H), 6.58 (s, 1H), 4.53-4.49 (m, 0.6H), 3.94-3.90 (m, 2.4H), 3.80 (s, 3H), 3.43-3.41 (m, 1H), 3.16-3.12 (m, 1H), 2.89 (s, 3H), 2.75 (t, J=7.4 Hz, 4H), 2.66 (t, J=7.6 Hz, 4H), 1.93-1.80 (m, 6H), 1.59-1.55 (m, 2H).

LCMS; m/z 502 (M+H)⁺ (ES⁺).

Example 61: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N,N-bis(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

HATU (67.9 mg, 0.178 mmol) was added to a solution of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (66.7 mg, 0.149 mmol) and 2,2′-azanediylbis(ethan-1-ol) (17.11 μL, 0.178 mmol) in DMF (1 mL) and the reaction mixture was stirred at room temperature for 20 hours. Water (1 mL) was slowly added and the reaction mixture was stirred for 1 hour. The suspension was filtered and the collected solid triturated in water (3 mL) for 0.5 hour. The suspension was filtered and the collected solid was washed with water (0.5 mL) and TBME (1 mL). The solid was dried under reduced pressure for 6 hours to afford the title compound (32 mg, 42%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 7.60 (d, J=10.0 Hz, 1H), 7.24 (br s, 1H), 6.80 (s, 1H), 6.69 (s, 1H), 4.95-4.77 (m, 2H), 3.78 (s, 3H), 3.78-3.52 (m, 8H), 2.76 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.6 Hz, 4H), 1.95-1.88 (m, 4H).

LCMS; m/z 492 (M+H)⁺ (ES⁺).

Example 62: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(2-hydroxyethyl)-N-(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N,N-bis(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 61) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and 2-((2-methoxyethyl)amino)ethan-1-ol to afford the title compound as a white solid (7 mg, 9%).

1H NMR (DMSO-d6), rotamers; δ 7.61 (s, 1H), 7.11 (br s, 1H), 6.81 (s, 1H), 6.60 (s, 1H), 4.89-4.82 (m, 1H), 3.78 (s, 3H), 3.67-3.36 (m, 8H), 3.28-3.15 (2×2s, 3H), 2.76 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.4 Hz, 4H), 1.95-1.88 (m, 4H).

LCMS; m/z 506 (M+H)⁺ (ES⁺).

Example 63: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N,1-dimethyl-N-(oxetan-3-yl)-1H-pyrazole-5-carboxamide

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N,N-bis(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 61) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and N-methyloxetan-3-amine to afford the title compound (27 mg, 36%) as a white solid.

1H NMR (DMSO-d6) rotamers: δ 10.95 (br s, 1H), 8.09 (s, 1H), 7.11 (s, 0.5H), 6.95 (s, 1H), 6.89 (s, 0.5H), 5.25-5.22 (m, 0.5H), 5.06-5.03 (m, 0.5H), 4.69-4.60 (m, 4H), 3.92 (s, 3H), 3.19-3.06 (m, 3H), 2.79 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.5 Hz, 4H), 2.00-1.92 (m, 4H).

LCMS; m/z 474 (M+H)⁺ (ES⁺).

Example 64: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(3-hydroxypropyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt

3-(Methylamino)propan-1-ol (19 μL, 0.195 mmol), NaHCO₃ (16 mg, 0.190 mmol) and HATU (72 mg, 0.189 mmol) were successively added to a suspension of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (70 mg, 0.156 mmol) in DMF (1 mL) and stirred for 2 days. The reaction was quenched with water (1 mL) and purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (37 mg, 48%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 7.81 (s, 1H), 7.61-6.99 (br s, 1H), 6.85 (s, 1H), 6.82-6.71 (m, 1H), 4.48 (br s, 1H), 3.94-3.78 (m, 3H), 3.59-3.13 (m, 4H), 3.07-2.90 (m, 3H), 2.76 (t, J=7.4 Hz, 4H), 2.62 (t, J=7.4 Hz, 4H), 1.92 (p, J=7.4 Hz, 4H), 1.79-1.57 (m, 2H).

LCMS; m/z 476.4 (M+H)⁺ (ES⁺); 474.4 (M−H)⁻ (ES⁻).

Example 65: N-(2,3-Dihydroxypropyl)-3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(3-hydroxypropyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 64) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and 3-(methylamino)propane-1,2-diol to afford the title compound (43 mg, 54%) as a white solid.

1H NMR (DMSO-d6), rotamers; δ 7.83-7.64 (m, 1H), 7.61-7.01 (m, 1H), 6.87-6.80 (m, 1H), 6.78-6.71 (m, 1H), 5.13-4.99 (m, 1H), 4.96-4.84 (m, 1H), 4.62 (s, 1H), 3.90-3.73 (m, 3H), 3.71-3.09 (m, 5H), 3.07 (s, 1H), 2.98 (s, 1H), 2.76 (t, J=7.4 Hz, 4H), 2.63 (t, J=7.4 Hz, 4H), 2.07-1.79 (m, 4H).

LCMS; m/z 492.4 (M+H)⁺ (ES⁺); 490.2 (M−H)− (ES−).

Example 66: N-Ethyl-3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(3-hydroxypropyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 64) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and 2-(ethylamino)ethan-1-ol to afford the title compound (39 mg, 52%) as a white solid.

1H NMR (DMSO-d6), rotamers; δ 8.16-6.99 (br s, 1H), 7.82 & 7.80 (2×s, 1H), 6.86 (s, 1H), 6.79 & 6.74 (2×s, 1H), 4.93 & 4.82 (2×m, 1H), 3.82 (s, 3H), 3.65-3.33 (m, 6H), 2.77 (t, J=7.4 Hz, 4H), 2.63 (t, J=7.3 Hz, 4H), 1.93 (quin, J=7.4 Hz, 4H), 1.15 & 1.08 (2×t, J=7.1 Hz, 3H).

LCMS; m/z 476.5 (M+H)⁺ (ES⁺); 474.3 (M−H)− (ES−).

Example 67: N-((2,6-Diisopropylphenyl)carbamoyl)-1-methyl-5-(morpholine-4-carbonyl)-1H-pyrazole-3-sulfonamide

Morpholine (19 μL, 0.220 mmol) and HATU (82 mg, 0.217 mmol) were successively added to a solution of 3-(N-((2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P46) (70 mg, 0.155 mmol) in DMF (1 mL) and stirred for 20 hours. The reaction was quenched with water (0.1 mL) and purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (41 mg, 53%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 11.11 (br s, 1H), 7.79 (s, 1H), 7.22 (t, J=7.7 Hz, 1H), 7.10 (d, J=7.7 Hz, 2H), 6.91 (s, 1H), 3.93 (s, 3H), 3.72-3.39 (m, 8H), 2.98 (sept, J=6.9 Hz, 2H), 1.05 (d, J=6.8 Hz, 12H).

LCMS; m/z 478.4 (M+H)⁺ (ES⁺); 476.4 (M−H)⁻ (ES⁻).

Example 68: 3-(N-((2,6-Diisopropylphenyl)carbamoyl)sulfamoyl)-N-(2-methoxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide

HATU (66.5 mg, 0.175 mmol) was added to a solution of 3-(N-((2,6-diisopropylphenyl) carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P46) (65.9 mg, 0.146 mmol) and 2-methoxy-N-methylethanamine (19.00 L, 0.175 mmol) in DMF (1 mL) and the mixture stirred at room temperature for 20 hours. Water (1 mL) was slowly added and the reaction mixture was stirred at room temperature for 1 hour. The suspension was filtered and the collected solid triturated in water (3 mL) for 0.5 hour. The suspension was filtered and the collected solid was washed with water (0.5 mL) and TBME (1 mL). The solid was dried under reduced pressure for 6 hours to afford the title compound (18 mg, 25%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 11.11 (s, 1H), 8.00-7.72 (m, 1H), 7.28-7.20 (m, 1H), 7.15-7.09 (m, 2H), 7.02-6.86 (m, 1H), 3.93 (s, 1H), 3.86 (s, 2H), 3.66-3.57 (m, 1H), 3.57-3.45 (m, 2H), 3.44-3.37 (m, 1H), 3.27 (s, 1H), 3.16 (s, 2H), 3.03-2.87 (m, 4H), 1.17-0.77 (m, 12H).

LCMS; m/z 480 (M+H)⁺ (ES⁺).

Example 69: 3-(N-((2,6-Diisopropylphenyl)carbamoyl) sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide

Prepared according to the general procedure of 3-(N-((2,6-diisopropylphenyl) carbamoyl)sulfamoyl)-N-(2-methoxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide (Example 68) from 3-(N-((2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P46) and bis(2-methoxyethyl)amine to afford the title compound (22 mg, 23%) as a white solid.

1H NMR (DMSO-d6), rotamers; δ 11.11 (s, 1H), 7.91 (s, 1H), 7.31-7.18 (m, 1H), 7.13 (s, 1H), 7.11 (s, 1H), 6.92 (s, 1H), 3.86 (s, 3H), 3.66-3.58 (m, 2H), 3.56-3.47 (m, 4H), 3.43-3.35 (m, 2H), 3.27 (s, 3H), 3.14 (s, 3H), 2.94 (sept, J=6.8 Hz, 2H), 1.18-0.87 (m, 12H).

LCMS; m/z 524 (M+H)⁺ (ES⁺).

Example 70: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(4-hydroxypiperidine-1-carbonyl)-1-methyl-1H-pyrazole-3-sulfonamide, partial ammonium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(3-hydroxypropyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 64) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and piperidin-4-ol to afford the title compound (44 mg, 57%) as a white solid.

1H NMR (DMSO-d6), rotamers; δ 7.88 (s, 1H), 7.48-6.92 (m, 1H), 6.88 (s, 1H), 6.78 (s, 1H), 4.83 (d, J=3.9 Hz, 1H), 3.96 (m, 1H), 3.87 (s, 3H), 3.77 (m, 1H), 3.63 (m, 1H), 3.32 (m, 2H), 2.78 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 1.94 (quin, J=7.5 Hz, 4H), 1.77 (m, 2H), 1.39 m, 2H).

LCMS; m/z 488.4 (M+H)⁺ (ES⁺); 486.3 (M−H)− (ES−).

Example 71: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxypyrrolidine-1-carbonyl)-1-methyl-1H-pyrazole-3-sulfonamide, partial ammonium salt

3-Methoxypyrrolidine (19 mg, 0.188 mmol) and HATU (72 mg, 0.189 mmol) were successively added to a suspension of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (70 mg, 0.156 mmol) in DMF (1 mL) and stirred for 20 hours. The solution was purified by chromatography on RP Flash C18 (12 g column, 5-50% MeCN/10 mM ammonium bicarbonate) to afford the title compound (25 mg, 32%) as a white solid.

¹H NMR (DMSO-d6), rotamers; δ 7.82 (s, 1H), 7.08 (s, 1H), 6.96 (d, J=2.6 Hz, 1H), 6.86 (s, 1H), 4.07-3.90 (m, 4H), 3.75-3.67 (m, 1H), 3.64-3.39 (m, 4H), 3.26 (s, 1H), 3.19 (s, 1H), 2.76 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 2.06-1.84 (m, 6H).

LCMS; m/z 488.43 (M+H)⁺ (ES⁺); 48635 (M−H)⁻ (ES⁻).

Example 72: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

Prepared according to the general procedure of N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-5-(3-methoxypyrrolidine-1-carbonyl)-1-methyl-1H-pyrazole-3-sulfonamide, partial ammonium salt (Example 71) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and bis(2-methoxyethyl)amine to afford the title compound (36 mg, 44%) as a white solid.

1H NMR (DMSO), rotamers; δ 7.79 (s, 1H), 7.10 (br s, 1H), 6.85 (s, 1H), 6.73 (s, 1H), 3.80 (s, 3H), 3.63 (t, J=5.8 Hz, 2H), 3.58-3.49 (m, 4H), 3.39 (t, J=5.0 Hz, 2H), 3.28 (s, 3H), 3.14 (s, 3H), 2.77 (t, J=7.4 Hz, 4H), 2.63 (t, J=7.3 Hz, 4H), 1.92 (quin, J=7.5 Hz, 4H).

LCMS; m/z 520.44 (M+H)⁺ (ES⁺); 518.30 (M−H)⁻ (ES⁻).

Example 73: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(2-methoxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, sodium salt

2-Methoxy-N-methylethanamine (19 μL, 0.173 mmol), HATU (71 mg, 0.187 mmol) and Hunig's base (65 μL, 0.372 mmol) were successively added to a solution of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid (Intermediate P45) (50 mg, 0.124 mmol) in DMF (1 mL) and stirred for 20 hours. The reaction was quenched with water (1 mL) and purified by chromatography on RP Flash C18 (12 g column, 5-50% MeCN/10 mM ammonium bicarbonate) to afford crude product. 18 mg of the crude product were partitioned between TBME (1 mL) and 0.1 M aqueous NaHCO₃ (340 μL, 0.034 mmol). The layers were separated and the aqueous layer washed with further TBME (2×1 mL). The aqueous layer was evaporated in vacuo and dried to afford the title compound (17 mg, 27%) as a white solid.

¹H NMR (DMSO), rotamers; δ 7.52 (s, 1H), 6.77 (s, 1H), 6.6 & 6.55 (2×s, 1H), 3.81 & 3.76 (2×s, 3H), 3.61 (m, 1H), 3.56 (m, 2H), 3.4 (m, 1H), 3.28 & 3.16 (2×s, 3H), 3.05 & 2.97 (2×s, 3H), 2.75 (t, J=7.4 Hz, 4H), 2.65 (t, J=7.5 Hz, 4H), 1.89 (quin, J=7.5 Hz, 4H).

LCMS; m/z 476.4 (M+H)⁺ (ES⁺); 474.3 (M−H)⁻ (ES⁻).

Example 74:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-5-(morpholine-4-carbonyl)-1H-pyrazole-3-sulfonamide, sodium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(2-methoxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide, sodium salt (Example 73) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid disodium salt (Intermediate P45) and morpholine to afford the title compound (12 mg, 16%) as a white solid.

1H NMR (DMSO), rotamers; δ 7.54 (s, 1H), 6.77 (s, 1H), 6.59 (s, 1H), 3.84 (s, 3H), 3.76-3.43 (m, 8H), 2.75 (t, J=7.4 Hz, 4H), 2.64 (t, J=7.3 Hz, 4H), 1.90 (quin, J=7.5 Hz, 4H).

LCMS; m/z 474.4 (M+H)⁺ (ES⁺); 472.3 (M−H)− (ES−).

Example 75:5-(3-(Dimethylamino)oxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide

5-(3-(Dimethylamino)oxetan-3-yl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P47) (65 mg, 0.21 mmol) was dissolved in 4:1 THF:DMF (2.5 mL) and sodium tert-butoxide (2 M in THF; 0.117 mL, 0.233 mmol) was added. After 1 hour, 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (46.5 mg, 0.233 mmol) was added and the mixture was stirred at room temperature for 18 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by chromatography on reversed phase flash chromatography C18 (12 g column, 10-40% MeCN/10 mM ammonium bicarbonate) to afford the title compound (20 mg, 20%) as a white solid.

¹H NMR (DMSO-d₆) δ 10.82 (br s, 1H), 7.98 (s, 1H), 6.92 (s, 1H), 6.84 (s, 1H), 4.95 (d, J=7.2 Hz, 2H), 4.76 (d, J=7.2 Hz, 2H), 3.76 (s, 3H), 2.78 (t, J=7.4 Hz, 4H), 2.58 (t, J=7.4 Hz, 4H), 2.21 (s, 6H), 1.93 (p, J=7.4 Hz, 4H).

LCMS; m/z 460.3 (M+H)⁺ (ES⁺); 458.2 (M−H)⁻ (ES⁻).

Example 76: N-((4-Fluoro-2,6-diisopropylphenyl)carbamoyl)-5-(((2-hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure for 5-(3-(dimethylamino)oxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide (Example 75) from 5-(((2-hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48) and 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) to afford the title compound (28 mg, 32%) as a white solid.

¹H NMR (DMSO-d6) δ 10.97 (br s, 1H), 7.82 (s, 1H), 6.93 (d, J=9.9 Hz, 2H), 6.64 (s, 1H), 4.48 (t, J=5.3 Hz, 1H), 3.90 (s, 3H), 3.59 (s, 2H), 3.52 (q, J=5.9 Hz, 2H), 2.97 (m, 2H), 2.46 (t, J=6.1 Hz, 2H), 2.15 (s, 3H), 1.06 (br s, 12H).

LCMS m/z 470.5 (M+H)⁺ (ES⁺); 468.2 (M−H)⁻ (ES⁻).

Example 77:N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(((2-hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure for 5-(3-(dimethylamino)oxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide (Example 75) from 5-(((2-hydroxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P48) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (22 mg, 27%) as a white solid.

¹H NMR (DMSO-d6) δ 10.71 (br s, 1H), 7.94 (s, 1H), 6.91 (s, 1H), 6.61 (s, 1H), 4.47 (t, J=5.3 Hz, 1H), 3.88 (s, 3H), 3.59 (s, 2H), 3.52 (q, J=5.9 Hz, 2H), 2.79 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.4 Hz, 4H), 2.46 (t, J=6.1 Hz, 2H), 2.15 (s, 3H), 1.94 (p, J=7.5 Hz, 4H).

LCMS m/z 448.5 (M+H)⁺ (ES⁺); 446.1 (M−H)⁻ (ES⁻).

Example 78: N-((4-fluoro-2,6-Diisopropylphenyl)carbamoyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt

5-(((2-Methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P49) (35 mg, 0.13 mmol) was dissolved in THF (2 mL) and sodium tert-butoxide (2M in THF; 0.074 mL, 0.148 mmol) was added. After 1 hour, 5-fluoro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A2) (35 mg, 0.16 mmol) was added and the mixture stirred at room temperature for 18 hours. The resulting solid was filtered off, washed with EtOAc, and dried to afford the title compound (22 mg, 39%) as a white solid.

¹H NMR (DMSO-d6) δ 7.37 (s, 1H), 6.79 (d, J=10.0 Hz, 2H), 6.27 (s, 1H), 3.76 (s, 3H), 3.50 (s, 2H), 3.45 (t, J=5.8 Hz, 2H), 3.23 (s, 3H), 3.14 (m, 2H), 2.51 (t, J=5.8 Hz, 2H), 2.15 (s, 3H), 1.03 (d, J=6.8 Hz, 12H).

LCMS m/z 484.5 (M+H)⁺ (ES⁺); 482.3 (M−H)− (ES−).

Example 79: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt

Prepared according to the general procedure for N-((4-fluoro-2,6-diisopropylphenyl) carbamoyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt (Example 78) from 5-(((2-methoxyethyl)(methyl)amino) methyl)-1-methyl-1H-pyrazole-3-sulfonamide (Intermediate P49) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (32 mg, 47%) as a white solid.

¹H NMR (DMSO-d6) δ 7.59 (m, 1H), 6.79 (s, 1H), 6.34 (s, 1H), 3.79 (s, 3H), 3.52 (s, 2H), 3.44 (t, J=5.8 Hz, 2H), 3.23 (s, 3H), 2.75 (t, J=7.3 Hz, 4H), 2.64 (t, J=7.4 Hz, 4H), 2.51 (t, J=5.8 Hz, 2H), 2.16 (s, 3H), 1.90 (p, J=7.5 Hz, 4H).

LCMS m/z 462.4 (M+H)⁺ (ES⁺); 460.4 (M−H)− (ES−).

Example 80: N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl)-1-methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide, sodium salt

Prepared according to the general procedure for N-((4-fluoro-2,6-diisopropylphenyl) carbamoyl)-5-(((2-methoxyethyl)(methyl)amino)methyl)-1-methyl-1H-pyrazole-3-sulfonamide, sodium salt (Example 78) from 1-methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide (Intermediate P50) and 5-chloro-2-isocyanato-1,3-diisopropylbenzene (Intermediate A9) to afford the title compound (38 mg, 53%) as a white solid.

¹H NMR (DMSO-d6) δ 7.45 (s, 1H), 7.01 (s, 2H), 6.28 (s, 1H), 3.77 (s, 3H), 3.56 (t, J=4.6 Hz, 4H), 3.48 (s, 2H), 3.13 (m, 2H), 2.36 (t, J=4.6 Hz, 4H), 1.03 (d, J=6.8 Hz, 12H).

LCMS m/z 498.4/500.5 (M+H)⁺ (ES⁺); 496.3/498.4 (M−H)⁻ (ES⁻).

Example 81: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide

Prepared according to the general procedure for 5-(3-(dimethylamino)oxetan-3-yl)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-methyl-1H-pyrazole-3-sulfonamide (Example 75) from 1-methyl-5-(morpholinomethyl)-1H-pyrazole-3-sulfonamide (Intermediate P50) and 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) to afford the title compound (12 mg, 18%) as a white solid.

¹H NMR (DMSO-d6) δ 10.81 (br s, 1H), 7.96 (s, 1H), 6.91 (s, 1H), 6.62 (s, 1H), 3.88 (s, 3H), 3.56 (s, 2H), 3.56 (m, 4H), 2.78 (t, J=7.4 Hz, 4H), 2.59 (t, J=7.4 Hz, 4H), 2.36 (m, 4H), 1.93 (p, J=7.5 Hz, 4H).

LCMS m/z 460.4 (M+H)⁺ (ES⁺); 458.4 (M−H)⁻ (ES⁻).

Example 82: 3-(N-((4-Chloro-2,6-diisopropylphenyl)carbamoyl) sulfamoyl)-N-(2-hydroxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide

HATU (51.4 mg, 0.135 mmol) was added to a solution of 3-(N-((4-chloro-2,6-diisopropylphenyl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P51) (54.8 mg, 0.113 mmol) and 2-(methylamino)-ethanol (9.19 μL, 0.124 mmol) in DMF (1 mL) and the mixture was stirred at room temperature for 20 hours. Water (1 mL) was slowly added and the reaction mixture was stirred for 1 hour. The suspension was filtered and the collected solid triturated in water (3 mL) for 0.5 hour. The suspension was filtered and the collected solid was washed with water (0.5 mL) and TBME (1 mL). The solid was dried under reduced pressure for 6 hours to afford the title compound (10 mg, 18%) as a white solid.

1H NMR (DMSO-d6) rotamers: δ 11.18 (s, 1H), 7.95 (s, 1H), 7.14 (s, 2H), 6.98 (s, 1H), 4.96-4.79 (m, 1H), 3.93-3.86 (m, 3H), 3.64-3.41 (m, 4H), 3.06-2.88 (m, 5H), 1.08 (br s, 12H).

LCMS m/z 500.4/502.4 (M+H)⁺ (ES⁺).

Example 83: 3-(N-((2,6-Diisopropylphenyl)carbamoyl)sulfamoyl)-N-(2-hydroxyethyl)-N,1-dimethyl-1H-pyrazole-5-carboxamide

2-(Methylamino)ethanol (18 μL, 0.224 mmol) and HATU (82 mg, 0.217 mmol) were successively added to a solution of 3-(N-((2,6-diisopropylphenyl)carbamoyl) sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P46) (70 mg, 0.155 mmol) in DMF (1 mL) and stirred for 20 hours. The reaction was quenched with water (0.1 mL) and purified by reversed phase prep-HPLC (General Methods, basic prep) to afford a white solid. The solid was dissolved in DMF (0.5 mL), diluted with water (1 mL) and stirred for 20 hours. The resulting precipitate was filtered off, washed with water and TBME, and dried to afford the title compound (8 mg, 11%), as a white solid.

1H NMR (DMSO-d6), rotamers; δ 11.07 (s, 1H), 7.88 (s, 1H), 7.25 (t, J=7.7 Hz, 1H), 7.12 (d, J=7.7 Hz, 2H), 7.02&7.0 (2×s, 1H), 4.96&4.81 (t, J=5.0&57 Hz, 1H), 3.94 &3.89 (2×s, 3H), 3.59&3.40 (2×t, J=5.6&5.1 Hz, 2H), 3.50 (2×t, J=5.6&5.2 Hz, 2H), 3.03 & 2.98 (2×s, 3H), 2.95 (m, 2H), 1.06 (br s, 12H).

LCMS; m/z 466.5 (M+H)⁺ (ES⁺); 464.4 (M−H)⁻ (ES⁻).

Example 84:3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

2-Aminoethanol (14 μL, 0.232 mmol) and HATU (83 mg, 0.219 mmol) were successively added to a suspension of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) (70 mg, 0.156 mmol) in DMF (1 mL) and stirred for 20 hours. The reaction was quenched with water (0.1 mL) and purified by reversed phase prep-HPLC (General Methods, basic prep) to afford the title compound (18 mg, 25%) as a white solid.

1H NMR (DMSO-d6) δ 8.61 (t, J=5.7 Hz, 1H), 7.84 (s, 1H), 7.32 (s, 1H), 6.88 (s, 1H), 4.73 (t, J=5.7 Hz, 1H), 4.10 (s, 3H), 3.48 (app q, J=6.0 Hz, 2H), 3.27 (app q, J=6.0 Hz, 2H), 2.78 (t, J=7.4 Hz, 4H), 2.60 (t, J=7.4 Hz, 4H), 1.93 (p, J=7.4 Hz, 4H). One exchangeable proton not seen.

LCMS; m/z 448.4 (M+H)⁺ (ES⁺); 446.4 (M−H)⁻ (ES⁻).

Example 85: 3-(N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl) sulfamoyl)-N-(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt

Prepared according to the general procedure of 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-N-(2-hydroxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, partial ammonium salt (Example 84) from 3-(N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxylic acid, disodium salt (Intermediate P45) and 2-methoxyethan-1-amine to afford the title compound (37 mg, 51%) as a colourless solid.

1H NMR (DMSO-d6) δ 10.93 (br s, 1H), 8.74 (t, J=5.5 Hz, 1H), 7.90 (s, 1H), 7.36 (s, 1H), 6.90 (s, 1H), 4.11 (s, 3H), 3.44 (t, J=5.5 Hz, 2H), 3.39 (t, J=5.5 Hz, 2H), 3.26 (s, 3H), 2.78 (t, J=7.4 Hz, 4H), 2.61 (t, J=7.3 Hz, 4H), 1.94 (p, J=7.5 Hz, 4H).

LCMS; m/z 462.4 (M+H)⁺ (ES⁺); 460.3 (M−H)− (ES−).

Example 86: 3-(N-((4-Fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropyl-phenyl)carbamoyl)sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, sodium salt Step A: 3-(N-((4-Fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropylphenyl)carbamoyl) sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide

A solution of N,N-bis(2-methoxyethyl)-1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxamide (Intermediate P52) (2.2 g, 6.87 mmol, 1 eq), 4-(5-fluoro-2-isocyanato-3-isopropylphenyl)-2-isopropoxypyridine (Intermediate A7) (2.16 g, 6.87 mmol, 1 eq) and t-BuONa (659 mg, 6.87 mmol, 1 eq) in THF (100 mL) was stirred at 25° C. for 30 minutes. The reaction mixture was concentrated in vacuo. The residue was purified by reversed phase flash chromatography (column: Welch Ultimate XB_C18, 41 mm*235 mm*20/40 μm, mobile phase: [A: water (10 mM NH₄HCO₃); B: MeCN]; B %: 0%-30%, 35 min) to give the title compound (2.5 g, 56% yield, 98% purity on LCMS) as a white solid.

¹H NMR (DMSO-d₆): δ 11.10 (br s, 1H), 8.06 (d, 1H), 7.79 (br s, 1H), 7.18 (d, 1H), 7.02 (d, 1H), 6.83-6.72 (m, 2H), 6.70 (s, 1H), 5.29-5.23 (m, 1H), 3.83 (s, 3H), 3.64-3.61 (m, 2H), 3.55-3.50 (m, 4H), 3.45-3.40 (m, 2H), 3.28 (s, 3H), 3.14 (s, 3H), 3.03-300 (m, 1H), 1.30 (d, 6H) and 1.09-1.05 (m, 6H).

LCMS: m/z 635.4 (M+H)⁺ (ES⁺).

Step B: 3-(N-((4-Fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropylphenyl)carbamoyl) sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide, sodium salt

To a solution of 3-(N-((4-fluoro-2-(2-isopropoxypyridin-4-yl)-6-isopropylphenyl) carbamoyl)sulfamoyl)-N,N-bis(2-methoxyethyl)-1-methyl-1H-pyrazole-5-carboxamide (2.5 g, 3-94 mmol, 1 eq, free form) in THF (100 mL) was added with t-BuONa (378 mg, 3.94 mmol, 1 eq). The reaction mixture was stirred at 25° C. for 1 hour and then concentrated in vacuo. The residue was triturated with isopropyl ether (20 mL) to give the title compound (2.2 g, 85% yield, 99% purity on LCMS, sodium salt) as a white solid.

¹H NMR (DMSO-d₆): 7.99-7.88 (m, 1H), 7.53-7.40 (m, 1H), 7.15-7.08 (m, 1H), 6.94-6.82 (m, 2H), 6.68 (s, 1H), 6.51-6.44 (m, 1H), 5.28-5.22 (m, 1H), 3.75 (s, 3H), 3.74-3.56 (m, 6H), 3.45-3.38 (m, 2H), 3.29 (s, 3H), 3.17 (s, 3H), 3.12-307 (m, 1H), 1.29 (d, 6H) and 1.20-1.04 (m, 6H).

LCMS: m/z 635.1 (M+H)⁺ (ES⁺).

Example 87: N,N-Bis(2-methoxyethyl)-3-(N-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxamide, sodium salt Step A: N,N-Bis(2-methoxyethyl)-3-(N-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxamide

A solution of N,N-bis(2-methoxyethyl)-1-methyl-3-sulfamoyl-1H-pyrazole-5-carboxamide (Intermediate P52) (2.56 g, 7.99 mmol, 1 eq) and t-BuONa (768 mg, 7.99 mmol, 1 eq) in THF (200 mL) was stirred at 25° C. for 30 minutes. Then 4(4-isocyanato-2,3-dihydro-1H-inden-5-yl)-2-methoxypyridine (Intermediate A8) (3.34 g, 8.79 mmol, 1.1 eq) was added. The reaction mixture was stirred at 70° C. for 2 hours and then concentrated in vacuo. The residue was purified by reversed phase flash chromatography (column: Welch Ultimate XB_C18, 41 mm*235 mm*20/40 μm, mobile phase: [A: water (0.05% ammonium hydroxide); B: MeCN]; B %: 0%-30%, 35 min) to give the title compound (1.35 g, 29% yield, 99% purity on LCMS) as a white solid.

¹H NMR (DMSO-d₆): δ 8.08 (d, 1H), 7.14-7.11 (m, 1H), 7.07-7.05 (m, 1H), 6.91 (d, 1H), 6.74 (s, 1H), 6.60 (s, 1H), 3.86 (s, 3H), 3.78 (s, 3H), 3.64-3.62 (m, 2H), 3.56-3.54 (m, 4H), 3.39-3.37 (m, 2H), 3.28 (s, 3H), 3.14 (s, 3H), 2.89 (t, 2H), 2.71 (t, 2H) and 1.99-1.94 (m, 2H).

LCMS: m/z 587.3 (M+H)⁺ (ES⁺).

Step B: N,N-Bis(2-methoxyethyl)-3-(N-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxamide, sodium salt

To a solution of N,N-bis(2-methoxyethyl)-3-(N-((5-(2-methoxypyridin-4-yl)-2,3-dihydro-1H-inden-4-yl)carbamoyl)sulfamoyl)-1-methyl-1H-pyrazole-5-carboxamide (1.35 g, 2.30 mmol, 1 eq, free form) in THF (20 mL) was added with t-BuONa (221 mg, 2.30 mmol, 1 eq). The reaction mixture was stirred at 25° C. for 1 hour and then concentrated in vacuo. The residue was triturated with isopropyl ether (20 mL) to give the title compound (1.2 g, 85% yield, 99% purity on HPLC) as a white solid.

¹H NMR (DMSO-d₆): δ 8.05 (d, 1H), 7.30 (br s, 1H), 7.04 (dd, 2H), 6.92 (d, 1H), 6.76 (s, 1H), 6.48 (d, 1H), 3.85 (s, 3H), 3.75 (s, 3H), 3.64-3.62 (m, 2H), 3.56-3.53 (m, 4H), 3.39-3.37 (m, 2H), 3.29 (s, 3H), 3.15 (s, 3H), 2.87 (t, 2H), 2.73-2.70 (m, 2H) and 1.98-1.91 (m, 2H).

LCMS: m/z 587.1 (M+H)⁺ (ES⁺).

Example 88: N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-sulfonamide

To a solution of 1-(2-hydroxy-2-methylpropyl)-1H-pyrazole-4-sulfonamide (Intermediate P53) (150 mg, 684.12 μmol, 1 eq) in THF (5 mL) was added CH₃ONa (37 mg, 684.12 μmol, 1 eq) and the resulting mixture was stirred at 25° C. for 30 minutes. Then a solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (136 mg, 684.12 μmol, 1 eq) in THF (2 mL) was added under nitrogen. The mixture was stirred at 70° C. for 1 hour under nitrogen. Then the reaction mixture was filtered and the filter cake was washed with EtOAc (10 mL. The filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150 mm*25 mm*5 μm; mobile phase: [water (0.05% ammonium hydroxide v/v)-acetonitrile]; B %: 0%-30%, 12 minutes) to give the title compound (79.1 mg, 179.55 μmol, 26% yield, 95% purity) as a white solid.

¹H NMR (DMSO-d₆): δ 7.98 (s, 1H), 7.63 (s, 1H), 7.57 (br s, 1H), 6.82 (s, 1H), 4.75 (s, 2H), 4.00 (s, 2H), 2.76 (t, 4H), 2.64 (t, 4H), 1.94-1.86 (m, 4H) and 1.05 (s, 6H).

LCMS: m/z 419.2 (M+H)⁺ (ES⁺).

Example 89: (R)—N-((1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl)-1-(2-hydroxypropyl)-1H-pyrazole-4-sulfonamide

To a solution of (R)-1-(2-hydroxypropyl)-1H-pyrazole-4-sulfonamide (Intermediate P54) (180 mg, 877.05 μmol, 1 eq) in THF (2 mL) was added CH₃ONa (47 mg, 877.05 μmol, 1 eq) and the resulting mixture was stirred at 25° C. for 30 minutes. Then a solution of 4-isocyanato-1,2,3,5,6,7-hexahydro-s-indacene (Intermediate A1) (175 mg, 877.05 μmol, 1 eq) in THF (2 mL) was added and the mixture was stirred at 60° C. for another 30 minutes. The reaction mixture was quenched with water (20 mL) at 25° C. and then filtered. The filtrate was concentrated under reduced pressure. The residue was purified by prep-HPLC (column: Phenomenex Gemini 150 mm*25 mm*10 μm; mobile phase: [water (0.04% NH₃. H₂O+10 mM NH₄HCO₃)-acetonitrile]; B %: 10%-40%, 10 minutes) to give the title compound (122.23 mg, 299.17 μmol, 34% yield, 99% purity) as a white solid.

¹H NMR (DMSO-d₆): δ 8.19 (s, 1H), 7.85 (br s, 1H), 7.76-7.78 (d, 1H), 6.89 (s, 1H), 4.96 (d, 1H), 4.06-4.03 (m, 2H), 4.00-3.95 (m, 1H), 2.78 (t, 4H), 2.61 (t, 4H), 1.89-1.97 (m, 4H) and 1.02 (d, 3H).

LCMS: m/z 405.2 (M+H)⁺ (ES⁺).

The compounds of examples 90-107 were synthesised by methods analogous to those outlined above.

TABLE 1 Ex Structure and Name ¹H NMR spectrum MS MW 90

1H NMR (DMSO-d6) δ 10.87 (br s, 1H), 8.15 (d, J = 5.3 Hz, 1H), 7.95-7.86 (m, 2H), 7.21 (d, J = 7.2 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 6.91-6.87 (m, 1H), 6.73 (br s, 1H), 6.62 (br s, 1H), 3.89 (s, 3H), 3.75 (p, J = 5.8 Hz, 1H), 3.19 (t, J = 6.8 Hz, 2H), 3.09 (s, 3H), 2.91 (t, J = 7.3 Hz, 2H), 2.75 (s, 2H), 2.72-2.62 (m, 4H), 1.98 (p, J = 7.4 Hz, 2H), 1.49 (s, 6H). m/z 555.2 (M + H)+ (ES+) 554.66 91

1H NMR (DMSO-d6) δ 8.57 (d, J = 5.1 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.63 (br s, 1H), 7.61 (dd, J = 5.1, 1.8 Hz, 1H), 7.12 (s, 2H), 6.25 (d, J = 2.4 Hz, 1H), 5.00 (ddt, J = 7.9, 6.1, 3.8 Hz, 1H), 3.99-3.91 (m, 2H), 3.86 (dd, J = 9.4, 3.7 Hz, 1H), 3.79 (td, J = 8.4, 5.6 Hz, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.39-2.33 (m, 1H), 2.22 (m, 1H), 1.97 (p, J = 7.5 Hz, 2H). m/z 479.3 (M + H)+ (ES+) 478.52 92

1H NMR (DMSO-d6) δ 8.56 (d, J = 5.1 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.64 (br s, 1H), 7.60 (dd, J = 5.1, 1.7 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.11 (s, 2H), 6.23 (d, J = 2.2 Hz, 1H), 4.90 (s, 1H), 4.04-3.90 (m, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.78 (t, J = 7.5 Hz, 2H), 1.98 (p, J = 7.6 Hz, 2H), 1.01 (d, J = 5.9 Hz, 3H). m/z 467.3 (M + H)+ (ES+) 466.51 93

1H NMR (DMSO-d6) δ 8.58 (d, J = 5.1 Hz, 1H), 7.90 (d, J = 1.6 Hz, 1H), 7.61 (dd, J = 5.1, 1.7 Hz, 1H), 7.58 (br s, 1H), 7.55 (d, J = 2.3 Hz, 1H), 7.11 (s, 2H), 6.24 (d, J = 2.2 Hz, 1H), 4.68 (s, 1H), 3.99 (s, 2H), 2.89 (t, J = 7.5 Hz, 2H), 2.77 (t, J = 7.4 Hz, 2H), 1.97 (p, J = 7.5 Hz, 2H), 1.03 (s, 6H). m/z 481.3 (M + H)+ (ES+) 480.53 94

1H NMR (DMSO-d6) δ 8.11 (d, J = 5.3 Hz, 1H), 7.80-7.64 (m, 2H), 7.16 (s, 1H), 7.09 (d, J = 7.7 Hz, 1H), 6.89 (d, J = 5.3 Hz, 1H), 6.73 (s, 1H), 6.55-6.43 (m, 1H), 4.99 (d, J = 5.0 Hz, 1H), 4.09- 4.01 (m, 2H), 3.97 (p, J = 5.9 Hz, 1H), 3.88 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.2 Hz, 2H), 1.98 (p, J = 7.5 Hz, 2H), 1.04 (d, J = 6.2 Hz, 3H). One exchangeable proton not observed. m/z 472.3 (M + H)+ (ES+) 471.53 95

1H NMR (DMSO-d6) δ 8.11 (d, J = 5.2 Hz, 1H), 7.74 (s, 1H), 7.67 (s, 1H), 7.17 (d, J = 7.7 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.88 (dd, J = 5.3, 1.5 Hz, 1H), 6.73 (s, 1H), 6.53 (s, 1H), 4.17 (s, 2H), 3.88 (s, 3H), 3.16 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.66 (t, J = 7.5 Hz, 2H), 1.96 (p, J = 7.5 Hz, 2H), 1.06 (s, 6H). One exchangeable proton not observed. m/z 500.3 (M + H)+ (ES+) 499.58 96

1H NMR (DMSO-d6) δ 8.11 (d, J = 5.3 Hz, 1H), 7.84-7.61 (m, 2H), 7.16 (d, J = 7.7 Hz, 1H), 7.08 (d, J = 7.6 Hz, 1H), 6.89 (dd, J = 5.3, 1.5 Hz, 1H), 6.73 (s, 1H), 6.51 (s, 1H), 4.76 (s, 1H), 4.06 (s, 2H), 3.88 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.67 (t, J = 7.5 Hz, 2H), 1.96 (p, J = 7.5 Hz, 2H), 1.05 (s, 6H). One exchangeable proton not observed. m/z 486.3 (M + H)+ (ES+) 485.56 97

1H NMR (DMSO-d6) δ 8.10 (d, J = 5.3 Hz, 1H), 7.87 (s, 1H), 7.76 (s, 1H), 7.17 (d, J = 7.7 Hz, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.88 (dd, J = 5.3, 1.5 Hz, 1H), 6.73 (s, 1H), 6.55 (s, 1H), 5.13-5.06 (m, 1H), 4.00-3.95 (m, 2H), 3.91- 3.86 (m, 4H), 3.82 (td, J = 8.4, 5.6 Hz, 1H), 2.90 (t, J = 7.4 Hz, 2H), 2.66 (t, J = 7.4 Hz, 2H), 2.49- 2.35 (m, 1H), 2.29-2.19 (m, 1H), 1.97 (p, J = 7.5 Hz, 2H). One exchangeable proton not observed. m/z 484.2 (M + H)+ (ES+) 483.54 98

1H NMR (DMSO-d6) δ 10.90 (s, 1H), 8.14 (d, J = 5.2 Hz, 1H), 7.82 (s, 1H), 7.19 (d, J = 7.7 Hz, 1H), 7.11 (d, J = 7.7 Hz, 1H), 6.96 (s, 1H), 6.90 (dd, J = 5.3, 1.5 Hz, 1H), 6.74- 6.72 (m, 1H), 4.87 (d, J = 7.3 Hz, 2H), 4.80 (d, J = 7.3 Hz, 2H), 3.73 (s, 3H), 3.32 (s, 3H), 2.98 (s, 3H), 2.90 (t, J = 7.4 Hz, 2H), 2.65 (t, J = 7.2 Hz, 2H), 1.96 (p, J = 7.5 Hz, 2H). m/z 514.3 (M + H)+ (ES+) 513.57 99

1H NM R (DMSO-d6) δ 7.96 (s, 1H), 7.56 (s, 1H), 7.35 (s, 1H), 6.76 (s, 1H), 4.38 (tt, J = 10.3, 5.2 Hz, 1H), 3.98-3.90 (m, 2H), 3.44 (td, J = 11.4, 3.3 Hz, 2H), 2.75 (t, J = 7.4 Hz, 4H), 2.65 (t, J = 7.4 Hz, 4H), 1.92-1.90 (m, 8H). LCMS; m/z 431 (M + H)⁺ (ES⁺) 430.5 100

1H NMR (DMSO-d6) δ 7.96 (s, 1H), 7.58 (s, 1H), 7-39 (s, 1H), 6.77 (s, 1H), 5.00 (ddt, J = 7.9, 6.4, 3.7 Hz, 1H), 4.09-3.76 (m, 4H), 2.75 (t, J = 7.4 Hz, 4H), 2.65 (t, J = 7.4 Hz, 4H), 2.43-2.29 (m, 1H), 2.24-2.18 (m, 1H), 1.92- 1.89 (m, 4H). LCMS; m/z 417 (M + H)⁺ (ES⁺) 416.5 101

1H NMR (DMSO-d6) δ 7.87 (d, J = 0.6 Hz, 1H), 7.55 (d, J = 0.6 Hz, 1H), 7.35 (br s, 1H), 6.76 (s, 1H), 4.21 (t, J = 5.3 Hz, 2H), 3.65 (t, J = 5.3 Hz, 2H), 3.23 (s, 3H), 2.75 (t, J = 7.4 Hz, 4H), 2.66 (t, J = 7.3 Hz, 4H), 1.94-1.88 (m, 4H). LCMS; m/z 405 (M + H)⁺ (ES⁺) 404.5 102

1H NMR (DMSO-d6) δ 10.78 (s, 1H), 8.32 (s, 1H), 7.90-7.71 (m, 2H), 6.91 (d, J = 9.9 Hz, 2H), 4.30 (t, J = 5.2 Hz, 2H), 3.68 (t, J = 5.2 Hz, 2H), 3.31 (s, 3H), 2.96-2.83 (m, 2H), 1.03 (s, 12H). LCMS; m/z 427.1 (M + H)⁺ (ES⁺) 426.5 103

1H NMR (DMSO-d6) δ 8.49 (s, 1H), 7.86 (s, 1H), 6.88 (s, 1H), 5.10 (d, J = 5.0 Hz, 1H), 4.38 (dd, J = 13.6, 4.3 Hz, 1H), 4.28 (dd, J = 13.7, 7.2 Hz, 1H), 4.06-3.95 (m, 1H), 2.77 (t, J = 7.4 Hz, 4H), 2.61 (t, J = 7.4 Hz, 4H), 1.92 (p, J = 7.4 Hz, 4H), 1.06 (d, J = 6.3 Hz, 3H). Acidic NH not observed. LCMS; m/z 406.4 (M + H)⁺ (ES⁺) 405.5 104

1H NMR (DMSO-d6) δ 7.84-7.73 (m, 1H), 7.74- 7.67 (m, 1H), 6.85 (s, 1H), 6.58-6.50 (m, 1H), 5.03 (d, J = 5.5 Hz, 1H), 4.77 (t, J = 5.6 Hz, 1H), 4.25 (dd, J = 13.7, 3.8 Hz, 1H), 4.03 (dd, J = 13.8, 7.8 Hz, 1H), 3.83-3.76 (m, 1H), 3.39-3.33 (m, 1H), 3.30- 3.25 (m, 1H), 2.77 (t, J = 7.4 Hz, 4H), 2.63 (t, J = 7.4 Hz, 4H), 1.93 (p, J = 7.5 Hz, 4H). Acidic NH not observed. LCMS; m/z 421.4 (M + H)+ (ES+) 420.5 105

1H NMR (DMSO-d6) δ 10.85 (br s, 1H), 7.89 (s, 1H), 6.89 (s, 1H), 6.68 (s, 1H), 5.68 (d, J = 4.4 Hz, 1H), 4.79 (s, 1H), 4.46- 4.42 (m, 1H), 4.18 (dd, J = 9.8, 6.4 Hz, 1H), 4.02 (dd, J = 9.4, 5.3 Hz, 1H), 3.97 (dd, J = 9.8, 3.8 Hz, 1H), 3.61 (dd, J = 9.4, 3.3 Hz, 1H), 2.78 (t, J = 7.5 Hz, 4H), 2.61 (t, J = 7.4 Hz, 4H), 1.94 (p, J = 7.4 Hz, 4H). OH not observed. LCMS; m/z 433.7 (M + H)⁺ (ES⁺) 432.5 106

1H NMR (DMSO-d6) δ 7.61 (d, J = 2.3 Hz, 1H), 7.52 (s, 1H), 6.38 (d, J = 2.3 Hz, 1H), 4.70 (br s, 1H), 4.01 (s, 2H), 2.78 (t, J = 7.5 Hz, 4H), 2.67 (t, J = 7.5 Hz, 4H), 1.95 (p, J = 7.5 Hz, 4H), 1.04 (s, 6H). LCMS; m/z 437.3 (M + H)+ (ES+) 436.5 107

1H NMR (DMSO-d6) δ 10.80 (br s, 1H), 7.98- 7.93 (m. 2H), 6.92 (br s, 1H), 6.72-6.69 (m, 1H), 3.71 (p, J = 5.8 Hz, 1H), 3.19-3.14 (m, 2H), 2.95 (s, 3H), 2.78 (t, J = 7.4 Hz, 4H), 2.74 (s, 2H), 2.70-2.65 (m, 2H), 2.62 (t, J = 7.4 Hz, 4H), 1.95 (p, J = 7.3 Hz, 4H), 1.49 (s, 6H). LCMS; m/z 488.3 (M + H)+ (ES+) 487.6 ¹H NMR and MS data

Examples—Biological Studies NLRP3 and Pyroptosis

It is well established that the activation of NLRP3 leads to cell pyroptosis and this feature plays an important part in the manifestation of clinical disease (Yan-gang Liu et al., Cell Death & Disease, 2017, 8(2), e2579; Alexander Wree et al., Hepatology, 2014, 59(3), 898-910; Alex Baldwin et al., Journal of Medicinal Chemistry, 2016, 59(5), 1691-1710; Ema Ozaki et al., Journal of Inflammation Research, 2015, 8, 15-27; Zhen Xie & Gang Zhao, Neuroimmunology Neuroinflammation, 2014, 1(2), 60-65; Mattia Cocco et al., Journal of Medicinal Chemistry, 2014, 57(24), 10366-10382; T. Satoh et al., Cell Death & Disease, 2013, 4, e644). Therefore, it is anticipated that inhibitors of NLRP3 will block pyroptosis, as well as the release of pro-inflammatory cytokines (e.g. IL-1β) from the cell.

THP-1 Cells: Culture and Preparation

THP-1 cells (ATCC # TIB-202) were grown in RPMI containing L-glutamine (Gibco #11835) supplemented with 1 mM sodium pyruvate (Sigma # S8636) and penicillin (100 units/ml)/streptomycin (0.1 mg/ml) (Sigma # P4333) in 10% Fetal Bovine Serum (FBS) (Sigma # F0804). The cells were routinely passaged and grown to confluency (˜10⁶ cells/ml). On the day of the experiment, THP-1 cells were harvested and resuspended into RPMI medium (without FBS). The cells were then counted and viability (>90%) checked by Trypan blue (Sigma # T8154). Appropriate dilutions were made to give a concentration of 625,000 cells/ml. To this diluted cell solution was added LPS (Sigma # L4524) to give a 1 μg/ml Final Assay Concentration (FAC). 40 μl of the final preparation was aliquoted into each well of a 96-well plate. The plate thus prepared was used for compound screening.

THP-1 Cells Pyroptosis Assay

The following method step-by-step assay was followed for compound screening.

-   1. Seed THP-1 cells (25,000 cells/well) containing 1.0 μg/ml LPS in     40 μl of RPMI medium (without FBS) in 96-well, black walled, clear     bottom cell culture plates coated with poly-D-lysine (VWR #734-0317) -   2. Add 5 μl compound (8 points half-log dilution, with 10 μM top     dose) or vehicle (DMSO 0.1% FAC) to the appropriate wells -   3. Incubate for 3 hrs at 37° C. and 5% CO₂ -   4. Add 5 μl nigericin (Sigma # N7143) (FAC 5 μM) to all wells -   5. Incubate for 1 hr at 37° C. and 5% CO₂ -   6. At the end of the incubation period, spin plates at 300×g for 3     mins and remove supernatant -   7. Then add 50 μl of resazurin (Sigma # R7017) (FAC 100 μM resazurin     in RPMI medium without FBS) and incubate plates for a further 1-2     hrs at 37° C. and 5% CO₂ -   8. Plates were read in an Envision reader at Ex 560 nm and Em 590 nm -   9. IC₅₀ data is fitted to a non-linear regression equation (log     inhibitor vs response-variable slope 4-parameters)

96-Well Plate Map

1 2 3 4 5 6 7 8 9 10 11 12 A High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low B High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low C High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low D High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low E High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low F High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low G High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low H High Comp 1 Comp 2 Comp 3 Comp 4 Comp 5 Comp 6 Comp 7 Comp 8 Comp 9 Comp 10 Low High MCC950 (10 uM) Compound 8-point half-log dilution Low Drug free control

The results of the pyroptosis assay performed are summarised in Table 2 below as THP IC₅₀.

Human Whole Blood IL1β Release Assay

For systemic delivery, the ability to inhibit NLRP3 when the compounds are present within the bloodstream is of great importance. For this reason, the NLRP3 inhibitory activity of a number of compounds in human whole blood was investigated in accordance with the following protocol.

Human whole blood in Li-heparin tubes was obtained from healthy donors from a volunteer donor panel.

-   1. Plate out 80 μl of whole blood containing 1 μg/ml of LPS in     96-well, clear bottom cell culture plate (Corning #3585) -   2. Add iol compound (8 points half-log dilution with 10 μM top dose)     or vehicle (DMSO 0.1% FAC) to the appropriate wells -   3. Incubate for 3 hrs at 37° C., 5% CO₂ -   4. Add 10 μl Nigericin (Sigma # N7143) (10 μM FAC) to all wells -   5. Incubate for 1 hr at 37° C., 5 CO₂ -   6. At the end of the incubation period, spin plates at 300×g for 5     mins to pellet cells and remove 20 μl of supernatant and add to     96-well v-bottom plates for IL-13 analysis (note: these plates     containing the supernatants can be stored at −80° C. to be analysed     at a later date) -   7. IL-1β was measured according to the manufacturer protocol (Perkin     Elmer-AlphaLisa IL-1 Kit AL220F-5000) -   8. IC₅₀ data is fitted to anon-linear regression equation (log     inhibitor vs response-variable slope 4-parameters)

The results of the human whole blood assay are summarised in Table 2 below as HWB IC₅₀.

TABLE 2 NLRP3 inhibitory activity Example No THP IC₅₀ HWB IC₅₀ 1 +++ *** 2 +++ *** 3 ++++ *** 4 ++++ * 5 ++++ *** 6 ++++ *** 7 ++++ **** 8 ++++ ***** 9 ++ * 10 ++++ **** 11 ++++ ***** 12 +++ *** 13 +++ ***** 14 +++++ **** 15 ++++ *** 16 ++++ **** 17 ++ * 18 ++ ** 19 ++ * 20 ++++ *** 21 ++++ *** 22 ++++ **** 23 ++++ ***** 24 ++++ ***** 25 +++ *** 26 ++++ ***** 27 ++ ND 28 +++ *** 29 +++ *** 30 ++++ *** 31 +++ ** 32 ++ * 33 +++ *** 34 +++ *** 35 +++ *** 36 +++ **** 37 +++ ***** 38 +++++ ***** 39 ++++ ** 40 +++ ***** 41 ++++ **** 42 +++++ ***** 43 ++ ND 44 +++ ND 45 +++++ ***** 46 +++++ ***** 47 ++++ **** 48 +++++ ***** 49 +++ *** 50 ++++ *** 51 ++++ ***** 52 +++ ND 53 +++++ ***** 54 ++ ND 55 +++ *** 56 ++++ * 57 +++ *** 58 ++ *** 59 ++++ ***** 60 + ND 61 +++ ***** 62 ++++ **** 63 ++ ND 64 +++ ** 65 ++ ND 66 +++ *** 67 ++ ND 68 + ND 69 + ND 70 + ND 71 + ND 72 ++++ **** 73 ++++ **** 74 ++ ND 75 +++ *** 76 +++ ***** 77 ++++ ***** 78 ++ ND 79 +++ ** 80 ++ ND 81 ++ ND 82 ++++ *** 83 ++ ND 84 + ND 85 + ND 86 + * 87 +++ ***** 88 ++ ND 89 ++ ND 90 +++++ ***** 91 +++++ ***** 92 +++++ ***** 93 +++++ ***** 94 +++++ ***** 95 +++++ ***** 96 +++++ ***** 97 ++++ ***** 98 +++++ ***** 99 + ND 100 ++ ND 101 ++ ND 102 ND ND 103 +++ *** 104 +++ *** 105 +++ ND 106 +++++ **** 107 ++++ *** [THP IC50 (≤0.04 μM = +++++, ≤0.16 μM = ++++, ≤0.64 μM = +++, ≤2.56 μM = ++, ≤10 μM = +, not determined = ND)] [HWB IC50 (≤0.4 μM = *****, ≤0.8 μM = ****, ≤1.6 μM = ***, ≤3.2 μM = **, ≤10 μM = *, not determined = ND)]

PK Protocol

Pharmacokinetic parameters were determined in male Sprague Dawley rats (Charles River, UK, 250-350 g; or Vital River Laboratory Animal Technology Co Ltd, Beijing, China, 7-9 weeks old). Animals were individually housed during the study and maintained under a 12 h light/dark cycle. Animals had free access to food and water except that some orally dosed animals were food deprived overnight prior to the study. For intravenous administration, compounds were formulated as a solution in water or DMSO:PBS [10:90] in 2 mL/kg dosing volume and administered via tail vein. For oral administration, compounds were formulated as a solution in water or DMSO:water [10:90] in 5 mL/kg dosing volume and administered orally.

Serial blood samples (about 120-300 μL) were taken from each animal at each of 8 time-points post dose (0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 h) or at each of 12 time-points post dose (0.03, 0.1, 0.17, 0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h) or pre-dose and at each of 9 time-points post dose (0.25, 0.5, 1, 2, 4, 6, 8, 12 and 24 h). Samples were held on ice for no longer than 30 minutes before centrifugation (10,000 rpm (8,385 g) for 3 minutes; or 5,696 rpm (3,000 g) for 15 minutes) for plasma generation. Plasma was frozen on dry ice prior to bioanalysis. PK parameters were generated from LC-MS/MS data using Dotmatics or Phoenix WinNonlin 6.3 software.

The pharmacokinetic parameters determined are summarised in Tables 3 and 4 below. Also included for comparative purposes in Table 3 are the intravenous pharmacokinetic parameters determined using the above protocol for MCC950, an NLRP3 inhibitor described in Baldwin et al., J. Med. Chem., 59(5), 1691-1710, 2016.

TABLE 3 PK data (intravenous administration) Example Dose AUC T_(1/2) V_(dss) Cl No (mg/kg) (ng · hr/mL) (hr) (L/kg) (mL/min/kg) 1 1 8622.1 3.4 0.43 1.9 2 1 1027.4 0.3 0.3 16.2 3 1 3680.6 6.7 1.57 4.5 10 1 4289.9 2.9 0.61 3.9 11 1 7383.2 2.9 0.36 2.3 13 1 38678.1 3.6 0.09 0.4 16 1 10217.1 3.8 0.41 1.8 23 1 20093.7 2.6 0.12 0.8 24 1 7029.4 3.5 0.37 2.4 26 1.74 8057.9 3.6 0.6 4.2 37 1 300.2 1.0 1.22 56.3 38 1 3881.3 1.1 0.35 4.6 42 1 2960.7 0.7 0.24 5.6 45 2.99 2319.1 0.8 1.11 21.6 46 1.42 2382.0 1.6 0.56 10.0 48 1 947.9 2.9 1.74 17.6 51 1 1857.3 6.6 1.18 9.0 53 1 1276.0 11.5 3.48 13.3 59 2.41 786.6 0.3 2.37 114.1 72 2.88 329.7 0.2 1.84 149.3 73 1 1162.1 2.9 2.24 14.4 77 1 2067.0 14.2 1.9 8.1 MCC950 1 611.1 1.2 0.53 27.8

TABLE 4 PK data (oral administration) Example Dose C_(max) AUC T_(max) T_(1/2) Cl/F No (mg/kg) (ng/mL) (ng · hr/mL) (hr) (hr) (mL/min/kg) Bioavailability 10 3 1772.4 9657.8 0.29 3.5 5.2 75 16 3 3958.1 19567.5 0.83 3.2 2.6 63.8 73 3 700.6 2415.2 0.08 4.9 21.5 67

As is evident from the results presented in Table 2, surprisingly in spite of the structural differences versus the prior art compounds, the compounds of the invention show high levels of NLRP3 inhibitory activity in the pyroptosis assay and in the human whole blood assay.

As is evident from the results presented in Tables 3 and 4, the compounds of the invention show advantageous pharmacokinetic properties, for example half-life T_(1/2), area under the curve AUC, clearance Cl and/or bioavailability, compared to the prior art compounds.

It will be understood that the present invention has been described above by way of example only. The examples are not intended to limit the scope of the invention. Various modifications and embodiments can be made without departing from the scope and spirit of the invention, which is defined by the following claims only. 

1. A compound of formula (I):

or a pharmaceutically acceptable salt, solvate or prodrug thereof, wherein: Q is selected from O or S; W, X, Y and Z are each independently N, O, S, NH or CH, wherein at least one of W, X, Y and Z is N or NH; L is a saturated or unsaturated hydrocarbylene group, wherein the hydrocarbylene group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbylene group may optionally be substituted, and wherein the hydrocarbylene group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; R¹ is hydrogen or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; optionally L and R¹ together with the oxygen atom to which they are attached may form a 3- to 12-membered saturated or unsaturated cyclic group, wherein the cyclic group may optionally be substituted; optionally R¹—O-L-, and any two adjacent W, X, Y or Z, may together form a 3- to 12-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted; R² is a cyclic group substituted at the α-position, wherein R² may optionally be further substituted; each R³ is independently a halo, —OH, —NO₂, —NH₂, —N₃, —SH, or a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; m is 0, 1, 2 or 3; and optionally any R³, and any two adjacent W, X, Y or Z, may together form a 3- to 12-membered saturated or unsaturated cyclic group fused to ring A, wherein the cyclic group fused to ring A may optionally be substituted; provided that any atom of L or R¹ that is directly attached to W, X, Y or Z is not the same atom of L or R that is directly attached to the oxygen atom of R¹—O-L-; and provided that the compound is not:


2. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein ring A is monocyclic.
 3. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein: (i) W, X, Y and Z are each independently N, NH or CH; and/or (ii) at least two of W, X, Y and Z are N or NH.
 4. (canceled)
 5. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R¹—O-L- is directly attached to a ring nitrogen atom of ring A.
 6. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein (i) the group R¹—O-L-, including any optional substituents, contains only atoms selected from the group consisting of carbon, hydrogen, oxygen and halogen atoms; and/or (ii) the oxygen atom of R¹—O-L- is not directly attached to a sp² hybridised atom.
 7. (canceled)
 8. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the group

contains from 8 to 16 atoms other than hydrogen or halogen.
 9. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein (i) Q is O; and/or (ii) each R³ is independently selected from halo; —CN; —NO₂; —N₃; —R^(β); —OH; —OR^(β); —R^(α)-halo; —R^(α)—CN; —R^(α)—NO₂; —R^(α)—N₃; —R^(α)—R^(β); —R^(α)—OH; —R^(α)—OR^(β); —SH; —SR^(β); —SOR^(β); —SO₂H; —SO₂R^(β); —SO₂NH₂; —SO₂NHR^(β); —SO₂N(R^(β))₂; —R^(α)—SH; —R^(α)—SR^(β); —R^(α)—SOR^(β); —R^(α)—SO₂H; —R^(α)—SO₂R^(β); —R^(α)—SO₂NH₂; —R^(α)—SO₂NHR^(β); —R^(α)—SO₂N(R^(β))₂; —NH₂; —NHR^(β); —N(R^(β))₂; —R^(α)—NH₂; —R^(α)—NHR^(β); —R^(α)—N(R^(β))₂; —CHO; —COR^(β); —COOH; —COOR^(β); —OCOR^(β); —R^(α)—CHO; —R^(α)—COR^(β); —R^(α)—COOH; —R^(α)—COOR^(β); or —R^(α)—OCOR^(β); wherein each —R^(α)— is independently selected from an alkylene, alkenylene or alkynylene group, wherein the alkylene, alkenylene or alkynylene group contains from 1 to 6 atoms in its backbone, wherein one or more carbon atoms in the backbone of the alkylene, alkenylene or alkynylene group may optionally be replaced by one or more heteroatoms N, O or S, and wherein the alkylene, alkenylene or alkynylene group may optionally be substituted with one or more halo and/or —R^(β) groups; and wherein each —R^(β) is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, and wherein any —R^(β) may optionally be substituted with one or more C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₇ cycloalkyl, —O(C₁-C₄ alkyl), —O(C₁-C₄ haloalkyl), —O(C₃-C₇ cycloalkyl), halo, —OH, —NH₂, —CN, —C≡CH, oxo (═O), or 4- to 6-membered heterocyclic group.
 10. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α-position, wherein R² may optionally be further substituted, and optionally wherein: (i) R² is an aryl or a heteroaryl group, wherein the aryl or the heteroaryl group is substituted at the α and α′ positions, and wherein R² may optionally be further substituted; or (ii) R² is a fused aryl or a fused heteroaryl group, wherein a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α,β positions and a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring is fused to the aryl or heteroaryl group across the α′,β′ positions, and wherein R² may optionally be further substituted.
 11. (canceled)
 12. (canceled)
 13. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R² is a cyclic group substituted at the α-position with a monovalent heterocyclic group or a monovalent aromatic group, wherein a ring atom of the heterocyclic or aromatic group is directly attached to the α-ring atom of the cyclic group, wherein the heterocyclic or aromatic group may optionally be substituted, and wherein the cyclic group may optionally be further substituted.
 14. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein R² is a cyclic group substituted at the α and α′ positions, wherein R² may optionally be further substituted, and optionally wherein each substituent at the α and α′ positions comprises a carbon atom.
 15. (canceled)
 16. (canceled)
 17. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein: Q is O; W, X, Y and Z are each independently N, NH or CH, wherein at least one of W, X, Y and Z is N or NH; R¹—O-L- is directly attached to X or Y; m is 0, 1 or 2; each R³ is independently selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group, wherein any C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group may optionally be substituted with one or more halo groups; R² is a phenyl or a 5- or 6-membered heteroaryl group, wherein: (i) the phenyl or 5- or 6-membered heteroaryl group is substituted with a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which is fused to the parent phenyl or 5- or 6-membered heteroaryl group across the α, β positions and which is optionally substituted with one or more halo groups; and the phenyl or 5- or 6-membered heteroaryl group is further substituted at the α′ position with a substituent selected from —R⁴, —OR⁴ and —COR⁴, wherein R⁴ is selected from a C₁-C₆ alkyl, C₂-C₆ alkenyl, C₂-C₆ alkynyl or C₂-C₆ cyclic group and wherein R⁴ is optionally substituted with one or more halo groups; and optionally the phenyl or 5- or 6-membered heteroaryl group is further substituted with one or two substituents independently selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group; or (ii) the phenyl or 5- or 6-membered heteroaryl group is substituted with a first cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which is fused to the parent phenyl or 5- or 6-membered heteroaryl group across the α,β positions and which is optionally substituted with one or more halo groups; and the phenyl or 5- or 6-membered heteroaryl group is substituted with a second cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which is fused to the parent phenyl or 5- or 6-membered heteroaryl group across the α′,β′ positions and which is optionally substituted with one or more halo groups; and optionally the phenyl group is further substituted with a substituent selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group; or (iii) the phenyl or 5- or 6-membered heteroaryl group is substituted at the α-position with a monovalent heterocyclic group or a monovalent aromatic group selected from phenyl, pyridinyl, pyrimidinyl, pyrazolyl, imidazolyl, triazolyl or tetrahydropyranyl, wherein the monovalent heterocyclic or aromatic group may optionally be substituted with one or two substituents independently selected from halo, C₁-C₃ alkyl, C₁-C₃ haloalkyl, —R⁴²—OR⁴³, —R⁴²—N(R⁴³)₂, —R⁴²—CN or —R⁴²—C≡CR⁴³, and wherein a ring atom of the monovalent heterocyclic or aromatic group is directly attached to the α-ring atom of the parent phenyl or 5- or 6-membered heteroaryl group; wherein each R⁴² is independently selected from a bond or a C₁-C₃ alkylene group; and each R⁴³ is independently selected from hydrogen or a C₁-C₃ alkyl or C₁-C₃ haloalkyl group; and the phenyl or 5- or 6-membered heteroaryl group is further substituted with a cycloalkyl, cycloalkenyl, non-aromatic heterocyclic, aryl or heteroaryl ring which is fused to the parent phenyl or 5- or 6-membered heteroaryl group across the α′,β′ positions and which is optionally substituted with one or more halo groups; and optionally the phenyl or 5- or 6-membered heteroaryl group is further substituted with one or two substituents independently selected from halo, —NO₂, —CN, —COOR⁴⁵, —CONH₂, —CONHR⁴⁵ or —CON(R⁴⁵)₂, wherein each —R⁴⁵ is independently selected from a C₁-C₄ alkyl or C₁-C₄ haloalkyl group; and L is an alkylene group, wherein the alkylene group may be straight-chained or branched, wherein the alkylene group may optionally include one or two heteroatoms N or O in its carbon skeleton, and wherein the alkylene group may be optionally substituted with (i) one or more substituents independently selected from halo and —OH, and/or (ii) a divalent bridging substituent selected from —O— and C₁-C₃ alkylene, wherein the C₁-C₃ alkylene group may be straight-chained or branched, wherein the C₁-C₃ alkylene group may optionally be substituted with one or more substituents independently selected from halo and —OH, and wherein the C₁-C₃ alkylene group may optionally include one heteroatom N or O in its carbon skeleton; and R^(i) is hydrogen or a C₁-C₆ alkyl or C₃-C₆ cycloalkyl group, wherein the C₁-C₆ alkyl or C₃-C₆ cycloalkyl group is optionally substituted with one or more substituents independently selected from halo, —OH and —NH₂; provided that L contains from 2 to 8 atoms other than hydrogen or halogen, and that the atom of L that is directly attached to X or Y is a carbon atom and is not the same atom of L that is directly attached to the oxygen atom of R¹—O-L-; or R¹—O-L- has the formula R¹⁰-L²-, wherein: R¹⁰ is a 4- to 6-membered saturated monocyclic group, wherein R¹⁰ includes at least one oxygen atom in the ring structure, wherein R¹⁰ optionally includes one or two additional heteroatoms N or O in the ring structure, wherein R¹⁰ is optionally substituted with one or more substituents independently selected from halo, —OH, —NH₂, —R²⁰, —OR²⁰, —NHR² and —N(R²)₂, wherein each R² is independently selected from a C₁-C₄ alkyl, C₁-C₄ haloalkyl, C₃-C₄ cycloalkyl or C₃-C₄ halocycloalkyl group, or any two R²⁰ directly attached to the same nitrogen atom may together form a C₂-C₅ alkylene or C₂-C₅ haloalkylene group; and L² is a bond or a —(C(R¹⁵)₂)_(x) group, wherein x is 1 or 2, and each R¹⁵ is independently selected from hydrogen or a halo, methyl or halomethyl group, or any two R¹⁵ directly attached to the same carbon atom may together form a C₂ alkylene or C₂ haloalkylene group; provided that the atom of R¹⁰-L²- that is directly attached to X or Y is a carbon atom and at least one oxygen atom in the ring structure of R¹⁰ is not directly attached to the same atom of R¹⁰-L²- that is directly attached to X or Y.
 18. A compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, wherein the compound is selected from the group consisting of:


19. (canceled)
 20. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, and a pharmaceutically acceptable excipient.
 21. A method of treating or preventing a disease, disorder or condition in a subject, the method comprising the step of administering an effective amount of a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, to the subject, thereby treating or preventing the disease, disorder or condition, optionally wherein the disease, disorder or condition is responsive to NLRP3 inhibition.
 22. (canceled)
 23. The method as claimed in claim 21, wherein the disease, disorder or condition is selected from: (i) inflammation; (ii) an auto-immune disease; (iii) cancer; (iv) an infection; (v) a central nervous system disease; (vi) a metabolic disease; (vii) a cardiovascular disease; (viii) a respiratory disease; (ix) a liver disease; (x) a renal disease; (xi) an ocular disease; (xii) a skin disease; (xiii) a lymphatic condition; (xiv) a psychological disorder; (xv) graft versus host disease; (xvi) allodynia; and (xvii) any disease where an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.
 24. The method as claimed in claim 23, wherein the disease, disorder or condition is selected from: (i) inflammation; (ii) an infection; (iii) a cardiovascular disease; (iv) a respiratory disease; (v) a liver disease; (vi) a renal disease; (vii) an ocular disease; (viii) a skin disease; (ix) a psychological disorder; (x) a lymphatic condition; and/or (xi) any disease, disorder or condition in which an individual has been determined to carry a germline or somatic non-silent mutation in NLRP3.
 25. The method as claimed in claim 21, wherein the disease, disorder or condition is selected from: (i) cryopyrin-associated periodic syndromes (CAPS); (ii) Muckle-Wells syndrome (MWS); (iii) familial cold autoinflammatory syndrome (FCAS); (iv) neonatal onset multisystem inflammatory disease (NOMID); (v) familial Mediterranean fever (FMF); (vi) pyogenic arthritis, pyoderma gangrenosum and acne syndrome (PAPA); (vii) hyperimmunoglobulinemia D and periodic fever syndrome (HIDS); (viii) Tumour Necrosis Factor (TNF) Receptor-Associated Periodic Syndrome (TRAPS); (ix) systemic juvenile idiopathic arthritis; (x) adult-onset Still's disease (AOSD); (xi) relapsing polychondritis; (xii) Schnitzler's syndrome; (xiii) Sweet's syndrome; (xiv) Behcet's disease; (xv) anti-synthetase syndrome; (xvi) deficiency of interleukin 1 receptor antagonist (DIRA); and (xvii) haploinsufficiency of A20 (HA20).
 26. A method of inhibiting NLRP3 in a subject, the method comprising administering a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, to the subject thereby inhibiting NLRP3.
 27. A method of analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 by a compound, comprising contacting a cell or non-human animal with a compound or a pharmaceutically acceptable salt, solvate or prodrug thereof, as claimed in claim 1, and analysing inhibition of NLRP3 or an effect of inhibition of NLRP3 in the cell or non-human animal by the compound.
 28. The method as claimed in claim 21, wherein the compound is administered as a pharmaceutical composition further comprising a pharmaceutically acceptable excipient. 